


**CUMULATIVE
SUPPLEMENT 7
JULY 2019**



**APPROVED
DRUG PRODUCTS**

**WITH
THERAPEUTIC EQUIVALENCE EVALUATIONS**

39th EDITION

Department of Health and Human Services

Food and Drug Administration
Office of Medical Products and Tobacco
Center for Drug Evaluation and Research
Office of Generic Drugs
Office of Generic Drug Policy

2019

Prepared By
Food and Drug Administration
Office of Medical Products and Tobacco
Center for Drug Evaluation and Research
Office of Generic Drugs
Office of Generic Drug Policy

**APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS**

39th EDITION

**Cumulative Supplement 7
July 2019**

CONTENTS

	<i>PAGE</i>
1.0 INTRODUCTION.....	v
1.1 How to use the Cumulative Supplement.....	v
1.2 Cumulative Supplement Content	vi
1.3 Applicant Name Changes	vii
1.4 Levothyroxine Sodium.....	ix
1.5 Availability of the Edition	x
1.6 Report of Counts for the Prescription Drug Product List.....	xi
1.7 Cumulative Supplement Legend.....	xii
 DRUG PRODUCT LISTS	
Prescription Drug Product List	1-1
OTC Drug Product List	2-1
Drug Products with Approval under Section 505 of the Act	
Administered by the Center for Biologics Evaluation and Research List	3-1
Orphan Product Designations and Approvals List	4-1
Drug Products Which Must Demonstrate <i>in vivo</i> Bioavailability	
Only if Product Fails to Achieve Adequate Dissolution	5-1
 PATENT AND EXCLUSIVITY INFORMATION ADDENDUM	
A. Patent and Exclusivity Lists	A-1
B. Patent and Exclusivity Terms	B-1

**APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS**

39th EDITION

**CUMULATIVE SUPPLEMENT 7
JULY 2019**

1.0 INTRODUCTION

1.1 HOW TO USE THE CUMULATIVE SUPPLEMENT

This Cumulative Supplement is one of a series of monthly updates to the Approved Drug Products with Therapeutic Equivalence Evaluations, 39th Edition (the List). The List is composed of four parts: approved prescription drug products with therapeutic equivalence evaluations; approved over-the-counter (OTC) drug products for those drugs that may not be marketed without NDAs or ANDAs because they are not covered under existing OTC monographs; drug products with approval under Section 505 of the Federal Food, Drug, and Cosmetic Act (FD&C Act) administered by the Center for Biologics Evaluation and Research; and approved products that have never been marketed, are for exportation, are for military use, have been discontinued from marketing and we have not determined that they were withdrawn for safety or effectiveness reasons, or that have had their approvals withdrawn for other than safety or efficacy reasons.

The Cumulative Supplement provides, among other things, information on newly approved drugs and, if necessary, revised therapeutic equivalence evaluations and updated patent and exclusivity data. The Addendum contains appropriate drug patent and exclusivity information required of the Agency by the "Drug Price Competition and Patent Term Restoration Act of 1984" for the Prescription, OTC, Discontinued Drug Product, and Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research Lists.

Because all parts of the publication are subject to changes, additions, or deletions, the List must be used in conjunction with the most current Cumulative Supplement. Users may wish to mark to the left of the ingredient(s) in the List to indicate that changes to that entry appear in the Cumulative Supplement. Drug product information is provided in each Cumulative Supplement for completeness to assist in locating the proper place in the List for the revision.

The presence of any therapeutic equivalence code indicates that the drug product is multisource; the deletion of a therapeutic equivalence code indicates that the drug product has become single source. (An infrequent exception exists when a therapeutic equivalence code is revised. In that case, the deletion of the therapeutic equivalence code is followed immediately by the addition of the revised one.)

Products that have never been marketed, are for exportation, are for military use, have been discontinued from marketing and we have not determined that they were withdrawn for safety or effectiveness reasons or that have had their approvals withdrawn for other than safety or efficacy reasons, will be flagged in this Cumulative Supplement with the "@" symbol to designate their non-marketed status. All products having a

"@" symbol in the 12th Cumulative Supplement of this Edition List will then be added to the "Discontinued Drug Product List" appearing in the next Edition. The current Annual Edition Section 2.1, How To Use The Drug Product Lists, describes the layout and usage of the List.

New additions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol >A>. The Patent and Exclusivity List new additions are indicated by the symbol >A> to the left of Patent Number or Exclusivity Code. The >A> symbol is then dropped in subsequent Cumulative Supplements for that item.

New deletions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol >D> (DELETE) to the left of the line. The information line with the >D> symbol is dropped in subsequent Cumulative Supplements for that item.

The Patent and Exclusivity List is arranged in alphabetical order by active ingredient name(s) and trade name. The trade name will follow the active ingredient name separated by a dash symbol. Also shown is the application number and product number (FDA's internal file number) for reference purposes. All patents with their expiration dates are displayed for each application number. Drug substance and drug product patents are indicated as such with DS or DP in the Patent codes column. Use patents are indicated with the symbol "U" followed by a number representing a specific use. Exclusivity information for a specific drug is indicated by an abbreviation followed by the date upon which the exclusivity expires. Refer to the Exclusivity Terms, Section B, in the Patent and Exclusivity Information Addendum for an explanation of all codes and abbreviations. Refer to Section 1.3 for internet access to the most current list of Patent and Exclusivity terms.

1.2 CUMULATIVE SUPPLEMENT CONTENT

Since February 2005, we have been providing daily Electronic Orange Book (EOB) product information for new generic drug approvals. Daily generic updates provide the consumer with the current list of approved generic products which is important for substitution purposes. Previously, a first-time-generic product approved early in the month would not be published in the Cumulative Supplement (CS) for several weeks.

The CS monthly update publish goal is by the end of the following month's second work week (e.g., November's supplement will be updated by the end of the second full work week in December).

Currently, the monthly PDF CS includes:

- Generic product ANDA (Abbreviated New Drug Approval) approvals as of the date of publication.
- All product changes received and processed as of the date of publication.
 - o Refer to CS Section 1.8 Cumulative Supplement Legend for types of changes
 - o Discontinued products will be processed as of the date of publication. There will be circumstances where a product is discontinued in one month, however, it will be reported in a different month's CS. For example, the Orange Book Staff received a letter November 7 that the product has been

discontinued from manufacturing and marketing. The Orange Book subsequently publishes the October CS on November 14. The product will show in the October CS that it is discontinued even though the date of discontinuance is the day that the Orange Book Staff receives notification (November 7).

- New Drug Application (NDA) approvals appear in the CS month they were approved.
- Patent information, also updated daily in the EOB, is current to the date of publication.
- Exclusivity information is updated monthly and current to the date of publication.

Every effort is made to ensure the Cumulative Supplement is current and accurate. Applicant holders are requested to inform the FDA Orange Book Staff (OBS) of any changes or corrections. The OBS can be contacted by email at orangebook@fda.hhs.gov.

mail to:
FDA/CDER Orange Book Staff
Office of Generic Drugs
7620 Standish Place
Rockville, MD 20855-2773

1.3 APPLICANT NAME CHANGES

It is not practical to identify in the Cumulative Supplement each and every product involved when an applicant transfers its entire line of approved drug products to another applicant, or when an applicant changes its name. Therefore, the cumulation of these transfers and name changes will be identified in this section only. Where only partial lines of approved products are transferred between applicants, each approved product involved will appear as an applicant name change entry in the Cumulative Supplement.

It is also not practical to identify each and every product involved when an applicant name is changed to meet internal publication standards (e.g., MSD or Zenith [Former Abbreviated Names] are changed, respectively to Merck Sharp Dohme or Zenith Labs [New Abbreviated Names]). When this occurs, each product involved (either currently in the Cumulative Supplement or in the following year's edition) will reflect the new abbreviated name. Consequently, it will not appear as an applicant name change entry in the Cumulative Supplement nor will the cumulation of these name changes appear in this section. The Electronic Orange Book Query, updated monthly, will contain the most current applicant holder name.

FORMER APPLICANT NAME
(FORMER ABBREVIATED NAME)

G AND W LABORATORIES INC
(G AND W LABS)

G AND W LABORATORIES INC
(G AND W LABS INC)

NEW APPLICANT NAME
(NEW ABBREVIATED NAME)

ACP NIMBLE BUYER INC
(ACP NIMBLE)

ACP NIMBLE BUYER INC
(ACP NIMBLE)

IVAX PHARMACEUTICALS INC (IVAX PHARMS)	ANI PHARMACEUTICALS INC (ANI PHARMS INC)
IVAX PHARMACEUTICALS INC SUB TEVA PHARMACEUTICALS USA (IVAX PHARMS)	ANI PHARMACEUTICALS INC (ANI PHARMS INC)
LUITPOLD PHARMACEUTICALS INC (LUITPOLD)	AMERICAN REGENT INC (AM REGENT)
RISING PHARMACEUTICALS INC (RISING PHARMS)	SUN PHARMACEUTICAL INDUSTRIES LTD (SUN PHARM)
SUN PHARMA GLOBAL FZE (SUN PHARMA GLOBAL)	SUN PHARMACEUTICAL INDUSTRIES LTD (SUN PHARM)
SUN PHARMA GLOBAL INC (SUN PHARMA GLOBAL)	ANI PHARMACEUTICALS INC (ANI PHARMS INC)
TEVA PHARMACEUTICALS USA (TEVA PHARMS)	ANI PHARMACEUTICALS INC (ANI PHARMS INC)
TEVA PHARMACEUTICALS USA (TEVA PHARMS USA)	ANI PHARMACEUTICALS INC (ANI PHARMS INC)
TEVA PHARMACEUTICALS USA INC (TEVA)	ANI PHARMACEUTICALS INC (ANI PHARMS INC)
WATSON LABORATORIES INC (WATSON LABS)	ANI PHARMACEUTICALS INC (ANI PHARMS INC)
WATSON LABORATORIES INC (WATSON LABS)	DR REDDYS LABORATORIES LTD (DR REDDYS)
WATSON LABORATORIES INC (WATSON LABS)	HERITAGE PHARMA LABS INC (HERITAGE PHARMA)
WATSON LABORATORIES INC (WATSON LABS INC)	ANI PHARMACEUTICALS INC (ANI PHARMS INC)
WATSON LABORATORIES INC (WATSON LABS INC)	HERITAGE PHARMA LABS INC (HERITAGE PHARMA)
WATSON LABORATORIES INC AN INDIRECT WHOLLY OWNED SUB OF TEVA PHARMACEUTICALS USA INC (WATSON LABS TEVA)	ANI PHARMACEUTICALS INC (ANI PHARMS INC)
WATSON LABORATORIES INC AN INDIRECT WHOLLY OWNED SUB OF TEVA PHARMACEUTICALS USA INC (WATSON LABS TEVA)	DR REDDYS LABORATORIES LTD (DR REDDYS)

WATSON LABORATORIES INC AN
INDIRECT WHOLLY OWNED SUB OF
TEVA PHARMACEUTICALS USA INC
(WATSON LABS TEVA)

HERITAGE PHARMA LABS INC
(HERITAGE PHARMA)

1.4 LEVOTHYROXINE SODIUM

Because there are multiple reference listed drugs of levothyroxine sodium tablets and some reference listed drugs' sponsors have conducted studies to establish their drugs' therapeutic equivalence to other reference listed drugs, FDA has determined that its usual practice of assigning two or three character TE codes may be potentially confusing and inadequate for these drug products. Accordingly, FDA provides the following explanation and chart of therapeutic equivalence evaluations for levothyroxine sodium drug products.

Levothyroxine Sodium (Mylan ANDA 076187), Levoxyl (King Pharms NDA 021301), Synthroid (AbbVie NDA 021402), and Levo-T (Cediprof Inc NDA 021342) tablets have been determined to be therapeutically equivalent to corresponding strengths of Unithroid (Jerome Stevens NDA 021210) tablets.

Levo-T (Cediprof Inc NDA 021342), Euthyrox (Provell Pharma LLC NDA 021292), Levothyroxine Sodium (Mylan ANDA 076187), and Unithroid (Jerome Stevens NDA 021210) tablets have been determined to be therapeutically equivalent to corresponding strengths of Synthroid (AbbVie NDA 021402) tablets.

Levo-T (Cediprof Inc NDA 021342), Unithroid (Jerome Stevens NDA 021210), and Levothyroxine Sodium (Mylan ANDA 076187) tablets have been determined to be therapeutically equivalent to corresponding strengths of Levoxyl (King Pharms NDA 021301) tablets.

Levothyroxine Sodium (Mylan ANDA 076187) tablets have been determined to be therapeutically equivalent to corresponding strengths of Levothroid (Lloyd NDA 021116) tablets.

The chart outlines TE codes for all 0.025mg products in the active section of the Orange Book. Other product strengths may be similar. Therapeutic equivalence has been established between products that have the same AB+number TE code. More than one TE code may apply to some products. One common TE code indicates therapeutic equivalence between products.

Trade Name	Applicant	Strength	TE Code	Appl No	Product No
UNITHROID	STEVENS J	0.025MG	AB1	021210	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB1	076187	001
LEVOXYL	KING PHARMS	0.025MG	AB1	021301	001
SYNTHROID	ABBVIE	0.025MG	AB1	021402	001
LEVO-T	CEDIPROF INC	0.025MG	AB1	021342	001
SYNTHROID	ABBVIE	0.025MG	AB2	021402	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB2	076187	001
LEVOTHYROXINE	LUPIN	0.025MG	AB2	209713	001

SODIUM	ATLANTIS				
EUTHYROX	PROVELL PHARMS	0.025MG	AB2	021292	001
LEVO-T	CEDIPROF INC	0.025MG	AB2	021342	001
UNITHROID	STEVENS J	0.025MG	AB2	021210	001
LEVOXYL	KING PHARMS	0.025MG	AB3	021301	001
LEVO-T	CEDIPROF INC	0.025MG	AB3	021342	001
UNITHROID	STEVENS J	0.025MG	AB3	021210	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB3	076187	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB4	076187	001

1.5 AVAILABILITY OF THE EDITION

Since 1997, the Electronic Orange Book Query (EOBQ) <http://www.accessdata.fda.gov/scripts/cder/ob/default.cfm>, has been available on the internet and has become the updated-every-month Orange Book. The Query provides searching of the approved drug list by active ingredient, proprietary name, applicant holder, applicant number or patent number. Product search categories are: prescription, over-the-counter, discontinued drugs. There are links to patent and exclusivity information that may be applicable to each product.

Commencing with the 25th edition, the Annual Edition and monthly Cumulative Supplements have been provided in downloadable Portable Document Format (PDF) at the EOB home page by clicking on Publications. The PDF annual and cumulative supplements duplicate previous paper versions. Over time, there will be an archive for the annuals and each year's December Cumulative Supplement.

The downloaded Annual Edition and Cumulative Supplements are also available in a paper version (Approved Drug Products with Therapeutic Equivalence Evaluations, ADP) from the U.S. Government Printing Office: <http://bookstore.gpo.gov>; toll free 866-512-1800.

There are historical lists of Orange Book cumulative supplement product monthly changes at <http://www.fda.gov/Drugs/InformationOnDrugs/ucm086229.htm>. There are ASCII text files of the Orange Book drug product, patent, and exclusivity data at <http://www.fda.gov/Drugs/InformationOnDrugs/ucm129689.htm>. The drug product text files are provided in eobzip.zip format. The files are updated concurrently with the monthly cumulative supplements. The annual Orange Book Edition Appendices A, B, and C in PDF format are updated quarterly.

Effective August 18, 2003, patent submissions for publication in the Orange Book and Docket *95S-0117 need to be submitted on form FDA-3542 which may be downloaded from the FDA Forms List,
 Effective August 18, 2003, patent submissions for publication in the Orange Book and Docket *95S-0117 need to be submitted on form FDA-3542 which may be downloaded from the FDA Forms List,
<https://www.fda.gov/about-fda/reports-manuals-forms/forms>.

The current listing of the Orphan Product Designations and Approvals is available at <https://www.fda.gov/industry/developing-products-rare-diseases-conditions/designating-orphan-product-drugs-and-biological-products>.

1.6 REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST

DESCRIPTION OF REPORT

This report provides summary counts derived from the product information in the Prescription Drug Product List and the current Cumulative Supplement. Products included in the counts are domestically marketed drug products approved for both safety and effectiveness under section 505 of the Federal Food, Drug, and Cosmetic Act. Excluded are approved drug products marketed by distributors; those marketed solely abroad; and those now regarded as medical devices, biologics or foods.

The baseline column (December of the previous Annual Edition) refers to the products in the Prescription Drug Product List. For each three-month period, a column of quarterly data is added which incorporates counts of product activity from the previous quarter(s) with those in the baseline count.

DEFINITIONS

Drug Product

For this report, a drug product is the representation in the Prescription Drug Product List of an active moiety (molecular entity and its salts, esters and derivatives) either as a single ingredient or as a combination product provided in a specific dosage form and strength for a given route of administration with approval for marketing by a firm under a particular generic or trade name.

New Molecular Entity

A new molecular entity is considered an active moiety that has not previously been approved (either as the parent compound or as a salt, ester or derivative of the parent compound) in the United States for use in a drug product either as a single ingredient or as part of a combination.

REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST **COUNTS CUMULATIVE BY QUARTER**

<u>CATEGORIES COUNTED</u>	<u>DEC 2018</u>	<u>MAR 2019</u>	<u>JUN 2019</u>	<u>SEP 2019</u>	<u>DEC 2019</u>
DRUG PRODUCTS	20295	20580	20693		
LISTED SINGLE SOURCE	2724 (13.4%)	2713 (13.2%)	2729 (13.2%)		
MULTISOURCE	17571 (86.6%)	17867 (86.8%)	17964 (86.8%)		
THERAPEUTICALLY EQUIVALENT	17483 (86.1%)	17777 (86.4%)	17964 (86.8%)		

NOT THERAPEUTICALLY EQUIVALENT	88 (0.4%)	90 (0.4%)	85 (0.4%)
EXCEPTIONS ¹	58 (0.3%)	58 (0.3%)	58 (0.3%)
NEW MOLECULAR ENTITIES APPROVED	25	3	16
NUMBER OF APPLICANTS	1133	1129	1132

¹Amino acid-containing products of varying composition (see Introduction, page xx of the List).

1.7 CUMULATIVE SUPPLEMENT LEGEND

The List is sorted by Ingredient(s) and, within each grouping, by the Dosage Form; Route of Administration and then by trade name (or established name of the active ingredient, if no trade name exists).

The individual product record contains the Therapeutic Equivalence Code, Reference Listed Drug symbol, Reference Standard symbol, applicant holder, strength(s), New Drug Application number, product number, and approval date. The application number preceded by "N" is a New Drug Application (NDA or innovator). The application number preceded by an "A" is an Abbreviated New Drug

Application (ANDA or generic). The last two columns describe the action. The Action Month is the CS month the action occurred. The OB Action is the type of change that has occurred.

New ingredient(s), new dosage form, new route(s) of administration, new trade names, and new product additions are preceded by >A> during the action month. The change month is the current CS month; the change code for new approvals is NEWA. Following months will display the same information without the >A>.

Changes to currently listed products will list two records. The deleted product record will be preceded by >D>. The product record change addition being made will be preceded by >A>. Following months will display only the >A> record without the >A>. All changes that occur to the product through the Annual year will be listed. The change month and change code will document the change.

The change code and description:

NEWA	New drug product approval usually in the supplement month.
NFTG	New first time generic approval.
CAHN**	Applicant holder firm name has changed.
CAIN	Change. There has been a change in the Ingredient(s) name. All products will be deleted under the old name and all products will be added under the changed ingredient(s) name.
CDFR	Change. Dosage Form; Route of Administration.
CFTG	Change. A first time generic for the innovator product. A TE Code is added.
CMFD	Change. The product is moved from the Discontinued Section due to a change in marketing status.

CMS1	Change. Miscellaneous addition to list.
CMS2	Change. Miscellaneous deletion from list.
CPOT	Change. Potency amount/unit.
CRLD	Change. Reference Listed Drug.
CHRS	Change. Reference Standard.
CTEC	Change. Therapeutic Equivalence Code.
CTNA	Change. Trade Name.
DISC	Discontinued. The Rx or OTC listed product is not being marketed and will be moved to the discontinued section in the next edition.

****Note:**

The Cumulative Supplement (CS) currently displays a condensed 20 character collapsed applicant holder firm name and the Electronic Orange Book (EOB) query may display up to a 240 character full applicant holder firm name. An applicant holder firm name change usually changes both the collapsed name and long name. On occasion, only the long name is changed resulting in the CS displaying only the collapsed name for the >D> and >A> action. The new firm long name will display in the EOB query.

ABACAVIR SULFATE; LAMIVUDINE

TABLET; ORAL

ABACAVIR SULFATE AND LAMIVUDINE

@ ZYDUS PHARMS EQ 600MG BASE; 300MG

A208990 001 Nov 15, 2018 Mar DISC

ABIRATERONE ACETATE

TABLET; ORAL

ABIRATERONE ACETATE

AB MSN LABS PVT LTD 250MG
AB WOCKHARDT BIO AG 250MG

A210686 001 Jul 10, 2019 Jun NEWA
A208380 001 Feb 27, 2019 Feb NEWA

ACARBOSE

TABLET; ORAL

ACARBOSE

@ MYLAN 25MG
@ 50MG
@ 100MG

A091053 001 Jan 06, 2011 Jun DISC
A091053 002 Jan 06, 2011 Jun DISC
A091053 003 Jan 06, 2011 Jun DISC

ACEBUTOLOL HYDROCHLORIDE

CAPSULE; ORAL

ACEBUTOLOL HYDROCHLORIDE

>A @ ANI PHARMS INC EQ 200MG BASE
>A @ EQ 400MG BASE
>D @ WATSON LABS EQ 200MG BASE
>D @ EQ 400MG BASE

A074007 001 Oct 18, 1995 Jul CAHN
A074007 002 Oct 18, 1995 Jul CAHN
A074007 001 Oct 18, 1995 Jul CAHN
A074007 002 Oct 18, 1995 Jul CAHN

ACETAMINOPHEN; BENZHYDROCODONE HYDROCHLORIDE

TABLET; ORAL

APADAZ

+ KEMPHARM 325MG; EQ 4.08MG BASE
+ KVK TECH INC 325MG; EQ 4.08MG BASE
+ 325MG; EQ 6.12MG BASE

N208653 002 Jan 04, 2019 Jan NEWA
N208653 002 Jan 04, 2019 Feb CAHN
N208653 001 Feb 23, 2018 Feb CAHN

ACETAMINOPHEN; CODEINE PHOSPHATE

SOLUTION; ORAL

ACETAMINOPHEN AND CODEINE PHOSPHATE

@ LANNETT CO INC 120MG/5ML; 12MG/5ML

A091238 001 Nov 10, 2011 Jan DISC

TABLET; ORAL

ACETAMINOPHEN AND CODEINE PHOSPHATE

AA WES PHARMA INC 300MG; 15MG
AA 300MG; 30MG
AA 300MG; 60MG

A211610 001 Jun 27, 2019 Jun NEWA
A211610 002 Jun 27, 2019 Jun NEWA
A211610 003 Jun 27, 2019 Jun NEWA

ACETAMINOPHEN; HYDROCODONE BITARTRATE

SOLUTION; ORAL

HYDROCODONE BITARTRATE AND ACETAMINOPHEN

AA WES PHARMA INC 325MG/15ML; 7.5MG/15ML

A211023 001 Mar 08, 2019 Feb NEWA

TABLET; ORAL

HYDROCODONE BITARTRATE AND ACETAMINOPHEN

@ ALVOGEN PINE BROOK 300MG; 5MG
@ 300MG; 7.5MG
@ 300MG; 10MG
@ 325MG; 2.5MG
@ 325MG; 5MG
@ 325MG; 7.5MG
@ 325MG; 10MG
@ ELITE LABS INC 325MG; 2.5MG
@ 325MG; 5MG
@ 325MG; 7.5MG
@ 325MG; 10MG
@ UPSHER SMITH LABS 325MG; 5MG
@ 325MG; 7.5MG
@ 325MG; 10MG

A208540 001 Nov 08, 2018 Apr DISC
A208540 002 Nov 08, 2018 Apr DISC
A208540 003 Nov 08, 2018 Apr DISC
A209958 001 Oct 24, 2018 Apr DISC
A209958 002 Oct 24, 2018 Apr DISC
A209958 003 Oct 24, 2018 Apr DISC
A209958 004 Oct 24, 2018 Apr DISC
A209924 001 Nov 16, 2018 May DISC
A209924 002 Nov 16, 2018 May DISC
A209924 003 Nov 16, 2018 May DISC
A209924 004 Nov 16, 2018 May DISC
A206484 001 Mar 24, 2017 Jan DISC
A206484 002 Mar 24, 2017 Jan DISC
A206484 003 Mar 24, 2017 Jan DISC

ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE

SOLUTION;ORAL

OXYCODONE AND ACETAMINOPHEN

@ MIKART INC 300MG/5ML;10MG/5ML

A202142 001 Nov 27, 2018 May DISC

ACETAZOLAMIDE

CAPSULE, EXTENDED RELEASE;ORAL

ACETAZOLAMIDE

@ ACCORD HLTHCARE 500MG

A207659 001 Oct 18, 2018 Apr DISC

AB ALEMBIC PHARMS LTD 500MG

A210423 001 Feb 19, 2019 Feb NEWA

AB CADILA 500MG

A205301 001 Jan 16, 2019 Mar CAHN

>A> AB HERITAGE PHARMA 500MG

A040904 001 Dec 10, 2008 Jul CAHN

>D> AB HERITAGE PHARMS INC 500MG

A090779 001 Jul 14, 2011 Jul CHRS

>A> AB ! 500MG

A090779 001 Jul 14, 2011 Jul CHRS

>D> AB MYLAN 500MG

A203917 001 Jun 18, 2019 Jul DISC

>A> AB @ 500MG

A203917 001 Jun 18, 2019 Jul DISC

AB 500MG

A203917 001 Jun 18, 2019 Jun NEWA

>D> AB ZYDUS PHARMS USA INC 500MG

A040904 001 Dec 10, 2008 Jul CAHN

>D> DIAMOX

>D> AB +! TEVA BRANDED PHARM 500MG

N012945 001 Jul DISC

>A> + @ 500MG

N012945 001 Jul DISC

INJECTABLE;INJECTION

ACETAZOLAMIDE SODIUM

AP ZYDUS PHARMS EQ 500MG BASE/VIAL A206533 001 Apr 15, 2019 Apr NEWA

ACETAZOLAMIDE SODIUM

INJECTABLE;INJECTION

ACETAZOLAMIDE SODIUM

@ PAR STERILE PRODUCTS EQ 500MG BASE/VIAL

A205358 001 Jun 20, 2017 Apr DISC

AP ZYDUS PHARMS EQ 500MG BASE/VIAL

A206533 001 Apr 15, 2019 Jun CAHN

ACETIC ACID, GLACIAL

SOLUTION/DROPS;OTIC

ACETIC ACID

AT SAPTALIS PHARMS 2% A040607 001 Feb 24, 2005 May CAHN

ACETIC ACID, GLACIAL; HYDROCORTISONE

SOLUTION/DROPS;OTIC

ACETASOL HC

@ ACTAVIS MID ATLANTIC 2%;1%

A087143 001 Jan 13, 1982 Jun DISC

ACETYLCYSTEINE

INJECTABLE;INTRAVENOUS

ACETYLCYSTEINE

@ MYLAN INSTITUTIONAL 6GM/30ML (200MG/ML)

A203624 001 Jun 19, 2015 Mar DISC

TABLET, EFFERVESCENT;ORAL

CETYLEV

+ @ ARBOR PHARMS LLC 500MG

N207916 001 Jan 29, 2016 Mar DISC

+ @ 2.5GM

N207916 002 Jan 29, 2016 Mar DISC

ACITRETIN

CAPSULE;ORAL

SORIATANE

+ @ STIEFEL LABS INC 17.5MG

N019821 003 Aug 06, 2009 Jan DISC

+ @ 22.5MG

N019821 004 Aug 06, 2009 Jan DISC

ACLIDINIUM BROMIDE

POWDER, METERED;INHALATION

TUDORZA PRESSAIR

+! CIRCASSIA 0.4MG/INH

N202450 001 Jul 23, 2012 Jun CAHN

ACLIDINIUM BROMIDE; FORMOTEROL FUMARATE

POWDER, METERED;INHALATION

DUAKLIR PRESSAIR

ASTRAZENECA PHARMS 0.4MG/INH;0.012MG/INH

N210595 001 Mar 29, 2019 Mar NEWA

CIRCASSIA 0.4MG/INH;0.012MG/INH

N210595 001 Mar 29, 2019 Apr CAHN

ACYCLOVIR

	CAPSULE;ORAL ACYCLOVIR						
AB	KENTON CREAM;TOPICAL ACYCLOVIR	200MG		A075090	001	Jan 26, 1999	Mar CAHN
AB	PERRIGO UK FINCO ZOVIRAX	5%		A208702	001	Feb 04, 2019	Jan NFTG
AB	+! BAUSCH	5%		N021478	001	Dec 30, 2002	Feb CAHN
AB	+! VIB	5%		N021478	001	Dec 30, 2002	Jan CFTG
	OINTMENT;OPHTHALMIC AVACLYR						
	+! FERA PHARMS LLC OINTMENT;TOPICAL ACYCLOVIR	3%		N202408	001	Mar 29, 2019	Mar NEWA
AB	CIPLA	5%		A211794	001	Jan 18, 2019	Jan NEWA
AB	GLENMARK PHARMS SA	5%		A205510	001	Jul 31, 2017	Jun CAHN
AB	PERRIGO UK FINCO	5%		A205659	001	Feb 20, 2019	Feb NEWA
AB	ZYDUS PHARMS ZOVIRAX	5%		A205974	001	Mar 15, 2019	Mar NEWA
AB	+! BAUSCH	5%		N018604	001	Mar 29, 1982	Feb CAHN

ACYCLOVIR SODIUM

	INJECTABLE;INJECTION ACYCLOVIR SODIUM						
!	ZYDUS PHARMS	EQ 500MG BASE/VIAL		A206535	001	Aug 31, 2018	Jan CHRS
!		EQ 1GM BASE/VIAL		A206535	002	Aug 31, 2018	Jan CHRS

ACYCLOVIR; HYDROCORTISONE

	CREAM;TOPICAL XERESE						
+!	BAUSCH	5%;1%		N022436	001	Jul 31, 2009	Feb CAHN

ADAPALENE

	GEL;TOPICAL ADAPALENE						
>A> AB	P AND L	0.1%		A090962	001	Jun 02, 2010	Jul CAHN
>D> AB	PLIVA HRVATSKA DOO	0.1%		A090962	001	Jun 02, 2010	Jul CAHN

ADAPALENE; BENZOYL PEROXIDE

	GEL;TOPICAL ADAPALENE AND BENZOYL PEROXIDE						
AB	PERRIGO UK FINCO	0.1%;2.5%		A205033	001	Jan 23, 2018	May CAHN
@	TARO	0.3%;2.5%		A209148	001	Oct 17, 2018	May DISC

ADENOSINE

	INJECTABLE;INJECTION ADENOSINE						
@	LUITPOLD	3MG/ML		A090010	001	Apr 28, 2009	Mar DISC

ALBENDAZOLE

	TABLET;ORAL ALBENDAZOLE						
AB	ACTAVIS ELIZABETH	200MG		A208094	001	May 20, 2019	May NEWA
AB	EDENBRIDGE PHARMS	200MG		A211117	001	May 14, 2019	Apr NEWA

ALBUTEROL SULFATE

	POWDER, METERED;INHALATION PROAIR DIGITALER						
+	TEVA BRANDED PHARM PROAIR RESPICLICK	EQ 0.09MG BASE/INH		N205636	002	Dec 21, 2018	Jan NEWA
+	TEVA BRANDED PHARM	EQ 0.09MG BASE/INH		N205636	001	Mar 31, 2015	Jan CPOT
	TABLET;ORAL ALBUTEROL SULFATE						
AB	AIZANT	EQ 2MG BASE		A210948	001	Mar 15, 2019	Mar NEWA
AB		EQ 4MG BASE		A210948	002	Mar 15, 2019	Mar NEWA
AB	APPCO PHARMA LLC	EQ 2MG BASE		A207046	001	Jun 29, 2018	Feb CAHN
AB		EQ 4MG BASE		A207046	002	Jun 29, 2018	Feb CAHN

ALENDRONATE SODIUM

TABLET;ORAL

ALENDRONATE SODIUM

>D>	AB	MYLAN	EQ 5MG BASE	A076584	001	Aug 04, 2008	Jul DISC
>A>	@		EQ 5MG BASE	A076584	001	Aug 04, 2008	Jul DISC
>D>	AB		EQ 10MG BASE	A076584	002	Aug 04, 2008	Jul DISC
>A>	@		EQ 10MG BASE	A076584	002	Aug 04, 2008	Jul DISC

ALFUZOSIN HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

ALFUZOSIN HYDROCHLORIDE

AB		HERITAGE PHARMA	10MG	A079056	001	Jul 18, 2011	May CAHN
----	--	-----------------	------	---------	-----	--------------	----------

ALISKIREN HEMIFUMARATE

TABLET;ORAL

ALISKIREN HEMIFUMARATE

AB		ANCHEN PHARMS	EQ 150MG BASE	A206665	001	Mar 22, 2019	Mar NFTG
AB			EQ 300MG BASE	A206665	002	Mar 22, 2019	Mar NFTG
		TEKTURNIA					
AB	+	NODEN PHARMA	EQ 150MG BASE	N021985	001	Mar 05, 2007	Mar CFTG
AB	+	!	EQ 300MG BASE	N021985	002	Mar 05, 2007	Mar CFTG

ALITRETIINOIN

GEL;TOPICAL

PANRETIN

>A>	+	CONCORDIA	EQ 0.1% BASE	N020886	001	Feb 02, 1999	Jul CAHN
>D>	+	EISAI INC	EQ 0.1% BASE	N020886	001	Feb 02, 1999	Jul CAHN

ALLOPURINOL

TABLET;ORAL

ALLOPURINOL

AB		UNICHEM LABS LTD	100MG	A211820	001	Mar 12, 2019	Feb NEWA
AB			300MG	A211820	002	Mar 12, 2019	Feb NEWA

ALLOPURINOL; LESINURAD

TABLET;ORAL

DUZALLO

+ @	IRONWOOD PHARMS INC	200MG;200MG	N209203	001	Aug 18, 2017	Apr DISC
+ @		300MG;200MG	N209203	002	Aug 18, 2017	Apr DISC

ALPELISIB

TABLET;ORAL

PIQRAY

+	NOVARTIS PHARMS CORP	50MG	N212526	001	May 24, 2019	May NEWA
+		150MG	N212526	002	May 24, 2019	May NEWA
+	!	200MG	N212526	003	May 24, 2019	May NEWA

ALPHA-TOCOPHEROL ACETATE; ASCORBIC ACID; BIOTIN; CHOLECALCIFEROL; CYANOCOBALAMIN; DEXPANTHENOL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN 5'-PHOSPHATE SODIUM; THIAMINE HYDROCHLORIDE; VITAMIN A PALMITATE; VITAMIN K

SOLUTION;INTRAVENOUS

INFUVITE ADULT

>A>	+	SANDOZ CANADA INC	2 IU/ML;40MG/ML;12MCG/ML;40 IU/ML;1MCG/ML;3MG/ML;120MCG/ML;8MG /ML;1.2MG/ML;0.72MG/ML;1.2MG/ML;66 0 IU/ML;0.03MG/ML	N021163	001	May 18, 2000	Jul CAHN
-----	---	-------------------	--	---------	-----	--------------	----------

>A>	+		2 IU/ML;40MG/ML;12MCG/ML;40 IU/ML;1MCG/ML;3MG/ML;120MCG/ML;8MG /ML;1.2MG/ML;0.72MG/ML;1.2MG/ML;66 0 IU/ML;30MCG/ML	N021559	001	Jun 16, 2003	Jul CAHN
-----	---	--	---	---------	-----	--------------	----------

>D>	+	SANDOZ INC	2 IU/ML;40MG/ML;12MCG/ML;40 IU/ML;1MCG/ML;3MG/ML;120MCG/ML;8MG /ML;1.2MG/ML;0.72MG/ML;1.2MG/ML;66 0 IU/ML;0.03MG/ML	N021163	001	May 18, 2000	Jul CAHN
-----	---	------------	--	---------	-----	--------------	----------

>D>	+		2 IU/ML;40MG/ML;12MCG/ML;40 IU/ML;1MCG/ML;3MG/ML;120MCG/ML;8MG /ML;1.2MG/ML;0.72MG/ML;1.2MG/ML;66 0 IU/ML;30MCG/ML	N021559	001	Jun 16, 2003	Jul CAHN
-----	---	--	---	---------	-----	--------------	----------

ALTRETAMINE

CAPSULE;ORAL
HEXALEN
+ @ EISAI INC 50MG N019926 001 Dec 26, 1990 Feb DISC

AMANTADINE HYDROCHLORIDE

CAPSULE;ORAL
AMANTADINE HYDROCHLORIDE
>A> AB UPSHER SMITH LABS 100MG A070589 001 Aug 05, 1986 Jul CAHN
>D> AB USL PHARMA 100MG A070589 001 Aug 05, 1986 Jul CAHN
TABLET;ORAL
AMANTADINE HYDROCHLORIDE
>A> AB ! UPSHER SMITH LABS 100MG A076186 001 Dec 16, 2002 Jul CAHN
>D> AB ! USL PHARMA 100MG A076186 001 Dec 16, 2002 Jul CAHN

AMBRISENTAN

TABLET;ORAL
AMBRISENTAN
AB CIPLA 5MG A210715 001 Apr 26, 2019 Apr NEWA
AB 10MG A210715 002 Apr 26, 2019 Apr NEWA
AB MYLAN 5MG A208441 001 Mar 28, 2019 Mar NFTG
AB 10MG A208441 002 Mar 28, 2019 Mar NFTG
AB PAR PHARM INC 5MG A209509 001 Apr 10, 2019 Mar NEWA
AB 10MG A209509 002 Apr 10, 2019 Mar NEWA
AB SIGMAPHARM LABS LLC 5MG A208354 001 Apr 10, 2019 Mar NEWA
AB 10MG A208354 002 Apr 10, 2019 Mar NEWA
AB SUN PHARM 5MG A210784 001 Mar 28, 2019 Mar NFTG
AB 10MG A210784 002 Mar 28, 2019 Mar NFTG
AB WATSON LABS INC 5MG A208252 001 Mar 28, 2019 Mar NFTG
AB 10MG A208252 002 Mar 28, 2019 Mar NFTG
AB ZYDUS PHARMS 5MG A210058 001 Mar 28, 2019 Mar NFTG
AB 10MG A210058 002 Mar 28, 2019 Mar NFTG
LETAIRIS
AB + GILEAD 5MG N022081 001 Jun 15, 2007 Mar CFTG
AB +! 10MG N022081 002 Jun 15, 2007 Mar CFTG

AMIFAMPRIDINE

TABLET;ORAL
RUZURGI
+! JACOBUS PHARM CO INC 10MG N209321 001 May 06, 2019 May NEWA

AMILORIDE HYDROCHLORIDE

TABLET;ORAL
AMILORIDE HYDROCHLORIDE
AB WINDLAS HLTHCARE 5MG A204180 001 Aug 07, 2015 Feb CAHN

AMINO ACIDS

INJECTABLE;INJECTION
AMINOSYN 10%
>D> ICU MEDICAL INC 10% (10GM/100ML) N017673 003 Jul DISC
>A> @ 10% (10GM/100ML) N017673 003 Jul DISC
>D> AMINOSYN 8.5%
>D> ICU MEDICAL INC 8.5% (8.5GM/100ML) N017673 004 Jul DISC
>A> @ 8.5% (8.5GM/100ML) N017673 004 Jul DISC

AMINO ACIDS; MAGNESIUM ACETATE; PHOSPHORIC ACID; POTASSIUM ACETATE; SODIUM CHLORIDE

INJECTABLE;INJECTION
AMINOSYN 3.5% M
>D> ICU MEDICAL INC 3.5%;21MG/100ML;40MG/100ML;128MG/100ML;234MG/100ML N017789 003 Jul DISC
>A> @ 3.5%;21MG/100ML;40MG/100ML;128MG/100ML;234MG/100ML N017789 003 Jul DISC

AMINO ACIDS; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM PHOSPHATE, DIBASIC

INJECTABLE;INJECTION
AMINOSYN 8.5% W/ELECTROLYTES
>D> ICU MEDICAL INC 8.5%;102MG/100ML;487MG/100ML;28MG/100ML;425MG/100ML N017673 009 Oct 25, 2002 Jul DISC
>A> @ 8.5%;102MG/100ML;487MG/100ML;28MG/100ML;425MG/100ML N017673 009 Oct 25, 2002 Jul DISC

AMINOCAPROIC ACID

TABLET;ORAL

AMICAR

AB	+	CLOVER PHARMS	1GM	N015197	002	Jun 24, 2004	Feb CHRS
AB	!	SUNNY PHARMTECH INC	1GM	A209060	002	Nov 27, 2018	Feb CHRS

AMINOPHYLLINE

INJECTABLE;INJECTION

AMINOPHYLLINE

!	HOSPIRA	25MG/ML	A087242	001	Oct 26, 1983	Feb CTEC
@	LUITPOLD	25MG/ML	A087600	001		Feb DISC

AMIODARONE HYDROCHLORIDE

INJECTABLE;INJECTION

AMIODARONE HYDROCHLORIDE

@ DR REDDYS 50MG/ML

A076163 001 Sep 05, 2003 May CAHN

TABLET;ORAL

AMIODARONE HYDROCHLORIDE

>D> AB	APOTEX INC	200MG	A078578	001	Nov 06, 2008	Jul CAHN
>A> AB	RUBICON	200MG	A078578	001	Nov 06, 2008	Jul CAHN

>A> AMLODIPINE BENZOATE

>A> SOLUTION;ORAL

>A> KATERZIA

>A> +! SILVERGATE PHARMS EQ 1MG BASE/ML

N211340 001 Jul 08, 2019 Jul NEWA

AMLODIPINE BESYLATE

TABLET;ORAL

AMLODIPINE BESYLATE

AB	STRIDES PHARMA	EQ 2.5MG BASE	A077516	001	Jul 11, 2007	Apr CAHN
AB		EQ 5MG BASE	A077516	002	Jul 11, 2007	Apr CAHN
AB		EQ 10MG BASE	A077516	003	Jul 11, 2007	Apr CAHN

AMLODIPINE BESYLATE; ATORVASTATIN CALCIUM

TABLET;ORAL

AMLODIPINE BESYLATE AND ATORVASTATIN CALCIUM

@ ZYDUS PHARMS	EQ 2.5MG BASE;EQ 10MG BASE	A207762	001	Jan 11, 2019	Jun DISC
@	EQ 2.5MG BASE;EQ 20MG BASE	A207762	002	Jan 11, 2019	Jun DISC
@	EQ 2.5MG BASE;EQ 40MG BASE	A207762	003	Jan 11, 2019	Jun DISC
@	EQ 5MG BASE;EQ 10MG BASE	A207762	004	Jan 11, 2019	Jun DISC
@	EQ 5MG BASE;EQ 20MG BASE	A207762	005	Jan 11, 2019	Jun DISC
@	EQ 5MG BASE;EQ 40MG BASE	A207762	006	Jan 11, 2019	Jun DISC
@	EQ 5MG BASE;EQ 80MG BASE	A207762	007	Jan 11, 2019	Jun DISC
@	EQ 10MG BASE;EQ 10MG BASE	A207762	008	Jan 11, 2019	Jun DISC
@	EQ 10MG BASE;EQ 20MG BASE	A207762	009	Jan 11, 2019	Jun DISC
@	EQ 10MG BASE;EQ 40MG BASE	A207762	010	Jan 11, 2019	Jun DISC
@	EQ 10MG BASE;EQ 80MG BASE	A207762	011	Jan 11, 2019	Jun DISC

A207762	001	Jan 11, 2019	Jun DISC
A207762	002	Jan 11, 2019	Jun DISC
A207762	003	Jan 11, 2019	Jun DISC
A207762	004	Jan 11, 2019	Jun DISC
A207762	005	Jan 11, 2019	Jun DISC
A207762	006	Jan 11, 2019	Jun DISC
A207762	007	Jan 11, 2019	Jun DISC
A207762	008	Jan 11, 2019	Jun DISC
A207762	009	Jan 11, 2019	Jun DISC
A207762	010	Jan 11, 2019	Jun DISC
A207762	011	Jan 11, 2019	Jun DISC

AMLODIPINE BESYLATE; BENAZEPRIL HYDROCHLORIDE

CAPSULE;ORAL

AMLODIPINE BESYLATE AND BENAZEPRIL HYDROCHLORIDE

@ CIPLA	EQ 2.5MG BASE;10MG	A077215	001	Dec 07, 2018	May DISC
@	EQ 5MG BASE;10MG	A077215	002	Dec 07, 2018	May DISC
@	EQ 5MG BASE;20MG	A077215	003	Dec 07, 2018	May DISC
@	EQ 10MG BASE;20MG	A077215	004	Dec 07, 2018	May DISC
@ MYLAN	EQ 2.5MG BASE;10MG	A077375	001	May 21, 2010	Feb DISC
@	EQ 5MG BASE;10MG	A077375	002	May 21, 2010	Feb DISC
@	EQ 5MG BASE;20MG	A077375	003	May 21, 2010	Feb DISC
@	EQ 5MG BASE;40MG	A079047	001	Jul 05, 2011	Feb DISC
@	EQ 10MG BASE;20MG	A077375	004	May 21, 2010	Feb DISC
@	EQ 10MG BASE;40MG	A079047	002	Jul 05, 2011	Feb DISC
@ TEVA PHARMS	EQ 2.5MG BASE;10MG	A077179	001	May 18, 2007	Jun DISC
@	EQ 5MG BASE;10MG	A077179	002	May 18, 2007	Jun DISC
@	EQ 5MG BASE;20MG	A077179	003	May 18, 2007	Jun DISC
@	EQ 5MG BASE;40MG	A077179	005	Jul 05, 2011	Jun DISC
@	EQ 10MG BASE;20MG	A077179	004	May 18, 2007	Jun DISC
@	EQ 10MG BASE;40MG	A077179	006	Jul 05, 2011	Jun DISC

A077215	001	Dec 07, 2018	May DISC
A077215	002	Dec 07, 2018	May DISC
A077215	003	Dec 07, 2018	May DISC
A077215	004	Dec 07, 2018	May DISC
A077375	001	May 21, 2010	Feb DISC
A077375	002	May 21, 2010	Feb DISC
A077375	003	May 21, 2010	Feb DISC
A079047	001	Jul 05, 2011	Feb DISC
A077375	004	May 21, 2010	Feb DISC
A079047	002	Jul 05, 2011	Feb DISC
A077179	001	May 18, 2007	Jun DISC
A077179	002	May 18, 2007	Jun DISC
A077179	003	May 18, 2007	Jun DISC
A077179	005	Jul 05, 2011	Jun DISC
A077179	004	May 18, 2007	Jun DISC
A077179	006	Jul 05, 2011	Jun DISC

AMLODIPINE BESYLATE; CELECOXIB

TABLET;ORAL

CONSENSI

+ COEPTIS	EQ 2.5MG BASE;200MG	N210045	001	May 31, 2018	Mar CAHN
+	EQ 5MG BASE;200MG	N210045	002	May 31, 2018	Mar CAHN
+!	EQ 10MG BASE;200MG	N210045	003	May 31, 2018	Mar CAHN

AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE; OLMESARTAN MEDOXOMIL

TABLET;ORAL

OLMESARTAN MEDOXOMIL, AMLODIPINE AND HYDROCHLOROTHIAZIDE

>D> AB	TEVA PHARMS USA	EQ 5MG BASE;12.5MG;20MG	A202491	001	Nov 03, 2016	Jul DISC
>A>	@	EQ 5MG BASE;12.5MG;20MG	A202491	001	Nov 03, 2016	Jul DISC
>D> AB		EQ 5MG BASE;12.5MG;40MG	A202491	002	Nov 03, 2016	Jul DISC
>A>	@	EQ 5MG BASE;12.5MG;40MG	A202491	002	Nov 03, 2016	Jul DISC
>D> AB		EQ 5MG BASE;25MG;40MG	A202491	003	Nov 03, 2016	Jul DISC
>A>	@	EQ 5MG BASE;25MG;40MG	A202491	003	Nov 03, 2016	Jul DISC
>D> AB		EQ 10MG BASE;12.5MG;40MG	A202491	004	Nov 03, 2016	Jul DISC
>A>	@	EQ 10MG BASE;12.5MG;40MG	A202491	004	Nov 03, 2016	Jul DISC
>D> AB		EQ 10MG BASE;25MG;40MG	A202491	005	Nov 03, 2016	Jul DISC
>A>	@	EQ 10MG BASE;25MG;40MG	A202491	005	Nov 03, 2016	Jul DISC

AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE; VALSARTAN

TABLET;ORAL

AMLODIPINE BESYLATE, VALSARTAN AND HYDROCHLOROTHIAZIDE

>D> AB	TEVA PHARMS	5MG;12.5MG;160MG	A200435	001	Sep 25, 2012	Jul DISC
>A>	@	5MG;12.5MG;160MG	A200435	001	Sep 25, 2012	Jul DISC
>D> AB		5MG;25MG;160MG	A200435	002	Sep 25, 2012	Jul DISC
>A>	@	5MG;25MG;160MG	A200435	002	Sep 25, 2012	Jul DISC
>D> AB		10MG;12.5MG;160MG	A200435	005	Sep 25, 2012	Jul DISC
>A>	@	10MG;12.5MG;160MG	A200435	005	Sep 25, 2012	Jul DISC
>D> AB		10MG;25MG;160MG	A200435	003	Sep 25, 2012	Jul DISC
>A>	@	10MG;25MG;160MG	A200435	003	Sep 25, 2012	Jul DISC
>D> AB		10MG;25MG;320MG	A200435	004	Sep 25, 2012	Jul DISC
>A>	@	10MG;25MG;320MG	A200435	004	Sep 25, 2012	Jul DISC

AMLODIPINE BESYLATE; OLMESARTAN MEDOXOMIL

TABLET;ORAL

AMLODIPINE AND OLMESARTAN MEDOXOMIL

@ ACCORD HLTHCARE INC	EQ 5MG BASE;20MG	A209600	001	Aug 30, 2018	Mar DISC
@	EQ 5MG BASE;40MG	A209600	003	Aug 30, 2018	Mar DISC
@	EQ 10MG BASE;20MG	A209600	002	Aug 30, 2018	Mar DISC
@	EQ 10MG BASE;40MG	A209600	004	Aug 30, 2018	Mar DISC
@ TEVA PHARMS USA	EQ 5MG BASE;20MG	A091154	001	Oct 26, 2016	Jun DISC
@	EQ 5MG BASE;40MG	A091154	002	Oct 26, 2016	Jun DISC
@	EQ 10MG BASE;20MG	A091154	003	Oct 26, 2016	Jun DISC
@	EQ 10MG BASE;40MG	A091154	004	Oct 26, 2016	Jun DISC

AMLODIPINE BESYLATE; PERINDOPRIL ARGININE

TABLET;ORAL

PRESTALIA

+ ADHERA	EQ 2.5MG BASE;3.5MG	N205003	001	Jan 21, 2015	Apr CAHN
+	EQ 5MG BASE;7MG	N205003	002	Jan 21, 2015	Apr CAHN
+!	EQ 10MG BASE;14MG	N205003	003	Jan 21, 2015	Apr CAHN

AMLODIPINE BESYLATE; VALSARTAN

TABLET;ORAL

AMLODIPINE BESYLATE AND VALSARTAN

>D> AB	TEVA PHARMS USA	EQ 5MG BASE;160MG	A091235	001	Mar 30, 2015	Jul DISC
>A>	@	EQ 5MG BASE;160MG	A091235	001	Mar 30, 2015	Jul DISC
>D> AB		EQ 5MG BASE;320MG	A091235	003	Mar 30, 2015	Jul DISC
>A>	@	EQ 5MG BASE;320MG	A091235	003	Mar 30, 2015	Jul DISC
>D> AB		EQ 10MG BASE;160MG	A091235	002	Mar 30, 2015	Jul DISC
>A>	@	EQ 10MG BASE;160MG	A091235	002	Mar 30, 2015	Jul DISC
>D> AB		EQ 10MG BASE;320MG	A091235	004	Mar 30, 2015	Jul DISC
>A>	@	EQ 10MG BASE;320MG	A091235	004	Mar 30, 2015	Jul DISC

AMMONIA N-13

INJECTABLE; INTRAVENOUS
AMMONIA N 13

AP DECATUR 30mCi-300mCi/8ML (3.75-37.5mCi/ML) A204465 001 Oct 23, 2014 Apr CAHN

AMMONIUM LACTATE

CREAM; TOPICAL
AMMONIUM LACTATE

AB ! PERRIGO ISRAEL EQ 12% BASE A075774 001 May 01, 2002 May CAHN

LOTION; TOPICAL

AMMONIUM LACTATE

AB ! PERRIGO ISRAEL EQ 12% BASE A075570 001 Jun 23, 2004 May CAHN

AMOXICILLIN

FOR SUSPENSION; ORAL
AMOXICILLIN
@ TEVA

125MG/5ML

A061931 001

Jun DISC

AMOXICILLIN; CLAVULANATE POTASSIUM

FOR SUSPENSION; ORAL
AMOXICILLIN AND CLAVULANATE POTASSIUM

AB AUROBINDO PHARMA LTD 125MG/5ML; EQ 31.25MG BASE/5ML A209371 001 Apr 19, 2019 Apr NFTG

AB 250MG/5ML; EQ 62.5MG BASE/5ML A209371 002 Apr 19, 2019 Apr NEWA

AUGMENTIN '125'

AB + NEOPHARMA TABLET; ORAL 125MG/5ML; EQ 31.25MG BASE/5ML N050575 001 Aug 06, 1984 Apr CFTG

AUGMENTIN '875'

AB + NEOPHARMA 875MG; EQ 125MG BASE N050720 001 Feb 13, 1996 Feb CAHN

AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE

CAPSULE, EXTENDED RELEASE; ORAL

DEXTROAMP SACCHARATE, AMP ASPARTATE, DETROAMP SULFATE AND AMP SULFATE

AB PAR PHARM INC 1.25MG;1.25MG;1.25MG;1.25MG A206159 001 May 31, 2019 May NEWA

AB 2.5MG;2.5MG;2.5MG;2.5MG A206159 002 May 31, 2019 May NEWA

AB 3.75MG;3.75MG;3.75MG;3.75MG A206159 003 May 31, 2019 May NEWA

AB 5MG;5MG;5MG;5MG A206159 004 May 31, 2019 May NEWA

AB 6.25MG;6.25MG;6.25MG;6.25MG A206159 005 May 31, 2019 May NEWA

AB 7.5MG;7.5MG;7.5MG;7.5MG A206159 006 May 31, 2019 May NEWA

DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE

AB AMERIGEN PHARMS LTD 1.25MG;1.25MG;1.25MG;1.25MG A205401 001 Jan 22, 2019 Jan NEWA

AB 2.5MG;2.5MG;2.5MG;2.5MG A205401 002 Jan 22, 2019 Jan NEWA

AB 3.75MG;3.75MG;3.75MG;3.75MG A205401 003 Jan 22, 2019 Jan NEWA

AB 5MG;5MG;5MG;5MG A205401 004 Jan 22, 2019 Jan NEWA

AB 6.25MG;6.25MG;6.25MG;6.25MG A205401 005 Jan 22, 2019 Jan NEWA

AB 7.5MG;7.5MG;7.5MG;7.5MG A205401 006 Jan 22, 2019 Jan NEWA

>A> AB NESHER PHARMS 1.25MG;1.25MG;1.25MG;1.25MG A210080 001 Jul 17, 2019 Jul NEWA

>A> AB 2.5MG;2.5MG;2.5MG;2.5MG A210080 002 Jul 17, 2019 Jul NEWA

>A> AB 3.75MG;3.75MG;3.75MG;3.75MG A210080 003 Jul 17, 2019 Jul NEWA

>A> AB 5MG;5MG;5MG;5MG A210080 004 Jul 17, 2019 Jul NEWA

>A> AB 6.25MG;6.25MG;6.25MG;6.25MG A210080 005 Jul 17, 2019 Jul NEWA

>A> AB 7.5MG;7.5MG;7.5MG;7.5MG A210080 006 Jul 17, 2019 Jul NEWA

AB RHODES PHARMS 1.25MG;1.25MG;1.25MG;1.25MG A210651 001 May 17, 2019 May NEWA

AB 2.5MG;2.5MG;2.5MG;2.5MG A210651 002 May 17, 2019 May NEWA

AB 3.75MG;3.75MG;3.75MG;3.75MG A210651 003 May 17, 2019 May NEWA

AB 5MG;5MG;5MG;5MG A210651 004 May 17, 2019 May NEWA

AB 6.25MG;6.25MG;6.25MG;6.25MG A210651 005 May 17, 2019 May NEWA

AB 7.5MG;7.5MG;7.5MG;7.5MG A210651 006 May 17, 2019 May NEWA

AB SPECGX LLC 1.25MG;1.25MG;1.25MG;1.25MG A211547 001 Apr 22, 2019 Apr NEWA

AB 2.5MG;2.5MG;2.5MG;2.5MG A211547 002 Apr 22, 2019 Apr NEWA

AB 3.75MG;3.75MG;3.75MG;3.75MG A211547 003 Apr 22, 2019 Apr NEWA

AB 5MG;5MG;5MG;5MG A211547 004 Apr 22, 2019 Apr NEWA

AB 6.25MG;6.25MG;6.25MG;6.25MG A211547 005 Apr 22, 2019 Apr NEWA

AB 7.5MG;7.5MG;7.5MG;7.5MG A211547 006 Apr 22, 2019 Apr NEWA

AB SUN PHARM INDUSTRIES 1.25MG;1.25MG;1.25MG;1.25MG A211715 001 May 17, 2019 May NEWA

AB 2.5MG;2.5MG;2.5MG;2.5MG A211715 002 May 17, 2019 May NEWA

AB 3.75MG;3.75MG;3.75MG;3.75MG A211715 003 May 17, 2019 May NEWA

AB 5MG;5MG;5MG;5MG A211715 004 May 17, 2019 May NEWA

AB 6.25MG;6.25MG;6.25MG;6.25MG A211715 005 May 17, 2019 May NEWA

AB 7.5MG;7.5MG;7.5MG;7.5MG A211715 006 May 17, 2019 May NEWA

AMPHETAMINE SULFATE

TABLET; ORAL

AMPHETAMINE SULFATE

AA	AUROLIFE PHARMA LLC	5MG	A 211639	001	Apr 17, 2019	Apr NEWA
AA		10MG	A 211639	002	Apr 17, 2019	Apr NEWA
>A> AA	GRANULES PHARMS	5MG	A 212619	001	Aug 05, 2019	Jul NEWA
>A> AA		10MG	A 212619	002	Aug 05, 2019	Jul NEWA
	TABLET, ORALLY DISINTEGRATING; ORAL EVEKEO ODT					
+	ARBOR PHARMS LLC	5MG	N 209905	001	Jan 30, 2019	Jan NEWA
+		10MG	N 209905	002	Jan 30, 2019	Jan NEWA
+		15MG	N 209905	003	Jan 30, 2019	Jan NEWA
+		20MG	N 209905	004	Jan 30, 2019	Jan NEWA

AMPICILLIN/AMPICILLIN TRIHYDRATE

CAPSULE; ORAL

AMPICILLIN TRIHYDRATE

@ HERITAGE PHARMA	EQ 250MG BASE	A 061502	001		May CAHN
@	EQ 500MG BASE	A 061502	002		May CAHN

ANASTROZOLE

TABLET; ORAL

ANASTROZOLE

AB	FRESENIUS KABI USA	1MG	A 090088	001	Jun 28, 2010	Feb CAHN
AB	KENTON	1MG	A 078944	001	Jun 28, 2010	Mar CAHN

ARIPIPRAZOLE

SOLUTION; ORAL

ARIPIPRAZOLE

AA	AUROBINDO PHARMA LTD	1MG/ML	A 210479	001	Jan 29, 2019	Jan NEWA
	TABLET; ORAL					
	ARIPIPRAZOLE					
AB	ALKEM LABS LTD	2MG	A 207105	001	Feb 21, 2019	Feb NEWA
AB		5MG	A 207105	002	Feb 21, 2019	Feb NEWA
AB		10MG	A 207105	003	Feb 21, 2019	Feb NEWA
AB		15MG	A 207105	004	Feb 21, 2019	Feb NEWA
AB		20MG	A 207105	005	Feb 21, 2019	Feb NEWA
AB		30MG	A 207105	006	Feb 21, 2019	Feb NEWA
	@ TEVA PHARMS USA	2MG	A 078607	001	Apr 28, 2015	Jun DISC
	@	5MG	A 078607	002	Apr 28, 2015	Jun DISC
	@	10MG	A 078608	001	Apr 28, 2015	May DISC
	@	15MG	A 078708	001	Apr 28, 2015	May DISC
	@	20MG	A 078708	002	Apr 28, 2015	May DISC
	@	30MG	A 078708	003	Apr 28, 2015	May DISC
	@ ZYDUS PHARMS	2MG	A 090472	001	Jan 07, 2019	Jun DISC
	@	5MG	A 090472	002	Jan 07, 2019	Jun DISC
	@	10MG	A 090472	003	Jan 07, 2019	Jun DISC
	@	15MG	A 090472	004	Jan 07, 2019	Jun DISC
	@	20MG	A 090472	005	Jan 07, 2019	Jun DISC
	@	30MG	A 090472	006	Jan 07, 2019	Jun DISC

ARMODAFINIL

TABLET; ORAL

ARMODAFINIL

AB	APOTEX INC	50MG	A 201514	001	Mar 25, 2019	Mar NEWA
AB		150MG	A 201514	002	Mar 25, 2019	Mar NEWA
AB		250MG	A 201514	003	Mar 25, 2019	Mar NEWA
AB	AUROBINDO PHARMA LTD	200MG	A 206069	004	Dec 07, 2018	Mar NEWA
AB	MYLAN PHARMS INC	100MG	A 200043	004	May 09, 2019	Apr NEWA
AB		200MG	A 200043	005	May 09, 2019	Apr NEWA
AB	NATCO PHARMA LTD	100MG	A 202768	004	Sep 28, 2017	Apr CTEC

ARSENIC TRIOXIDE

INJECTABLE; INJECTION

ARSENIC TRIOXIDE

AP	STI PHARMA LLC	1MG/ML	A 209873	001	May 06, 2019	Apr NEWA
----	----------------	--------	----------	-----	--------------	----------

ASCORBIC ACID; BIOTIN; CHOLECALCIFEROL; CYANOCOBALAMIN; DEXPANTHENOL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE; RIBOFLAVIN; THIAMINE; TOCOPHEROL ACETATE; VITAMIN A; VITAMIN K

INJECTABLE; INTRAVENOUS
INFUVITE PEDIATRIC

>A>	+! Sandoz Canada Inc	80MG/VIAL;0.02MG/VIAL;400 IU/VIAL;0.001MG/VIAL;5MG/VIAL;0.14 MG/VIAL;17MG/VIAL;1MG/VIAL;1.4MG/V IAL;1.2MG/VIAL;7 IU/VIAL;2,300 IU/VIAL;0.2MG/VIAL	N 021265 001 Feb 21, 2001 Jul CAHN
>D>	+! Sandoz Inc	80MG/VIAL;0.02MG/VIAL;400 IU/VIAL;0.001MG/VIAL;5MG/VIAL;0.14 MG/VIAL;17MG/VIAL;1MG/VIAL;1.4MG/V IAL;1.2MG/VIAL;7 IU/VIAL;2,300 IU/VIAL;0.2MG/VIAL	N 021265 001 Feb 21, 2001 Jul CAHN

ASENAPINE MALEATE

TABLET; SUBLINGUAL
ASENAPINE MALEATE

@ SIGMAPHARM LABS LLC	EQ 5MG BASE	A 206107 001 Jul 17, 2018 Feb DISC
@	EQ 10MG BASE	A 206107 002 Jul 17, 2018 Feb DISC
SAPHRIS		
+ FOREST LABS LLC	EQ 5MG BASE	N 022117 001 Aug 13, 2009 Feb CTEC

+! EQ 10MG BASE N 022117 002 Aug 13, 2009 Feb CTEC

ASPIRIN; CAFFEINE; ORPHENADRINE CITRATE

TABLET; ORAL
ORPHENADRINE CITRATE, ASPIRIN, AND CAFFEINE

AB !	SANDOZ	770MG;60MG;50MG	A 074654 002 Dec 31, 1996 May CTEC
AB	ORPHENGESIC FORTE		

AB	GALT PHARMS	770MG;60MG;50MG	A 075141 002 May 29, 1998 May CMFD
----	-------------	-----------------	------------------------------------

ASPIRIN; DIPYRIDAMOLE

CAPSULE, EXTENDED RELEASE; ORAL
ASPIRIN AND DIPYRIDAMOLE

AB	GLENMARK PHARMS LTD	25MG;200MG	A 210318 001 May 24, 2019 May NEWA
AB	GLENMARK PHARMS SA	25MG;200MG	A 210318 001 May 24, 2019 Jun CAHN
AB	LANNETT CO INC	25MG;200MG	A 204552 001 Mar 20, 2019 Mar NEWA

ATENOLOL; CHLORTHALIDONE

TABLET; ORAL
ATENOLOL AND CHLORTHALIDONE

AB	ZYDUS PHARMS	50MG;25MG	A 210028 001 Mar 08, 2019 Feb NEWA
AB		100MG;25MG	A 210028 002 Mar 08, 2019 Feb NEWA

ATOMOXETINE HYDROCHLORIDE

CAPSULE; ORAL
ATOMOXETINE HYDROCHLORIDE

AB	ZYDUS PHARMS USA INC	18MG	A 079017 001 Sep 17, 2010 Mar CMFD
AB		25MG	A 079017 002 Sep 17, 2010 Mar CMFD
AB		40MG	A 079017 003 Sep 17, 2010 Mar CMFD
AB		60MG	A 079017 004 Sep 17, 2010 Mar CMFD
AB		80MG	A 079017 005 Sep 17, 2010 Mar CMFD
AB		100MG	A 079017 006 Sep 17, 2010 Mar CMFD

ATORVASTATIN CALCIUM

TABLET; ORAL
ATORVASTATIN CALCIUM

AB	LUPIN LTD	EQ 10MG BASE	A 204991 001 Mar 06, 2019 Feb NEWA
AB		EQ 20MG BASE	A 204991 002 Mar 06, 2019 Feb NEWA
AB		EQ 40MG BASE	A 204991 003 Mar 06, 2019 Feb NEWA
AB		EQ 80MG BASE	A 204991 004 Mar 06, 2019 Feb NEWA
AB	MSN LABS PVT LTD	EQ 10MG BASE	A 211933 001 Feb 08, 2019 Feb NEWA
AB		EQ 20MG BASE	A 211933 002 Feb 08, 2019 Feb NEWA
AB		EQ 40MG BASE	A 211933 003 Feb 08, 2019 Feb NEWA
AB		EQ 80MG BASE	A 211933 004 Feb 08, 2019 Feb NEWA

ATOVAQUONE

SUSPENSION; ORAL
ATOVAQUONE

AB	ABHAI LLC	750MG/5ML	A 210510 001 May 31, 2019 May NEWA
----	-----------	-----------	------------------------------------

ATRACURIUM BESYLATE

INJECTABLE; INJECTION
ATRACURIUM BESYLATE

AP	HONG KONG	10MG/ML	A091489	001	Feb 17, 2012	Feb CAHN
AP	ATRACURIUM BESYLATE PRESERVATIVE FREE					
AP	HONG KONG	10MG/ML	A091488	001	Feb 17, 2012	Feb CAHN

ATROPINE

SOLUTION; INTRAMUSCULAR
ATROOPEN

+!	MERIDIAN MEDCL TECHN	EQ 0.25MG SULFATE/0.3ML	N017106	004	Sep 17, 2004	Mar CPOT
+!		EQ 0.5MG SULFATE/0.7ML	N017106	003	Jun 19, 2003	Mar CPOT
+!		EQ 1MG SULFATE/0.7ML	N017106	002	Jun 19, 2003	Mar CPOT
+!		EQ 2MG SULFATE/0.7ML	N017106	001		Mar CPOT
ATROPINE						
@	ABBVIE	EQ 2MG SULFATE/0.7ML	A071295	001	Jan 30, 1987	Mar CDFR

ATROPINE SULFATE

SOLUTION; INTRAVENOUS, INTRAMUSCULAR, SUBCUTANEOUS, INTRAOSSEOUS, ENDOTRACHEAL
ATROPINE SULFATE

+!	FRESENIUS KABI USA	8MG/20ML (0.4MG/ML)	N209260	001	Jan 26, 2018	May CDFR
----	--------------------	---------------------	---------	-----	--------------	----------

AZACITIDINE

POWDER; INTRAVENOUS, SUBCUTANEOUS
AZACITIDINE

AP	LUPIN LTD	100MG/VIAL	A210748	001	Feb 27, 2019	Feb NEWA
----	-----------	------------	---------	-----	--------------	----------

AZELAIC ACID

CREAM; TOPICAL
AZELEX

+!	ALMIRALL	20%	N020428	001	Sep 13, 1995	Apr CAHN
----	----------	-----	---------	-----	--------------	----------

AZELASTINE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC
AZELASTINE HYDROCHLORIDE

AT	ALEMBIC PHARMS LTD	0.05%	A209620	001	Mar 20, 2019	Mar NEWA
AT	SOMERSET THERAPS LLC	0.05%	A207411	001	Mar 29, 2019	Mar NEWA
SPRAY, METERED; NASAL						
AZELASTINE HYDROCHLORIDE						
AB	HI TECH	EQ 0.125MG BASE/SPRAY	A207610	001	May 17, 2019	May NEWA

AZITHROMYCIN

TABLET; ORAL
AZITHROMYCIN

AB	BIONPHARMA INC	EQ 250MG BASE	A210000	001	Feb 26, 2019	Feb NEWA
AB		EQ 500MG BASE	A210001	001	Feb 26, 2019	Feb NEWA
AB	CSPC OUYI	EQ 250MG BASE	A208250	001	Apr 17, 2019	Apr NEWA
>D> AB	PLIVA	EQ 600MG BASE	A065218	001	Nov 14, 2005	Jul CHRS
>A> AB	!	EQ 600MG BASE	A065218	001	Nov 14, 2005	Jul CHRS
>D> AB	TEVA	EQ 250MG BASE	A065153	001	Nov 14, 2005	Jul DISC
>A>	@	EQ 250MG BASE	A065153	001	Nov 14, 2005	Jul DISC
>D> AB		EQ 600MG BASE	A065150	001	Nov 14, 2005	Jul DISC
>A>	@	EQ 600MG BASE	A065150	001	Nov 14, 2005	Jul DISC
ZITHROMAX						
>D> AB	+! PFIZER	EQ 600MG BASE	N050730	001	Jun 12, 1996	Jul DISC
>A>	+ @	EQ 600MG BASE	N050730	001	Jun 12, 1996	Jul DISC

AZTREONAM

INJECTABLE; INJECTION
AZACTAM IN PLASTIC CONTAINER

>D>	BRISTOL MYERS SQUIBB	20MG/ML	N050632	002	May 24, 1989	Jul DISC
>A>	+ @	20MG/ML	N050632	002	May 24, 1989	Jul DISC
>D>	+ !	40MG/ML	N050632	001	May 24, 1989	Jul DISC
>A>	+ @	40MG/ML	N050632	001	May 24, 1989	Jul DISC

BACLOFEN

INJECTABLE; INTRATHECAL

BACLOFEN

>A> AP	MAIA PHARMS INC	1MG/ML	A210315	001	Jul 30, 2019	Jul NEWA
	TABLET; ORAL					
	BACLOFEN					
AB	EYWA PHARMA	10MG	A211555	001	Feb 01, 2019	Jan NEWA
AB		20MG	A211555	002	Feb 01, 2019	Jan NEWA
>A> AB	UPSHER SMITH LABS	10MG	A074584	001	Aug 19, 1996	Jul CAHN
>A> AB		20MG	A074584	002	Aug 19, 1996	Jul CAHN
>D> AB	USL PHARMA	10MG	A074584	001	Aug 19, 1996	Jul CAHN
>D> AB		20MG	A074584	002	Aug 19, 1996	Jul CAHN

BALSALAZIDE DISODIUM

CAPSULE; ORAL

BALSALAZIDE DISODIUM

@ MYLAN

750MG

A077807 001 Dec 28, 2007 Feb DISC

TABLET; ORAL

BALSALAZIDE DISODIUM

@ PAR PHARM INC

1.1GM

A206336 001 Sep 08, 2015 Apr DISC

GIAZO

+ @ VALEANT PHARMS INTL

1.1GM

N022205 001 Feb 03, 2012 Apr DISC

BARIUM SULFATE

FOR SUSPENSION; ORAL

VARIBAR THIN LIQUID

+! BRACCO

81% (120GM/BOT)

N208036 004 Apr 30, 2019 May NEWA

BELINOSTAT

POWDER; INTRAVENOUS

BELEODAQ

+! ACROTECH

500MG/VIAL

N206256 001 Jul 03, 2014 Mar CAHN

BENAZEPRIL HYDROCHLORIDE

TABLET; ORAL

BENAZEPRIL HYDROCHLORIDE

@ HERITAGE PHARMA

5MG

A076267 001 Feb 11, 2004 Feb CAHN

@

10MG

A076267 002 Feb 11, 2004 Feb CAHN

@

20MG

A076267 003 Feb 11, 2004 Feb CAHN

@

40MG

A076267 004 Feb 11, 2004 Feb CAHN

BENAZEPRIL HYDROCHLORIDE; HYDROCHLORTHIAZIDE

TABLET; ORAL

BENAZEPRIL HYDROCHLORIDE AND HYDROCHLORTHIAZIDE

@ ANI PHARMS INC

5MG; 6.25MG

A076342 001 Feb 11, 2004 May CAHN

@

10MG; 12.5MG

A076342 002 Feb 11, 2004 May CAHN

@

20MG; 12.5MG

A076342 003 Feb 11, 2004 May CAHN

@

20MG; 25MG

A076342 004 Feb 11, 2004 May CAHN

BENDAMUSTINE HYDROCHLORIDE

POWDER; IV (INFUSION)

TREANDA

+! CEPHALON

25MG/VIAL

N022249 002 May 01, 2009 Feb CTEC

+!

100MG/VIAL

N022249 001 Mar 20, 2008 Feb CTEC

BENZONATATE

CAPSULE; ORAL

BENZONATATE

AA	ASCENT PHARMS INC	100MG	A211518	001	Feb 22, 2019	Feb NEWA
AA		150MG	A211518	002	Feb 22, 2019	Feb NEWA
AA		200MG	A211518	003	Feb 22, 2019	Feb NEWA
AA	CSPC OUYI	100MG	A202765	002	Aug 25, 2017	Feb CAHN
AA		200MG	A202765	001	Jul 31, 2015	Feb CAHN
AA	QINGDAO BAHEAL PHARM	100MG	A210562	001	Nov 09, 2018	May CAHN
AA		150MG	A210562	002	Nov 09, 2018	May CAHN
AA		200MG	A210562	003	Nov 09, 2018	May CAHN

BENZOYL PEROXIDE; CLINDAMYCIN PHOSPHATE

GEL;TOPICAL

CLINDAMYCIN PHOSPHATE AND BENZOYL PEROXIDE

AB	GLENMARK PHARMS	5%;EQ 1% BASE	A209252	001	Mar 14, 2019	Jun CMS1
AB		5%;1% BASE	A209252	001	Mar 14, 2019	Mar NEWA
AB	PERRIGO UK FINCO	5%;EQ 1% BASE	A202440	001	Sep 21, 2015	May CAHN
@ TARO		3.75%;EQ 1.2% BASE	A208683	001	Jun 05, 2018	May DISC
ONEXTON						
+! DOW PHARM		3.75%;EQ 1.2% BASE	N050819	002	Nov 24, 2014	May CTEC

BENZTROPINE MESYLATE

INJECTABLE; INJECTION

BENZTROPINE MESYLATE

@ LUITPOLD 1MG/ML

A091152 001 Mar 29, 2010 Feb DISC

TABLET;ORAL

BENZTROPINE MESYLATE

AA	! ASPEN GLOBAL INC	0.5MG	A204713	001	Apr 14, 2015	Apr CHRS
AA	!	1MG	A204713	002	Apr 14, 2015	Apr CHRS
AA	!	2MG	A204713	003	Apr 14, 2015	Apr CHRS
	@ OXFORD PHARMS	0.5MG	A040706	002	Feb 14, 2008	Mar DISC
	@	1MG	A040706	003	Feb 14, 2008	Mar DISC
>A>	@ UPSHER SMITH LABS	0.5MG	A040103	001	Dec 12, 1996	Jul CAHN
>A>	@	1MG	A040103	002	Dec 12, 1996	Jul CAHN
>A>	@	2MG	A040103	003	Dec 12, 1996	Jul CAHN
>D>	@ USL PHARMA	0.5MG	A040103	001	Dec 12, 1996	Jul CAHN
>D>	@	0.5MG	A040103	001	Dec 12, 1996	Apr DISC
>D>	@	1MG	A040103	002	Dec 12, 1996	Jul CAHN
>D>	@	1MG	A040103	002	Dec 12, 1996	Apr DISC
>D>	@	2MG	A040103	003	Dec 12, 1996	Jul CAHN
>D>	@	2MG	A040103	003	Dec 12, 1996	Apr DISC

BEPOTASTINE BESILATE

SOLUTION/DROPS;OPHTHALMIC

BEPOTASTINE BESILATE

AT	APOTEX INC	1.5%	A206066	001	Mar 05, 2019	Feb NFTG
AT	MICRO LABS	1.5%	A206220	001	Mar 18, 2019	Mar NEWA
AT	MYLAN	1.5%	A206220	001	Mar 18, 2019	Apr CAHN
	BEPREVE					
AT	+! BAUSCH AND LOMB INC	1.5%	N022288	001	Sep 08, 2009	Feb CFTG

BETAMETHASONE DIPROPIONATE

CREAM, AUGMENTED;TOPICAL

BETAMETHASONE DIPROPIONATE

AB	PERRIGO ISRAEL	EQ 0.05% BASE	A076592	001	Dec 09, 2003	May CAHN
	SPRAY;TOPICAL					
	SERNIVO					
+!	ENCORE DERMAT	EQ 0.05% BASE/SPRAY	N208079	001	Feb 05, 2016	Mar CAHN

BETAMETHASONE DIPROPIONATE; CALCIPOTRIENE

OINTMENT;TOPICAL

CALCIPOTRIENE AND BETAMETHASONE DIPROPIONATE

AB	PERRIGO ISRAEL	0.064%;0.005%	A200174	001	Dec 12, 2014	Mar CAIN
AB	PERRIGO UK FINCO	0.064%;0.005%	A200174	001	Dec 12, 2014	May CAHN
AB	TOLMAR	0.064%;0.005%	A201615	001	Jan 14, 2013	Mar CAIN
	TACLONEX					
AB	+! LEO PHARMA AS	0.064%;0.005%	N021852	001	Jan 09, 2006	Mar CAIN
	SUSPENSION;TOPICAL					
	TACLONEX					
+!	LEO PHARMA AS	0.064%;0.005%	N022185	001	May 09, 2008	Mar CAIN

BETHANECHOL CHLORIDE

TABLET;ORAL

DUVOID

AA	CHARTWELL RX	10MG	A086262	001		Mar CAHN
AA		25MG	A086263	001		Mar CAHN
AA		50MG	A085882	003		Mar CAHN

BEXAROTENE

GEL;TOPICAL

TARGRETIN

+! BAUSCH

1%

N021056 001 Jun 28, 2000 Jun CAHN

BICALUTAMIDE

TABLET;ORAL

BICALUTAMIDE

AB FRESENIUS KABI USA 50MG

AB KENTON 50MG

A079045 001 May 13, 2010 Feb CAHN

A091011 001 Jun 10, 2015 Jun CAHN

BIMATOPROST

SOLUTION/DROPS;OPHTHALMIC

BIMATOPROST

AT ALEMBIC PHARMS LTD 0.03%

A210263 001 Apr 12, 2019 Apr NEWA

AT GLAND PHARMA LTD 0.03%

A210126 001 Mar 22, 2019 Mar NEWA

>D> AT HI-TECH PHARMA CO 0.03%

A203299 001 Nov 08, 2018 Jul DISC

>A> @ 0.03%

A203299 001 Nov 08, 2018 Jul DISC

AT SOMERSET THERAPS LLC 0.03%

A207601 001 Jun 19, 2019 Jun NEWA

BISOPROLOL FUMARATE

TABLET;ORAL

BISOPROLOL FUMARATE

>D> @ FRONTIDA BIOPHARM 5MG

A075474 001 Oct 25, 2002 Jul CMFD

>A> AB @ 5MG

A075474 001 Oct 25, 2002 Jul CMFD

>D> @ 10MG

A075474 002 Oct 25, 2002 Jul CMFD

>A> AB @ 10MG

A075474 002 Oct 25, 2002 Jul CMFD

>D> AB ! MYLAN 10MG

A075831 002 Dec 14, 2005 Jul CHRS

>A> AB @ 10MG

A075831 002 Dec 14, 2005 Jul CHRS

>D> AB UNICHEM PHARMS (USA) 10MG

A078635 002 Aug 18, 2009 Jul CHRS

>A> AB ! 10MG

A078635 002 Aug 18, 2009 Jul CHRS

BISOPROLOL FUMARATE; HYDROCHLOROTHIAZIDE

TABLET;ORAL

BISOPROLOL FUMARATE AND HYDROCHLOROTHIAZIDE

>D> AB MYLAN 2.5MG;6.25MG

A075768 001 Sep 25, 2000 Jul DISC

>A> @ 2.5MG;6.25MG

A075768 001 Sep 25, 2000 Jul DISC

>D> AB @ 5MG;6.25MG

A075768 002 Sep 25, 2000 Jul DISC

>A> @ 5MG;6.25MG

A075768 002 Sep 25, 2000 Jul DISC

>D> AB @ 10MG;6.25MG

A075768 003 Sep 25, 2000 Jul DISC

>A> @ 10MG;6.25MG

A075768 003 Sep 25, 2000 Jul DISC

BIVALIRUDIN

SOLUTION;INTRAVENOUS

ANGIOMAX RTU

>A> +! MAIA PHARMS INC 250MG/50ML (5MG/ML)

N211215 001 Jul 25, 2019 Jul NEWA

BLEOMYCIN SULFATE

INJECTABLE;INJECTION

BLEOMYCIN SULFATE

AP CIPLA EQ 15 UNITS BASE/VIAL

A209439 001 Mar 11, 2019 Feb NEWA

BORTEZOMIB

POWDER;INTRAVENOUS, SUBCUTANEOUS

BORTEZOMIB

+ @ HOSPIRA INC 1MG/VIAL

N209191 002 Dec 28, 2018 Mar DISC

BOSENTAN

TABLET;ORAL

BOSENTAN

AB ALVOGEN PINE BROOK 62.5MG

A206002 001 Apr 26, 2019 Apr NFTG

AB 125MG

A206002 002 Apr 26, 2019 Apr NFTG

AB AMNEAL PHARMS CO 62.5MG

A209742 001 Apr 26, 2019 Apr NFTG

AB 125MG

A209742 002 Apr 26, 2019 Apr NFTG

AB NATCO PHARMA LTD 62.5MG

A206987 001 Apr 26, 2019 Apr NFTG

AB 125MG

A206987 002 Apr 26, 2019 Apr NFTG

AB PAR PHARM INC 62.5MG

A205699 001 Apr 26, 2019 Apr NFTG

AB 125MG

A205699 002 Apr 26, 2019 Apr NFTG

AB SUN PHARM 62.5MG

A209324 001 Apr 26, 2019 Apr NFTG

	TABLET;ORAL BOSENTAN						
AB		125MG		A209324	002	Apr 26, 2019	Apr NFTG
AB	WATSON LABS INC	62.5MG		A207110	001	Apr 26, 2019	Apr NFTG
AB		125MG		A207110	002	Apr 26, 2019	Apr NFTG
AB	WEST-WARD PHARMS INT	62.5MG		A208695	001	Apr 26, 2019	Apr NFTG
AB		125MG		A208695	002	Apr 26, 2019	Apr NFTG
AB	ZYDUS PHARMS	62.5MG		A207760	001	Apr 26, 2019	Apr NFTG
AB		125MG		A207760	002	Apr 26, 2019	Apr NFTG
	TRACLEER						
AB	+ ACTELION PHARMS LTD	62.5MG		N021290	001	Nov 20, 2001	Apr CFTG
AB	+!	125MG		N021290	002	Nov 20, 2001	Apr CFTG
	<u>BREMELANOTIDE ACETATE</u>						
	SOLUTION;SUBCUTANEOUS VYLEESI (AUTOINJECTOR)						
+!	AMAG PHARMS INC	EQ 1.75MG BASE/0.3ML (EQ 1.75MG BASE/0.3 ML)		N210557	001	Jun 21, 2019	Jun NEWA
	<u>BRETYLIUM TOSYLATE</u>						
	INJECTABLE;INJECTION BRETYLIUM TOSYLATE						
!	BAS ANDA	50MG/ML		A204386	001	Dec 21, 2018	Jun CAHN
	<u>BREXANOLONE</u>						
	SOLUTION;INTRAVENOUS ZULRESSO						
+!	SAGE THERAP	100MG/20ML (5MG/ML)		N211371	001	Jun 17, 2019	Jun NEWA
	<u>BRIMONIDINE TARTRATE</u>						
	SOLUTION/DROPS;OPHTHALMIC BRIMONIDINE TARTRATE						
AT	SOMERSET THERAPS LLC	0.2%		A208992	001	Mar 11, 2019	Feb NEWA
	<u>BROMFENAC SODIUM</u>						
	SOLUTION/DROPS;OPHTHALMIC BROMFENAC SODIUM						
AT2	ALEMBIC PHARMS LTD	EQ 0.09% ACID		A210560	001	Jun 21, 2019	Jun NEWA
AT2	! HI TECH	EQ 0.09% ACID		A203395	001	Jan 22, 2014	May CTEC
AT2	INNOPHARMA LICENSING	EQ 0.09% ACID		A203368	001	Jun 03, 2019	May NEWA
	<u>BUDESONIDE</u>						
	CAPSULE;ORAL BUDESONIDE						
AB	APPCO PHARMA LLC	3MG		A207367	001	Apr 07, 2017	Feb CAHN
	CAPSULE, EXTENDED RELEASE;ORAL ORTIKOS						
+	SUN PHARMA GLOBAL	6MG		N211929	001	Jun 13, 2019	Jun NEWA
+	!	9MG		N211929	002	Jun 13, 2019	Jun NEWA
	TABLET, EXTENDED RELEASE;ORAL UCERIS						
AB	+! SALIX	9MG		N203634	001	Jan 14, 2013	Mar CAHN
	<u>BUMETANIDE</u>						
	TABLET;ORAL BUMETANIDE						
AB	HERITAGE PHARMA	0.5MG		A074225	001	Apr 24, 1995	Feb CAHN
AB		1MG		A074225	002	Apr 24, 1995	Feb CAHN
AB		2MG		A074225	003	Apr 24, 1995	Feb CAHN
	<u>BUPIVACAINE HYDROCHLORIDE</u>						
	INJECTABLE;INJECTION BUPIVACAINE HYDROCHLORIDE						
AP	@ NOVOCOL HEALTHCARE	0.5%		A211096	001	Feb 19, 2019	Jun DISC
AP		0.5%		A211096	001	Feb 19, 2019	Feb NEWA
	INJECTABLE;SPINAL BUPIVACAINE HYDROCHLORIDE						
AP	B BRAUN MEDICAL INC	0.75%		A209087	001	Apr 02, 2019	Mar NEWA

BUPRENORPHINE HYDROCHLORIDE

TABLET; SUBLINGUAL

BUPRENORPHINE HYDROCHLORIDE

>D> AB	BARR	EQ 2MG BASE	A090360	001	May 07, 2010	Jul DISC
>A>	@	EQ 2MG BASE	A090360	001	May 07, 2010	Jul DISC
>D> AB		EQ 8MG BASE	A090360	002	May 07, 2010	Jul DISC
>A>	@	EQ 8MG BASE	A090360	002	May 07, 2010	Jul DISC

BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE

FILM; BUCCAL, SUBLINGUAL

BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE

AB	ALVOGEN PINE BROOK	EQ 2MG BASE; EQ 0.5MG BASE	A205954	001	Jan 24, 2019	Jan NEWA
AB		EQ 4MG BASE; EQ 1MG BASE	A205954	002	Jan 24, 2019	Jan NEWA
AB		EQ 8MG BASE; EQ 2MG BASE	A205954	003	Jan 24, 2019	Jan NEWA
AB		EQ 12MG BASE; EQ 3MG BASE	A205954	004	Jan 24, 2019	Jan NEWA

FILM; SUBLINGUAL

CASSIPA

+ @ TEVA PHARMS USA

EQ 16MG BASE; EQ 4MG BASE

N208042 001 Sep 07, 2018 Mar DISC

TABLET; SUBLINGUAL

BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE

@ TEVA PHARMS USA

EQ 2MG BASE; EQ 0.5MG BASE

A091149 001 Sep 08, 2014 Jan DISC

@

EQ 8MG BASE; EQ 2MG BASE

A091149 002 Sep 08, 2014 Jan DISC

BUPROPION HYDROCHLORIDE

TABLET; ORAL

BUPROPION HYDROCHLORIDE

AB	APNAR PHARMA LP	75MG	A075584	001	Feb 07, 2000	Jun CAHN
AB		100MG	A075584	002	Feb 07, 2000	Jun CAHN
	@ HERITAGE PHARMA	75MG	A075310	001	Nov 29, 1999	May CAHN
	@	100MG	A075310	002	Nov 29, 1999	May CAHN

TABLET, EXTENDED RELEASE; ORAL

BUPROPION HYDROCHLORIDE

>D> AB2	ACTAVIS LABS FL INC	150MG	A079094	001	Mar 24, 2009	Jul CHRS
>A> AB2	!	150MG	A079094	001	Mar 24, 2009	Jul CHRS
AB3	GRAVITI PHARMS	150MG	A211020	001	Jan 28, 2019	Jan NEWA
AB3		300MG	A211020	002	Jan 28, 2019	Jan NEWA
>D> AB3	MYLAN	150MG	A090942	001	Jul 14, 2010	Jul DISC
>A>	@	150MG	A090942	001	Jul 14, 2010	Jul DISC
	@ YICHANG HUMANWELL	100MG	A211347	001	Oct 16, 2018	Apr DISC
	@	150MG	A211347	002	Oct 16, 2018	Apr DISC
	@	200MG	A211347	003	Oct 16, 2018	Apr DISC
	ZYBAN					
>D> AB2	+! GLAXOSMITHKLINE	150MG	N020711	003	May 14, 1997	Jul DISC
>A>	+ @	150MG	N020711	003	May 14, 1997	Jul DISC

BUSPIRONE HYDROCHLORIDE

TABLET; ORAL

BUSPIRONE HYDROCHLORIDE

AB	EPIC PHARMA LLC	5MG	A208972	001	Apr 16, 2019	Apr NEWA
AB		7.5MG	A208972	002	Apr 16, 2019	Apr NEWA
AB		10MG	A208972	003	Apr 16, 2019	Apr NEWA
AB		15MG	A208972	004	Apr 16, 2019	Apr NEWA
AB		30MG	A208972	005	Apr 16, 2019	Apr NEWA

BUSULFAN

INJECTABLE; INJECTION

BUSULFAN

AP	ACCORD HLTHCARE INC	6MG/ML	A210148	001	Feb 22, 2019	Feb NEWA
AP	APOTEX INC	6MG/ML	A210448	001	May 07, 2019	Apr NEWA
AP	ATHENEX INC	6MG/ML	A205106	001	Sep 21, 2018	Jan CAHN
AP	@ HOSPIRA INC	6MG/ML	A205672	001	Jul 31, 2018	Feb DISC
AP	SHILPA MEDICARE LTD	6MG/ML	A210931	001	Apr 18, 2019	Apr NEWA
	MYLERAN					
>D> AP	ASPEN GLOBAL INC	6MG/ML	A208536	001	Nov 20, 2017	Jul CAHN
>A> AP	MYLAN INSTITUTIONAL	6MG/ML	A208536	001	Nov 20, 2017	Jul CAHN

CAFFEINE CITRATE

SOLUTION;ORAL

CAFFEINE CITRATE

@ LUITPOLD

EQ 30MG BASE/3ML (EQ 10MG BASE/ML) A090064 001 Nov 20, 2009 Mar DISC

CAFFEINE; ERGOTAMINE TARTRATE

SUPPOSITORY;RECTAL

MIGERGOT

>A>	!	COSETTE	100MG;2MG	A086557	001	Oct 04, 1983	Jul CAHN
>D>	!	HZNP	100MG;2MG	A086557	001	Oct 04, 1983	Jul CAHN

CALCITRIOL

CAPSULE;ORAL

CALCITRIOL

>D> AB	SUN PHARM	0.25MCG	A204556	001	Feb 21, 2019	Jul DISC
>A>	@	0.25MCG	A204556	001	Feb 21, 2019	Jul DISC
AB		0.25MCG	A204556	001	Feb 21, 2019	Feb NEWA
>D> AB		0.5MCG	A204556	002	Feb 21, 2019	Jul DISC
>A>	@	0.5MCG	A204556	002	Feb 21, 2019	Jul DISC
AB		0.5MCG	A204556	002	Feb 21, 2019	Feb NEWA

CALCIUM ACETATE

TABLET;ORAL

CALCIUM ACETATE

AB	CHARTWELL MOLECULAR	667MG	A202420	001	Feb 05, 2013	Jan CAHN
----	---------------------	-------	---------	-----	--------------	----------

CALCIUM CHLORIDE

INJECTABLE;INJECTION

CALCIUM CHLORIDE 10%

AP	MEDEFIL INC	100MG/ML	A211553	001	May 01, 2019	Apr NEWA
----	-------------	----------	---------	-----	--------------	----------

CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE

SOLUTION;INTRAPERITONEAL

DIANEAL LOW CALCIUM W/ DEXTROSE 1.5% IN PLASTIC CONTAINER

AT	+	BAXTER HLTHCARE	18.3MG/100ML;1.5GM/100ML;5.08MG/10 OML;538MG/100ML;448MG/100ML	N020183	001	Dec 04, 1992	Jun CRLD
	+	BAXTER HLTHCARE	18.3MG/100ML;2.5GM/100ML;5.08MG/10 OML;538MG/100ML;448MG/100ML	N020183	002	Dec 04, 1992	Jun CRLD
	+	BAXTER HLTHCARE	18.3MG/100ML;3.5GM/100ML;5.08MG/10 OML;538MG/100ML;448MG/100ML	N020183	003	Dec 04, 1992	Jun CRLD
	+	BAXTER HLTHCARE	18.3MG/100ML;4.25GM/100ML;5.08MG/10 OML;538MG/100ML;448MG/100ML	N020183	004	Dec 04, 1992	Jun CRLD
	+	BAXTER HLTHCARE	18.3MG/100ML;1.5GM/100ML;5.08MG/10 OML;538MG/100ML;448MG/100ML	N017512	004		Jun CRLD
AT	+	BAXTER HLTHCARE	25.7MG/100ML;1.5GM/100ML;5.08MG/10 OML;538MG/100ML;448MG/100ML	N020163	001	Dec 04, 1992	Jun CRLD
	+	BAXTER HLTHCARE	25.7MG/100ML;2.5GM/100ML;5.08MG/10 OML;538MG/100ML;448MG/100ML	N020163	002	Dec 04, 1992	Jun CRLD
	+	BAXTER HLTHCARE	25.7MG/100ML;3.5GM/100ML;5.08MG/10 OML;538MG/100ML;448MG/100ML	N017512	011	Nov 18, 1985	Jun CRLD
	+	BAXTER HLTHCARE	25.7MG/100ML;4.25GM/100ML;5.08MG/10 OML;538MG/100ML;448MG/100ML	N017512	006		Jun CRLD
AT	+	BAXTER HLTHCARE	25.7MG/100ML;1.5GM/100ML;5.08MG/10 OML;538MG/100ML;448MG/100ML	N020163	003	Dec 04, 1992	Jun CRLD

CALCIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE

INJECTABLE;INJECTION

LACTATED RINGER'S IN PLASTIC CONTAINER

AP	FRESENIUS KABI USA	20MG/100ML;30MG/100ML;600MG/100ML; 310MG/100ML	A209338	001	Jan 28, 2019	Jan NEWA
----	--------------------	--	---------	-----	--------------	----------

CAPECITABINE

	TABLET;ORAL	CAPECITABINE					
AB	SUN PHARM	150MG	A204668	001	Jun 21, 2019	Jun NEWA	
AB		500MG	A204668	002	Jun 21, 2019	Jun NEWA	

CAPTOPRIL

	TABLET;ORAL	CAPTOPRIL					
AB	BOSCOGEN	12.5MG	A074677	004	May 30, 1997	Jun CMFD	
AB		25MG	A074677	002	May 30, 1997	Jun CMFD	
AB		50MG	A074677	001	May 30, 1997	Jun CMFD	
AB		100MG	A074677	003	May 30, 1997	Jun CMFD	

CARBAMAZEPINE

	CAPSULE, EXTENDED RELEASE;ORAL	CARBAMAZEPINE					
>D>	AB	MYLAN IRELAND LTD	100MG	A076697	001	May 20, 2011	Jul DISC
>A>	@		100MG	A076697	001	May 20, 2011	Jul DISC
>D>	AB		200MG	A076697	002	May 20, 2011	Jul DISC
>A>	@		200MG	A076697	002	May 20, 2011	Jul DISC
>D>	AB		300MG	A076697	003	May 20, 2011	Jul DISC
>A>	@		300MG	A076697	003	May 20, 2011	Jul DISC
		CARBATROL					
AB	+	SHIRE DEV LLC	100MG	N020712	003	Sep 30, 1997	Jan CAHN
AB	+		200MG	N020712	001	Sep 30, 1997	Jan CAHN
AB	+!		300MG	N020712	002	Sep 30, 1997	Jan CAHN
		TABLET, EXTENDED RELEASE;ORAL					
		CARBAMAZEPINE					
AB	ZYDUS PHARMS	100MG	A205571	001	Feb 07, 2019	Jan NEWA	
AB		200MG	A205571	002	Feb 07, 2019	Jan NEWA	
AB		400MG	A205571	003	Feb 07, 2019	Jan NEWA	

CARBIDOPA; LEVODOPA

	TABLET, EXTENDED RELEASE;ORAL	CARBIDOPA AND LEVODOPA					
AB	ALEMBIC PHARMS LTD	25MG;100MG	A210341	001	Jun 05, 2019	May NEWA	
AB		50MG;200MG	A210341	002	Jun 05, 2019	May NEWA	

CARBINOXAMINE MALEATE

	SOLUTION;ORAL	CARBINOXAMINE MALEATE					
!	MIKART	4MG/5ML	A040458	001	Apr 25, 2003	Jun CTEC	
@	VINTAGE PHARMS	4MG/5ML	A040814	001	Feb 26, 2008	Jun DISC	
		TABLET;ORAL					
		CARBINOXAMINE MALEATE					
!	MIKART	6MG	A207484	001	May 31, 2016	Mar CHRS	

CARBOPLATIN

	INJECTABLE; INTRAVENOUS	CARBOPLATIN					
AP	ACCORD HLTHCARE	50MG/5ML (10MG/ML)	A206775	001	Feb 09, 2017	May CDFR	
AP		150MG/15ML (10MG/ML)	A206775	002	Feb 09, 2017	May CDFR	
AP		450MG/45ML (10MG/ML)	A206775	003	Feb 09, 2017	May CDFR	
AP		600MG/60ML (10MG/ML)	A206775	004	Feb 09, 2017	May CDFR	
	@ ACTAVIS TOTOWA	50MG/5ML (10MG/ML)	A078732	001	Feb 06, 2012	Mar CDFR	
	@	150MG/15ML (10MG/ML)	A078732	002	Feb 06, 2012	Mar CDFR	
	@	450MG/45ML (10MG/ML)	A078732	003	Feb 06, 2012	Mar CDFR	
	@	600MG/60ML (10MG/ML)	A078732	004	Feb 06, 2012	Mar CDFR	
AP	AKORN	50MG/5ML (10MG/ML)	A090475	001	Jul 29, 2009	May CDFR	
AP		150MG/15ML (10MG/ML)	A090475	002	Jul 29, 2009	May CDFR	
AP		450MG/45ML (10MG/ML)	A090475	003	Jul 29, 2009	May CDFR	
AP		600MG/60ML (10MG/ML)	A091268	002	Jul 28, 2010	May CDFR	
AP	CIPLA LTD	50MG/5ML (10MG/ML)	A077861	001	Jan 18, 2007	May CDFR	
AP		150MG/15ML (10MG/ML)	A077861	002	Jan 18, 2007	May CDFR	
AP		450MG/45ML (10MG/ML)	A077861	003	Jan 18, 2007	May CDFR	
AP		600MG/60ML (10MG/ML)	A077861	004	Jan 18, 2007	May CDFR	
AP	EUGIA PHARMA	50MG/5ML (10MG/ML)	A205487	001	Mar 28, 2016	May CDFR	
AP		150MG/15ML (10MG/ML)	A205487	002	Mar 28, 2016	May CDFR	
AP		450MG/45ML (10MG/ML)	A205487	003	Mar 28, 2016	May CDFR	
AP	FRESENIUS KABI USA	50MG/5ML (10MG/ML)	A077432	001	Sep 29, 2006	May CDFR	

INJECTABLE; INTRAVENOUS
CARBOPLATIN

AP		150MG/15ML (10MG/ML)	A077432	002	Sep 29, 2006	May CDFR
AP		450MG/45ML (10MG/ML)	A077432	003	Sep 29, 2006	May CDFR
	@	50MG/5ML (10MG/ML)	A077247	001	Oct 21, 2004	Mar CDFR
	@	50MG/5ML (10MG/ML)	A077266	001	Feb 15, 2006	Mar CDFR
	@	150MG/15ML (10MG/ML)	A077247	002	Oct 21, 2004	Mar CDFR
	@	150MG/15ML (10MG/ML)	A077266	002	Feb 15, 2006	Mar CDFR
AP		450MG/45ML (10MG/ML)	A077247	003	Oct 21, 2004	Mar CDFR
AP		450MG/45ML (10MG/ML)	A077266	003	Feb 15, 2006	May CDFR
AP		600MG/60ML (10MG/ML)	A077266	004	Feb 15, 2006	May CDFR
AP	GLAND PHARMA LTD	150MG/15ML (10MG/ML)	A207324	002	Feb 15, 2017	May CDFR
AP		450MG/45ML (10MG/ML)	A207324	003	Feb 15, 2017	May CDFR
AP		600MG/60ML (10MG/ML)	A207324	004	Feb 15, 2017	May CDFR
AP	HONG KONG	50MG/5ML (10MG/ML)	A077096	001	Jun 14, 2005	May CDFR
AP		150MG/15ML (10MG/ML)	A077096	002	Jun 14, 2005	May CDFR
AP		450MG/45ML (10MG/ML)	A077096	003	Jun 14, 2005	May CDFR
AP		600MG/60ML (10MG/ML)	A077096	004	Jun 03, 2013	May CDFR
AP	HOSPIRA	50MG/5ML (10MG/ML)	A076517	001	Oct 14, 2004	May CDFR
AP		150MG/15ML (10MG/ML)	A076517	002	Oct 14, 2004	May CDFR
AP		450MG/45ML (10MG/ML)	A076517	003	Oct 14, 2004	May CDFR
AP		600MG/60ML (10MG/ML)	A077059	001	Nov 23, 2004	May CDFR
AP	INGENUS PHARMS LLC	50MG/5ML (10MG/ML)	A208487	001	Apr 26, 2017	May CDFR
AP		150MG/15ML (10MG/ML)	A208487	002	Apr 26, 2017	May CDFR
AP		450MG/45ML (10MG/ML)	A208487	003	Apr 26, 2017	May CDFR
AP		600MG/60ML (10MG/ML)	A208487	004	Apr 26, 2017	May CDFR
	@ MYLAN INSTITUTIONAL	50MG/5ML (10MG/ML)	A077998	001	Apr 24, 2007	Apr CDFR
	@	150MG/15ML (10MG/ML)	A077998	002	Apr 24, 2007	Apr CDFR
	@	450MG/45ML (10MG/ML)	A077998	003	Apr 24, 2007	Apr CDFR
AP	MYLAN LABS LTD	50MG/5ML (10MG/ML)	A091063	001	Nov 09, 2011	May CDFR
AP		150MG/15ML (10MG/ML)	A091063	002	Nov 09, 2011	May CDFR
AP		450MG/45ML (10MG/ML)	A091063	003	Nov 09, 2011	May CDFR
AP		600MG/60ML (10MG/ML)	A091063	004	Nov 09, 2011	May CDFR
	@	1GM/100ML (10MG/ML)	A091478	001	Nov 23, 2011	Mar CDFR
AP	! PHARMACHEMIE BV	50MG/5ML (10MG/ML)	A077269	001	Oct 14, 2004	May CDFR
	@	50MG/5ML (10MG/ML)	A077679	001	Feb 25, 2009	Mar CDFR
AP	!	150MG/15ML (10MG/ML)	A077269	002	Oct 14, 2004	May CDFR
	@	150MG/15ML (10MG/ML)	A077679	002	Feb 25, 2009	Mar CDFR
AP	!	450MG/45ML (10MG/ML)	A077269	003	Oct 14, 2004	May CDFR
	@	450MG/45ML (10MG/ML)	A077679	003	Feb 25, 2009	Mar CDFR
AP	!	600MG/60ML (10MG/ML)	A077269	004	Dec 28, 2007	May CDFR
AP	PLIVA LACHEMA	50MG/5ML (10MG/ML)	A078631	001	Dec 02, 2008	May CDFR
AP		150MG/15ML (10MG/ML)	A078631	002	Dec 02, 2008	May CDFR
AP		450MG/45ML (10MG/ML)	A078631	003	Dec 02, 2008	May CDFR
AP		600MG/60ML (10MG/ML)	A078631	004	Dec 02, 2008	May CDFR
AP	SANDOZ INC	50MG/5ML (10MG/ML)	A078280	001	May 08, 2008	May CDFR
AP		150MG/15ML (10MG/ML)	A078280	002	May 08, 2008	May CDFR
AP		450MG/45ML (10MG/ML)	A078280	003	May 08, 2008	May CDFR
AP	SUN PHARM	50MG/5ML (10MG/ML)	A077926	001	Sep 19, 2008	May CDFR
AP		150MG/15ML (10MG/ML)	A077926	002	Sep 19, 2008	May CDFR
AP		450MG/45ML (10MG/ML)	A077926	003	Sep 19, 2008	May CDFR
	@ TEVA PARENTERAL	50MG/5ML (10MG/ML)	A077389	001	Mar 30, 2007	Mar CDFR
	@	150MG/15ML (10MG/ML)	A077389	002	Mar 30, 2007	Mar CDFR
	@	450MG/45ML (10MG/ML)	A077389	003	Mar 30, 2007	Mar CDFR
AP	! TEVA PHARMS USA	50MG/5ML (10MG/ML)	A077139	001	Sep 21, 2005	May CDFR
AP	!	150MG/15ML (10MG/ML)	A077139	002	Sep 21, 2005	May CDFR
AP	!	450MG/45ML (10MG/ML)	A077139	003	Sep 21, 2005	May CDFR
AP	!	600MG/60ML (10MG/ML)	A077139	004	Sep 21, 2005	May CDFR
AP	WEST-WARD PHARMS INT	50MG/5ML (10MG/ML)	A077244	001	Oct 15, 2004	May CDFR
AP		150MG/15ML (10MG/ML)	A077244	002	Oct 15, 2004	May CDFR
AP		450MG/45ML (10MG/ML)	A077244	003	Oct 15, 2004	May CDFR
AP		600MG/60ML (10MG/ML)	A077244	004	Jan 20, 2006	May CDFR
	PARAPLATIN					
+ @ CORDENPHARMA		50MG/5ML (10MG/ML)	N020452	001	Jul 14, 2003	Mar CDFR
+ @		150MG/15ML (10MG/ML)	N020452	002	Jul 14, 2003	Mar CDFR
+ @		450MG/45ML (10MG/ML)	N020452	003	Jul 14, 2003	Mar CDFR
+ @		600MG/60ML (10MG/ML)	N020452	004	Jan 15, 2004	Mar CDFR
	INJECTABLE; IV (INFUSION)					
	CARBOPLATIN					
AP	GLAND PHARMA LTD	50MG/5ML (10MG/ML)	A207324	001	Feb 15, 2017	May CDFR
AP	HONG KONG	50MG/5ML (10MG/ML)	A077096	001	Jun 14, 2005	Feb CAHN
AP		150MG/15ML (10MG/ML)	A077096	002	Jun 14, 2005	Feb CAHN
AP		450MG/45ML (10MG/ML)	A077096	003	Jun 14, 2005	Feb CAHN
AP		600MG/60ML (10MG/ML)	A077096	004	Jun 03, 2013	Feb CAHN

INJECTABLE;IV (INFUSION)

CARBOPLATIN

@	MYLAN INSTITUTIONAL	50MG/5ML (10MG/ML)	A077998	001	Apr 24, 2007	Mar DISC
@		150MG/15ML (10MG/ML)	A077998	002	Apr 24, 2007	Mar DISC
@		450MG/45ML (10MG/ML)	A077998	003	Apr 24, 2007	Mar DISC

CARBOPROST TROMETHAMINE

INJECTABLE;INJECTION

CARBOPROST TROMETHAMINE

AP	DR REDDYS LABS LTD	EQ 0.25MG BASE/ML	A211941	001	Jul 02, 2019	Jun NFTG
AP	+! PHARMACIA AND UPJOHN	EQ 0.25MG BASE/ML	N017989	001		Jun CFTG

CARGLUMIC ACID

TABLET;ORAL

CARBAGLU

+! RECORDATI RARE

200MG

N022562 001 Mar 18, 2010 May CAHN

CARMUSTINE

INJECTABLE;INJECTION

CARMUSTINE

AP	STI PHARMA LLC	100MG/VIAL	A209278	001	Apr 02, 2019	Mar NEWA
----	----------------	------------	---------	-----	--------------	----------

CARTEOLOL HYDROCHLORIDESOLUTION/DROPS;OPHTHALMIC
CARTEOLOL HYDROCHLORIDE

@ BAUSCH AND LOMB	1%	A075546	001	Jan 20, 2000	May DISC
! SANDOZ INC	1%	A075476	001	Jan 03, 2000	May CTEC

CASPOFUNGIN ACETATEPOWDER;INTRAVENOUS
CASPOFUNGIN ACETATE

@ CIPLA	50MG/VIAL	A209489	001	Jul 12, 2018	Jan DISC
@	70MG/VIAL	A209489	002	Jul 12, 2018	Jan DISC

CEFIXIME

FOR SUSPENSION;ORAL

CEFIXIME

@ SANDOZ INC	100MG/5ML	A206144	001	Nov 17, 2017	Feb DISC
@	200MG/5ML	A206144	002	Nov 17, 2017	Feb DISC

AB	SUPRAX ! LUPIN PHARMS	200MG/5ML	A065355	001	Apr 10, 2007	Apr CHRS
----	-----------------------	-----------	---------	-----	--------------	----------

CEFPODOXIME PROXETILFOR SUSPENSION;ORAL
CEFPODOXIME PROXETIL

! AUROBINDO PHARMA LTD	EQ 50MG BASE/5ML	A065409	001	Jun 08, 2007	Jan CTEC
!	EQ 100MG BASE/5ML	A065409	002	Jun 08, 2007	Jan CHRS
	EQ 100MG BASE/5ML	A065409	002	Jun 08, 2007	Jan CTEC
@ SANDOZ	EQ 50MG BASE/5ML	A090031	001	Jan 14, 2009	Jan DISC
@	EQ 100MG BASE/5ML	A090031	002	Jan 14, 2009	Jan DISC

CELECOXIBCAPSULE;ORAL
CELECOXIB

>A> AB	QINGDAO BAHEAL PHARM	50MG	A208856	001	Aug 07, 2019	Jul NEWA
>A> AB		100MG	A208856	002	Aug 07, 2019	Jul NEWA
>A> AB		200MG	A208856	003	Aug 07, 2019	Jul NEWA
>A> AB		400MG	A208856	004	Aug 07, 2019	Jul NEWA

CEPHALEXINFOR SUSPENSION;ORAL
CEPHALEXIN

AB	ALKEM LABS LTD	EQ 125MG BASE/5ML	A210221	001	Mar 26, 2019	Mar NEWA
AB		EQ 250MG BASE/5ML	A210221	002	Mar 26, 2019	Mar NEWA

CERITINIB

CAPSULE;ORAL ZYKADIA	+ @ NOVARTIS PHARMS CORP 150MG	N 205755 001 Apr 29, 2014	Jun DISC
TABLET;ORAL ZYKADIA	+! NOVARTIS PHARMS CORP 150MG	N 211225 001 Mar 18, 2019	Mar NEWA

CETIRIZINE HYDROCHLORIDE

SYRUP;ORAL CETIRIZINE HYDROCHLORIDE	@ LANNETT CO INC 5MG/5ML	A 078496 001 Sep 25, 2009	May DISC
	@ PD PARTNERS 5MG/5ML	A 078412 001 Jun 18, 2008	May CAHN
AA ! PERRIGO PHARMS CO 5MG/5ML	A 078398 001 Jun 17, 2008	May CAHN	
AA TORRENT 5MG/5ML	A 078870 001 Apr 27, 2009	Jan CAHN	

CHLORDIAZEPOXIDE HYDROCHLORIDE

INJECTABLE; INJECTION LIBRIUM	@ BAUSCH 100MG/AMP	N 012301 001	Mar CAHN
----------------------------------	--------------------	--------------	----------

CHLORHEXIDINE GLUCONATE

SOLUTION;DENTAL CHLORHEXIDINE GLUCONATE	AT PD PARTNERS 0.12%	A 074522 001 Dec 15, 1995	Jun CAHN
--	----------------------	---------------------------	----------

CHLORPHENIRAMINE MALEATE; HYDROCODONE BITARTRATE

SOLUTION;ORAL VITUZ	AA +! PERSION 4MG/5ML;5MG/5ML	N 204307 001 Feb 20, 2013	Apr CAHN
------------------------	-------------------------------	---------------------------	----------

CHLORPHENIRAMINE MALEATE; HYDROCODONE BITARTRATE; PSEUDOEPHEDRINE HYDROCHLORIDE

SOLUTION;ORAL HYDROCODONE BITARTRATE, CHLORPHENIRAMINE MALEATE AND PSEUDOEPHEDRINE HYDROCHLORIDE	AA ! PADDOCK LLC 4MG/5ML;5MG/5ML;60MG/5ML	A 204627 001 Apr 29, 2014	Jun CHRS
	@ TORRENT 4MG/5ML;5MG/5ML;60MG/5ML	A 206660 001 May 15, 2017	Jan CAHN
>D>	ZUTRIPIRO		
>D> AA	+! PERSION 4MG/5ML;5MG/5ML;60MG/5ML	N 022439 001 Jun 08, 2011	Jul DISC
>A>	+ @ 4MG/5ML;5MG/5ML;60MG/5ML	N 022439 001 Jun 08, 2011	Jul DISC
AA	+! 4MG/5ML;5MG/5ML;60MG/5ML	N 022439 001 Jun 08, 2011	Apr CAHN

CHLORPROMAZINE HYDROCHLORIDE

TABLET;ORAL CHLORPROMAZINE HYDROCHLORIDE	>A> AB UPSHER SMITH LABS 10MG	A 083386 001	Jul CAHN
	>A> AB ! 25MG	A 084112 001	Jul CAHN
	>A> AB 50MG	A 084113 001	Jul CAHN
	>A> AB ! 100MG	A 084114 001	Jul CAHN
	>A> AB 200MG	A 084115 001	Jul CAHN
>D> AB	USL PHARMA 10MG	A 083386 001	Jul CAHN
>D> AB	! 25MG	A 084112 001	Jul CAHN
>D> AB	50MG	A 084113 001	Jul CAHN
>D> AB	! 100MG	A 084114 001	Jul CAHN
>D> AB	200MG	A 084115 001	Jul CAHN

CHLORPROPAMIDE

TABLET;ORAL CHLORPROPAMIDE	@ MYLAN 100MG	A 088549 002 Jun 01, 1984	May DISC
	@ 250MG	A 088549 001 Jun 01, 1984	May DISC

CHLORTHALIDONE

TABLET;ORAL CHLORTHALIDONE	AB AMNEAL PHARMS CO 25MG	A 207204 001 Jul 01, 2019	Jun NEWA
	AB 50MG	A 207204 002 Jul 01, 2019	Jun NEWA
	AB INVATECH PHARMA 25MG	A 211063 001 Feb 26, 2019	Feb NEWA
	AB 50MG	A 211063 002 Feb 26, 2019	Feb NEWA
>A> AB	UNICHEM LABS LTD 25MG	A 211627 001 Aug 06, 2019	Jul NEWA
>A> AB	50MG	A 211627 002 Aug 06, 2019	Jul NEWA
AB	ZYDUS PHARMS 25MG	A 207813 001 May 10, 2019	Apr NEWA

	TABLET;ORAL CHLORTHALIDONE	50MG	A207813 002 May 10, 2019	Apr NEWA
AB	<u>CHOLINE C-11</u> INJECTABLE; INTRAVENOUS CHOLINE C-11			
AP	DECATUR	4-33.1mCi/ML	A206319 001 Nov 13, 2015	Apr CAHN
	<u>CHOLINE FENOFOBIRATE</u> CAPSULE, DELAYED RELEASE;ORAL FENOFOBIRIC ACID			
>A> AB	AUROBINDO PHARMA LTD	EQ 45MG FENOFOBIRIC ACID	A212598 001 Jul 25, 2019	Jul NEWA
>A> AB		EQ 135MG FENOFOBIRIC ACID	A212598 002 Jul 25, 2019	Jul NEWA
>A> AB	GRAVITI PHARMS	EQ 45MG FENOFOBIRIC ACID	A211626 001 Jul 18, 2019	Jul NEWA
>A> AB		EQ 135MG FENOFOBIRIC ACID	A211626 002 Jul 18, 2019	Jul NEWA
	@ MYLAN PHARMS INC	EQ 45MG FENOFOBIRIC ACID	A200913 001 Mar 25, 2013	May DISC
	@	EQ 135MG FENOFOBIRIC ACID	A200913 002 Mar 25, 2013	May DISC
AB	TWI PHARMS	EQ 45MG FENOFOBIRIC ACID	A210469 001 Jul 05, 2019	Jun NEWA
AB		EQ 135MG FENOFOBIRIC ACID	A210469 002 Jul 05, 2019	Jun NEWA
	<u>CHROMIC PHOSPHATE P-32</u> INJECTABLE; INJECTION PHOSPHOCOL P32	5mCi/ML	N017084 001	Jan CAHN
	<u>CICLESONIDE</u> AEROSOL, METERED; INHALATION ALVESCO			
+! AB	COVIS PHARMA BV	0.08MG/INH	N021658 002 Jan 10, 2008	Mar CAHN
+!		0.16MG/INH	N021658 003 Jan 10, 2008	Mar CAHN
	AEROSOL, METERED;NASAL ZETONNA			
+! AT	COVIS PHARMA BV	0.037MG/INH	N202129 001 Jan 20, 2012	Mar CAHN
	SPRAY, METERED;NASAL OMNARIS			
+! AT	COVIS PHARMA BV	0.05MG/INH	N022004 001 Oct 20, 2006	Mar CAHN
	<u>CICLOPIROX</u> CREAM;TOPICAL CICLOPIROX			
AB	PERRIGO ISRAEL	0.77%	A077364 001 Mar 03, 2006	May CAHN
	SHAMPOO;TOPICAL LOPROX			
AT	+! BAUSCH	1%	N021159 001 Feb 28, 2003	Apr CAHN
	SOLUTION;TOPICAL CICLOPIROX			
AT	ACELLA	8%	A078172 001 Sep 18, 2007	May CAHN
>A>	<u>CILASTATIN SODIUM; IMIPENEM; RELEBACTAM</u>			
>A>	POWDER; INTRAVENOUS			
>A>	RECARBRI			
>A>	+! MSD MERCK CO	EQ 500MG BASE/VIAL;500MG/VIAL;250MG/VIAL	N212819 001 Jul 16, 2019	Jul NEWA
	<u>CIMETIDINE</u> TABLET;ORAL CIMETIDINE			
AB	HIKMA	200MG	A074890 001 Dec 18, 1998	Jun CAHN
AB		300MG	A074890 002 Dec 18, 1998	Jun CAHN
AB		400MG	A074890 003 Dec 18, 1998	Jun CAHN
AB		800MG	A074890 004 Dec 18, 1998	Jun CAHN
	<u>CIMETIDINE HYDROCHLORIDE</u> SOLUTION;ORAL CIMETIDINE HYDROCHLORIDE			
	@ PD PARTNERS	EQ 300MG BASE/5ML	A075560 001 Mar 15, 2000	May CAHN

CINACALCET HYDROCHLORIDE

TABLET;ORAL

CINACALCET HYDROCHLORIDE

AB	ALKEM LABS LTD	EQ 30MG BASE	A210570	001	May 17, 2019	May NEWA
AB		EQ 60MG BASE	A210570	002	May 17, 2019	May NEWA
AB		EQ 90MG BASE	A210570	003	May 17, 2019	May NEWA
AB	LUPIN LTD	EQ 30MG BASE	A210548	001	Jun 28, 2019	Jun NEWA
AB		EQ 60MG BASE	A210548	002	Jun 28, 2019	Jun NEWA
AB		EQ 90MG BASE	A210548	003	Jun 28, 2019	Jun NEWA

CIPROFLOXACIN

INJECTABLE;INJECTION

CIPROFLOXACIN

@ DR REDDYS	200MG/20ML (10MG/ML)	A077782	001	Aug 28, 2006	May CAHN
@	400MG/40ML (10MG/ML)	A077782	002	Aug 28, 2006	May CAHN

CIPROFLOXACIN HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC

CIPROFLOXACIN HYDROCHLORIDE

>D>	@ APOTEX INC	EQ 0.3% BASE	A075928	001	Jun 09, 2004	Jul CAHN
>A>	@ RUBICON	EQ 0.3% BASE	A075928	001	Jun 09, 2004	Jul CAHN

TABLET;ORAL

CIPROFLOXACIN HYDROCHLORIDE

>D> AB	APOTEX	EQ 250MG BASE	A076896	001	Nov 04, 2004	Jul CAHN
>D> AB		EQ 500MG BASE	A076896	002	Nov 04, 2004	Jul CAHN
>D> AB		EQ 750MG BASE	A076896	003	Nov 04, 2004	Jul CAHN
>A> AB	CHARTWELL MOLECULES	EQ 250MG BASE	A076896	001	Nov 04, 2004	Jul CAHN
>A> AB		EQ 500MG BASE	A076896	002	Nov 04, 2004	Jul CAHN
>A> AB		EQ 750MG BASE	A076896	003	Nov 04, 2004	Jul CAHN

CIPROFLOXACIN; CIPROFLOXACIN HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

CIPROFLOXACIN EXTENDED RELEASE

AB	! ANCHEN PHARMS	212.6MG;EQ 287.5MG BASE	A078166	002	Nov 27, 2007	May CTEC
AB	!	212.6MG;EQ 287.5MG BASE	A078166	002	Nov 27, 2007	May CHRS
AB	!	425.2MG;EQ 574.9MG BASE	A078166	001	Nov 27, 2007	May CHRS
	@ ANI PHARMS INC	212.6MG;EQ 287.5MG BASE	A077417	001	Nov 30, 2010	May CAHN
	@	425.2MG;EQ 574.9MG BASE	A077809	001	Nov 30, 2010	May CAHN
	@ MYLAN PHARMS INC	212.6MG;EQ 287.5MG BASE	A078183	001	Mar 22, 2007	May DISC
	@	425.2MG;EQ 574.9MG BASE	A078183	002	Mar 22, 2007	May DISC

CISATRACURIUM BESYLATE

INJECTABLE;INJECTION

CISATRACURIUM BESYLATE

AP	@ ACCORD HLTHCARE	EQ 2MG BASE/ML	A205873	001	Jun 16, 2017	Feb DISC
AP	NANJING KING-FRIEND	EQ 2MG BASE/ML	A211668	001	Apr 25, 2019	Apr NEWA
AP		EQ 2MG BASE/ML	A211669	001	Apr 25, 2019	Apr NEWA
AP		EQ 10MG BASE/ML	A211668	002	Apr 25, 2019	Apr NEWA
AP	SOMERSET THERAPS LLC	EQ 2MG BASE/ML	A209132	001	Apr 24, 2019	Apr NEWA
	CISATRACURIUM BESYLATE	PRESERVATIVE FREE				
	@ ACCORD HLTHCARE	EQ 2MG BASE/ML	A205872	001	Jun 16, 2017	Feb DISC
	@	EQ 10MG BASE/ML	A205872	002	Jun 16, 2017	Feb DISC
AP	SOMERSET THERAPS LLC	EQ 2MG BASE/ML	A206791	001	Feb 20, 2019	Feb NEWA
AP		EQ 10MG BASE/ML	A206791	002	Feb 20, 2019	Feb NEWA
	NIMBEX PRESERVATIVE FREE					
AP	+! ABBVIE	EQ 10MG BASE/ML	N020551	002	Dec 15, 1995	Feb CTEC

CITALOPRAM HYDROBROMIDE

SOLUTION;ORAL

CITALOPRAM HYDROBROMIDE

@ PD PARTNERS	EQ 10MG BASE/5ML	A077601	001	Nov 15, 2005	May CAHN
---------------	------------------	---------	-----	--------------	----------

AB	TABLET;ORAL	CITALOPRAM HYDROBROMIDE				
	@ HERITAGE PHARMA	EQ 10MG BASE	A077033	001	Oct 28, 2004	May CAHN
	@	EQ 10MG BASE	A077213	001	Mar 31, 2006	May CAHN
		EQ 10MG BASE	A077232	001	Oct 31, 2005	May CAHN
	@	EQ 20MG BASE	A077033	002	Oct 28, 2004	May CAHN
	@	EQ 20MG BASE	A077213	002	Mar 31, 2006	May CAHN
AB		EQ 20MG BASE	A077232	002	Oct 31, 2005	May CAHN
	@	EQ 40MG BASE	A077033	003	Oct 28, 2004	May CAHN
	@	EQ 40MG BASE	A077213	003	Mar 31, 2006	May CAHN

TABLET;ORAL

CITALOPRAM HYDROBROMIDE

AB EQ 40MG BASE A077232 003 Oct 31, 2005 May CAHN

CITRIC ACID; MAGNESIUM OXIDE; SODIUM PICOSULFATE

FOR SOLUTION;ORAL

PREPOPIK

+! FERRING PHARMS INC 12GM/PACKET;3.5GM/PACKET;10MG/PACK N202535 001 Jul 16, 2012 Jun CMFD ET

+ @ 12GM/PACKET;3.5GM/PACKET;10MG/PACK N202535 001 Jul 16, 2012 Apr DISC ET

CLADBINE

TABLET;ORAL

MAVENCLAD

+! EMD SERONO INC 10MG N022561 001 Mar 29, 2019 Mar NEWA

CLARITHROMYCIN

TABLET;ORAL

CLARITHROMYCIN

AB AJANTA PHARMA LTD 250MG A206714 001 Apr 25, 2019 Apr NEWA

AB 500MG A206714 002 Apr 25, 2019 Apr NEWA

AB STRIDES PHARMA 250MG A202710 001 Jun 10, 2013 Feb CAHN

AB 500MG A202710 002 Jun 10, 2013 Feb CAHN

TABLET, EXTENDED RELEASE;ORAL

CLARITHROMYCIN

>D> AB ALLIED 500MG A203243 001 Feb 29, 2016 Jul CAHN

>A> AB NOSTRUM LABS INC 500MG A203243 001 Feb 29, 2016 Jul CAHN

CLINDAMYCIN PALMITATE HYDROCHLORIDE

FOR SOLUTION;ORAL

CLINDAMYCIN PALMITATE HYDROCHLORIDE

@ MYLAN EQ 75MG BASE/5ML

A203063 001 May 25, 2016 Mar DISC

CLINDAMYCIN PHOSPHATE

GEL;TOPICAL

CLINDAGEL

BT +! BAUSCH EQ 1% BASE N050782 001 Nov 27, 2000 May CAHN

SOLUTION;TOPICAL

CLINDAMYCIN PHOSPHATE

AT ENCUBE ETHICALS EQ 1% BASE A209914 001 Jan 28, 2019 Jan NEWA

CLINDAMYCIN PHOSPHATE; TRETINOIN

GEL;TOPICAL

VELTIN

BX +! ALMIRALL 1.2%;0.025% N050803 001 Jul 16, 2010 Feb CAHN

CLOBAZAM

SUSPENSION;ORAL

CLOBAZAM

AB TARO PHARM 2.5MG/ML A210978 001 Apr 15, 2019 Apr NEWA

AB VISTAPHARM 2.5MG/ML A210746 001 Jul 10, 2019 Jun NEWA

TABLET;ORAL

CLOBAZAM

AB ACCORD HLTHCARE 10MG A212398 001 May 23, 2019 May NEWA

AB 20MG A212398 002 May 23, 2019 May NEWA

AB MICRO LABS 10MG A211711 001 Jan 30, 2019 Jan NEWA

AB 20MG A211711 002 Jan 30, 2019 Jan NEWA

>D> AB TARO PHARM 10MG A209440 001 Oct 22, 2018 Jul DISC

>A> @ 10MG A209440 001 Oct 22, 2018 Jul DISC

>D> AB 20MG A209440 002 Oct 22, 2018 Jul DISC

>A> @ 20MG A209440 002 Oct 22, 2018 Jul DISC

CLOBETASOL PROPIONATE

AEROSOL, FOAM;TOPICAL

CLOBETASOL PROPIONATE

AB1 GLENMARK PHARMS LTD 0.05% A210809 001 Feb 15, 2019 Feb NEWA

AB2 PERRIGO UK FINCO 0.05% A201402 001 Aug 14, 2012 May CAHN

LOTION;TOPICAL

CLOBETASOL PROPIONATE

>D> AB HI TECH 0.05% A211348 001 Oct 26, 2018 Jul DISC

>A> @ 0.05% A211348 001 Oct 26, 2018 Jul DISC

OINTMENT;TOPICAL

CLOBETASOL PROPIONATE

AB	ALEOR DERMACEUTICALS	0.05%	A211800	001	Mar 04, 2019	Feb NEWA
@	AMNEAL PHARMS LLC	0.05%	A210551	001	Aug 21, 2018	Feb DISC
AB	TELIGENT PHARMA INC	0.05%	A208589	001	Jan 23, 2019	Jan NEWA

CLOFARABINE

SOLUTION;INTRAVENOUS

CLOFARABINE

AP	ACCORD HLTHCARE	20MG/20ML (1MG/ML)	A212034	001	Feb 22, 2019	Feb NEWA
@	HOSPIRA INC	20MG/20ML (1MG/ML)	A210283	001	Dec 27, 2018	Feb DISC

CLOMIPRAMINE HYDROCHLORIDE

CAPSULE;ORAL

CLOMIPRAMINE HYDROCHLORIDE

AB	MANKIND PHARMA	25MG	A211767	001	Apr 08, 2019	Mar NEWA
AB		50MG	A211767	002	Apr 08, 2019	Mar NEWA
AB		75MG	A211767	003	Apr 08, 2019	Mar NEWA

CLONAZEPAMTABLET, ORALLY DISINTEGRATING;ORAL
CLONAZEPAM

AB	ALEMBIC PHARMS LTD	0.125MG	A211033	001	Jun 28, 2019	Jun NEWA
AB		0.25MG	A211033	002	Jun 28, 2019	Jun NEWA
AB		0.5MG	A211033	003	Jun 28, 2019	Jun NEWA
AB		1MG	A211033	004	Jun 28, 2019	Jun NEWA
AB		2MG	A211033	005	Jun 28, 2019	Jun NEWA

CLONIDINE HYDROCHLORIDE

INJECTABLE;INJECTION

CLONIDINE HYDROCHLORIDE

@	LUITPOLD	1MG/10ML (0.1MG/ML)
@		5MG/10ML (0.5MG/ML)

A091104	001	Oct 08, 2009	Feb DISC
A091104	002	Oct 08, 2009	Feb DISC

TABLET;ORAL

CLONIDINE HYDROCHLORIDE

AB	FRONTIDA BIOPHARM	0.1MG	A070923	003	Sep 04, 1987	Apr CMS1
AB		0.2MG	A070923	002	Sep 04, 1987	Apr CMS1

TABLET, EXTENDED RELEASE;ORAL

CLONIDINE HYDROCHLORIDE

AB1	NOVAST LABS	0.1MG	A209675	001	Mar 05, 2019	Feb NEWA
@	UPSHER SMITH LABS	0.1MG	A211433	001	Oct 12, 2018	May DISC

CLOPIDOGREL BISULFATE

TABLET;ORAL

CLOPIDOGREL BISULFATE

AB	ANI PHARMS INC	EQ 300MG BASE	A091216	001	May 17, 2012	May CAHN
@	CADILA	EQ 75MG BASE	A201686	001	Oct 10, 2012	Jun DISC
AB		EQ 75MG BASE	A201686	001	Oct 10, 2012	Apr CAHN

A077665	002	May 17, 2012	Feb DISC
---------	-----	--------------	----------

CLORAZEPATE DIPOTASSIUM

TABLET;ORAL

CLORAZEPATE DIPOTASSIUM

@	AUROLIFE PHARMA LLC	3.75MG
@		7.5MG

A072514	002	May 11, 1990	Jan CMS1
A072514	003	May 11, 1990	Jan CMS1

CLOTIMAZOLE

SOLUTION;TOPICAL

CLOTIMAZOLE

AT	NOVITIUM PHARMA	1%	A209815	001	Feb 14, 2019	Feb NEWA
>A> AT	TASMAN PHARMA	1%	A212281	001	Jul 25, 2019	Jul NEWA

A212281	001	Jul 25, 2019	Jul NEWA
---------	-----	--------------	----------

CLOZAPINE

TABLET;ORAL

CLOZARIL

AB	HERITAGE LIFE	50MG	N019758	003	May 20, 2019	May NEWA
AB	+	200MG	N019758	004	May 20, 2019	May NEWA

N019758	004	May 20, 2019	May NEWA
---------	-----	--------------	----------

TABLET, ORALLY DISINTEGRATING;ORAL

FAZACLO ODT

AB	JAZZ	12.5MG	N021590	004	May 30, 2007	Jun CAHN
AB	+	25MG	N021590	001	Feb 10, 2004	Jun CAHN
@		50MG	N021590	003	Jun 03, 2005	Jun CAHN

N021590	003	Jun 03, 2005	Jun CAHN
---------	-----	--------------	----------

**TABLET, ORALLY DISINTEGRATING;ORAL
FAZACLO ODT**

AB	+!	100MG	N 021590	002	Feb 10, 2004	Jun CAHN
AB	+	150MG	N 021590	005	Jul 09, 2010	Jun CAHN
AB	+	200MG	N 021590	006	Jul 09, 2010	Jun CAHN

CODEINE SULFATE

SOLUTION;ORAL CODEINE SULFATE @ HIKMA	30MG/5ML	N 202245	001	Jun 30, 2011	Mar CAHN	
TABLET;ORAL CODEINE SULFATE						
AB	+ HIKMA	15MG	N 022402	001	Jul 16, 2009	Mar CAHN
AB	+	30MG	N 022402	002	Jul 16, 2009	Mar CAHN
AB	+!	60MG	N 022402	003	Jul 16, 2009	Mar CAHN

COLCHICINE

CAPSULE;ORAL COLCHICINE @ PAR PHARM INC MITIGARE	0.6MG	A 208678	001	Nov 29, 2018	May DISC	
+! HIKMA INTL PHARMS	0.6MG	N 204820	001	Sep 26, 2014	May CTEC	
SOLUTION;ORAL GLOPERBA						
>A>	+! AVION PHARMS	0.6MG/5ML	N 210942	001	Jan 30, 2019	Jul CAHN
>D>	+! ROMEG THERAPS LLC	0.6MG/5ML	N 210942	001	Jan 30, 2019	Jul CAHN
	+!	0.6MG/5ML	N 210942	001	Jan 30, 2019	Jan NEWA
TABLET;ORAL COLCHICINE						
AB	ALKEM LABS LTD	0.6MG	A 211250	001	Feb 08, 2019	Feb NEWA
AB	AMNEAL PHARMS	0.6MG	A 204711	001	Sep 28, 2016	Jan NEWA
>A> AB	WATSON LABS INC	0.6MG	A 204461	001	Jul 31, 2019	Jul NEWA
>D> AB	ZYDUS PHARMS	0.6MG	A 211519	001	Feb 19, 2019	Jul DISC
>A>	@	0.6MG	A 211519	001	Feb 19, 2019	Jul DISC
AB		0.6MG	A 211519	001	Feb 19, 2019	Feb NEWA
COLCRYS						
AB	+! TAKEDA PHARMS USA	0.6MG	N 022352	001	Jul 29, 2009	Jan CTEC

COLESEVELAM HYDROCHLORIDE

BAR, CHEWABLE;ORAL WELCHOL						
+! DAIICHI SANKYO INC	3.75GM	N 210895	001	Apr 03, 2019	Apr NEWA	
FOR SUSPENSION;ORAL COLESEVELAM HYDROCHLORIDE						
AB	ALKEM LABS LTD	3.75GM/PACKET	A 210316	001	May 06, 2019	Apr NEWA
	GLENMARK PHARMS LTD	1.875GM/PACKET	A 202190	001	Jul 16, 2018	Mar CTEC
WELCHOL						
+ @ DAIICHI SANKYO	1.875GM/PACKET	N 022362	001	Oct 02, 2009	Mar DISC	

CROMOLYN SODIUM

SOLUTION;INHALATION CROMOLYN SODIUM @ HIKMA	10MG/ML	A 075333	001	Apr 30, 2002	Jun CAHN
@ MYLAN SPECIALITY LP	10MG/ML	A 074209	001	Apr 26, 1994	Mar DISC

CYCLOBENZAPRINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL AMRIX						
AB	+ TEVA PHARMS INTL	15MG	N 021777	001	Feb 01, 2007	Mar CTEC
	+	15MG	N 021777	001	Feb 01, 2007	Jan CTEC
AB	+!	30MG	N 021777	002	Feb 01, 2007	Mar CTEC
	+	30MG	N 021777	002	Feb 01, 2007	Jan CTEC
AB	APOTEX INC	15MG	A 206703	001	Jul 24, 2018	Feb CMFD
	@	15MG	A 206703	001	Jul 24, 2018	Jan DISC
AB		30MG	A 206703	002	Jul 24, 2018	Feb CMFD
	@	30MG	A 206703	002	Jul 24, 2018	Jan DISC
AB	TWI PHARMS INC	15MG	A 091281	001	Jan 31, 2013	Mar CMFD
AB		30MG	A 091281	002	Jan 31, 2013	Mar CMFD

CYCLOPHOSPHAMIDE

CAPSULE;ORAL
CYCLOPHOSPHAMIDE

AB	CIPILA	25MG	A211608	001	Jan 18, 2019	Jan NEWA
AB		50MG	A211608	002	Jan 18, 2019	Jan NEWA

CYCLOSPORINE

CAPSULE;ORAL
CYCLOSPORINE

AB1	APOTEX INC	25MG	A210721	001	Jul 10, 2019	Jun NEWA
AB1		50MG	A210721	002	Jul 10, 2019	Jun NEWA
AB1		100MG	A210721	003	Jul 10, 2019	Jun NEWA
AB1	IVAX SUB TEVA PHARMS	50MG	A065110	001	Mar 29, 2005	Jun CTEC
	SOLUTION;ORAL CYCLOSPORINE @ PD PARTNERS	100MG/ML	A065167	001	Jan 05, 2005	May CAHN

CYPROHEPTADINE HYDROCHLORIDE

SYRUP;ORAL
CYPROHEPTADINE HYDROCHLORIDE

>A> AA	PATRIN PHARMA INC	2MG/5ML	A204823	001	Dec 27, 2016	Jul CAHN
AA	QUAGEN	2MG/5ML	A212423	001	May 22, 2019	May NEWA
>D> AA	TORRENT	2MG/5ML	A204823	001	Dec 27, 2016	Jul CAHN
AA		2MG/5ML	A204823	001	Dec 27, 2016	Jan CAHN
	TABLET;ORAL CYPROHEPTADINE HYDROCHLORIDE					
AA	BEXIMCO PHARMS USA	4MG	A206676	001	Apr 12, 2019	Apr NEWA
AA	! HERITAGE PHARMA	4MG	A087056	001		Feb CAHN

CYSTEINE HYDROCHLORIDE

SOLUTION;INTRAVENOUS
ELCYS

+!	EXELA PHARMA SCS LLC	500MG/10ML (50MG/ML)	N210660	001	Apr 16, 2019	Apr NEWA
----	----------------------	----------------------	---------	-----	--------------	----------

DACLATASVIR DIHYDROCHLORIDE

TABLET;ORAL
DAKLINZA

+ @	BRISTOL-MYERS SQUIBB	EQ 30MG BASE	N206843	001	Jul 24, 2015	Jun DISC
+ @		EQ 60MG BASE	N206843	002	Jul 24, 2015	Jun DISC
+ @		EQ 90MG BASE	N206843	003	Apr 13, 2016	Feb DISC

DACTINOMYCIN

INJECTABLE;INJECTION
DACTINOMYCIN

>A> AP	HISUN PHARM HANGZHOU	0.5MG/VIAL	A207232	001	Jul 16, 2019	Jul NEWA
AP	X-GEN PHARMS INC	0.5MG/VIAL	A203999	001	May 20, 2019	May NEWA

DALFAMPRIDINE

TABLET, EXTENDED RELEASE;ORAL
DALFAMPRIDINE

AB	MICRO LABS	10MG	A210158	001	Mar 11, 2019	Feb NEWA
AB	SUN PHARM	10MG	A208292	001	May 21, 2019	May NEWA

DANTROLENE SODIUM

INJECTABLE;INJECTION
DANTROLENE SODIUM

@	MYLAN INSTITUTIONAL	20MG/VIAL	A205239	001	Feb 18, 2016	Mar DISC
---	---------------------	-----------	---------	-----	--------------	----------

DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE; SAXagliptin HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL
QTERNMET XR

+	ASTRAZENECA AB	2.5MG;1GM;EQ 2.5MG BASE	N210874	001	May 02, 2019	May NEWA
+		5MG;1GM;EQ 2.5MG BASE	N210874	002	May 02, 2019	May NEWA
+		5MG;1GM;EQ 5MG BASE	N210874	003	May 02, 2019	May NEWA
+		10MG;1GM;EQ 5MG BASE	N210874	004	May 02, 2019	May NEWA

DAPAGLIFLOZIN; SAXagliptin Hydrochloride

TABLET;ORAL

QTERN

+ ASTRazeneca AB 5MG;EQ 5MG BASE

N209091 002 May 02, 2019 May NEWA

DAPIprazole Hydrochloride

SOLUTION/DROPS;OPHTHALMIC

DAPIprazole Hydrochloride

BARADAINA LLC 0.5%

A204902 001 May 30, 2019 May NEWA

Dapsone

GEL;TOPICAL

ACZONE

AB	+! ALMIRALL	7.5%	N207154	001	Feb 24, 2016	Jun CFTG
	+!	7.5%	N207154	001	Feb 24, 2016	Feb CAHN
	DAPSONE					
AB	TARO PHARMS	7.5%	A210191	001	Jun 26, 2019	Jun NFTG
	TABLET;ORAL					
	DAPSONE					
AB	SAI LIFE SCIENCES	100MG	A207165	001	May 08, 2019	Apr NEWA
	@ TARO PHARM	25MG	A209430	001	Mar 01, 2019	May DISC
AB		25MG	A209430	001	Mar 01, 2019	Feb NEWA
	@	100MG	A209430	002	Mar 01, 2019	May DISC
AB		100MG	A209430	002	Mar 01, 2019	Feb NEWA

Daptomycin

POWDER;INTRAVENOUS

DAPTOMYCIN

AP	ACCORD HLTHCARE	500MG/VIAL	A211961	001	Jun 24, 2019	Jun NEWA
AP	BE PHARMS	500MG/VIAL	A212513	001	Jun 26, 2019	Jun NEWA
AP	DR REDDYS	500MG/VIAL	A208375	001	May 01, 2019	Apr NEWA
AP	XELLIA PHARMS APS	500MG/VIAL	A206005	001	Jun 15, 2016	Mar CAHN
	POWDER;IV (INFUSION)					
	DAPTOMYCIN					
>A> AP	ACCORD HLTHCARE	350MG/VIAL	A212667	001	Jul 12, 2019	Jul NFTG
>D>	+! SAGENT PHARMS	350MG/VIAL	N208385	001	Sep 12, 2017	Jul CTEC
>A> AP	+!	350MG/VIAL	N208385	001	Sep 12, 2017	Jul CTEC

>A> Darolutamide

>A> TABLET;ORAL

>A> NUBEQA

>A> +! BAYER HEALTHCARE 300MG N212099 001 Jul 30, 2019 Jul NEWA

Dasabuvir Sodium; Ombitasvir; Paritaprevir; Ritonavir

TABLET, EXTENDED RELEASE;ORAL

VIEKIRA XR

+ @ ABBVIE INC EQ 200MG BASE;8.33MG;50MG;33.33MG N208624 001 Jul 22, 2016 Apr DISC

Daunorubicin Hydrochloride

INJECTABLE;INJECTION

DAUNORUBICIN HYDROCHLORIDE

AP	HISUN PHARM HANGZHOU	EQ 5MG BASE/ML	A208759	001	Apr 12, 2019	Apr NEWA
AP		EQ 20MG BASE/VIAL	A206195	001	Apr 25, 2019	Apr NEWA

Decitabine

INJECTABLE;INTRAVENOUS

DECITABINE

AP WOCKHARDT BIO AG 50MG/VIAL A209056 001 Apr 09, 2019 Mar NEWA

Deferiprone

TABLET;ORAL

DEFERIPRONE

AB	@ TARO PHARM INDs LTD	500MG	A208800	001	Feb 08, 2019	May DISC
		500MG	A208800	001	Feb 08, 2019	Feb NFTG
	FERRIPROX					
AB	+! APOPHARMA INC	500MG	N021825	001	Oct 14, 2011	May CTEC
	+!	500MG	N021825	001	Oct 14, 2011	Feb CFTG
>A>	+	1GM	N021825	002	Jul 25, 2019	Jul NEWA

DELAVIRDINE MESYLATE

TABLET;ORAL
RESCRIPTOR
+ @ VIIV HLTHCARE 100MG N020705 001 Apr 04, 1997 Jun DISC

DESLORATADINE

TABLET;ORAL
DESLORATADINE
AB @ MYLAN PHARMS INC 5MG A078351 001 Feb 10, 2012 May DISC
PERRIGO 5MG A078361 001 Dec 22, 2011 Apr CAHN

DESMOPRESSIN ACETATE

INJECTABLE;INJECTION
DESMOPRESSIN ACETATE
AP TEVA PHARMS USA 0.004MG/ML A074888 001 Oct 15, 1997 Mar CMFD
SOLUTION;NASAL
DDAVP

>D> AB +! FERRING PHARMS INC 0.01% N017922 001 Jul CTEC
>A> +! 0.01% N017922 001 Jul CTEC
>D> DESMOPRESSIN ACETATE
>D> AB SUN PHARM IND 0.01% A077212 001 Apr 12, 2012 Jul DISC
>A> @ 0.01% A077212 001 Apr 12, 2012 Jul DISC
SPRAY, METERED;NASAL
NOCTIVA
+ @ ALYVANT 0.00083MG/SPRAY N201656 001 Mar 03, 2017 Jun DISC
+ 0.00083MG/SPRAY N201656 001 Mar 03, 2017 Apr CAHN
+ @ 0.00166MG/SPRAY N201656 002 Mar 03, 2017 Jun DISC
+! 0.00166MG/SPRAY N201656 002 Mar 03, 2017 Apr CAHN

TABLET;ORAL
DESMOPRESSIN ACETATE

AB ABHAI LLC 0.1MG A210371 001 Jan 28, 2019 Jan NEWA
AB 0.2MG A210371 002 Jan 28, 2019 Jan NEWA
AB NOVAST LABS 0.1MG A208357 001 Jun 06, 2019 May NEWA
AB 0.2MG A208357 002 Jun 06, 2019 May NEWA

DESOGESTREL; ETHINYLN ESTRADIOL

TABLET;ORAL-28
DESOGEN
@ ORGANON USA INC 0.15MG;0.03MG N020071 002 Dec 10, 1992 May DISC
DESOGESTREL AND ETHINYLN ESTRADIOL
@ ACCORD HLTHCARE 0.15MG;0.03MG A207067 001 Sep 13, 2018 Mar DISC

DESONIDE

AEROSOL, FOAM;TOPICAL
VERDESO
+! ALMIRALL 0.05% N021978 001 Sep 19, 2006 Feb CAHN
OINTMENT;TOPICAL
DESONIDE
AB ENCUBE ETHICALS 0.05% A210998 001 Jan 30, 2019 Jan NEWA
AB TELIGENT PHARMA INC 0.05% A212002 001 Mar 12, 2019 Feb NEWA

DESOXIMETASONE

CREAM;TOPICAL
DESOXIMETASONE
@ ZYDUS PHARMS 0.25% A205620 001 Sep 28, 2018 Feb DISC

DESVENLAFAXINE

TABLET, EXTENDED RELEASE;ORAL
DESVENLAFAXINE
+! ALEMBIC PHARMS LTD 50MG N204150 001 Mar 04, 2013 May CTEC
+! 100MG N204150 002 Mar 04, 2013 May CTEC
KHEDEZLA
@ OSMOTICA PHARM CORP 50MG N204683 001 Jul 10, 2013 May DISC
@ 100MG N204683 002 Jul 10, 2013 May DISC

DESVENLAFAXINE SUCCINATE

TABLET, EXTENDED RELEASE;ORAL

DESVENLAFAXINE SUCCINATE

AB	INTELLIPHARMACEUTICS	EQ 50MG BASE	A204805	001	May 07, 2019	Apr NEWA
AB		EQ 100MG BASE	A204805	002	May 07, 2019	Apr NEWA
>D>	@ MYLAN	EQ 50MG BASE	A204095	001	Jun 29, 2015	Jul CMFD
>A> AB		EQ 50MG BASE	A204095	001	Jun 29, 2015	Jul CMFD
	@	EQ 50MG BASE	A204095	001	Jun 29, 2015	May DISC
	@	EQ 100MG BASE	A204095	002	Jun 29, 2015	May DISC
	@ YICHANG HUMANWELL	EQ 50MG BASE	A210014	001	Oct 01, 2018	Mar DISC
	@	EQ 100MG BASE	A210014	002	Oct 01, 2018	Mar DISC

DEXAMETHASONE SODIUM PHOSPHATE

INJECTABLE; INJECTION

DEXAMETHASONE SODIUM PHOSPHATE

AP	AUROBINDO PHARMA LTD	EQ 10MG PHOSPHATE/ML	A210967	001	Jun 07, 2019	May NEWA
AP	! FRESENIUS KABI USA	EQ 4MG PHOSPHATE/ML	A084916	001		Feb CHRS
	@ LUITPOLD	EQ 4MG PHOSPHATE/ML	A087440	001	Jul 21, 1982	Feb DISC
AP	SOMERSET THERAPS LLC	EQ 10MG PHOSPHATE/ML	A211036	001	May 10, 2019	Apr NEWA
	SOLUTION/DROPS;OPHTHALMIC, OTIC					
	DEXAMETHASONE SODIUM PHOSPHATE					
	! BAUSCH AND LOMB	EQ 0.1% PHOSPHATE	A040069	001	Jul 26, 1996	May CTEC
	@ SANDOZ INC	EQ 0.1% PHOSPHATE	A088771	001	Jan 16, 1985	May DISC

DEXMEDETOMIDINE HYDROCHLORIDE

INJECTABLE; INJECTION

DEXMEDETOMIDINE HYDROCHLORIDE

>D> AP	CIPLA	EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML)	A204843	001	Jan 18, 2019	Jul DISC
>A>	@	EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML)	A204843	001	Jan 18, 2019	Jul DISC
AP		EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML)	A204843	001	Jan 18, 2019	Jan NEWA
	SOLUTION;INTRAVENOUS					
	DEXMEDETOMIDINE HYDROCHLORIDE					
+ +	HQ SPCLT PHARMA	EQ 200MCG BASE/50ML (EQ 4MCG BASE/ML)	N206628	003	Jun 22, 2018	Mar CPOT
+ +		EQ 400MCG BASE/100ML (EQ 4MCG BASE/ML)	N206628	004	Jun 22, 2018	Mar CPOT

DEXMETHYLPHENIDATE HYDROCHLORIDE

TABLET;ORAL

DEXMETHYLPHENIDATE HYDROCHLORIDE

>A> AB	ALKEM LABS LTD	2.5MG	A212631	001	Jul 19, 2019	Jul NEWA
>A> AB		5MG	A212631	002	Jul 19, 2019	Jul NEWA
>A> AB		10MG	A212631	003	Jul 19, 2019	Jul NEWA
	@ TEVA PHARMS	2.5MG	A077107	003	Jan 29, 2007	May DISC
	@	5MG	A077107	001	Jan 29, 2007	May DISC
	@	10MG	A077107	002	Jan 29, 2007	May DISC

DEXTROAMPHETAMINE SULFATE

CAPSULE, EXTENDED RELEASE;ORAL

DEXTROAMPHETAMINE SULFATE

AB	PII	5MG	A205077	001	Jun 21, 2019	Jun NEWA
AB		10MG	A205077	002	Jun 21, 2019	Jun NEWA
AB		15MG	A205077	003	Jun 21, 2019	Jun NEWA

DEXTROMETHORPHAN HYDROBROMIDE; PROMETHAZINE HYDROCHLORIDE

SYRUP;ORAL

PROMETHAZINE DM

@ VINTAGE 15MG/5ML; 6.25MG/5ML

A040649 001 Feb 14, 2006 May DISC

DEXTROSE; POTASSIUM CHLORIDE

INJECTABLE; INJECTION

POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% IN PLASTIC CONTAINER

>D> AP	ICU MEDICAL INC	5GM/100ML;224MG/100ML	N018371	003		Jul DISC
>A>	@	5GM/100ML;224MG/100ML	N018371	003		Jul DISC
	POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% IN PLASTIC CONTAINER					
>D>	ICU MEDICAL INC	5GM/100ML;298MG/100ML	N018371	002		Jul DISC
>A>	@	5GM/100ML;298MG/100ML	N018371	002		Jul DISC

DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE; INJECTION

POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER

>D>	+ ICU MEDICAL INC	5GM/100ML;74.5MG/100ML;225MG/100ML	N 018365	002	Jul 05, 1983	Jul DISC
>A>	+ @	5GM/100ML;74.5MG/100ML;225MG/100ML	N 018365	002	Jul 05, 1983	Jul DISC
>D>	+ @	5GM/100ML;149MG/100ML;225MG/100ML	N 018365	006	Mar 28, 1988	Jul DISC
>A>	+ @	5GM/100ML;149MG/100ML;225MG/100ML	N 018365	006	Mar 28, 1988	Jul DISC
	POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER					
>D>	ICU MEDICAL INC	5GM/100ML;74.5MG/100ML;300MG/100ML	N 018876	001	Jan 17, 1986	Jul DISC
>A>	@	5GM/100ML;74.5MG/100ML;300MG/100ML	N 018876	001	Jan 17, 1986	Jul DISC
>D>		5GM/100ML;149MG/100ML;300MG/100ML	N 018876	006	Mar 28, 1988	Jul DISC
>A>	@	5GM/100ML;149MG/100ML;300MG/100ML	N 018876	006	Mar 28, 1988	Jul DISC
	POTASSIUM CHLORIDE 15MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER					
>D>	ICU MEDICAL INC	5GM/100ML;224MG/100ML;225MG/100ML	N 018365	008	Mar 28, 1988	Jul DISC
>A>	@	5GM/100ML;224MG/100ML;225MG/100ML	N 018365	008	Mar 28, 1988	Jul DISC
	POTASSIUM CHLORIDE 15MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER					
>D>	ICU MEDICAL INC	5GM/100ML;224MG/100ML;300MG/100ML	N 018876	007	Mar 28, 1988	Jul DISC
>A>	@	5GM/100ML;224MG/100ML;300MG/100ML	N 018876	007	Mar 28, 1988	Jul DISC
	POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER					
>D>	+ ICU MEDICAL INC	5GM/100ML;298MG/100ML;225MG/100ML	N 018365	009	Mar 28, 1988	Jul DISC
>A>	+ @	5GM/100ML;298MG/100ML;225MG/100ML	N 018365	009	Mar 28, 1988	Jul DISC
	POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER					
>D>	ICU MEDICAL INC	5GM/100ML;298MG/100ML;300MG/100ML	N 018876	008	Mar 28, 1988	Jul DISC
>A>	@	5GM/100ML;298MG/100ML;300MG/100ML	N 018876	008	Mar 28, 1988	Jul DISC
	POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% IN SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER					
>D>	ICU MEDICAL INC	5GM/100ML;149MG/100ML;300MG/100ML	N 018876	002	Jan 17, 1986	Jul DISC
>A>	@	5GM/100ML;149MG/100ML;300MG/100ML	N 018876	002	Jan 17, 1986	Jul DISC
	POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER					
>D>	ICU MEDICAL INC	5GM/100ML;224MG/100ML;225MG/100ML	N 018365	003	Jul 05, 1983	Jul DISC
>A>	@	5GM/100ML;224MG/100ML;225MG/100ML	N 018365	003	Jul 05, 1983	Jul DISC
	POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER					
>D>	ICU MEDICAL INC	5GM/100ML;224MG/100ML;300MG/100ML	N 018876	003	Jan 17, 1986	Jul DISC
>A>	@	5GM/100ML;224MG/100ML;300MG/100ML	N 018876	003	Jan 17, 1986	Jul DISC
	POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER					
>D>	ICU MEDICAL INC	5GM/100ML;298MG/100ML;225MG/100ML	N 018365	004	Jul 05, 1983	Jul DISC
>A>	@	5GM/100ML;298MG/100ML;225MG/100ML	N 018365	004	Jul 05, 1983	Jul DISC
	POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER					
>D>	ICU MEDICAL INC	5GM/100ML;298MG/100ML;225MG/100ML	N 018876	004	Mar 28, 1988	Jul DISC
>A>	@	5GM/100ML;298MG/100ML;300MG/100ML	N 018876	004	Mar 28, 1988	Jul DISC
	POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER					
>D>	ICU MEDICAL INC	5GM/100ML;298MG/100ML;300MG/100ML	N 018876	004	Mar 28, 1988	Jul DISC
>A>	@	5GM/100ML;298MG/100ML;300MG/100ML	N 018876	004	Mar 28, 1988	Jul DISC
	POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER					
>D>	ICU MEDICAL INC	5GM/100ML;74.5MG/100ML;225MG/100ML	N 018365	005	Mar 28, 1988	Jul DISC
>A>	@	5GM/100ML;74.5MG/100ML;225MG/100ML	N 018365	005	Mar 28, 1988	Jul DISC
>D>		5GM/100ML;149MG/100ML;225MG/100ML	N 018365	007	Mar 28, 1988	Jul DISC
>A>	@	5GM/100ML;149MG/100ML;225MG/100ML	N 018365	007	Mar 28, 1988	Jul DISC
	POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER					
>D>	ICU MEDICAL INC	5GM/100ML;74.5MG/100ML;300MG/100ML	N 018876	005	Mar 28, 1988	Jul DISC
>A>	@	5GM/100ML;74.5MG/100ML;300MG/100ML	N 018876	005	Mar 28, 1988	Jul DISC
>D>		5GM/100ML;149MG/100ML;300MG/100ML	N 018876	009	Mar 28, 1988	Jul DISC
>A>	@	5GM/100ML;149MG/100ML;300MG/100ML	N 018876	009	Mar 28, 1988	Jul DISC

DIAZEPAM

GEL; RECTAL

DIASTAT

+ BAUSCH	2.5MG/0.5ML (5MG/ML)	N 020648	001	Jul 29, 1997	Feb CAHN
+ @	5MG/ML (5MG/ML)	N 020648	002	Jul 29, 1997	Feb CAHN
+ @	10MG/2ML (5MG/ML)	N 020648	003	Jul 29, 1997	Feb CAHN
+ @	15MG/3ML (5MG/ML)	N 020648	004	Jul 29, 1997	Feb CAHN
+ @	20MG/4ML (5MG/ML)	N 020648	005	Jul 29, 1997	Feb CAHN

DIASTAT ACUDIAL

+ BAUSCH	10MG/2ML (5MG/ML)	N 020648	007	Sep 15, 2005	Feb CAHN
+ !	20MG/4ML (5MG/ML)	N 020648	006	Sep 15, 2005	Feb CAHN

INJECTABLE; INJECTION

DIAZEPAM

AP BELOTECA INC	10MG/2ML (5MG/ML)	A 210363	001	Mar 18, 2019	Mar NEWA
AP ! HOSPIRA	10MG/2ML (5MG/ML)	A 072079	001	Dec 20, 1988	Mar CTEC

DICLOFENAC

CAPSULE;ORAL	ZORVOLEX					
>D>	+ EGALET	18MG	N204592	001	Oct 18, 2013	Jul CAHN
	+	18MG	N204592	001	Oct 18, 2013	Feb CAHN
>D>	+!	35MG	N204592	002	Oct 18, 2013	Jul CAHN
	+	35MG	N204592	002	Oct 18, 2013	Feb CAHN
>A>	+ ZYLA	18MG	N204592	001	Oct 18, 2013	Jul CAHN
>A>	+!	35MG	N204592	002	Oct 18, 2013	Jul CAHN

DICLOFENAC EPOLAMINE

SYSTEM;TOPICAL	LICART					
+ @ IBSA INST BIO	1.3%	N206976	001	Dec 19, 2018	Feb DISC	

DICLOFENAC POTASSIUM

TABLET;ORAL	DICLOFENAC POTASSIUM					
AB	AMICI	50MG	A076561	001	Mar 18, 2004	May CAHN

DICLOFENAC SODIUM

GEL;TOPICAL	DICLOFENAC SODIUM					
AB	MYLAN	1%	A204306	001	May 06, 2019	Apr NEWA
AB	PERRIGO UK FINCO	1%	A211253	001	May 16, 2019	May NEWA
SOLUTION;INTRAVENOUS	DICLOFENAC SODIUM					
>D>	MYLAN LABS LTD	37.5MG/ML (37.5MG/ML)	A208786	001	Jun 18, 2019	Jul DISC
>A>	@	37.5MG/ML (37.5MG/ML)	A208786	001	Jun 18, 2019	Jul DISC
		37.5MG/ML (37.5MG/ML)	A208786	001	Jun 18, 2019	Jun NEWA
TABLET, EXTENDED RELEASE;ORAL	DICLOFENAC SODIUM					
@ MYLAN	100MG	A076152	001	Dec 13, 2001	Jun DISC	

DICYCLOMINE HYDROCHLORIDE

INJECTABLE;INJECTION	DICYCLOMINE HYDROCHLORIDE					
@ APC PHARMS LLC	10MG/ML	A210979	001	Jul 02, 2018	Feb DISC	
AP CUSTOPHARM INC	10MG/ML	A210788	001	Feb 11, 2019	Jan NEWA	
AP FRESENIUS KABI USA	10MG/ML	A210257	001	Jan 25, 2019	Jan NEWA	
AP NEXUS PHARMS	10MG/ML	A206468	001	Feb 01, 2019	Jan NEWA	
AP SLATE	10MG/ML	A207076	001	Nov 02, 2018	Feb CAHN	
AP SUNGEN PHARMA	10MG/ML	A212058	001	Apr 26, 2019	Apr NEWA	

DIETHYLPROPION HYDROCHLORIDE

TABLET;ORAL	DIETHYLPROPION HYDROCHLORIDE					
>D> AA	LANNETT CO INC	25MG	A200177	001	Jul 18, 2011	Jul CHRS
>A> AA	!	25MG	A200177	001	Jul 18, 2011	Jul CHRS
>D>	TENUATE					
>D> AA	+! TEVA BRANDED PHARM	25MG	N011722	002		Jul DISC
>A>	+ @	25MG	N011722	002		Jul DISC
TABLET, EXTENDED RELEASE;ORAL	DIETHYLPROPION HYDROCHLORIDE					
>D> AB	LANNETT CO INC	75MG	A091680	001	Oct 24, 2011	Jul CHRS
>A> AB	!	75MG	A091680	001	Oct 24, 2011	Jul CHRS
>D>	TENUATE DOSPAN					
>D> AB	+! TEVA BRANDED PHARM	75MG	N012546	001		Jul DISC
>A>	+ @	75MG	N012546	001		Jul DISC

DIGOXIN

ELIXIR;ORAL	DIGOXIN					
+! HIKMA	0.05MG/ML	N021648	001	Aug 26, 2004	Apr CAHN	

DIHYDROERGOTAMINE MESYLATE

INJECTABLE; INJECTION

D.H.E. 45

AP	+! BAUSCH	1MG/ML	N 005929	001	Apr CAHN
	SPRAY, METERED; NASAL				
	MIGRANAL				
	+! BAUSCH	0.5MG/SPRAY	N 020148	001	Dec 08, 1997
	+! VALEANT	0.5MG/SPRAY	N 020148	001	Dec 08, 1997

DILTIAZEM HYDROCHLORIDECAPSULE, EXTENDED RELEASE; ORAL
CARDIZEM CD

AB3	+ BAUSCH	120MG	N 020062	001	Aug 10, 1992	Feb CAHN
AB3	+ BAUSCH	180MG	N 020062	002	Dec 27, 1991	Feb CAHN
AB3	+ BAUSCH	240MG	N 020062	003	Dec 27, 1991	Feb CAHN
AB3	+ BAUSCH	300MG	N 020062	004	Dec 27, 1991	Feb CAHN
AB3	+! BAUSCH	360MG	N 020062	005	Aug 24, 1999	Feb CAHN
	DILTIAZEM HYDROCHLORIDE					
AB2	! APOTEX	240MG	A 074943	001	Aug 06, 1998	May CHRS
AB2	MYLAN	240MG	A 075124	001	Mar 18, 1998	May CHRS
AB3	NOVAST LABS	120MG	A 208783	001	Jun 14, 2019	Jun NEWA
AB3		180MG	A 208783	002	Jun 14, 2019	Jun NEWA
AB3		240MG	A 208783	003	Jun 14, 2019	Jun NEWA
AB3		300MG	A 208783	004	Jun 14, 2019	Jun NEWA
AB3		360MG	A 208783	005	Jun 14, 2019	Jun NEWA
AB3	@ PAR PHARM	360MG	A 209766	001	May 30, 2018	Mar DISC
	TIAZAC					
AB4	+ BAUSCH	120MG	N 020401	001	Sep 11, 1995	Feb CAHN
AB4	+ BAUSCH	180MG	N 020401	002	Sep 11, 1995	Feb CAHN
AB4	+ BAUSCH	240MG	N 020401	003	Sep 11, 1995	Feb CAHN
AB4	+ BAUSCH	300MG	N 020401	004	Sep 11, 1995	Feb CAHN
AB4	+ BAUSCH	360MG	N 020401	005	Sep 11, 1995	Feb CAHN
AB4	+! BAUSCH	420MG	N 020401	006	Oct 16, 1998	Feb CAHN
	INJECTABLE; INJECTION					
	DILTIAZEM HYDROCHLORIDE					
	@ DR REDDYS	5MG/ML	A 074894	001	Aug 26, 1997	May CAHN
	TABLET; ORAL					
	CARDIZEM					
AB	+ BAUSCH	30MG	N 018602	001	Nov 05, 1982	Mar CAHN
AB	+ BAUSCH	60MG	N 018602	002	Nov 05, 1982	Mar CAHN
AB	+ BAUSCH	90MG	N 018602	003	Dec 08, 1986	Mar CAHN
AB	+! BAUSCH	120MG	N 018602	004	Dec 08, 1986	Mar CAHN
	TABLET, EXTENDED RELEASE; ORAL					
	CARDIZEM LA					
AB	+ BAUSCH	120MG	N 021392	001	Feb 06, 2003	Mar CAHN
AB	+ BAUSCH	180MG	N 021392	002	Feb 06, 2003	Mar CAHN
AB	+ BAUSCH	240MG	N 021392	003	Feb 06, 2003	Mar CAHN
AB	+ BAUSCH	300MG	N 021392	004	Feb 06, 2003	Mar CAHN
AB	+ BAUSCH	360MG	N 021392	005	Feb 06, 2003	Mar CAHN
AB	+! BAUSCH	420MG	N 021392	006	Feb 06, 2003	Mar CAHN

DIMETHYL SULFOXIDESOLUTION; INTRAVESICAL
DIMETHYL SULFOXIDE

@ MYLAN INSTITUTIONAL	50%	A 076185	001	Nov 29, 2002	Mar DISC
RIMSO-50					
+! MYLAN INSTITUTIONAL	50%	N 017788	001		Mar CTEC

DIPHENHYDRAMINE HYDROCHLORIDE

CAPSULE; ORAL

DIPHENHYDRAMINE HYDROCHLORIDE

! HERITAGE PHARMA	50MG	A 080738	001	May CAHN
	INJECTABLE; INJECTION			
	DIPHENHYDRAMINE HYDROCHLORIDE			
@ DR REDDYS	10MG/ML	A 080873	001	May CAHN
@ DR REDDYS	50MG/ML	A 080873	002	May CAHN
	DIPHENHYDRAMINE HYDROCHLORIDE PRESERVATIVE FREE			
@ DR REDDYS	50MG/ML	A 080873	003	May CAHN

DIPYRIDAMOLE

INJECTABLE; INJECTION

DIPYRIDAMOLE

@ DR REDDYS

5MG/ML

A074952 001 Nov 26, 1997 May CAHN

DOCETAXEL

INJECTABLE; INJECTION

DOCETAXEL

AP	ACTAVIS LLC	160MG/8ML (20MG/ML)	N203551	004	Sep 21, 2015	Jun NEWA
@	CIPLA	20MG/2ML (10MG/ML)	A209634	001	Aug 24, 2018	Mar DISC
@		80MG/8ML (10MG/ML)	A209634	002	Aug 24, 2018	Mar DISC
@		160MG/16ML (10MG/ML)	A209634	003	Aug 24, 2018	Mar DISC
AP	MYLAN LABS LTD	160MG/8ML (20MG/ML)	A208137	001	Apr 01, 2019	Mar NEWA
AP	SHILPA MEDICARE LTD	20MG/ML (20MG/ML)	A210327	001	May 16, 2019	May NEWA
AP		80MG/4ML (20MG/ML)	A210327	002	May 16, 2019	May NEWA
AP		160MG/8ML (20MG/ML)	A210327	003	May 16, 2019	May NEWA
AP	TEIKOKU PHARMA	20MG/ML (20MG/ML)	N205934	001	Dec 22, 2015	Mar CAHN
AP		80MG/4ML (20MG/ML)	N205934	002	Dec 22, 2015	Mar CAHN
AP		160MG/8ML (20MG/ML)	N205934	003	Dec 22, 2015	Mar CAHN
SOLUTION; INTRAVENOUS						
DOCETAXEL						
AP	SUN PHARMA GLOBAL	20MG/ML (20MG/ML)	N022534	003	Jan 08, 2019	Jan NEWA
AP		80MG/4ML (20MG/ML)	N022534	004	Jan 08, 2019	Jan NEWA
AP		160MG/8ML (20MG/ML)	N022534	005	Jan 08, 2019	Jan NEWA

DOFETILIDE

CAPSULE; ORAL

DOFETILDE

AB	AUROBINDO PHARMA LTD	0.125MG	A210740	001	Jan 22, 2019	Jan NEWA
AB		0.25MG	A210740	002	Jan 22, 2019	Jan NEWA
AB		0.5MG	A210740	003	Jan 22, 2019	Jan NEWA

DOLUTEGRAVIR SODIUM; LAMIVUDINE

TABLET; ORAL

DOVATO

+! VII V HLTHCARE

EQ 50MG BASE; 300MG

N211994 001 Apr 08, 2019 Apr NEWA

DONEPEZIL HYDROCHLORIDE

TABLET; ORAL

DONEPEZIL HYDROCHLORIDE

AB	CADILA	5MG	A090100	001	Oct 24, 2012	Mar CAHN
AB		10MG	A090100	002	Oct 24, 2012	Mar CAHN
AB	HERITAGE PHARMA	5MG	A077344	001	May 31, 2011	May CAHN
AB		10MG	A077344	002	May 31, 2011	May CAHN
@	OSMOTICA PHARM US	23MG	A203114	001	Jan 26, 2016	Mar DISC
AB	STRIDES PHARMA	5MG	A090551	001	May 31, 2011	Apr CAHN
AB		10MG	A090551	002	May 31, 2011	Apr CAHN
>D> AB	SUN PHARM	23MG	A204293	001	Jun 05, 2015	Jul DISC
>A>	@	23MG	A204293	001	Jun 05, 2015	Jul DISC
>D> AB	WOCKHARDT	5MG	A091267	001	May 31, 2011	Jul DISC
>A>	@	5MG	A091267	001	May 31, 2011	Jul DISC
>D> AB		10MG	A091267	002	May 31, 2011	Jul DISC
>A>	@	10MG	A091267	002	May 31, 2011	Jul DISC
TABLET, ORALLY DISINTEGRATING; ORAL						
DONEPEZIL HYDROCHLORIDE						
@	HERITAGE PHARMA	5MG	A078388	002	Nov 26, 2010	May CAHN
@		10MG	A078388	001	Nov 26, 2010	May CAHN

DORZOLAMIDE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

DORZOLAMIDE HYDROCHLORIDE

>A> AT	ALEMBIC PHARMS LTD	EQ 2% BASE	A212639	001	Aug 09, 2019	Jul NEWA
AT	FDC LTD	EQ 2% BASE	A205294	001	Jan 24, 2019	Jan NEWA
@	LUITPOLD	EQ 2% BASE	A079186	001	Nov 18, 2009	Mar DISC

DORZOLAMIDE HYDROCHLORIDE; TIMOLOL MALEATE

SOLUTION/DROPS; OPHTHALMIC

DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE

>D>	@ APOTEX INC	EQ 2% BASE; EQ 0.5% BASE	A078201	001	Oct 28, 2008	Jul CAHN
AT	FDC LTD	EQ 2% BASE; EQ 0.5% BASE	A205295	001	Jun 13, 2019	Jun NEWA
>A>	@ RUBICON	EQ 2% BASE; EQ 0.5% BASE	A078201	001	Oct 28, 2008	Jul CAHN

SOLUTION/DROPS;OPHTHALMIC

DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE

AT SOMERSET THERAPS LLC EQ 2% BASE;EQ 0.5% BASE

A207523 001 Jun 25, 2019 Jun NEWA

DOXAPRAM HYDROCHLORIDE

INJECTABLE;INJECTION

DOPRAM

AP +! HIKMA 20MG/ML

N014879 001

Mar CAHN

DOXEPIN HYDROCHLORIDE

CAPSULE;ORAL

DOXEPIN HYDROCHLORIDE

AB AUROBINDO PHARMA LTD EQ 10MG BASE

A211603 001 Mar 27, 2019 Mar NEWA

AB EQ 25MG BASE

A211603 002 Mar 27, 2019 Mar NEWA

AB EQ 50MG BASE

A211603 003 Mar 27, 2019 Mar NEWA

AB EQ 75MG BASE

A211603 004 Mar 27, 2019 Mar NEWA

AB EQ 100MG BASE

A211603 005 Mar 27, 2019 Mar NEWA

AB PAR PHARM EQ 10MG BASE

A071697 001 Nov 09, 1987 Jan CMFD

AB EQ 25MG BASE

A071437 001 Nov 09, 1987 Jan CMFD

AB EQ 75MG BASE

A071608 001 Nov 09, 1987 Jan CMFD

TABLET;ORAL

SILENOR

+ CURRAX

EQ 3MG BASE

N022036 001 Mar 17, 2010 Apr CAHN

+!

EQ 6MG BASE

N022036 002 Mar 17, 2010 Apr CAHN

+ PERNIX

EQ 3MG BASE

N022036 001 Mar 17, 2010 Feb CAHN

+!

EQ 6MG BASE

N022036 002 Mar 17, 2010 Feb CAHN

DOXERCALCIFEROL

INJECTABLE;INJECTION

DOXERCALCIFEROL

+ @ HOSPIRA INC

10MCG/5ML (2MCG/ML)

N208614 002 Jul 24, 2018 Jun DISC

DOXORUBICIN HYDROCHLORIDE

INJECTABLE;INJECTION

DOXORUBICIN HYDROCHLORIDE

AP HISUN PHARM HANGZHOU 20MG/VIAL

A206062 001 May 13, 2019 Apr NEWA

DOXYCYCLINE

CAPSULE;ORAL

MONODOX

AB + ALMIRALL EQ 50MG BASE

N050641 002 Feb 10, 1992 Feb CAHN

AB + EQ 75MG BASE

N050641 003 Oct 18, 2006 Feb CAHN

AB +! EQ 100MG BASE

N050641 001 Dec 29, 1989 Feb CAHN

TABLET;ORAL

DOXYCYCLINE

@ MYLAN

EQ 50MG BASE

A065377 001 Nov 07, 2006 Apr DISC

@

EQ 75MG BASE

A065377 002 Nov 07, 2006 Apr DISC

@

EQ 100MG BASE

A065377 003 Nov 07, 2006 May DISC

@

EQ 150MG BASE

A065427 001 Jun 07, 2007 May DISC

DOXYCYCLINE HYCLATE

CAPSULE;ORAL

ACTICLATE CAP

+ @ ALMIRALL EQ 75MG BASE

N208253 001 Apr 26, 2016 Feb CAHN

DOXYCYCLINE HYCLATE

@ AJANTA PHARMA LTD EQ 50MG BASE

A211012 001 Sep 24, 2018 Mar DISC

@ EQ 100MG BASE

A211012 002 Sep 24, 2018 Mar DISC

@ MYLAN EQ 50MG BASE

A062337 001 Mar 29, 1982 Apr DISC

@ EQ 100MG BASE

A062337 002 Mar 29, 1982 Apr DISC

TABLET;ORAL

ACTICLATE

AB + ALMIRALL EQ 75MG BASE

N205931 001 Jul 25, 2014 Feb CAHN

AB +! EQ 150MG BASE

N205931 002 Jul 25, 2014 Feb CAHN

DOXYCYCLINE HYCLATE

AB APOTEX INC EQ 75MG BASE

A209243 001 Apr 15, 2019 Apr NEWA

AB EQ 150MG BASE

A209243 002 Apr 15, 2019 Apr NEWA

AB CADILA EQ 100MG BASE

A207773 001 Oct 30, 2017 Feb CAHN

AB HERITAGE PHARMA EQ 20MG BASE

A065163 001 May 13, 2005 May CAHN

TABLET, DELAYED RELEASE;ORAL

DOXYCYCLINE HYCLATE

>D> AB MYLAN EQ 75MG BASE

A090431 001 Dec 28, 2010 Jul DISC

>A> @ EQ 75MG BASE

A090431 001 Dec 28, 2010 Jul DISC

**TABLET, DELAYED RELEASE;ORAL
DOXYCYCLINE HYCLATE**

>D> AB		EQ 100MG BASE	A090431	002	Dec 28, 2010	Jul DISC
>A>	@	EQ 100MG BASE	A090431	002	Dec 28, 2010	Jul DISC
>D> AB		EQ 200MG BASE	A090431	005	May 19, 2016	Jul DISC
>A>	@	EQ 200MG BASE	A090431	005	May 19, 2016	Jul DISC
	@ ZYDUS PHARMS	EQ 75MG BASE	A206772	001	Dec 21, 2018	May DISC
	@	EQ 100MG BASE	A206772	002	Dec 21, 2018	May DISC
	@	EQ 150MG BASE	A206772	003	Dec 21, 2018	May DISC

DROSPIRENONONE

TABLET;ORAL
SLYND
+! EXELTIS USA INC 4MG

N211367 001 May 23, 2019 May NEWA

DROSPIRENONE; ETHINYL ESTRADIOL

TABLET;ORAL
DROSPIRENONE AND ETHINYL ESTRADIOL
AB HETERO LABS LTD 3MG;0.02MG
>A> KYRA
>A> AB SUN PHARM 3MG;0.02MG
TABLET;ORAL-28
KEMEYA
AB SUN PHARM 3MG;0.03MG

A211944 001 Mar 22, 2019 Mar NEWA
A202318 001 Jul 23, 2019 Jul NEWA
A202138 001 Mar 13, 2019 Feb NEWA

DULOXETINE HYDROCHLORIDE

CAPSULE, DELAYED REL PELLETS;ORAL
DULOXETINE HYDROCHLORIDE
AB AJANTA PHARMA LTD EQ 40MG BASE
AB QINGDAO BAHEAL PHARM EQ 20MG BASE
AB EQ 30MG BASE
AB EQ 60MG BASE
>A> CAPSULE, DELAYED RELEASE;ORAL
>A> DRIZALMA SPRINKLE
>A> + SUN PHARMA GLOBAL EQ 20MG BASE
>A> + EQ 30MG BASE
>A> + EQ 40MG BASE
>A> +! EQ 60MG BASE

A208706 004 Mar 11, 2019 Feb NEWA
A210599 001 Apr 17, 2019 Apr NEWA
A210599 002 Apr 17, 2019 Apr NEWA
A210599 003 Apr 17, 2019 Apr NEWA
N212516 001 Jul 19, 2019 Jul NEWA
N212516 002 Jul 19, 2019 Jul NEWA
N212516 003 Jul 19, 2019 Jul NEWA
N212516 004 Jul 19, 2019 Jul NEWA

DUTASTERIDE

CAPSULE;ORAL
DUTASTERIDE
@ BRECKENRIDGE PHARM 0.5MG
@ 0.5MG
AB CADILA 0.5MG

A204705 001 Nov 20, 2015 Jun DISC
A208227 001 Jun 22, 2018 Jun DISC
A204373 001 Oct 04, 2017 Feb CAHN

ECONAZOLE NITRATE

CREAM;TOPICAL
ECONAZOLE NITRATE
@ CASI PHARMS INC 1%
AB ! PERRIGO ISRAEL 1%

A076075 001 Nov 26, 2002 Jun DISC
A076479 001 Jun 23, 2004 May CAHN

EFAVIRENZ

TABLET;ORAL
EFAVIRENZ
@ AUROBINDO PHARMA LTD 600MG

A077673 001 Sep 21, 2018 Feb DISC

EFAVIRENZ; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE

TABLET;ORAL
EFAVIRENZ, EMTRICITABINE, AND TENOFOVIR DISOPROXIL FUMARATE
AB CIPLA 600MG;200MG;300MG
@ TEVA PHARMS USA 600MG;200MG;300MG

A206894 001 Jun 03, 2019 May NEWA
A091215 001 Nov 09, 2018 May DISC

EFAVIRENZ; LAMIVUDINE; TENOFOVIR DISOPROXIL FUMARATE

TABLET;ORAL
EFAVIRENZ, LAMIVUDINE AND TENOFOVIR DISOPROXIL FUMARATE
@ MACLEODS PHARMS LTD 400MG;300MG;300MG
400MG;300MG;300MG

N210649 001 Mar 15, 2019 Jun DISC
N210649 001 Mar 15, 2019 Mar NEWA

EFINAConazole

SOLUTION;TOPICAL

JUBLIA

+! BAUSCH

10%

N203567 001 Jun 06, 2014 Feb CAHN

ELTROMBOPAG OLAMINE

TABLET;ORAL

PROMACTA

+ @ NOVARTIS PHARMS CORP EQ 100MG ACID

N022291 005 Nov 16, 2012 Feb DISC

EMEDASTINE DIFUMARATE

>D> SOLUTION/DROPS;OPHTHALMIC

EMADINE

>D> +! NOVARTIS PHARMS CORP 0.05%

N020706 001 Dec 29, 1997 Jul DISC

>A> + @ 0.05%

N020706 001 Dec 29, 1997 Jul DISC

EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE

TABLET;ORAL

EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE

@ AMNEAL PHARMS CO 100MG;150MG

A209721 001 Aug 22, 2018 Feb DISC

@ 133MG;200MG

A209721 002 Aug 22, 2018 Feb DISC

@ 167MG;250MG

A209721 003 Aug 22, 2018 Feb DISC

@ 200MG;300MG

A209721 004 Aug 22, 2018 Feb DISC

>A> AB LAURUS LABS LTD 200MG;300MG

A212114 001 Jul 26, 2019 Jul NEWA

TRUVADA

+ GILEAD 100MG;150MG

N021752 002 Mar 10, 2016 Feb CTEC

+ 133MG;200MG

N021752 003 Mar 10, 2016 Feb CTEC

+ 167MG;250MG

N021752 004 Mar 10, 2016 Feb CTEC

ENALAPRIL MALEATE

FOR SOLUTION;ORAL

EPANED KIT

+ @ SILVERGATE PHARMS 1MG/ML

N204308 001 Aug 13, 2013 Mar DISC

TABLET;ORAL

ENALAPRIL MALEATE

@ BEXIMCO PHARMS USA 2.5MG

A075621 001 Aug 22, 2000 Feb CAHN

@ 5MG

A075621 002 Aug 22, 2000 Feb CAHN

@ 10MG

A075621 003 Aug 22, 2000 Feb CAHN

@ 20MG

A075621 004 Aug 22, 2000 Feb CAHN

AB HERITAGE PHARMA 2.5MG

A075479 001 Aug 22, 2000 Feb CAHN

AB 5MG

A075479 002 Aug 22, 2000 Feb CAHN

AB 10MG

A075479 003 Aug 22, 2000 Feb CAHN

AB 20MG

A075479 004 Aug 22, 2000 Feb CAHN

@ MYLAN 5MG

A075480 002 Aug 22, 2000 Jun DISC

@ 10MG

A075480 003 Aug 22, 2000 Feb DISC

VASOTEC

AB + BAUSCH 2.5MG

N018998 005 Jul 26, 1988 Mar CAHN

AB + 5MG

N018998 001 Dec 24, 1985 Mar CAHN

AB + 10MG

N018998 002 Dec 24, 1985 Mar CAHN

AB +! 20MG

N018998 003 Dec 24, 1985 Mar CAHN

ENALAPRIL MALEATE; HYDROCHLOROTHIAZIDE

TABLET;ORAL

VASERETIC

AB + BAUSCH 5MG;12.5MG

N019221 003 Jul 12, 1995 Mar CAHN

AB +! 10MG;25MG

N019221 001 Oct 31, 1986 Mar CAHN

ENALAPRILAT

INJECTABLE;INJECTION

ENALAPRILAT

AP DR REDDYS 1.25MG/ML

A075578 001 Aug 22, 2000 May CAHN

ENCORAFENIB

CAPSULE;ORAL

BRAFTOVI

>D> + ARRAY BIOPHARMA INC 50MG

N210496 001 Jun 27, 2018 Jul DISC

>A> + @ 50MG

N210496 001 Jun 27, 2018 Jul DISC

ENOXAPARIN SODIUM

INJECTABLE; INTRAVENOUS, SUBCUTANEOUS

ENOXAPARIN SODIUM

AB AMPHASTAR PHARMS INC 300MG/3ML (100MG/ML) A208600 001 Mar 14, 2019 Mar NEWA

ENTECAVIR

TABLET; ORAL

ENTECAVIR

AB MYLAN 0.5MG A206226 001 Mar 26, 2019 Mar NEWA

AB 1MG A206226 002 Mar 26, 2019 Mar NEWA

EPINASTINE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

EPINASTINE HYDROCHLORIDE

>D> AT @ CASI PHARMS INC 0.05% A203384 001 Dec 07, 2016 Jun DISC

>A> SUN PHARM INDNS 0.05% A091626 001 Oct 31, 2011 Jul DISC

>A> @ 0.05% A091626 001 Oct 31, 2011 Jul DISC

EPINEPHRINE

INJECTABLE; INTRAMUSCULAR, SUBCUTANEOUS

EPINEPHRINE (AUTOINJECTOR)

>D> @ TEVA PHARMS USA 0.15MG/DELIVERY A090589 002 Aug 16, 2018 Jul CMFD

>A> AB @ 0.15MG/DELIVERY A090589 002 Aug 16, 2018 Jul CMFD

@ EPIPEN JR. A090589 002 Aug 16, 2018 Mar DISC

>D> +! MYLAN SPECIALITY LP 0.15MG/DELIVERY N019430 002 Dec 22, 1987 Jul CTEC

>A> AB +! 0.15MG/DELIVERY N019430 002 Dec 22, 1987 Jul CTEC

+! 0.15MG/DELIVERY N019430 002 Dec 22, 1987 Mar CTEC

SOLUTION; INTRAMUSCULAR, INTRAVENOUS, SUBCUTANEOUS

ADRENALIN

+! PAR STERILE PRODUCTS EQ 30MG BASE/30ML (EQ 1MG BASE/ML) N204640 001 Dec 18, 2013 Jan CDFR

SOLUTION; INTRAVENOUS, INTRAOCULAR, INTRAMUSCULAR, SUBCUTANEOUS

EPINEPHRINE

+! BELCHER PHARMS LLC EQ 1MG BASE/ML (EQ 1MG BASE/ML) N205029 001 Jul 29, 2014 May CDFR

EPIRUBICIN HYDROCHLORIDE

INJECTABLE; INJECTION

EPIRUBICIN HYDROCHLORIDE

FRESENIUS KABI USA 150MG/75ML (2MG/ML)

A065408 003 Oct 15, 2007 Mar CTEC

EPTIFIBATIDE

INJECTABLE; INJECTION

EPTIFIBATIDE

AP BAXTER HLTHCARE CORP 2MG/ML A208554 001 Nov 23, 2018 Jan CAHN

AP 75MG/100ML A208554 002 Nov 23, 2018 Jan CAHN

AP HAINAN POLY PHARM 2MG/ML A209864 001 Jan 25, 2019 Jan NEWA

AP 75MG/100ML A209864 002 Jan 25, 2019 Jan NEWA

AP USV 2MG/ML A204361 001 Mar 14, 2019 Mar NEWA

AP 2MG/ML A204362 001 Mar 11, 2019 Feb NEWA

AP 75MG/100ML A204361 002 Mar 14, 2019 Mar NEWA

ERDAFITINIB

TABLET; ORAL

BALVERSA

+ JANSSEN BIOTECH 3MG N212018 001 Apr 12, 2019 Apr NEWA

+ 4MG N212018 002 Apr 12, 2019 Apr NEWA

+! 5MG N212018 003 Apr 12, 2019 Apr NEWA

ERLOTINIB HYDROCHLORIDE

TABLET; ORAL

ERLOTINIB HYDROCHLORIDE

AB MYLAN EQ 25MG BASE A091002 001 Jun 11, 2014 Feb CMFD

AB EQ 100MG BASE A091002 002 Jun 11, 2014 Feb CMFD

AB EQ 150MG BASE A091002 003 Jun 11, 2014 Feb CMFD

AB TEVA PHARMS USA EQ 100MG BASE A091059 002 Aug 28, 2015 Mar CMFD

AB EQ 150MG BASE A091059 003 Aug 28, 2015 Mar CMFD

TARCEVA

AB + OSI PHARMS EQ 25MG BASE N021743 001 Nov 18, 2004 Mar CAHN

AB + EQ 25MG BASE N021743 001 Nov 18, 2004 Feb CTEC

AB + EQ 100MG BASE N021743 002 Nov 18, 2004 Mar CAHN

AB + EQ 100MG BASE N021743 002 Nov 18, 2004 Feb CTEC

	TABLET;ORAL TARCEVA					
AB	+!	EQ 150MG BASE	N 021743	003	Nov 18, 2004	Mar CAHN
AB	+!	EQ 150MG BASE	N 021743	003	Nov 18, 2004	Feb CTEC
<u>ERTAPENEM SODIUM</u>						
INJECTABLE;INTRAMUSCULAR, INTRAVENOUS ERTAPENEM SODIUM						
AP	SAVIOR LIFETEC CORP	EQ 1GM BASE/VIAL	A 207647	001	Mar 19, 2019	Mar NEWA
<u>ERYTHROMYCIN</u>						
OINTMENT;TOPICAL AKNE-MYCIN						
+ @ BAUSCH	2%		N 050584	001	Jan 10, 1985	Apr CAHN
TABLET, DELAYED RELEASE;ORAL ERY-TAB						
AB	ARBOR PHARMS LLC	250MG	A 062298	001		Jun CTEC
AB		333MG	A 062298	003	Mar 29, 1982	Jun CTEC
AB	!	500MG	A 062298	002		Jun CTEC
ERYTHROMYCIN						
AB	AMNEAL PHARMS CO	250MG	A 210954	001	Jul 02, 2019	Jun NEWA
AB		333MG	A 210954	002	Jul 02, 2019	Jun NEWA
AB		500MG	A 210954	003	Jul 02, 2019	Jun NEWA
<u>ESCITALOPRAM OXALATE</u>						
TABLET;ORAL ESCITALOPRAM OXALATE						
AB	CADILA	EQ 5MG BASE	A 077734	001	Sep 11, 2012	Apr CAHN
AB		EQ 10MG BASE	A 077734	002	Sep 11, 2012	Apr CAHN
AB		EQ 20MG BASE	A 077734	003	Sep 11, 2012	Apr CAHN
<u>ESKETAMINE HYDROCHLORIDE</u>						
SPRAY;NASAL SPRAVATO						
+ !	JANSSEN PHARMS	EQ 28MG BASE	N 211243	001	Mar 05, 2019	Mar NEWA
<u>ESMOLOL HYDROCHLORIDE</u>						
INJECTABLE;INJECTION ESMOLOL HYDROCHLORIDE						
>A> AP	GLAND PHARMA LTD	10MG/ML	A 208538	001	Aug 14, 2019	Jul NEWA
<u>ESOMEPRAZOLE MAGNESIUM</u>						
CAPSULE, DELAYED REL PELLETS;ORAL ESOMEPRAZOLE MAGNESIUM						
AB	@ AMNEAL PHARMS NY	EQ 20MG BASE	A 209647	001	Apr 10, 2019	Jun DISC
		EQ 20MG BASE	A 209647	001	Apr 10, 2019	Mar NEWA
AB	@	EQ 40MG BASE	A 209647	002	Apr 10, 2019	Jun DISC
AB		EQ 40MG BASE	A 209647	002	Apr 10, 2019	Mar NEWA
AB	GLENMARK PHARMS	EQ 20MG BASE	A 209495	001	May 10, 2019	Apr NEWA
AB		EQ 40MG BASE	A 209495	002	May 10, 2019	Apr NEWA
	@ HEC PHARM	EQ 20MG BASE	A 207265	002	May 18, 2018	Mar DISC
AB	HETERO LABS LTD III	EQ 20MG BASE	A 207265	001	May 18, 2018	Mar DISC
AB		EQ 40MG BASE	A 202784	001	Sep 21, 2015	Jun CTEC
AB	ZYDUS PHARMS	EQ 20MG BASE	A 202784	002	Sep 21, 2015	Jun CTEC
AB		EQ 40MG BASE	A 206296	001	May 22, 2019	May NEWA
			A 206296	002	May 22, 2019	May NEWA
<u>ESTRADIOOL</u>						
FILM, EXTENDED RELEASE;TRANSDERMAL ESTRADIOL						
AB1	AMNEAL PHARMS LLC	0.025MG/24HR	A 211293	001	Feb 04, 2019	Jan NEWA
AB1		0.0375MG/24HR	A 211293	002	Feb 04, 2019	Jan NEWA
AB1		0.05MG/24HR	A 211293	003	Feb 04, 2019	Jan NEWA
AB1		0.075MG/24HR	A 211293	004	Feb 04, 2019	Jan NEWA
AB1		0.1MG/24HR	A 211293	005	Feb 04, 2019	Jan NEWA
GEL;TRANSDERMAL DIVIGEL						
+ !	VERTICAL PHARMS LLC	0.1%	N 022038	001	Jun 04, 2007	Jan CHRS

ESTRADIOL VALERATE

INJECTABLE; INJECTION

ESTRADIOL VALERATE

@ DR REDDYS

40MG/ML

A083714 001

May CAHN

ESTRADIOL; NORETHINDRONE ACETATE

TABLET; ORAL

ESTRADIOL AND NORETHINDRONE ACETATE

@ ACCORD HLTHCARE

1MG; 0.5MG

AB NOVAST LABS

0.5MG; 0.1MG

AB

1MG; 0.5MG

A210233 001 Feb 28, 2018

Mar DISC

A210612 001 Apr 03, 2019

Mar NEWA

A210612 002 Apr 03, 2019

Mar NEWA

ESTROGENS, CONJUGATED SYNTHETIC A

TABLET; ORAL

CENESTIN

+ @ ASPEN

0.3MG

N020992 001 Jun 21, 2002

Feb CAHN

+ @

0.45MG

N020992 005 Feb 05, 2004

Feb CAHN

+ @

0.625MG

N020992 002 Mar 24, 1999

Feb CAHN

+ @

0.9MG

N020992 003 Mar 24, 1999

Feb CAHN

+ @

1.25MG

N020992 004 Mar 13, 2000

Feb CAHN

ESTROGENS, CONJUGATED SYNTHETIC B

TABLET; ORAL

ENJUVIA

@ ASPEN

0.3MG

N021443 001 Dec 20, 2004

Feb CAHN

@

0.45MG

N021443 002 Dec 20, 2004

Feb CAHN

@

0.625MG

N021443 003 May 10, 2004

Feb CAHN

@

0.9MG

N021443 005 Apr 27, 2007

Feb CAHN

@

1.25MG

N021443 004 May 10, 2004

Feb CAHN

ESZOPICLONE

TABLET; ORAL

ESZOPICLONE

@ BRECKENRIDGE PHARM

1MG

A203087 001 May 08, 2019

May DISC

AB

1MG

A203087 001 May 08, 2019

Apr NEWA

@

2MG

A203087 002 May 08, 2019

May DISC

AB

2MG

A203087 002 May 08, 2019

Apr NEWA

@

3MG

A203087 003 May 08, 2019

May DISC

AB

3MG

A203087 003 May 08, 2019

Apr NEWA

ETHACRYNATE SODIUM

INJECTABLE; INJECTION

EDECRIN

AP

+! BAUSCH

EQ 50MG BASE/VIAL

N016093 001

Mar CAHN

AP

+! VALEANT PHARMS INTL

EQ 50MG BASE/VIAL

N016093 001

Jan CAHN

ETHACRYNIC ACID

TABLET; ORAL

EDECRIN

AB

+! BAUSCH

25MG

N016092 001

Mar CAHN

@

50MG

N016092 002

Mar CAHN

AB

+! VALEANT PHARMS INTL

25MG

N016092 001

Jan CAHN

@

50MG

N016092 002

Jan CAHN

ETHACRYNIC ACID

>A> AB AGNITIO

25MG

A211809 001 Jul 12, 2019

Jul NEWA

ETHINYL ESTRADIOL; ETHYNODIOL DIACETATE

TABLET; ORAL-28

LO-MALMOREDE

AB

NOVAST LABS

0.035MG; 1MG

A209548 001 Feb 11, 2019

Jan NEWA

ETHINYL ESTRADIOL; LEVONORGESTREL

TABLET; ORAL

SYLEVIA

AB

SUN PHARM

0.03MG; 0.15MG

A202988 001 Feb 06, 2019

Jan NEWA

TABLET; ORAL-28

LEVONORGESTREL AND ETHINYL ESTRADIOL

@ MYLAN LABS LTD

0.02MG; 0.1MG

A202247 001 Dec 08, 2014

Jun DISC

ETHINYL ESTRADIOL; NORETHINDRONE

	TABLET;ORAL-28 NORTREL 1/35-28					
AB	! BARR ORTHO-NOVUM 1/35-28	0.035MG;1MG	A072696	001	Feb 28, 1992	Mar CHRS
	+ @ JANSSEN PHARMS	0.035MG;1MG	N017919	002		Mar DISC
	TABLET, CHEWABLE;ORAL FEMCON FE					
	+ @ APIL NORETHINDRONE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE	0.035MG;0.4MG	N021490	001	Nov 14, 2003	Mar DISC
AB	! MYLAN LABS LTD	0.035MG;0.4MG	A202086	001	Apr 01, 2015	Mar CHRS

ETHINYL ESTRADIOL; NORETHINDRONE ACETATE

	TABLET;ORAL-21 HAILEY 1.5/30					
AB	GLENMARK PHARMS LOESTRIN 21 1.5/30	0.03MG;1.5MG	A209297	001	Jun 05, 2018	Jan CDFR
AB	+ APIL LOESTRIN 21 1/20	0.03MG;1.5MG	N017875	001		Jan CRLD
AB	+ APIL	0.02MG;1MG	N017876	001		Jan CRLD

ETHINYL ESTRADIOL; NORGESTIMATE

	TABLET;ORAL-28 NORGESTIMATE AND ETHINYL ESTRADIOL					
	@ MYLAN LABS LTD	0.025MG,0.025MG,0.025MG;0.18MG,0.2 15MG,0.25MG	A202132	001	Sep 09, 2015	Jan DISC
	ORTHO CYCLEN-28		N019653	002	Dec 29, 1989	Apr DISC
	+ @ JANSSEN PHARMS SPRINTEC	0.035MG;0.25MG				
AB	! BARR	0.035MG;0.25MG	A075804	001	Sep 25, 2002	Apr CHRS

ETHINYL ESTRADIOL; SEGESTERONE ACETATE

	RING;VAGINAL ANNOVERA					
	+! THERAPEUTICSMD INC	0.013MG/24HR;0.15MG/24HR	N209627	001	Aug 10, 2018	May CMFD
	+ @	0.013MG/24HR;0.15MG/24HR	N209627	001	Aug 10, 2018	Feb DISC

ETHOSUXIMIDE

	CAPSULE;ORAL ETHOSUXIMIDE					
AB	STRIDES PHARMA	250MG	A211928	001	Feb 19, 2019	Feb NEWA
	SYRUP;ORAL ETHOSUXIMIDE					
	@ TEVA PHARMS	250MG/5ML	A081306	001	Jul 30, 1993	May DISC

ETOMIDATE

	INJECTABLE;INJECTION ETOMIDATE					
	@ LUITPOLD	2MG/ML	A078867	001	Dec 22, 2009	Feb DISC
	@ PAR STERILE PRODUCTS	2MG/ML	A091297	001	Jun 20, 2012	Apr DISC

ETOPOSIDE PHOSPHATE

	INJECTABLE;INJECTION ETOPOPHOS PRESERVATIVE FREE					
	+! CHEPLAPHARM	EQ 100MG BASE/VIAL	N020457	001	May 17, 1996	May CAHN

EVEROLIMUS

	TABLET;ORAL AFINITOR					
	+! NOVARTIS	5MG	N022334	001	Mar 30, 2009	Apr CHRS
	+	10MG	N022334	002	Mar 30, 2009	Apr CHRS
	ZORTRESS					
	+ NOVARTIS	1MG	N021560	004	Aug 10, 2018	Mar NEWA
	TABLET, FOR SUSPENSION;ORAL AFINITOR DISPERZ					
	+ NOVARTIS PHARM	2MG	N203985	001	Aug 29, 2012	Apr CTEC
AB	+	2MG	N203985	001	Aug 29, 2012	Apr CFTG
	+	3MG	N203985	002	Aug 29, 2012	Apr CTEC
AB	+	3MG	N203985	002	Aug 29, 2012	Apr CFTG
	+	5MG	N203985	003	Aug 29, 2012	Apr CTEC

**TABLET, FOR SUSPENSION;ORAL
AFINITOR DISPERZ**

AB	+!	5MG	N 203985	003	Aug 29, 2012	Apr CFTG
	EVEROLIMUS					
	@ MYLAN	2MG	A 210130	001	Apr 19, 2019	Apr NFTG
	@	3MG	A 210130	002	Apr 19, 2019	Apr NFTG
	@	5MG	A 210130	003	Apr 19, 2019	Apr NFTG

EXEMESTANE

**TABLET;ORAL
EXEMESTANE**

>D> AB	AMNEAL PHARMS	25MG	A 206421	001	Dec 28, 2018	Jul DISC
>A>	@	25MG	A 206421	001	Dec 28, 2018	Jul DISC
	@ BRECKENRIDGE PHARM	25MG	A 211031	001	Feb 21, 2019	May DISC
AB		25MG	A 211031	001	Feb 21, 2019	Feb NEWA
>A> AB	MAYNE PHARMA INC	25MG	A 208764	001	Aug 08, 2019	Jul NEWA

EZETIMIBE

**TABLET;ORAL
EZETIMIBE**

AB	@ ACCORD HLTHCARE	10MG	A 211550	001	Oct 26, 2018	Apr DISC
	MYLAN	10MG	A 201790	001	Apr 26, 2019	Apr NEWA

EZETIMIBE; SIMVASTATIN

**TABLET;ORAL
EZETIMIBE AND SIMVASTATIN**

AB	GLENMARK PHARMS LTD	10MG;10MG	A 208699	001	Jun 27, 2019	Jun NEWA
AB		10MG;20MG	A 208699	002	Jun 27, 2019	Jun NEWA
AB		10MG;40MG	A 208699	003	Jun 27, 2019	Jun NEWA
AB		10MG;80MG	A 208699	004	Jun 27, 2019	Jun NEWA

FAMOTIDINE

**TABLET;ORAL
FAMOTIDINE**

AB	@ MYLAN	40MG	A 075704	002	Apr 16, 2001	Apr DISC
----	---------	------	----------	-----	--------------	----------

FEBUXOSTAT

**TABLET;ORAL
FEBUXOSTAT**

AB	ALEMBIC PHARMS LTD	40MG	A 205421	001	Jul 01, 2019	Jun NFTG
AB		80MG	A 205421	002	Jul 01, 2019	Jun NFTG
AB	MYLAN	40MG	A 205385	001	Jul 01, 2019	Jun NFTG
AB		80MG	A 205385	002	Jul 01, 2019	Jun NFTG
AB	SUN PHARM	40MG	A 205467	001	Jul 01, 2019	Jun NFTG
AB		80MG	A 205467	002	Jul 01, 2019	Jun NFTG
	ULORIC					
AB	+ TAKEDA PHARMS USA	40MG	N 021856	001	Feb 13, 2009	Jun CFTG
AB	+!	80MG	N 021856	002	Feb 13, 2009	Jun CFTG

FELBAMATE

**SUSPENSION;ORAL
FELBAMATE**

AB	VISTAPHARM	600MG/5ML	A 211333	001	May 31, 2019	May NEWA
	TABLET;ORAL					
	FELBAMATE					
>A> AB	CADILA	400MG	A 208970	001	May 30, 2017	Jul CAHN
>A> AB		600MG	A 208970	002	May 30, 2017	Jul CAHN
>D> AB	ZYDUS PHARMS	400MG	A 208970	001	May 30, 2017	Jul CAHN
>D> AB		600MG	A 208970	002	May 30, 2017	Jul CAHN

FELODIPINE

**TABLET, EXTENDED RELEASE;ORAL
FELODIPINE**

AB	YUNG SHIN PHARM	2.5MG	A 204800	001	Apr 29, 2019	Apr NEWA
AB		5MG	A 204800	002	Apr 29, 2019	Apr NEWA
AB		10MG	A 204800	003	Apr 29, 2019	Apr NEWA

FENOFIBRATE

CAPSULE;ORAL

FENOFIBRATE (MICRONIZED)

AB	AUSTARPHARMA	67MG	A207805	001	Nov 16, 2017	Jan CAHN
AB		134MG	A207805	002	Nov 16, 2017	Jan CAHN
AB		200MG	A207805	003	Nov 16, 2017	Jan CAHN
AB	INGENUS PHARMS LLC	67MG	A207564	001	Apr 19, 2019	Apr NEWA
AB		134MG	A207564	002	Apr 19, 2019	Apr NEWA
AB		200MG	A207564	003	Apr 19, 2019	Apr NEWA

TABLET;ORAL

FENOFIBRATE

>A> AB	ALEMBIC PHARMS LTD	48MG	A210476	001	Aug 09, 2019	Jul NEWA
>A> AB		145MG	A210476	002	Aug 09, 2019	Jul NEWA
AB	AUSTARPHARMA	54MG	A207803	001	Dec 19, 2017	Jan CAHN
AB		160MG	A207803	002	Dec 19, 2017	Jan CAHN
	@ GRAVITI PHARMS	54MG	A210606	001	Aug 17, 2018	Feb DISC
	@	160MG	A210606	002	Aug 17, 2018	Feb DISC
AB	ORIT LABS LLC	54MG	A209660	001	Feb 11, 2019	Jan NEWA
AB		160MG	A209660	002	Feb 11, 2019	Jan NEWA
	FENOGLIDE					
AB	+ SALIX	40MG	N022118	001	Aug 10, 2007	Mar CAHN
AB	+!	120MG	N022118	002	Aug 10, 2007	Mar CAHN

FENOFIBRIC ACID

TABLET;ORAL

FIBRICOR

+ ATHENA

+!

35MG

105MG

N022418 001 Aug 14, 2009 Feb CAHN
N022418 002 Aug 14, 2009 Feb CAHNFENOPROFEN CALCIUM

TABLET;ORAL

FENOPROFEN CALCIUM

@ ANI PHARMS INC

EQ 600MG BASE

A072274 001 May 02, 1988 May CAHN

FENTANYL

FILM, EXTENDED RELEASE;TRANSDERMAL

FENTANYL-100

>D> AB	MAYNE PHARMA	100MCG/HR	A077062	004	Aug 20, 2007	Jul DISC
>A>	@	100MCG/HR	A077062	004	Aug 20, 2007	Jul DISC
	FENTANYL-25					
>D> AB	MAYNE PHARMA	25MCG/HR	A077062	001	Aug 20, 2007	Jul DISC
>A>	@	25MCG/HR	A077062	001	Aug 20, 2007	Jul DISC
	FENTANYL-50					
>D> AB	MAYNE PHARMA	50MCG/HR	A077062	002	Aug 20, 2007	Jul DISC
>A>	@	50MCG/HR	A077062	002	Aug 20, 2007	Jul DISC
	FENTANYL-75					
>D> AB	MAYNE PHARMA	75MCG/HR	A077062	003	Aug 20, 2007	Jul DISC
>A>	@	75MCG/HR	A077062	003	Aug 20, 2007	Jul DISC

FENTANYL CITRATE

INJECTABLE;INJECTION

FENTANYL CITRATE PRESERVATIVE FREE

AP	FRESENIUS KABI USA	EQ 0.05MG BASE/ML	A210762	001	May 03, 2019	Apr NEWA
----	--------------------	-------------------	---------	-----	--------------	----------

FERRIC CARBOXYMALTOSE

INJECTABLE;INTRAVENOUS

INJECTAFER

+! AM REGENT

750MG IRON/15ML (50MG IRON/ML)

N203565 001 Jul 25, 2013 Jun CAHN

FERRIC MALTOL

>A> CAPSULE;ORAL

>A> ACCRUFER

>A> +! SHIELD TX

30MG IRON

N212320 001 Jul 25, 2019 Jul NEWA

FESOTERODINE FUMARATE

TABLET, EXTENDED RELEASE;ORAL

FESOTERODINE FUMARATE

>A> AB	DR REDDYS LABS LTD	4MG	A204975	001	Aug 13, 2019	Jul NEWA
>A> AB		8MG	A204975	002	Aug 13, 2019	Jul NEWA

FEXOFENADINE HYDROCHLORIDE

TABLET;ORAL

FEXOFENADINE HYDROCHLORIDE

>D>	AB	MYLAN	30MG	A077081	002	Apr 11, 2008	Jul DISC
>A>	@		30MG	A077081	002	Apr 11, 2008	Jul DISC

FINAFLOXACIN

SUSPENSION/DROPS;OTIC

XTORO

+ @ MERLION PHARMS GMBH 0.3%

N206307 001 Dec 17, 2014 Apr DISC

FINASTERIDE

TABLET;ORAL

FINASTERIDE

>D>	AB	MYLAN	5MG	A077578	001	Dec 18, 2006	Jul DISC
>A>	@		5MG	A077578	001	Dec 18, 2006	Jul DISC

FLOXURIDINE

INJECTABLE;INJECTION

FLOXURIDINE

@ LUITPOLD 500MG/VIAL

A203008 001 Nov 22, 2017 Mar DISC

FLUCONAZOLE

INJECTABLE;INJECTION

FLUCONAZOLE IN SODIUM CHLORIDE 0.9%

@ DR REDDYS 200MG/100ML (2MG/ML)

A076653 001 Jul 29, 2004 May CAHN

@ 400MG/200ML (2MG/ML)

A076653 002 Jul 29, 2004 May CAHN

FLUCONAZOLE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

@ DR REDDYS 200MG/100ML (2MG/ML)

A076837 001 Jan 13, 2005 May CAHN

@ 400MG/200ML (2MG/ML)

A076837 002 Jan 13, 2005 May CAHN

TABLET;ORAL

FLUCONAZOLE

AB	CHARTWELL	50MG	A076665	001	Jul 29, 2004	Jun CAHN
AB		100MG	A076665	002	Jul 29, 2004	Jun CAHN
AB		150MG	A076665	003	Jul 29, 2004	Jun CAHN
AB		200MG	A076665	004	Jul 29, 2004	Jun CAHN

FLUCYTOSINE

CAPSULE;ORAL

ANCOBON

AB	+	BAUSCH	250MG	N017001	001	Feb CAHN
AB	+!		500MG	N017001	002	Feb CAHN

FLUDEOXYGLUCOSE F-18

INJECTABLE;INTRAVENOUS

FLUDEOXYGLUCOSE F18

AP	DECATUR	20-300mCi/ML	A204463	001	Oct 21, 2014	Apr CAHN
----	---------	--------------	---------	-----	--------------	----------

FLUMAZENIL

INJECTABLE;INJECTION

FLUMAZENIL

@ DR REDDYS 0.5MG/5ML (0.1MG/ML)

A076589 002 Oct 12, 2004 May CAHN

@ 1MG/10ML (0.1MG/ML)

A076589 001 Oct 12, 2004 May CAHN

FLUNISOLIDE

>D>		AEROSOL, METERED;INHALATION					
>D>		AEROSAN HFA					
>D>	+	MYLAN SPECIALITY LP	0.078MG/INH	N021247	001	Jan 27, 2006	Jul DISC
>A>	+	@	0.078MG/INH	N021247	001	Jan 27, 2006	Jul DISC
		SPRAY, METERED;NASAL					
		FLUNISOLIDE					
		APOTEX INC	0.029MG/SPRAY	A077436	001	Aug 09, 2007	Jun CMFD
AB			0.029MG/SPRAY	A077436	001	Aug 09, 2007	Jun CMFD

FLUOCINOLONE ACETONIDE

SOLUTION;TOPICAL

FLUOCINOLONE ACETONIDE

AT		@ ACTAVIS LABS UT INC	0.01%	A208386	001	Oct 21, 2016	Mar DISC
AT		ENCUBE ETHICALS	0.01%	A209913	001	Feb 13, 2019	Jan NEWA
AT		GLASSHOUSE PHARMS	0.01%	A209596	001	Dec 26, 2017	Jan CMFD
AT		LUPIN	0.01%	A206422	001	Sep 02, 2015	Feb CAHN

FLUOCINONIDE

CREAM;TOPICAL					
FLUOCINONIDE					
AB @ AMNEAL PHARMS LLC	0.05%	A210554	001	Aug 21, 2018	Feb DISC
AB TELIGENT PHARMA INC	0.1%	A211758	001	Apr 03, 2019	Mar NEWA
SOLUTION;TOPICAL					
FLUOCINONIDE					
AT TELIGENT PHARMA INC	0.05%	A207554	001	Mar 18, 2019	Mar NEWA

FLUOROMETHOLONE

SUSPENSION/DROPS;OPHTHALMIC					
FML FORTE					
+! ALLERGAN	0.25%	N019216	001	Apr 23, 1986	Jun CHRS
+	0.25%	N019216	001	Apr 23, 1986	Jun CRLD

FLUOROMETHOLONE ACETATE

SUSPENSION/DROPS;OPHTHALMIC					
FLAREX					
+! EYEVANCE	0.1%	N019079	001	Feb 11, 1986	Feb CAHN

FLUOROMETHOLONE ACETATE; TOBRAMYCIN

SUSPENSION/DROPS;OPHTHALMIC					
TOBRASONE					
AB EYEVANCE	0.1%;0.3%	N050628	001	Jul 21, 1989	May CAHN

FLUOROURACIL

CREAM;TOPICAL					
FLUOROPLEX					
+! ALMIRALL	1%	N016988	001		Feb CAHN

FLUOXETINE HYDROCHLORIDE

CAPSULE;ORAL					
FLUOXETINE HYDROCHLORIDE					
AB1 APNAR PHARMA LP	EQ 10MG BASE	A075049	001	Aug 02, 2001	Jun CAHN
AB1	EQ 20MG BASE	A075049	002	Jan 29, 2002	Jun CAHN
AB	EQ 40MG BASE	A075049	003	Jan 29, 2002	Jun CAHN
AB @ BEXIMCO PHARMS USA	EQ 10MG BASE	A075807	001	Jan 29, 2002	Feb CAHN
AB1 CADILA PHARMS LTD	EQ 10MG BASE	A075807	002	Jan 29, 2002	Feb CAHN
AB1	EQ 20MG BASE	A206993	001	May 23, 2019	May NEWA
AB	EQ 40MG BASE	A206993	002	May 23, 2019	May NEWA
AB @ PAR PHARM	EQ 40MG BASE	A206993	003	May 23, 2019	May NEWA
AB A076922		003	Dec 16, 2004	Mar DISC	

CAPSULE, DELAYED REL PELLETS;ORAL

FLUOXETINE HYDROCHLORIDE					
@ BARR	EQ 90MG BASE	A076237	001	Mar 24, 2010	Apr DISC
! DR REDDYS LABS LTD	EQ 90MG BASE	A078572	001	Mar 22, 2010	Apr CTEC
AB !	EQ 90MG BASE	A078572	001	Mar 22, 2010	Apr CHRS

PROZAC WEEKLY

+ @ LILLY	EQ 90MG BASE	N021235	001	Feb 26, 2001	Apr DISC
-----------	--------------	---------	-----	--------------	----------

SOLUTION;ORAL

FLUOXETINE HYDROCHLORIDE					
AB @ NOSTRUM LABS INC	EQ 20MG BASE/5ML	A075292	001	Feb 07, 2002	May CAHN

TABLET;ORAL

FLUOXETINE HYDROCHLORIDE					
--------------------------	--	--	--	--	--

AB APPCO PHARMA LLC	EQ 10MG BASE	A211696	001	Jan 30, 2019	Jan NEWA
AB	EQ 20MG BASE	A211696	002	Jan 30, 2019	Jan NEWA
AB DR REDDYS LABS LTD	EQ 60MG BASE	A211721	001	Jan 25, 2019	Jan NEWA
AB G AND W LABS INC	EQ 60MG BASE	A212191	001	Jul 05, 2019	Jun NEWA
AB LUPIN LTD	EQ 10MG BASE	A211653	001	Apr 15, 2019	Apr NEWA
AB	EQ 20MG BASE	A211653	002	Apr 15, 2019	Apr NEWA
AB	EQ 60MG BASE	A211632	001	Feb 08, 2019	Feb NEWA
AB SCIEGEN PHARMS INC	EQ 10MG BASE	A210935	001	Mar 20, 2019	Mar NEWA
AB	EQ 20MG BASE	A210935	002	Mar 20, 2019	Mar NEWA
AB UPSHER SMITH LABS	EQ 10MG BASE	A211696	001	Jan 30, 2019	May CAHN
AB	EQ 20MG BASE	A211696	002	Jan 30, 2019	May CAHN

FLUOXYMESTERONE

TABLET;ORAL

FLUOXYMESTERONE

>A>	! UPSHER SMITH LABS	10MG	A088342	001	Oct 21, 1983	Jul CAHN
>D>	! USL PHARMA	10MG	A088342	001	Oct 21, 1983	Jul CAHN

FLUPHENAZINE HYDROCHLORIDE

TABLET;ORAL

FLUPHENAZINE HYDROCHLORIDE

AB	! LANNETT CO INC	10MG	A089743	001	Aug 25, 1988	May CHRS
AB	MYLAN	10MG	A089804	001	Aug 12, 1988	May CHRS

FLURANDRENOLIDE

CREAM;TOPICAL

CORDRAN SP

AT	+! ALMIRALL	0.025%	N012806	003	Feb CAHN
AT	+!	0.05%	N012806	002	Feb CAHN
AT	LOTION;TOPICAL				
AT	CORDRAN				
AT	+! ALMIRALL	0.05%	N013790	001	Feb CAHN
AT	OINTMENT;TOPICAL				
AT	CORDRAN				
AT	+ @ ALMIRALL	0.025%	N012806	004	Feb CAHN
AT	+!	0.05%	N012806	001	Feb CAHN
AT	TAPE;TOPICAL				
AT	CORDRAN				
AT	+! ALMIRALL	0.004MG/SQ CM	N016455	001	Feb CAHN

FLUTAMIDE

CAPSULE;ORAL

FLUTAMIDE

@ ACTAVIS LABS FL INC 125MG

A075820 001 Sep 18, 2001 Apr DISC

FLUTICASONE PROPIONATE

CREAM;TOPICAL

FLUTICASONE PROPIONATE

AB	! PERRIGO ISRAEL	0.05%	A076793	001	May 14, 2004	May CAHN
AB	POWDER;INHALATION					
AB	ARMONAIR RESPICLICK					
>D>	+ TEVA PHARM	0.113MG/INH	N208798	002	Jan 27, 2017	Jul DISC
>A>	+ @	0.113MG/INH	N208798	002	Jan 27, 2017	Jul DISC

FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE

POWDER;INHALATION

ADVAIR DISKUS 100/50

AB	+! GLAXO GRP LTD	0.1MG/INH;EQ 0.05MG BASE/INH	N021077	001	Aug 24, 2000	Jan CFTG
AB	+! GLAXO GRP LTD	0.25MG/INH;EQ 0.05MG BASE/INH	N021077	002	Aug 24, 2000	Jan CFTG
AB	+! GLAXO GRP LTD	0.5MG/INH;EQ 0.05MG BASE/INH	N021077	003	Aug 24, 2000	Jan CFTG
>A>	AIRDUO DIGIHALER					
>A>	+ TEVA PHARM	0.055MG/INH;EQ 0.014MG BASE/INH	N208799	004	Jul 12, 2019	Jul NEWA
>A>	+	0.113MG/INH;EQ 0.014MG BASE/INH	N208799	005	Jul 12, 2019	Jul NEWA
>A>	+	0.232MG/INH;EQ 0.014MG BASE/INH	N208799	006	Jul 12, 2019	Jul NEWA
	AIRDUO RESPICLICK					
>D>	+! TEVA PHARM	0.232MG;EQ 0.014MG BASE/INH	N208799	003	Jan 27, 2017	Jul CMS1
>A>	+	0.232MG/INH;EQ 0.014MG BASE/INH	N208799	003	Jan 27, 2017	Jul CMS1
	WIXELA INHUB					
AB	MYLAN	0.1MG/INH;EQ 0.05MG BASE/INH	A208891	001	Jan 30, 2019	Jan NFTG
AB		0.25MG/INH;EQ 0.05MG BASE/INH	A208891	002	Jan 30, 2019	Jan NFTG
AB		0.5MG/INH;EQ 0.05MG BASE/INH	A208891	003	Jan 30, 2019	Jan NFTG

FLUVASTATIN SODIUM

TABLET, EXTENDED RELEASE;ORAL

FLUVASTATIN SODIUM

@ MYLAN EQ 80MG BASE

A202458 001 Sep 11, 2015 Jun DISC

FLUVOXAMINE MALEATE

TABLET;ORAL

FLUVOXAMINE MALEATE

@ MYLAN	25MG	A075889	001	Nov 29, 2000	May DISC
@	50MG	A075889	002	Nov 29, 2000	May DISC
@	100MG	A075889	003	Nov 29, 2000	May DISC

FOLIC ACID

TABLET;ORAL

FOLIC ACID

AA	INVATECH PHARMA	1MG	A211064	001	Mar 08, 2019	Feb NEWA
AA	QINGDAO BAHEAL PHARM	1MG	A091145	001	Jul 12, 2013	May CAHN

FOMEPIZOLE

INJECTABLE;INJECTION

ANTIZOL

+ @ PAR PHARM INC	1.5GM/1.5ML (1GM/ML)	N020696	001	Dec 04, 1997	Jun DISC
FOMEPIZOLE					

AP ! MYLAN INSTITUTIONAL	1.5GM/1.5ML (1GM/ML)	A078639	001	Mar 03, 2008	Jun CHRS
--------------------------	----------------------	---------	-----	--------------	----------

FOSINOPRIL SODIUM; HYDROCHLOROTHIAZIDE

TABLET;ORAL

FOSINOPRIL SODIUM AND HYDROCHLOROTHIAZIDE

@ ANI PHARMS INC	10MG;12.5MG	A076608	001	Dec 03, 2004	May CAHN
@	20MG;12.5MG	A076608	002	Dec 03, 2004	May CAHN

FOSPHENYTOIN SODIUM

INJECTABLE;INJECTION

FOSPHENYTOIN SODIUM

@ DR REDDYS	EQ 50MG PHENYTOIN NA/ML	A076886	001	Aug 06, 2007	May CAHN
@ LUITPOLD	EQ 50MG PHENYTOIN NA/ML	A078277	001	Aug 06, 2007	Feb DISC
@	EQ 50MG PHENYTOIN NA/ML	A090099	001	May 13, 2010	Feb DISC

FROVATRIPTAN SUCCINATE

TABLET;ORAL

FROVATRIPTAN SUCCINATE

@ AMNEAL PHARMS CO	EQ 2.5MG BASE	A211292	001	Nov 06, 2018	May DISC
--------------------	---------------	---------	-----	--------------	----------

FULVESTRANT

INJECTABLE;INTRAMUSCULAR

FASLODEX

AO +! ASTRAZENECA	50MG/ML	N021344	001	Apr 25, 2002	Apr CMS1
AP +!	50MG/ML	N021344	001	Apr 25, 2002	Feb CFTG
FULVESTRANT					
AO AMNEAL PHARMS CO	50MG/ML	A210044	001	Mar 04, 2019	Apr CMS1
AP	50MG/ML	A210044	001	Mar 04, 2019	Feb NFTG
>A> AO MYLAN INSTITUTIONAL	50MG/ML	A208811	001	Jul 23, 2019	Jul NEWA
AO SANDOZ INC	50MG/ML	A205935	001	May 14, 2019	Apr NEWA
SOLUTION;INTRAMUSCULAR					
FULVESTRANT					
FRESENIUS KABI USA	250MG/5ML (50MG/ML)	N210326	001	May 20, 2019	May NEWA

FUROSEMIDE

INJECTABLE;INJECTION

FUROSEMIDE

AP AUROBINDO PHARMA LTD	10MG/ML	A212174	001	May 03, 2019	Apr NEWA
TABLET;ORAL					
FUROSEMIDE					
>A> @ ANI PHARMS INC	20MG	A071379	001	Jan 02, 1987	Jul CAHN
AB HERITAGE PHARMA	20MG	N018413	001	Nov 30, 1983	Feb CAHN
	40MG	N018413	002	Nov 30, 1983	Feb CAHN
AB HIKMA	20MG	N018823	001	Nov 10, 1983	Apr CAHN
AB	40MG	N018823	002	Nov 10, 1983	Apr CAHN
>D> @ WATSON LABS	20MG	A071379	001	Jan 02, 1987	Jul CAHN

GABAPENTIN

CAPSULE; ORAL

GABAPENTIN

AB	GRANULES INDIA LTD	100MG	A075360	001	Apr 06, 2005	Jun CAHN
AB		300MG	A075360	002	Apr 06, 2005	Jun CAHN
AB		400MG	A075360	003	Apr 06, 2005	Jun CAHN
TABLET;ORAL						
GABAPENTIN						
AB	IVAX SUB TEVA PHARMS	600MG	A076017	004	Apr 29, 2005	Jul DISC
	@	600MG	A076017	004	Apr 29, 2005	Jul DISC
AB		800MG	A076017	005	Apr 29, 2005	Jul DISC
	@	800MG	A076017	005	Apr 29, 2005	Jul DISC
AB	LUPIN LTD	600MG	A209306	001	Aug 24, 2018	Mar DISC
	@	800MG	A209306	002	Aug 24, 2018	Mar DISC

GALANTAMINE HYDROBROMIDE

TABLET; ORAL

GALANTAMINE HYDROBROMIDE

	© HERITAGE PHARMA	EQ 4MG BASE	A 077585	001	Sep 15, 2009	May CAHN
AB		EQ 4MG BASE	A 077587	001	Jul 09, 2009	May CAHN
	©	EQ 8MG BASE	A 077585	002	Sep 15, 2009	May CAHN
AB		EQ 8MG BASE	A 077587	002	Jul 09, 2009	May CAHN
	©	EQ 12MG BASE	A 077585	003	Sep 15, 2009	May CAHN
AB		EQ 12MG BASE	A 077587	003	Jul 09, 2009	May CAHN

GALLIUM CITRATE GA-67

INJECTABLE; INJECTION

GALLIUM CITRATE GA 67

BS CURIUM 2mCi/ML N 018058 001 Jan CAHN

GANCICLOVIR SODIUM

INJECTABLE; INJECTION

GANCICLOVIR

AP	FRESENIUS KABI USA	EQ 500MG BASE/VIAL	A090658	001	Jun 21, 2010	Jul CTNA
AP	HAINAN POLY PHARM	EQ 500MG BASE/VIAL	A204204	001	Nov 08, 2018	Jul CTNA
@	LUITPOLD	EQ 500MG BASE/VIAL	A202624	001	Sep 18, 2013	Jul CTNA
@		EQ 500MG BASE/VIAL	A202624	001	Sep 18, 2013	Feb DISC
AP	MYLAN LABS LTD	EQ 500MG BASE/VIAL	A204560	001	Nov 17, 2017	Jul CTNA
AP	PAR STERILE PRODUCTS	EQ 500MG BASE/VIAL	A204950	001	Dec 06, 2016	Jul CTNA
	GANCICLOVIR SODIUM					
AP	CUSTOPHARM INC	EQ 500MG BASE/VIAL	A212001	001	Jun 20, 2019	Jun NEWA
AP	FRESENIUS KABI USA	EQ 500MG BASE/VIAL	A090658	001	Jun 21, 2010	Jul CTNA
AP	HAINAN POLY PHARM	EQ 500MG BASE/VIAL	A204204	001	Nov 08, 2018	Jul CTNA
@	LUITPOLD	EQ 500MG BASE/VIAL	A202624	001	Sep 18, 2013	Jul CTNA
AP	MYLAN LABS LTD	EQ 500MG BASE/VIAL	A204560	001	Nov 17, 2017	Jul CTNA
AP	PAR STERILE PRODUCTS	EQ 500MG BASE/VIAL	A204950	001	Dec 06, 2016	Jul CTNA

GANIRELIX ACETATE

INJECTABLE; INJECTION

GANIRELIX ACETATE

AP +! ORGANON USA INC 250MCG/0.5ML N021057 001 Jul 29, 1999 Mar CPOT
AP SUN PHARM 250MCG/0.5ML A204246 001 Nov 30, 2018 Mar CPOT

GEMCITABINE HYDROCHLORIDE

INJECTABLE; INJECTION

GEMCITABINE HYDROCHLORIDE

AP	FRESENIUS KABI USA	EQ 200MG BASE/VIAL	A090799	001	Jul 25, 2011	Jan CAHN
AP		EQ 1GM BASE/VIAL	A090799	002	Jul 25, 2011	Jan CAHN
AP		EQ 2GM BASE/VIAL	A090799	003	May 16, 2011	Jan CAHN
AP	INGENUS PHARMS LLC	200MG/5.26ML (38MG/ML)	A210383	001	Feb 14, 2019	Feb NEWA
AP		1GM/26.3ML (38MG/ML)	A210383	002	Feb 14, 2019	Feb NEWA
AP		2GM/52.6ML (38MG/ML)	A210383	003	Feb 14, 2019	Feb NEWA
@	LUITPOLD	EQ 200MG BASE/VIAL	A202031	001	May 07, 2013	Feb DISC
@		EQ 1GM BASE/VIAL	A202031	002	May 07, 2013	Feb DISC
AP	SHILPA MEDICARE LTD	EQ 200MG BASE/VIAL	A207575	001	Feb 22, 2019	Feb NEWA
AP		EQ 1GM BASE/VIAL	A207575	002	Feb 22, 2019	Feb NEWA

GENTAMICIN SULFATE

INJECTABLE; INJECTION

GENTAMICIN SULFATE

>D>	AP	FRESENIUS KABI USA	EQ 10MG BASE/ML	A062366	002	Feb 06, 1986	Jul CHRS
>A>	AP	!	EQ 10MG BASE/ML	A062366	002	Feb 06, 1986	Jul CHRS

GLASDEGIB MALEATE

TABLET; ORAL

DAURISMO

+ PFIZER INC

+!

EQ 25MG BASE

EQ 100MG BASE

N210656	001	Nov 21, 2018	Feb CAIN
N210656	002	Nov 21, 2018	Feb CAIN

GLIMEPIRIDE

TABLET; ORAL

GLIMEPIRIDE

AB	MICRO LABS	1MG	A091220	001	Jun 29, 2012	Mar CAHN
AB		2MG	A091220	002	Jun 29, 2012	Mar CAHN
		3MG	A091220	003	Jun 29, 2012	Mar CAHN
AB		4MG	A091220	004	Jun 29, 2012	Mar CAHN
		6MG	A091220	005	Jun 29, 2012	Mar CAHN
AB		8MG	A091220	006	Jun 29, 2012	Mar CAHN

GLIPIZIDE

TABLET; ORAL

GLIPIZIDE

@ BEXIMCO PHARMS USA

5MG

@

10MG

A074542	001	Jun 20, 1995	Feb CAHN
A074542	002	Jun 20, 1995	Feb CAHN

TABLET, EXTENDED RELEASE; ORAL

GLIPIZIDE

@ MYLAN

2.5MG

@

5MG

@

10MG

A202298	001	May 19, 2015	Feb DISC
A202298	002	May 19, 2015	Feb DISC
A202298	003	May 19, 2015	Feb DISC

GLIPIZIDE; METFORMIN HYDROCHLORIDE

TABLET; ORAL

GLIPIZIDE AND METFORMIN HYDROCHLORIDE

@ MYLAN

2.5MG; 250MG

A078083	001	Apr 12, 2007	Apr DISC
---------	-----	--------------	----------

GLUCAGON

>A> POWDER; NASAL

BAQSIMI

>A>	+! ELI LILLY AND CO	3MG	N210134	001	Jul 24, 2019	Jul NEWA
-----	---------------------	-----	---------	-----	--------------	----------

GLYBURIDE

TABLET; ORAL

GLYBURIDE

>D>	AB1	ORIENT PHARMA CO LTD	1.25MG	A206483	001	Feb 22, 2019	Jul DISC
>A>		@	1.25MG	A206483	001	Feb 22, 2019	Jul DISC
	AB1		1.25MG	A206483	001	Feb 22, 2019	Feb NEWA
>D>	AB1		2.5MG	A206483	002	Feb 22, 2019	Jul DISC
>A>		@	2.5MG	A206483	002	Feb 22, 2019	Jul DISC
	AB1		2.5MG	A206483	002	Feb 22, 2019	Feb NEWA
>D>	AB1		5MG	A206483	003	Feb 22, 2019	Jul DISC
>A>		@	5MG	A206483	003	Feb 22, 2019	Jul DISC
	AB1		5MG	A206483	003	Feb 22, 2019	Feb NEWA

GLYCEROL PHENYLBUTYRATE

LIQUID; ORAL

RAVICTI

+! HORIZON THERAP

1.1GM/ML

N203284	001	Feb 01, 2013	Feb CAHN
---------	-----	--------------	----------

GLCOPYRROLATE

INJECTABLE; INJECTION

GLCOPYRROLATE

AP	CAPLIN	0.2MG/ML	A211705	001	Mar 20, 2019	Mar NEWA
AP	PIRAMAL CRITICAL	0.2MG/ML	A210842	001	Oct 25, 2018	Jun CAHN
AP	SANDOZ INC	0.2MG/ML	A211334	001	May 14, 2019	Apr NEWA
	TABLET; ORAL					
	GLCOPYRROLATE					
AA	AUROLIFE PHARMA LLC	2MG	A202675	002	Oct 30, 2018	May NEWA
AA	KENTON	1MG	A091182	001	Feb 03, 2014	Mar CAHN

TABLET;ORAL
GLYCOPYRROLATE

AA 2MG A091182 002 Feb 03, 2014 Mar CAHN

GRANISETRON HYDROCHLORIDE

INJECTABLE; INJECTION

GRANISETRON HYDROCHLORIDE

AP BIONPHARMA INC	EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML)	A078863 001 Jun 30, 2008 Apr CAHN
AP DR REDDYS	EQ 4MG BASE/4ML (EQ 1MG BASE/ML)	A078880 001 Jun 30, 2008 Apr CAHN
AP ! DR REDDYS	EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML)	A078392 001 Dec 31, 2007 May CAHN
AP ! @ LUITPOLD	EQ 4MG BASE/4ML (EQ 1MG BASE/ML) GRANISETRON HYDROCHLORIDE PRESERVATIVE FREE	A077297 001 Jun 30, 2008 May CAHN
AP BIONPHARMA INC	EQ 1MG BASE/ML (EQ 1MG BASE/ML)	A078863 002 Jun 30, 2008 Apr CAHN
AP @ DR REDDYS	EQ 1MG BASE/ML (EQ 1MG BASE/ML)	A077165 001 Dec 31, 2007 May CAHN
TABLET;ORAL		
GRANISETRON HYDROCHLORIDE		
AB ! TEVA PHARMS	EQ 1MG BASE	A078080 001 Dec 31, 2007 Jan DISC
AB ! WEST-WARD PHARMS INT	EQ 1MG BASE	A077842 001 Dec 31, 2007 Jan CHRS

GUAIFENESIN; HYDROCODONE BITARTRATE

SOLUTION;ORAL

OBREDON

+ @ SOVEREIGN PHARMS 200MG/5ML;2.5MG/5ML

N205474 001 Nov 14, 2014 Jun DISC

TABLET;ORAL

XTRELUS

+ @ ECI PHARMS LLC 400MG;5MG

N208085 001 Apr 25, 2018 Jun DISC

GUANFACINE HYDROCHLORIDE

TABLET;ORAL

GUANFACINE HYDROCHLORIDE

AB EPIC PHARMA LLC	EQ 1MG BASE	A074673 001 Feb 28, 1997 Apr CMFD
AB	EQ 2MG BASE	A074673 002 Feb 28, 1997 Apr CMFD
TABLET, EXTENDED RELEASE;ORAL		
GUANFACINE HYDROCHLORIDE		
@ MYLAN	EQ 1MG BASE	A202578 001 Jun 02, 2015 May DISC
@	EQ 2MG BASE	A202578 002 Jun 02, 2015 May DISC
@	EQ 3MG BASE	A202578 003 Jun 02, 2015 May DISC
@	EQ 4MG BASE	A202578 004 Jun 02, 2015 May DISC

HALCINONIDE

CREAM;TOPICAL

HALCINONIDE

>A> AB MYLAN 0.1% A211027 001 Aug 12, 2019 Jul NEWA

HALOBETASOL PROPIONATE

LOTION;TOPICAL

BRYHALI

+! BAUSCH	0.01%	N209355 001 Nov 06, 2018 Apr CAHN
+! DOW PHARM	0.01%	N209355 001 Nov 06, 2018 Jan CHRS
+	0.01%	N209355 001 Nov 06, 2018 Jan CRLD

HALOBETASOL PROPIONATE; TAZAROTENE

LOTION;TOPICAL

DUOBRII

+! BAUSCH 0.01%;0.045% N209354 001 Apr 25, 2019 Apr NEWA

HALOPERIDOL

TABLET;ORAL

HALOPERIDOL

@ INNOGENIX	0.5MG	A071173 002 Jan 02, 1987 May CMS1
@	1MG	A071173 003 Jan 02, 1987 May CMS1
@	2MG	A071173 004 Jan 02, 1987 May CMS1
@	5MG	A071173 005 Jan 07, 1988 May CMS1
@	10MG	A071173 001 Jan 07, 1988 Mar CAHN
@	20MG	A071173 006 Jan 07, 1988 May CMS1
AB ! MYLAN	2MG	A070278 001 Jun 10, 1986 Jan CTEC
AB !	2MG	A070278 001 Jun 10, 1986 Jan CHRS
AB @ SANDOZ	2MG	A071208 001 Nov 17, 1986 Jan DISC

HALOPERIDOL LACTATE

CONCENTRATE;ORAL	HALOPERIDOL				
AA ! PHARM ASSOC	EQ 2MG BASE/ML	A073037	001	Feb 26, 1993	May CHRS
@ TEVA PHARMS	EQ 2MG BASE/ML	A071617	001	Dec 01, 1988	May DISC
INJECTABLE;INJECTION	HALOPERIDOL				
AP FRESENIUS KABI USA	EQ 5MG BASE/ML	A210356	001	Jul 01, 2019	Jun NEWA

HEPARIN SODIUM

INJECTABLE;INJECTION	HEPARIN SODIUM				
AP +! HIKMA	1,000 UNITS/ML	N017037	001	Feb CAHN	
AP +!	5,000 UNITS/ML	N017037	002	Feb CAHN	
@	5,000 UNITS/0.5ML	N017037	013	Apr 07, 1986	Feb CAHN
AP +!	10,000 UNITS/ML	N017037	003	Feb CAHN	
AP NANJING KING-FRIEND	1,000 UNITS/ML	A211007	001	May 28, 2019	May NEWA
AP	5,000 UNITS/ML	A211007	002	May 28, 2019	May NEWA
AP	10,000 UNITS/ML	A211007	003	May 28, 2019	May NEWA

HOMATROPINE METHYLBROMIDE; HYDROCODONE BITARTRATE

SYRUP;ORAL	HYCODAN				
AA + GENUS LIFESCIENCES	1.5MG/5ML;5MG/5ML	N005213	002	Jul 26, 1988	Jun CMFD
HYDROCODONE BITARTRATE AND HOMATROPINE METHYLBROMIDE					
>D> AA BRECKENRIDGE PHARM	1.5MG/5ML;5MG/5ML	A210663	001	Jun 11, 2019	Jul DISC
>A> @	1.5MG/5ML;5MG/5ML	A210663	001	Jun 11, 2019	Jul DISC
AA	1.5MG/5ML;5MG/5ML	A210663	001	Jun 11, 2019	May NEWA
AA TORRENT	1.5MG/5ML;5MG/5ML	A204765	001	Mar 06, 2017	May CMFD
@	1.5MG/5ML;5MG/5ML	A204765	001	Mar 06, 2017	Jan CAHN

HYDRALAZINE HYDROCHLORIDE

INJECTABLE;INJECTION	HYDRALAZINE HYDROCHLORIDE				
@ LUITPOLD	20MG/ML	A040136	001	Jun 30, 1997	Feb DISC
TABLET;ORAL	HYDRALAZINE HYDROCHLORIDE				
AA UPSHER SMITH LABS	10MG	A209251	001	Jul 09, 2018	Jun CAHN
AA	25MG	A209251	002	Jul 09, 2018	Jun CAHN
AA	50MG	A209251	003	Jul 09, 2018	Jun CAHN
AA	100MG	A209251	004	Jul 09, 2018	Jun CAHN

HYDROCHLOROTHIAZIDE; IRBESARTAN

TABLET;ORAL	IRBESARTAN AND HYDROCHLOROTHIAZIDE				
>D> AB APOTEX INC	12.5MG;150MG	A201505	001	Oct 15, 2012	Jul DISC
>A> @	12.5MG;150MG	A201505	001	Oct 15, 2012	Jul DISC
>D> AB	12.5MG;300MG	A201505	002	Oct 15, 2012	Jul DISC
>A> @	12.5MG;300MG	A201505	002	Oct 15, 2012	Jul DISC

HYDROCHLOROTHIAZIDE; LISINOPRIL

TABLET;ORAL	LISINOPRIL AND HYDROCHLOROTHIAZIDE				
AB HERITAGE PHARMA	12.5MG;10MG	A075776	001	Jul 01, 2002	Feb CAHN
AB	12.5MG;20MG	A075776	002	Jul 01, 2002	Feb CAHN
AB	25MG;20MG	A075776	003	Jul 01, 2002	Feb CAHN

HYDROCHLOROTHIAZIDE; OLMESARTAN MEDOXOMIL

TABLET;ORAL	OLMESARTAN MEDOXOMIL AND HYDROCHLOROTHIAZIDE				
>D> AB TEVA PHARMS USA	12.5MG;20MG	A200532	001	Apr 24, 2017	Jul DISC
>A> @	12.5MG;20MG	A200532	001	Apr 24, 2017	Jul DISC
>D> AB	25MG;40MG	A200532	003	Apr 24, 2017	Jul DISC
>A> @	25MG;40MG	A200532	003	Apr 24, 2017	Jul DISC

HYDROCHLOROTHIAZIDE; QUINAPRIL HYDROCHLORIDE

TABLET;ORAL	QUINAPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE				
@ MYLAN	12.5MG;EQ 10MG BASE	A077093	001	Mar 28, 2005	May DISC
@	12.5MG;EQ 20MG BASE	A077093	002	Mar 28, 2005	May DISC
@	25MG;EQ 20MG BASE	A077093	003	Mar 28, 2005	May DISC

	TABLET;ORAL QUINARETIC					
AB	LUPIN	12.5MG;EQ 10MG BASE	A076374	001	Mar 31, 2004	Feb CAHN
AB		12.5MG;EQ 20MG BASE	A076374	002	Mar 31, 2004	Feb CAHN
AB		25MG;EQ 20MG BASE	A076374	003	Mar 31, 2004	Feb CAHN
<u>HYDROCHLOROTHIAZIDE; TELMISARTAN</u>						
	TABLET;ORAL TELMISARTAN AND HYDROCHLOROTHIAZIDE					
AB	GLENMARK PHARMS LTD	12.5MG;40MG	A202544	001	Mar 04, 2019	Feb NEWA
AB		12.5MG;80MG	A202544	002	Mar 04, 2019	Feb NEWA
AB		25MG;80MG	A202544	003	Mar 04, 2019	Feb NEWA
<u>HYDROCHLOROTHIAZIDE; TRIAMTERENE</u>						
	CAPSULE;ORAL TRIAMTERENE AND HYDROCHLOROTHIAZIDE					
@	ANI PHARMS INC	25MG;50MG	A074259	001	Mar 30, 1995	Jun DISC
@	CASI PHARMS INC	25MG;50MG	A073191	001	Jul 31, 1991	Jun DISC
AB	ZYDUS PHARMS	25MG;37.5MG	A208358	001	Feb 11, 2019	Jan NEWA
<u>HYDROCODONE BITARTRATE</u>						
	CAPSULE, EXTENDED RELEASE;ORAL ZOHYDRO ER					
+!	PERSIAN	10MG	N202880	001	Oct 25, 2013	Apr CAHN
+		15MG	N202880	002	Oct 25, 2013	Apr CAHN
+		20MG	N202880	003	Oct 25, 2013	Apr CAHN
+		30MG	N202880	004	Oct 25, 2013	Apr CAHN
+		40MG	N202880	005	Oct 25, 2013	Apr CAHN
+		50MG	N202880	006	Oct 25, 2013	Apr CAHN
	TABLET, EXTENDED RELEASE;ORAL HYSINGLA					
>D>	+! PURDUE PHARMA LP	20MG	N206627	001	Nov 20, 2014	Jul CMS1
>D>	+	30MG	N206627	002	Nov 20, 2014	Jul CMS1
>D>	+	40MG	N206627	003	Nov 20, 2014	Jul CMS1
>D>	+	60MG	N206627	004	Nov 20, 2014	Jul CMS1
>D>	+	80MG	N206627	005	Nov 20, 2014	Jul CMS1
>D>	+	100MG	N206627	006	Nov 20, 2014	Jul CMS1
>D>	+	120MG	N206627	007	Nov 20, 2014	Jul CMS1
	HYSINGLA ER					
>A>	+! PURDUE PHARMA LP	20MG	N206627	001	Nov 20, 2014	Jul CMS1
>A>	+	30MG	N206627	002	Nov 20, 2014	Jul CMS1
>A>	+	40MG	N206627	003	Nov 20, 2014	Jul CMS1
>A>	+	60MG	N206627	004	Nov 20, 2014	Jul CMS1
>A>	+	80MG	N206627	005	Nov 20, 2014	Jul CMS1
>A>	+	100MG	N206627	006	Nov 20, 2014	Jul CMS1
>A>	+	120MG	N206627	007	Nov 20, 2014	Jul CMS1
<u>HYDROCODONE BITARTRATE; IBUPROFEN</u>						
	TABLET;ORAL HYDROCODONE BITARTRATE AND IBUPROFEN					
@	ANI PHARMS INC	5MG;200MG	A077454	001	Jun 23, 2010	May CAHN
<u>HYDROCODONE BITARTRATE; PSEUDOEPHENDRINE HYDROCHLORIDE</u>						
	SOLUTION;ORAL HYDROCODONE BITARTRATE AND PSEUDOEPHENDRINE HYDROCHLORIDE					
@	MAYNE PHARMA INC	5MG/5ML;60MG/5ML	A205658	001	Nov 17, 2015	Jun DISC
@	PADDICK LLC	5MG/5ML;60MG/5ML	A204658	001	Apr 29, 2014	Jun DISC
@	TORRENT	5MG/5ML;60MG/5ML	A206661	001	Jan 23, 2019	Feb DISC
AA		5MG/5ML;60MG/5ML	A206661	001	Jan 23, 2019	Jan NEWA
	REZIRA					
	+ @ PERSIAN	5MG/5ML;60MG/5ML	N022442	001	Jun 08, 2011	Jun DISC
AA	+	5MG/5ML;60MG/5ML	N022442	001	Jun 08, 2011	Apr CAHN
<u>HYDROCORTISONE</u>						
	CREAM;TOPICAL NUTRACORT					
@	BAUSCH	0.5%	A080442	002		Feb CAHN
@		1%	A080442	003		Feb CAHN
	LOTION;TOPICAL CETACORT					
@	BAUSCH	0.5%	A080426	002		Feb CAHN
@		1%	A080426	001		Feb CAHN

HYDROCORTISONE BUTYRATE

	CREAM;TOPICAL LOCOID						
AB1	+! BAUSCH	0.1%		N018514	001	Mar 31, 1982	May CAHN
	LOTION;TOPICAL LOCOID						
AB	+! BAUSCH	0.1%		N022076	001	May 18, 2007	May CAHN
	SOLUTION;TOPICAL LOCOID						
AT	+! BAUSCH	0.1%		N019116	001	Feb 25, 1987	May CAHN

HYDROCORTISONE VALERATE

	CREAM;TOPICAL HYDROCORTISONE VALERATE						
AB	PERRIGO ISRAEL	0.2%		A075666	001	May 24, 2000	May CAHN

HYDROMORPHONE HYDROCHLORIDE

	TABLET, EXTENDED RELEASE;ORAL EXALGO						
	+ @ SPECGX LLC	8MG		N021217	001	Mar 01, 2010	Mar DISC
	+ @	12MG		N021217	002	Mar 01, 2010	Mar DISC
	+ @	16MG		N021217	003	Mar 01, 2010	Mar DISC
	+ @	32MG		N021217	004	Aug 24, 2012	Mar DISC
	HYDROMORPHONE HYDROCHLORIDE						
AB	! OSMOTICA	32MG		A205629	004	Jul 07, 2016	Mar CHRS

HYDROXYCHLOROQUINE SULFATE

	TABLET;ORAL HYDROXYCHLOROQUINE SULFATE						
AB	LAURUS LABS LTD	200MG		A210959	001	Jan 15, 2019	Jan CAHN
	@ LUPIN LTD	200MG		A210543	001	Jul 06, 2018	Feb DISC

HYDROXYPROGESTERONE CAPROATE

	SOLUTION;INTRAMUSCULAR HYDROXYPROGESTERON CAPROATE						
>A> AP1	AM REGENT	1250MG/5ML (250MG/ML)		A210724	001	Aug 09, 2019	Jul NEWA
	HYDROXYPROGESTERONE CAPROATE						
>A> AP	ASPEN	250MG/ML (250MG/ML)		A211777	001	Aug 08, 2019	Jul NEWA
AP2	! ASPEN GLOBAL INC	1250MG/5ML (250MG/ML)		A200271	001	Aug 24, 2015	Apr CPOT
AP2	!	250MG/ML (250MG/ML)		A200271	001	Aug 24, 2015	Apr CTEC
AP	EUGIA PHARMA	250MG/ML (250MG/ML)		A211071	001	Apr 16, 2019	Apr NEWA
AP1		1250MG/5ML (250MG/ML)		A211070	001	Apr 16, 2019	Apr NEWA
AP2		1250MG/5ML (250MG/ML)		A211142	001	May 09, 2019	Apr NEWA
AP	SLAYBACK PHARMA LLC	250MG/ML (250MG/ML)		A210877	001	Mar 22, 2019	Mar NEWA
AP1		1250MG/5ML (250MG/ML)		A210618	001	Dec 28, 2018	Apr CTEC
AP1	SUN PHARM	1250MG/5ML (250MG/ML)		A208381	001	Apr 09, 2019	Apr CTEC
AP		1250MG/5ML (250MG/ML)		A208381	001	Apr 09, 2019	Mar NEWA
	MAKENA						
AP1	+! AMAG PHARMA USA	1250MG/5ML (250MG/ML)		N021945	001	Feb 03, 2011	Apr CTEC

HYDROXYPROPYL CELLULOSE

	INSERT;OPHTHALMIC LACRISERT						
	+! VALEANT PHARMS INTL	5MG		N018771	001		Jan CAHN

HYDROXYZINE HYDROCHLORIDE

	INJECTABLE;INJECTION HYDROXYZINE HYDROCHLORIDE						
	! LUITPOLD	50MG/ML		A087408	002		Mar CMFD
	@	50MG/ML		A087408	002		Feb DISC
	SYRUP;ORAL HYDROXYZINE HYDROCHLORIDE						
AA	TORRENT	10MG/5ML		A210634	001	Feb 26, 2019	Feb NEWA
	TABLET;ORAL HYDROXYZINE HYDROCHLORIDE						
AB	EPIC PHARMA LLC	10MG		A040604	002	Dec 28, 2004	Jan CAHN
AB		25MG		A040604	003	Dec 28, 2004	Jan CAHN
AB		50MG		A040604	001	Dec 28, 2004	Jan CAHN
AB	KVK TECH	25MG		A040786	002	Mar 20, 2007	Feb CMS1
AB		50MG		A040786	003	Mar 20, 2007	Feb CMS1

HYDROXYZINE PAMOATE

CAPSULE;ORAL

HYDROXYZINE PAMOATE

@ BEXIMCO PHARMS USA

EQ 25MG HYDROCHLORIDE

A081127 001 Jun 28, 1991 Feb CAHN

IBUPROFEN

SOLUTION;INTRAVENOUS

CALDOLOR

+! CUMBERLAND PHARMS

800MG/200ML (4MG/ML)

N022348 003 Jan 25, 2019 Jan NEWA

SUSPENSION;ORAL

IBUPROFEN

AB	L PERRIGO CO	100MG/5ML	A076925	001	Sep 23, 2004	May CAHN
	TABLET;ORAL					
	IBUPROFEN					
	@ HEC PHARM	400MG	A204062	001	Sep 10, 2018	Mar DISC
	@	600MG	A204062	002	Sep 10, 2018	Mar DISC
	@	800MG	A204062	003	Sep 10, 2018	Mar DISC
AB	PERRIGO PHARMS CO	400MG	A077114	001	Jul 18, 2005	May CAHN
AB		600MG	A077114	002	Jul 18, 2005	May CAHN
AB		800MG	A077114	003	Jul 18, 2005	May CAHN

IBUTILIDE FUMARATE

INJECTABLE;INJECTION

IBUTILIDE FUMARATE

@ LUITPOLD

0.1MG/ML

A090240 001 Jan 11, 2010 Feb DISC

ICATIBANT ACETATE

INJECTABLE;SUBCUTANEOUS

FIRAZYR

>D>	+! SHIRE ORPHAN THERAP	EQ 30MG BASE/3ML (EQ 10MG BASE/ML)	N022150	001	Aug 25, 2011	Jul CFTG
>A> AP	+!	EQ 30MG BASE/3ML (EQ 10MG BASE/ML)	N022150	001	Aug 25, 2011	Jul CFTG
>A>	ICATIBANT ACETATE					
>A> AP	TEVA PHARMS USA	EQ 30MG BASE/3ML (EQ 10MG BASE/ML)	A210118	001	Jul 15, 2019	Jul NFTG

ILOPERIDONE

TABLET;ORAL

ILOPERIDONE

>D> AB	INVENTIA HLTHCARE	1MG	A207231	001	Nov 28, 2016	Jul DISC
>A>	@	1MG	A207231	001	Nov 28, 2016	Jul DISC
>D> AB		2MG	A207231	002	Nov 28, 2016	Jul DISC
>A>	@	2MG	A207231	002	Nov 28, 2016	Jul DISC
>D> AB		4MG	A207231	003	Nov 28, 2016	Jul DISC
>A>	@	4MG	A207231	003	Nov 28, 2016	Jul DISC
>D> AB		6MG	A207231	004	Nov 28, 2016	Jul DISC
>A>	@	6MG	A207231	004	Nov 28, 2016	Jul DISC
>D> AB		8MG	A207231	005	Nov 28, 2016	Jul DISC
>A>	@	8MG	A207231	005	Nov 28, 2016	Jul DISC
>D> AB		10MG	A207231	006	Nov 28, 2016	Jul DISC
>A>	@	10MG	A207231	006	Nov 28, 2016	Jul DISC
>D> AB		12MG	A207231	007	Nov 28, 2016	Jul DISC
>A>	@	12MG	A207231	007	Nov 28, 2016	Jul DISC
>A> AB	TARO PHARM INDS LTD	1MG	A207098	001	Jul 22, 2019	Jul NEWA
>A> AB		2MG	A207098	002	Jul 22, 2019	Jul NEWA
>A> AB		4MG	A207098	003	Jul 22, 2019	Jul NEWA
>A> AB		6MG	A207098	004	Jul 22, 2019	Jul NEWA
>A> AB		8MG	A207098	005	Jul 22, 2019	Jul NEWA
>A> AB		10MG	A207098	006	Jul 22, 2019	Jul NEWA
>A> AB		12MG	A207098	007	Jul 22, 2019	Jul NEWA

IMATINIB MESYLATE

TABLET;ORAL

IMATINIB MESYLATE

AB	BRECKENRIDGE PHARM	EQ 100MG BASE	A205990	001	Feb 08, 2019	Feb NEWA
AB		EQ 400MG BASE	A205990	002	Feb 08, 2019	Feb NEWA
AB	NATCO PHARMA LTD	EQ 100MG BASE	A207818	001	Mar 01, 2019	Feb NEWA
AB		EQ 400MG BASE	A207818	002	Mar 01, 2019	Feb NEWA
AB	SHILPA MEDICARE LTD	EQ 100MG BASE	A208302	001	Jan 17, 2019	Jan NEWA
AB		EQ 400MG BASE	A208302	002	Jan 17, 2019	Jan NEWA
AB	WOCKHARDT BIO AG	EQ 100MG BASE	A208429	001	Jan 17, 2019	Jan NEWA
AB		EQ 400MG BASE	A208429	002	Jan 17, 2019	Jan NEWA

IMIPRAMINE HYDROCHLORIDE

TABLET;ORAL

IMIPRAMINE HYDROCHLORIDE

@ OXFORD PHARMS	10MG	A040751	003	Feb 28, 2008	Mar DISC
@	25MG	A040751	002	Feb 28, 2008	Mar DISC

INDIUM IN-111 CHLORIDE

INJECTABLE;INJECTION

INDICLOR

+ @ GE HEALTHCARE	2mCi/0.2ML	N019862	001	Dec 29, 1992	Jun DISC
INDIUM IN 111 CHLORIDE		N019841	001	Sep 27, 1994	Jan CAHN
+! CURIUM	5mCi/0.5ML				

INDIUM IN-111 PENTETREOTIDE KIT

INJECTABLE;INJECTION

OCTREOSCAN

+! CURIUM	3mCi/ML	N020314	001	Jun 02, 1994	Jan CAHN
-----------	---------	---------	-----	--------------	----------

INDOMETHACIN

CAPSULE;ORAL

INDOCIN

+ @ EGALET	25MG	N016059	001		Feb CAHN
+ @	50MG	N016059	002		Feb CAHN

INDOMETHACIN

@ ANI PHARMS INC	25MG	A071148	001	Mar 18, 1987	May CAHN
@	50MG	A071149	001	Mar 18, 1987	May CAHN

AB CADILA

	25MG	A090403	001	Nov 15, 2010	May CAHN
--	------	---------	-----	--------------	----------

AB

	50MG	A090403	002	Nov 15, 2010	May CAHN
--	------	---------	-----	--------------	----------

AB HERITAGE PHARMA

	25MG	A070719	001	Feb 12, 1986	Feb CAHN
--	------	---------	-----	--------------	----------

AB

	50MG	A070756	001	Feb 12, 1986	Feb CAHN
--	------	---------	-----	--------------	----------

TIVORBEX

+ EGALET	20MG	N204768	001	Feb 24, 2014	Feb CAHN
+!	40MG	N204768	002	Feb 24, 2014	Feb CAHN

CAPSULE, EXTENDED RELEASE;ORAL

INDOCIN SR

+ @ EGALET	75MG	N018185	001	Feb 23, 1982	Feb CAHN
------------	------	---------	-----	--------------	----------

SUPPOSITORY;RECTAL

INDOCIN

+ @ EGALET	50MG	N017814	001	Aug 13, 1984	Feb CAHN
------------	------	---------	-----	--------------	----------

SUSPENSION;ORAL

INDOCIN

+! EGALET	25MG/5ML	N018332	001	Oct 10, 1985	Feb CAHN
-----------	----------	---------	-----	--------------	----------

INSULIN ASPART

SOLUTION;SUBCUTANEOUS

FIASP PENFILL

+! NOVO	300 UNITS/3ML (100 UNITS/ML)	N208751	003	Sep 24, 2018	Jun NEWA
---------	------------------------------	---------	-----	--------------	----------

INSULIN ASPART; INSULIN DEGLUDEC

SOLUTION;SUBCUTANEOUS

RYZODEG 70/30

+ @ NOVO	90 UNITS/3ML;210 UNITS/3ML (30 UNITS/ML;70 UNITS/ML)	N203313	001	Sep 25, 2015	Jun DISC
----------	--	---------	-----	--------------	----------

INSULIN DEGLUDEC

SOLUTION;SUBCUTANEOUS

TRESIBA

NOVO	1000 UNITS/10ML (100 UNITS/ML)	N203314	003	Nov 21, 2018	Jun NEWA
------	--------------------------------	---------	-----	--------------	----------

INSULIN HUMAN

SOLUTION;INTRAVENOUS

MYXREDLIN

>A> +! BAXTER HLTHCARE CORP	100 UNITS/100ML (1 UNIT/ML)	N208157	001	Jun 20, 2019	Jul CAHN
-----------------------------	-----------------------------	---------	-----	--------------	----------

>D> +! CELERITY PHARMS	100 UNITS/100ML (1 UNIT/ML)	N208157	001	Jun 20, 2019	Jul CAHN
------------------------	-----------------------------	---------	-----	--------------	----------

+!	100 UNITS/100ML (1 UNIT/ML)	N208157	001	Jun 20, 2019	Jun NEWA
----	-----------------------------	---------	-----	--------------	----------

IOTHALAMATE MEGLUMINE

INJECTABLE; INJECTION
CONRAY 43
+ @ LIEBEL-FLARSHEIM 43% N013295 002 Jun DISC

IPRATROPIUM BROMIDE

SPRAY, METERED; NASAL
IPRATROPIUM BROMIDE
@ MYLAN SPECIALITY LP 0.021MG/SPRAY A075552 001 Mar 31, 2003 Mar DISC
@ 0.042MG/SPRAY A075553 001 Mar 31, 2003 Mar DISC

IRINOTECAN HYDROCHLORIDE

INJECTABLE; INJECTION
IRINOTECAN HYDROCHLORIDE
AP FRESENIUS KABI USA 40MG/2ML (20MG/ML) A078188 001 Feb 27, 2008 Jan CAHN
AP 100MG/5ML (20MG/ML) A078188 002 Feb 27, 2008 Jan CAHN

IRON DEXTRAN

INJECTABLE; INJECTION
DEXFERRUM
@ LUITPOLD EQ 50MG IRON/ML N040024 001 Feb 23, 1996 Mar DISC
PROFERDEX
@ NEW RIVER EQ 50MG IRON/ML N017807 001 Mar DISC

IRON SUCROSE

INJECTABLE; INTRAVENOUS
VENOFEER
+ AM REGENT EQ 50MG BASE/2.5ML (EQ 20MG BASE/ML) N021135 002 Mar 20, 2005 Apr CAHN
@ EQ 65MG BASE/3.25ML (EQ 20MG BASE/ML) N021135 005 Mar 29, 2013 Apr CAHN
@ EQ 75MG BASE/3.75ML (EQ 20MG BASE/ML) N021135 003 Mar 29, 2005 Apr CAHN
+! EQ 100MG BASE/5ML (EQ 20MG BASE/ML) N021135 001 Nov 06, 2000 Apr CAHN
+ EQ 200MG BASE/10ML (EQ 20MG BASE/ML) N021135 004 Feb 09, 2007 Apr CAHN

ISOPROPYL ALCOHOL

SOLUTION; TOPICAL
ZURAGARD
+! ZUREX PHARMA 70% (10.5ML) N210872 001 Apr 26, 2019 Apr NEWA

ISOPROTERENOL HYDROCHLORIDE

INJECTABLE; INJECTION
ISOPROTERENOL HYDROCHLORIDE
AP CIPLA 0.2MG/ML A211738 001 Jun 28, 2019 Jun NEWA
ISUPREL
AP +! BAUSCH 0.2MG/ML N010515 001 Mar CAHN

ISOSORBIDE DINITRATE

TABLET; ORAL
ISORDIL
AB + BAUSCH 5MG N012093 007 Jul 29, 1988 Mar CAHN
+ @ 10MG N012093 002 Jul 29, 1988 Mar CAHN
+ @ 20MG N012093 006 Jul 29, 1988 Mar CAHN
+ @ 30MG N012093 005 Jul 29, 1988 Mar CAHN
+! 40MG N012093 001 Jul 29, 1988 Mar CAHN

ISOSORBIDE MONONITRATE

TABLET, EXTENDED RELEASE; ORAL
ISOSORBIDE MONONITRATE
AB HIKMA INTL PHARMS 30MG A076813 002 Mar 30, 2006 Mar CAHN
AB 60MG A076813 001 Jan 07, 2005 Mar CAHN

ISOSULFAN BLUE

INJECTABLE; INJECTION
ISOSULFAN BLUE
>D> AP BELOTECA INC 1% A210714 001 Jan 16, 2019 Jul DISC
>A> @ 1% A210714 001 Jan 16, 2019 Jul DISC
>A> AP SOMERSET THERAPS LLC 1% A210558 001 Jul 12, 2019 Jul NEWA

ITRACONAZOLE

CAPSULE;ORAL ITRACONAZOLE	AB PII 100MG	A206410 001 Jul 02, 2019 Jun NEWA
SOLUTION;ORAL ITRACONAZOLE	>A> AA APOTEX INC 10MG/ML	A208481 001 Aug 02, 2019 Jul NEWA

IVABRADINE

SOLUTION;ORAL CORLANOR	+! AMGEN INC 5MG/5ML (1MG/ML)	N209964 001 Apr 22, 2019 Apr NEWA
---------------------------	-------------------------------	-----------------------------------

IVACAFTOR

GRANULE;ORAL KALYDECO	+ VERTEX PHARMS INC 25MG/PACKET	N207925 003 Apr 29, 2019 May NEWA
TABLET;ORAL KALYDECO	+ VERTEX PHARMS 75MG	N203188 002 May 20, 2019 May NEWA

IVACAFTOR; IVACAFTOR, TEZACAFTOR

TABLET, TABLET;ORAL SYMDEKO (COPACKAGED)	>A> +! VERTEX PHARMS INC 75MG,N/A;75MG, 50MG	N210491 002 Jun 21, 2019 Jul NEWA
---	--	-----------------------------------

KETOCONAZOLE

GEL;TOPICAL XOLEGEL	+! ALMIRALL 2%	N021946 001 Jul 28, 2006 Feb CAHN
SHAMPOO;TOPICAL KETOCONAZOLE	AB PERRIGO ISRAEL 2%	A076419 001 Jan 07, 2004 May CAHN
TABLET;ORAL KETOCONAZOLE	@ HERITAGE PHARMA 200MG	A074971 001 Jun 15, 1999 May CAHN
	@ 200MG	A075362 001 Jun 15, 1999 May CAHN
AB ! TARO 200MG	A075319 001 Jun 15, 1999 Apr CHRS	
@ TEVA 200MG	A075273 001 Jun 15, 1999 Apr DISC	

KETOROLAC TROMETHAMINE

INJECTABLE;INJECTION KETOROLAC TROMETHAMINE	AP WEST-WARD PHARMS INT 15MG/ML	A075772 001 Jul 21, 2004 Feb CMFD
	AP 30MG/ML	A075772 002 Jul 21, 2004 Feb CMFD
SOLUTION/DROPS;OPHTHALMIC KETOROLAC TROMETHAMINE	AT @ AUROBINDO PHARMA LTD 0.4%	A205191 001 Nov 15, 2018 May DISC
	AT MICRO LABS LTD INDIA 0.5%	A203410 001 Apr 05, 2019 Mar NEWA
	AT @ SANDOZ INC 0.4%	A078721 001 Nov 05, 2009 May DISC
SPRAY, METERED;NASAL SPRIX	>D> +! EGALET 15.75MG/SPRAY	N022382 001 May 14, 2010 Jul CAHN
	>A> +! ZYLA 15.75MG/SPRAY	N022382 001 May 14, 2010 Jul CAHN

KETOROLAC TROMETHAMINE; PHENYLEPHRINE HYDROCHLORIDE

SOLUTION;IRRIGATION KETOROLAC TROMETHAMINE AND PHENYLEPHRINE HYDROCHLORIDE	AT LUPIN LTD EQ 0.3% BASE;EQ 1% BASE	A210183 001 Jul 01, 2019 Jun NFTG
OMIDRIA	AT +! OMEROS EQ 0.3% BASE;EQ 1% BASE	N205388 001 May 30, 2014 Jun CFTG

L-GLUTAMINE

FOR SOLUTION;ORAL NUTRESTORE	+ @ EMMAUS MEDCL 5GM/PACKET	N021667 001 Jun 10, 2004 Jun DISC
---------------------------------	-----------------------------	-----------------------------------

LABETALOL HYDROCHLORIDE

TABLET; ORAL

LABETALOL HYDROCHLORIDE

AB	CADILA PHARMS LTD	100MG	A211325	001	May 13, 2019	Apr NEWA
AB		200MG	A211325	002	May 13, 2019	Apr NEWA
AB		300MG	A211325	003	May 13, 2019	Apr NEWA
AB	HERITAGE PHARMA	100MG	A074787	001	Aug 03, 1998	Feb CAHN
AB		200MG	A074787	002	Aug 03, 1998	Feb CAHN
AB		300MG	A074787	003	Aug 03, 1998	Feb CAHN
AB	INVATECH PHARMA	100MG	A207863	001	Feb 04, 2019	Jan NEWA
AB		200MG	A207863	002	Feb 04, 2019	Jan NEWA
AB		300MG	A207863	003	Feb 04, 2019	Jan NEWA
	TRANDATE					
AB	+ CNTY LINE PHARMS	100MG	N018716	001	May 24, 1985	Jan CRLD
AB	+	200MG	N018716	002	Aug 01, 1984	Jan CRLD
AB	+	300MG	N018716	003	Aug 01, 1984	Jan CRLD

LACTULOSE

SOLUTION; ORAL

LACTULOSE

AA	@ BAJAJ	10GM/15ML	A075911	001	Feb 21, 2002	Jan CAHN
AA	TORRENT	10GM/15ML	A207786	001	Jun 11, 2018	Jan CAHN
AA	@ XTRIUM LABS INC	10GM/15ML	A075911	001	Feb 21, 2002	Mar CAHN
	SOLUTION; ORAL, RECTAL					
	LACTULOSE					
AA	@ BAJAJ	10GM/15ML	A076645	001	Jul 28, 2003	Jan CAHN
AA	TORRENT	10GM/15ML	A203762	001	Mar 27, 2015	Jan CAHN

LAMIVUDINE

TABLET; ORAL

LAMIVUDINE

AB	ANNORA	100MG	A211306	001	Mar 21, 2019	Mar NEWA
AB	MACLEODS PHARMS LTD	150MG	A090198	001	May 01, 2019	Apr NEWA
AB		300MG	A090198	002	May 01, 2019	Apr NEWA
	@ MYLAN	150MG	A204528	001	Mar 04, 2016	Apr DISC
	@	300MG	A204528	002	Mar 04, 2016	Apr DISC
AB	MYLAN LABS LTD	150MG	A078545	001	Mar 05, 2019	Feb NEWA
AB		300MG	A078545	002	Mar 05, 2019	Feb NEWA

LAMIVUDINE; ZIDOVUDINE

TABLET; ORAL

LAMIVUDINE AND ZIDOVUDINE

>A> AB	MYLAN	150MG;300MG	A079079	001	Aug 12, 2019	Jul NEWA
	@	150MG;300MG	A204005	001	Aug 28, 2014	Jan DISC

LAMOTRIGINE

TABLET; ORAL

LAMOTRIGINE

>D> AB	APOTEX INC	25MG	A078625	001	Jan 27, 2009	Jul CAHN
>D> AB		100MG	A078625	002	Jan 27, 2009	Jul CAHN
>D> AB		150MG	A078625	003	Jan 27, 2009	Jul CAHN
>D> AB		200MG	A078625	004	Jan 27, 2009	Jul CAHN
>A> AB	RUBICON	25MG	A078625	001	Jan 27, 2009	Jul CAHN
>A> AB		100MG	A078625	002	Jan 27, 2009	Jul CAHN
>A> AB		150MG	A078625	003	Jan 27, 2009	Jul CAHN
>A> AB		200MG	A078625	004	Jan 27, 2009	Jul CAHN

TABLET, CHEWABLE; ORAL

LAMOTRIGINE

>D> AB	TEVA	5MG	A076420	001	Jun 21, 2006	Jul DISC
>A>	@	5MG	A076420	001	Jun 21, 2006	Jul DISC
>D> AB		25MG	A076420	002	Jun 21, 2006	Jul DISC
>A>	@	25MG	A076420	002	Jun 21, 2006	Jul DISC

TABLET, EXTENDED RELEASE; ORAL

LAMOTRIGINE

	@ RUBICON	25MG	A202887	001	Jun 17, 2013	Mar CAHN
	@	50MG	A202887	002	Jun 17, 2013	Mar CAHN
AB		100MG	A202887	003	Jun 17, 2013	Mar CAHN
AB		200MG	A202887	004	Jun 17, 2013	Mar CAHN

LANSOPRAZOLE

CAPSULE, DELAYED REL PELLETS;ORAL
LANSOPRAZOLE

AB	ALKEM LABS LTD	15MG	A207394	001	Jan 18, 2019	Jan NEWA
AB		30MG	A207394	002	Jan 18, 2019	Jan NEWA
@	BRECKENRIDGE PHARM	15MG	A203964	001	Oct 17, 2018	May DISC
@		30MG	A203964	002	Oct 17, 2018	May DISC
@	KRKA TOVARNA ZDRAVIL	15MG	A091212	001	Sep 16, 2013	Feb DISC
@		30MG	A091212	002	Sep 16, 2013	Feb DISC

LAROTRECTINIB

	CAPSULE;ORAL VITRAKVI					
+	BAYER HLTHCARE	25MG	N210861	001	Nov 26, 2018	Feb CAHN
+		100MG	N210861	002	Nov 26, 2018	Feb CAHN
	SOLUTION;ORAL VITRAKVI					
+	BAYER HEALTHCARE	20MG/ML	N211710	001	Nov 26, 2018	Feb CAHN

LAROTRECTINIB SULFATE

	CAPSULE;ORAL VITRAKVI					
+	BAYER HLTHCARE	EQ 25MG BASE	N210861	001	Nov 26, 2018	Jun CAIN
+		EQ 25MG BASE	N210861	001	Nov 26, 2018	Jun CPOT
+		EQ 100MG BASE	N210861	002	Nov 26, 2018	Jun CAIN
+		EQ 100MG BASE	N210861	002	Nov 26, 2018	Jun CPOT
	SOLUTION;ORAL VITRAKVI					
+	BAYER HEALTHCARE	EQ 20MG BASE/ML	N211710	001	Nov 26, 2018	Jun CAIN
+		EQ 20MG BASE/ML	N211710	001	Nov 26, 2018	Jun CPOT

LATANOPROST; NETARSUDIL DIMESYLATE

	SOLUTION/DROPS;OPHTHALMIC ROCKLATAN					
+	AERIE PHARMS INC	0.005%;EQ 0.02% BASE	N208259	001	Mar 12, 2019	Mar NEWA

LEFLUNOMIDE

	TABLET;ORAL LEFLUNOMIDE					
AB	ABHAI LLC	10MG	A212453	001	Jun 03, 2019	May NEWA
AB		20MG	A212453	002	Jun 03, 2019	May NEWA
AB	ZYDUS	10MG	A212308	001	Apr 24, 2019	Apr NEWA
AB		20MG	A212308	002	Apr 24, 2019	Apr NEWA

LESINURAD

	TABLET;ORAL ZURAMPIC					
+	@ IRONWOOD PHARMS INC	200MG	N207988	001	Dec 22, 2015	Apr DISC

LETROZOLE

	TABLET;ORAL LETROZOLE					
>D>	AB EUGIA PHARMA	2.5MG	A211717	001	Jan 11, 2019	Jul DISC
>A>	@	2.5MG	A211717	001	Jan 11, 2019	Jul DISC
AB	FRESENIUS KABI USA	2.5MG	A090491	001	Jun 03, 2011	Feb CAHN

LEUCOVORIN CALCIUM

	INJECTABLE;INJECTION LEUCOVORIN CALCIUM					
AP	INGENUS PHARMS LLC	EQ 10MG BASE/ML	A210917	001	Nov 23, 2018	Feb CPOT

LEUPROLIDE ACETATE

	FOR SUSPENSION;INTRAMUSCULAR LUTRATE DEPOT KIT					
+	@ GP-PHARM SA	22.5MG/VIAL	N205054	001	Aug 28, 2018	Jun DISC

LEVETIRACETAM

INJECTABLE; INTRAVENOUS
KEPPRA

AP	+! UCB INC	500MG/5ML (100MG/ML)	N 021872	001	Jul 31, 2006	Jun CDFR
	LEVETIRACETAM					
AP	AUROBINDO PHARMA LTD	500MG/5ML (100MG/ML)	A 204312	001	Feb 01, 2016	Jun CDFR
AP	FRESENIUS KABI USA	500MG/5ML (100MG/ML)	A 090813	001	May 26, 2010	Jun CDFR
AP		500MG/5ML (100MG/ML)	A 090876	001	Aug 13, 2015	Jun CDFR
AP	HAINAN POLY PHARM	500MG/5ML (100MG/ML)	A 209781	001	Mar 20, 2018	Jun CDFR
AP	HIKMA FARMACEUTICA	500MG/5ML (100MG/ML)	A 090981	001	Oct 13, 2011	Jun CDFR
AP	HOSPIRA INC	500MG/5ML (100MG/ML)	A 202869	001	Apr 06, 2012	Jun CDFR
AP	JUBILANT GENERICS	500MG/5ML (100MG/ML)	A 206838	001	Jun 02, 2016	Jun CDFR
>A>	AP MICRO LABS	500MG/5ML (100MG/ML)	A 211954	001	Aug 09, 2019	Jul NEWA
AP	MYLAN LABS LTD	500MG/5ML (100MG/ML)	A 203308	001	Sep 16, 2016	Jun CDFR
AP	SAGENT PHARMS	500MG/5ML (100MG/ML)	A 091627	001	Jun 26, 2013	Jun CDFR
AP	SUN PHARM INDs LTD	500MG/5ML (100MG/ML)	A 090754	001	Jun 16, 2010	Jun CDFR
AP	X GEN PHARMS	500MG/5ML (100MG/ML)	A 091485	001	Aug 05, 2011	Jun CDFR
	LEVETIRACETAM IN SODIUM CHLORIDE					
AP	AUROBINDO PHARMA LTD	500MG/100ML (5MG/ML)	A 207160	001	Jan 04, 2017	Jun CDFR
AP		1000MG/100ML (10MG/ML)	A 207160	002	Jan 04, 2017	Jun CDFR
AP		1500MG/100ML (15MG/ML)	A 207160	003	Jan 04, 2017	Jun CDFR
AP	GLAND PHARMA LTD	500MG/100ML (5MG/ML)	A 206880	001	Oct 25, 2017	Jun CDFR
AP		1000MG/100ML (10MG/ML)	A 206880	002	Oct 25, 2017	Jun CDFR
AP		1500MG/100ML (15MG/ML)	A 206880	003	Oct 25, 2017	Jun CDFR
AP	+! HQ SPECIALITY PHARMA	500MG/100ML (5MG/ML)	N 202543	001	Nov 09, 2011	Jun CDFR
AP	+!	1000MG/100ML (10MG/ML)	N 202543	002	Nov 09, 2011	Jun CDFR
AP	+!	1500MG/100ML (15MG/ML)	N 202543	003	Nov 09, 2011	Jun CDFR

LEVOBUNOLOL HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC
LEVOBUNOLOL HYDROCHLORIDE
@ SANDOZ INC

0.5%

A 074850 001 Oct 28, 1996 May DISC

LEVOCARNITINE

SOLUTION; ORAL
LEVOCARNITINE

>A> AA	NOVITIUM PHARMA	1GM/10ML	A 211676	001	Aug 14, 2019	Jul NEWA
>A> AA	NOVITIUM PHARMA	1GM/10ML	A 211676	002	Aug 14, 2019	Jul NEWA

LEVOSETIRIZINE DIHYDROCHLORIDE

SOLUTION; ORAL
LEVOSETIRIZINE HYDROCHLORIDE
AA HETERO LABS LTD III 2.5MG/5ML

A 210914 001 Apr 01, 2019 Mar NEWA

LEVOFLOXACIN

SOLUTION/DROPS; OPHTHALMIC
LEVOFLOXACIN

MICRO LABS LTD INDIA 1.5%

A 205600 001 Feb 27, 2019 Feb NEWA

TABLET; ORAL

LEVOFLOXACIN

AB	HEC PHARM	250MG	A 204968	001	Feb 05, 2019	Jan NEWA
AB		500MG	A 204968	002	Feb 05, 2019	Jan NEWA
AB		750MG	A 204968	003	Feb 05, 2019	Jan NEWA

LEVOLEUCOVORIN

POWDER; INTRAVENOUS
KHPAZORY

+! ACROTECH 175MG/VIAL
+! 300MG/VIAL

N 211226 001 Oct 19, 2018 Mar CAHN
N 211226 002 Oct 19, 2018 Mar CAHNLEVOLEUCOVORIN CALCIUM

POWDER; INTRAVENOUS
FUSILEV

AP	+! ACROTECH	EQ 50MG BASE/VIAL	N 020140	001	Mar 07, 2008	Mar CAHN
	LEVOLEUCOVORIN CALCIUM					
+ @ ACTAVIS LLC		EQ 175MG BASE/VIAL	N 208723	001	Sep 29, 2016	Jun DISC
SOLUTION; INTRAVENOUS FUSILEV						
+ @ ACROTECH		EQ 175MG BASE/17.5ML (EQ 10MG BASE/ML)	N 020140	002	Apr 29, 2011	Mar CAHN

SOLUTION; INTRAVENOUS

FUSILEV

+ @	EQ 250MG BASE/25ML (EQ 10MG BASE/ML)	N 020140 003 Apr 29, 2011	Mar CAHN
-----	---	---------------------------	----------

LEVOMILNACIPRAN HYDROCHLORIDECAPSULE, EXTENDED RELEASE; ORAL
FETZIMA

AB	+ ALLERGAN SALES LLC	EQ 20MG BASE	N 204168 001 Jul 25, 2013	Jun CTEC
	+	EQ 20MG BASE	N 204168 001 Jul 25, 2013	Jan CFTG
	+	EQ 40MG BASE	N 204168 002 Jul 25, 2013	Jun CTEC
AB	+	EQ 40MG BASE	N 204168 002 Jul 25, 2013	Jan CFTG
	+	EQ 80MG BASE	N 204168 003 Jul 25, 2013	Jun CTEC
AB	+	EQ 80MG BASE	N 204168 003 Jul 25, 2013	Jan CFTG
	+!	EQ 120MG BASE	N 204168 004 Jul 25, 2013	Jun CTEC
AB	+!	EQ 120MG BASE	N 204168 004 Jul 25, 2013	Jan CFTG
	LEVOMILNACIPRAN HYDROCHLORIDE			
AB	@ AMNEAL PHARMS CO	EQ 20MG BASE	A 210790 001 Feb 04, 2019	Jun DISC
		EQ 20MG BASE	A 210790 001 Feb 04, 2019	Jan NFTG
	@	EQ 40MG BASE	A 210790 002 Feb 04, 2019	Jun DISC
AB	@	EQ 40MG BASE	A 210790 002 Feb 04, 2019	Jan NFTG
	@	EQ 80MG BASE	A 210790 003 Feb 04, 2019	Jun DISC
AB	@	EQ 80MG BASE	A 210790 003 Feb 04, 2019	Jan NFTG
	@	EQ 120MG BASE	A 210790 004 Feb 04, 2019	Jun DISC
AB		EQ 120MG BASE	A 210790 004 Feb 04, 2019	Jan NFTG

LEVONORGESTRELTABLET; ORAL
LEVONORGESTREL

AB	! L PERRIGO CO	0.75MG	A 090740 001 Dec 30, 2010	May CAHN
----	----------------	--------	---------------------------	----------

LEVORPHANOL TARTRATETABLET; ORAL
LEVORPHANOL TARTRATE

AB	@ SENTYNL THERAPS INC	1MG	A 074278 002 Jun 18, 2018	Feb DISC
	!	3MG	A 074278 003 Jun 18, 2018	May CMFD
	@	3MG	A 074278 003 Jun 18, 2018	Feb DISC

LEVOOTHYROXINE SODIUM

POWDER; INTRAVENOUS

LEVOOTHYROXINE SODIUM

AB	@ PAR STERILE PRODUCTS	200MCG/VIAL	A 205366 001 Dec 07, 2015	Apr DISC
----	------------------------	-------------	---------------------------	----------

SOLUTION; INTRAVENOUS

LEVOOTHYROXINE SODIUM

AB	+! FRESENIUS KABI USA	100MCG/5ML (20MCG/ML)	N 210632 001 Apr 11, 2019	Apr NEWA
	+!	200MCG/5ML (40MCG/ML)	N 210632 002 Apr 11, 2019	Apr NEWA
	+!	500MCG/5ML (100MCG/ML)	N 210632 003 Apr 11, 2019	Apr NEWA

SOLUTION; ORAL

TIROSINT-SOL

AB	+ INSTITUT BIOCHIMIQUE	13MCG/ML	N 206977 001 Dec 15, 2016	Jan CMFD
	+	25MCG/ML	N 206977 002 Dec 15, 2016	Jan CMFD
	+	50MCG/ML	N 206977 003 Dec 15, 2016	Jan CMFD
	+	75MCG/ML	N 206977 004 Dec 15, 2016	Jan CMFD
	+	88MCG/ML	N 206977 005 Dec 15, 2016	Jan CMFD
	+	100MCG/ML	N 206977 006 Dec 15, 2016	Jan CMFD
	+	112MCG/ML	N 206977 007 Dec 15, 2016	Jan CMFD
	+	125MCG/ML	N 206977 008 Dec 15, 2016	Jan CMFD
	+	137MCG/ML	N 206977 009 Dec 15, 2016	Jan CMFD
	+	150MCG/ML	N 206977 010 Dec 15, 2016	Jan CMFD
	+	175MCG/ML	N 206977 011 Dec 15, 2016	Jan CMFD
	+!	200MCG/ML	N 206977 012 Dec 15, 2016	Jan CMFD

LEVOOTHYROXINE SODIUM **

**See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium

TABLET; ORAL

LEVOOTHYROXINE SODIUM

AB2	@ AMNEAL PHARMS LLC	0.025MG	A 210831 001 Feb 19, 2019	Jun DISC
AB1,		0.025MG	A 210831 001 Feb 19, 2019	May CTEC
AB2		0.025MG	A 210831 001 Feb 19, 2019	Feb NEWA
	@	0.05MG	A 210831 002 Feb 19, 2019	Jun DISC
AB2		0.05MG	A 210831 002 Feb 19, 2019	May CTEC
AB1,		0.05MG	A 210831 002 Feb 19, 2019	Feb NEWA

TABLET;ORAL
LEVOTHYROXINE SODIUM

AB2	@	0.075MG	A210831	003	Feb 19, 2019	Jun DISC
AB2		0.075MG	A210831	003	Feb 19, 2019	May CTEC
AB1, AB2		0.075MG	A210831	003	Feb 19, 2019	Feb NEWA
	@	0.088MG	A210831	004	Feb 19, 2019	Jun DISC
AB2		0.088MG	A210831	004	Feb 19, 2019	May CTEC
AB1, AB2		0.088MG	A210831	004	Feb 19, 2019	Feb NEWA
	@	0.1MG	A210831	005	Feb 19, 2019	Jun DISC
AB2		0.1MG	A210831	005	Feb 19, 2019	May CTEC
AB1, AB2		0.1MG	A210831	005	Feb 19, 2019	Feb NEWA
	@	0.112MG	A210831	006	Feb 19, 2019	Jun DISC
AB2		0.112MG	A210831	006	Feb 19, 2019	May CTEC
AB1, AB2		0.112MG	A210831	006	Feb 19, 2019	Feb NEWA
	@	0.125MG	A210831	007	Feb 19, 2019	Jun DISC
AB2		0.125MG	A210831	007	Feb 19, 2019	May CTEC
AB1, AB2		0.125MG	A210831	007	Feb 19, 2019	Feb NEWA
	@	0.137MG	A210831	008	Feb 19, 2019	Jun DISC
AB2		0.137MG	A210831	008	Feb 19, 2019	May CTEC
AB1, AB2		0.137MG	A210831	008	Feb 19, 2019	Feb NEWA
	@	0.15MG	A210831	009	Feb 19, 2019	Jun DISC
AB2		0.15MG	A210831	009	Feb 19, 2019	May CTEC
AB1, AB2		0.15MG	A210831	009	Feb 19, 2019	Feb NEWA
	@	0.175MG	A210831	010	Feb 19, 2019	Jun DISC
AB2		0.175MG	A210831	010	Feb 19, 2019	May CTEC
AB1, AB2		0.175MG	A210831	010	Feb 19, 2019	Feb NEWA
	@	0.2MG	A210831	011	Feb 19, 2019	Jun DISC
AB2		0.2MG	A210831	011	Feb 19, 2019	May CTEC
AB1, AB2		0.2MG	A210831	011	Feb 19, 2019	Feb NEWA
	@	0.3MG	A210831	012	Feb 19, 2019	Jun DISC
AB2		0.3MG	A210831	012	Feb 19, 2019	May CTEC
AB1, AB2		0.3MG	A210831	012	Feb 19, 2019	Feb NEWA
AB2	LUPIN ATLANTIS	0.025MG	A209713	001	Jan 18, 2019	Jan NEWA
AB2		0.05MG	A209713	002	Jan 18, 2019	Jan NEWA
AB2		0.075MG	A209713	003	Jan 18, 2019	Jan NEWA
AB2		0.088MG	A209713	004	Jan 18, 2019	Jan NEWA
AB2		0.1MG	A209713	005	Jan 18, 2019	Jan NEWA
AB2		0.112MG	A209713	006	Jan 18, 2019	Jan NEWA
AB2		0.125MG	A209713	007	Jan 18, 2019	Jan NEWA
AB2		0.137MG	A209713	008	Jan 18, 2019	Jan NEWA
AB2		0.15MG	A209713	009	Jan 18, 2019	Jan NEWA
AB2		0.175MG	A209713	010	Jan 18, 2019	Jan NEWA
AB2		0.2MG	A209713	011	Jan 18, 2019	Jan NEWA
AB2		0.3MG	A209713	012	Jan 18, 2019	Jan NEWA
THYRO-TABS						
AB2, +	ALVOGEN	0.025MG	N021116	001	Oct 24, 2002	Mar CAHN
AB4			N021116	002	Oct 24, 2002	Mar CAHN
AB2, +		0.05MG	N021116	003	Oct 24, 2002	Mar CAHN
AB4			N021116	010	Oct 24, 2002	Mar CAHN
AB2, +		0.075MG	N021116	004	Oct 24, 2002	Mar CAHN
AB4			N021116	011	Oct 24, 2002	Mar CAHN
AB2, +		0.088MG	N021116	012	Oct 24, 2002	Mar CAHN
AB4			N021116	005	Oct 24, 2002	Mar CAHN
AB2, +		0.1MG	N021116	006	Oct 24, 2002	Mar CAHN
AB4			N021116	013	Oct 24, 2002	Mar CAHN
AB2, +		0.112MG	N021116	014	Oct 24, 2002	Mar CAHN
AB4			N021116	007	Oct 24, 2002	Mar CAHN
AB2, +		0.125MG	N021116	015	Oct 24, 2002	Mar CAHN
AB4			N021116	016	Oct 24, 2002	Mar CAHN
AB2, +		0.137MG	N021116	017	Dec 07, 2004	Mar CAHN
AB4			N021116	008	Oct 24, 2002	Mar CAHN
AB2, +		0.15MG	N021116	009	Oct 24, 2002	Mar CAHN
AB4			N021116	018	Oct 24, 2002	Mar CAHN
AB2, +		0.175MG	N021116	019	Oct 24, 2002	Mar CAHN
AB4			N021116	010	Oct 24, 2002	Mar CAHN
AB2, +		0.2MG	N021116	020	Oct 24, 2002	Mar CAHN
AB4			N021116	011	Oct 24, 2002	Mar CAHN

TABLET;ORAL
THYRO-TABS

AB2, +!	0.3MG	N 021116 009 Oct 24, 2002	Mar CAHN
AB4			
AB2, + LLOYD	0.025MG	N 021116 001 Oct 24, 2002	Feb CMFD
AB4			
AB2, +	0.05MG	N 021116 002 Oct 24, 2002	Feb CMFD
AB4			
AB2, +	0.075MG	N 021116 003 Oct 24, 2002	Feb CMFD
AB4			
AB2, +	0.088MG	N 021116 010 Oct 24, 2002	Feb CMFD
AB4			
AB2, +	0.1MG	N 021116 004 Oct 24, 2002	Feb CMFD
AB4			
AB2, +	0.112MG	N 021116 011 Oct 24, 2002	Feb CMFD
AB4			
AB2, +	0.125MG	N 021116 005 Oct 24, 2002	Feb CMFD
AB4			
AB2, +	0.137MG	N 021116 012 Dec 07, 2004	Feb CMFD
AB4			
AB2, +	0.15MG	N 021116 006 Oct 24, 2002	Feb CMFD
AB4			
AB2, +	0.175MG	N 021116 007 Oct 24, 2002	Feb CMFD
AB4			
AB2, +	0.2MG	N 021116 008 Oct 24, 2002	Feb CMFD
AB4			
AB2, +!	0.3MG	N 021116 009 Oct 24, 2002	Feb CMFD
AB4			

LIDOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION
LIDOCAINE HYDROCHLORIDE

AP	FRESENIUS KABI USA	1%	A 080404 002	Jun CTNA
AP		2%	A 080404 003	Jun CTNA
@	LUITPOLD	1%	A 080850 001	Mar DISC
@		1%	A 091564 001 Aug 14, 2015	Feb DISC

JELLY; TOPICAL

ANESTACON

@ BIONPHARMA INC

2%

A 080429 001

Apr CAHN

LIDOCAINE; PRILOCaine

CREAM; TOPICAL
EMLA

AB	+! TEVA BRANDED PHARM	2.5%;2.5%	N 019941 001 Dec 30, 1992	Apr CAHN
----	-----------------------	-----------	---------------------------	----------

LINEZOLID

TABLET;ORAL
LINEZOLID

AB	CELLTRION	600MG	A 210702 001 Apr 25, 2019	Apr NEWA
@	MYLAN	600MG	A 078845 001 Dec 21, 2015	Jun DISC

LIOTHYRONINE SODIUM

TABLET;ORAL
CYTOMEL

AB	+ KING PHARMS	EQ 0.05MG BASE	N 010379 003	Jun CHRS
	LIOTHYRONINE SODIUM			
@	MYLAN	EQ 0.005MG BASE	A 090326 001 Jul 14, 2009	Mar DISC
@		EQ 0.025MG BASE	A 090326 002 Jul 14, 2009	Mar DISC
@		EQ 0.05MG BASE	A 090326 003 Jul 14, 2009	Mar DISC
AB	! SIGMAPHARM LABS LLC	EQ 0.05MG BASE	A 200295 003 Nov 29, 2012	Jun CHRS
@	SUN PHARM	EQ 0.005MG BASE	A 091382 001 Apr 20, 2016	Jun DISC
@		EQ 0.025MG BASE	A 091382 002 Apr 20, 2016	Jun DISC
@		EQ 0.05MG BASE	A 091382 003 Apr 20, 2016	Jun DISC
@	TEVA PHARMS USA	EQ 0.005MG BASE	A 211510 001 Oct 26, 2018	Apr DISC
@		EQ 0.025MG BASE	A 211510 002 Oct 26, 2018	Apr DISC
@		EQ 0.05MG BASE	A 211510 003 Oct 26, 2018	Apr DISC

LISINOPRIL

TABLET;ORAL
LISINOPRIL

AB	HERITAGE PHARMA	2.5MG	A 075752 001 Jul 01, 2002	Feb CAHN
AB		5MG	A 075752 002 Jul 01, 2002	Feb CAHN
AB		10MG	A 075752 003 Jul 01, 2002	Feb CAHN
AB		20MG	A 075752 004 Jul 01, 2002	Feb CAHN
AB		30MG	A 075752 005 Jul 01, 2002	Feb CAHN

	TABLET;ORAL LISINOPRIL	40MG	A 075752 006 Jul 01, 2002	Feb CAHN
<u>LITHIUM CARBONATE</u>				
	CAPSULE;ORAL LITHIUM CARBONATE			
AB	+ HIKMA	150MG	N 017812 002 Jan 28, 1987	Apr CAHN
AB	+	300MG	N 017812 001	Apr CAHN
AB	+! @ MYLAN	600MG 600MG	N 017812 003 Jan 28, 1987 A 078763 001 Apr 15, 2008	Apr CAHN Jun DISC
	TABLET, EXTENDED RELEASE;ORAL LITHIUM CARBONATE			
	@ HERITAGE PHARMA	300MG	A 076170 001 Jun 10, 2002	May CAHN
	@	450MG	A 076366 001 Aug 21, 2003	May CAHN
<u>LITHIUM CITRATE</u>				
	SYRUP;ORAL LITHIUM CITRATE			
AA	+! HIKMA	EQ 300MG CARBONATE/5ML	N 018421 001	Apr CAHN
<u>LORAZEPAM</u>				
	CONCENTRATE;ORAL LORAZEPAM			
>A> AA	LANNETT CO INC	2MG/ML	A 079244 001 Apr 28, 2009	Jul CAHN
>D> AA	SAPTALIS PHARMS	2MG/ML	A 079244 001 Apr 28, 2009	Jul CAHN
AA		2MG/ML	A 079244 001 Apr 28, 2009	Feb CAHN
	INJECTABLE;INJECTION ATIVAN			
AP	+! HIKMA	2MG/ML	N 018140 001	Mar CAHN
AP	+!	4MG/ML	N 018140 002	Mar CAHN
	TABLET;ORAL ATIVAN			
AB	+ BAUSCH	0.5MG	N 017794 001	Feb CAHN
AB	+	1MG	N 017794 002	Feb CAHN
AB	+!	2MG	N 017794 003	Feb CAHN
<u>LOSARTAN POTASSIUM</u>				
	TABLET;ORAL LOSARTAN POTASSIUM			
AB	HISUN PHARM HANGZHOU	25MG	A 204795 001 Apr 04, 2019	Mar NEWA
AB		50MG	A 204795 002 Apr 04, 2019	Mar NEWA
AB		100MG	A 204795 003 Apr 04, 2019	Mar NEWA
AB	MICRO LABS	25MG	A 091541 001 Sep 24, 2012	Mar CAHN
AB		50MG	A 091541 002 Sep 24, 2012	Mar CAHN
AB		100MG	A 091541 003 Sep 24, 2012	Mar CAHN
AB	STRIDES PHARMA	25MG	A 090382 001 Oct 06, 2010	Apr CAHN
AB		50MG	A 090382 002 Oct 06, 2010	Apr CAHN
AB		100MG	A 090382 003 Oct 06, 2010	Apr CAHN
>D> AB	TEVA	25MG	A 076958 001 Apr 06, 2010	Jul DISC
>A>	@	25MG	A 076958 001 Apr 06, 2010	Jul DISC
>D> AB		50MG	A 076958 002 Apr 06, 2010	Jul DISC
>A>	@	50MG	A 076958 002 Apr 06, 2010	Jul DISC
>D> AB		100MG	A 076958 003 Apr 06, 2010	Jul DISC
>A>	@	100MG	A 076958 003 Apr 06, 2010	Jul DISC
<u>LOTEPREDNOL ETABONATE</u>				
	GEL;OPHTHALMIC LOTEMAX SM			
+!	BAUSCH AND LOMB INC	0.38%	N 208219 001 Feb 22, 2019	Feb NEWA
	SUSPENSION/DROPS;OPHTHALMIC LOTEMAX			
AB	+! BAUSCH AND LOMB	0.5%	N 020583 001 Mar 09, 1998	Apr CFTG
	LOTEPREDNOL ETABONATE			
AB	HI TECH	0.5%	A 207609 001 Apr 17, 2019	Apr NFTG

LOVASTATIN

TABLET;ORAL

LOVASTATIN

AB	BEXIMCO PHARMS USA	10MG	A075300	001	Dec 17, 2001	Feb CAHN
AB		20MG	A075300	002	Dec 17, 2001	Feb CAHN
AB		40MG	A075300	003	Dec 17, 2001	Feb CAHN
@	MYLAN	10MG	A075451	001	Dec 17, 2001	Feb DISC
@		20MG	A075451	002	Dec 17, 2001	Feb DISC
@		40MG	A075451	003	Dec 17, 2001	Feb DISC

LOXAPINE HYDROCHLORIDE

CONCENTRATE;ORAL

LOXITANE C

@ TEVA BRANDED PHARM

EQ 25MG BASE/ML

N017658 001

Feb CAHN

LOXAPINE SUCCINATE

CAPSULE;ORAL

LOXITANE

+ @ TEVA BRANDED PHARM

EQ 5MG BASE

N017525 001

Feb CAHN

+ @

EQ 10MG BASE

N017525 002

Feb CAHN

+ @

EQ 25MG BASE

N017525 003

Feb CAHN

+ @

EQ 50MG BASE

N017525 004

Feb CAHN

TABLET;ORAL

LOXITANE

+ @ TEVA BRANDED PHARM

EQ 10MG BASE

N017525 006

Feb CAHN

+ @

EQ 25MG BASE

N017525 007

Feb CAHN

+ @

EQ 50MG BASE

N017525 008

Feb CAHN

+ @

EQ 50MG BASE

N017525 008

Feb CAHN

LURASIDONE HYDROCHLORIDE

TABLET;ORAL

LURASIDONE HYDROCHLORIDE

@ AMNEAL PHARMS CO

20MG

A208002 001

Jun DISC

@

40MG

A208002 002

Jun DISC

@

60MG

A208002 003

Jun DISC

@

80MG

A208002 004

Jun DISC

@

120MG

A208002 005

Jun DISC

>D> AB INVAGEN PHARMS

20MG

A208028 001

Jul DISC

>A> @

20MG

A208028 001

Jul DISC

>D> AB 40MG

A208028 002

Jul DISC

>A> @

40MG

A208028 002

Jul DISC

>D> AB 60MG

A208028 003

Jul DISC

>A> @

60MG

A208028 003

Jul DISC

>D> AB 80MG

A208028 004

Jul DISC

>A> @

80MG

A208028 004

Jul DISC

>D> AB 120MG

A208028 005

Jul DISC

>A> @

120MG

A208028 005

Jul DISC

>D> AB LUPIN LTD

20MG

A208031 001

Jul DISC

>A> @

20MG

A208031 001

Jul DISC

>D> AB 40MG

A208031 002

Jul DISC

>A> @

40MG

A208031 002

Jul DISC

>D> AB 60MG

A208031 003

Jul DISC

>A> @

60MG

A208031 003

Jul DISC

>D> AB 80MG

A208031 004

Jul DISC

>A> @

80MG

A208031 004

Jul DISC

>D> AB 120MG

A208031 005

Jul DISC

>A> @

120MG

A208031 005

Jul DISC

AB TEVA PHARMS USA

20MG

A208060 001

May NEWA

AB

40MG

A208060 002

May NEWA

AB

60MG

A208060 003

May NEWA

AB

80MG

A208060 004

May NEWA

AB

120MG

A208060 005

May NEWA

@ TORRENT

20MG

A208055 001

Feb DISC

@

40MG

A208055 002

Feb DISC

@

80MG

A208055 003

Feb DISC

@

120MG

A208055 004

Feb DISC

MAGNESIUM SULFATE

SOLUTION; INTRAMUSCULAR, INTRAVENOUS
MAGNESIUM SULFATE

AP +!	FRESENIUS KABI USA	10GM/20ML (500MG/ML)	N019316 003 Jan 29, 2016	Jan CTEC
AP	HOSPIRA INC	10GM/20ML (500MG/ML)	A202411 001 May 14, 2015	Jan CTEC

MAGNESIUM SULFATE; POTASSIUM SULFATE; SODIUM SULFATE

POWDER; ORAL
COLPREP KIT

+ @ GATOR PHARMS	1.6GM/BOT; 3.13GM/BOT; 17.5GM/BOT	N204553 001 Dec 27, 2016	Mar DISC
------------------	-----------------------------------	--------------------------	----------

MANNITOL

INJECTABLE; INJECTION
MANNITOL 25%

@ LUITPOLD	12.5GM/50ML	A087409 001 Jan 21, 1982	Mar DISC
------------	-------------	--------------------------	----------

MECLIZINE HYDROCHLORIDE

TABLET; ORAL
ANTIVERT

AA +	CASPER PHARMA LLC	12.5MG	N010721 006 Feb CMFD
	+ @	12.5MG	N010721 006 Jan CRLD
AA +		25MG	N010721 004 Feb CMFD
	+ @	25MG	N010721 004 Jan CRLD
AA +		50MG	N010721 001 Jan 20, 1982 Feb CMFD
	+ @	50MG	N010721 001 Jan 20, 1982 Jan CRLD

MECLIZINE HYDROCHLORIDE

AA !	AMNEAL PHARMS	12.5MG	A201451 001 Feb 23, 2011 Jan CHRS
AA !		25MG	A201451 002 Feb 23, 2011 Jan CHRS
	@ ANI PHARMS INC	12.5MG	A088732 001 Dec 11, 1985 May CAHN
AA	INDICUS PHARMA	12.5MG	A205136 001 Feb 22, 2019 Feb NEWA
AA		25MG	A205136 002 Feb 22, 2019 Feb NEWA
		50MG	A205136 003 Feb 22, 2019 Feb NEWA

TABLET, CHEWABLE; ORAL
ANTIVERT

AA +	CASPER PHARMA LLC	25MG	N010721 005 Feb CMFD
	+ @	25MG	N010721 005 Jan CRLD

MEDROXYPROGESTERONE ACETATE

INJECTABLE; INJECTION
MEDROXYPROGESTERONE ACETATE

>D> AB	CIPLA	150MG/ML	A210335 001 Jan 25, 2019 Jul DISC
>A>	@	150MG/ML	A210335 001 Jan 25, 2019 Jul DISC
AB		150MG/ML	A210335 001 Jan 25, 2019 Jan NEWA
AB	SUN PHARM	150MG/ML	A210760 001 May 01, 2019 Apr NEWA
AB		150MG/ML	A210761 001 Apr 24, 2019 Apr NEWA

TABLET; ORAL
MEDROXYPROGESTERONE ACETATE

>A>	@ UPSHER SMITH LABS	10MG	A088484 001 Jul 26, 1984 Jul CAHN
>D>	@ USL PHARMA	10MG	A088484 001 Jul 26, 1984 Jul CAHN

MEFENAMIC ACID

CAPSULE; ORAL
MEFENAMIC ACID

@ BRECKENRIDGE PHARM	250MG	A090359 001 Feb 05, 2013 Feb DISC
----------------------	-------	-----------------------------------

MEGESTROL ACETATE

SUSPENSION; ORAL
MEGESTROL ACETATE

@ PD PARTNERS	40MG/ML	A077404 001 Feb 16, 2006 May CAHN
---------------	---------	-----------------------------------

MELOXICAM

CAPSULE; ORAL
VIVLODEX

>D>	+ EGALET	5MG	N207233 001 Oct 22, 2015 Jul CAHN
	+ @	5MG	N207233 001 Oct 22, 2015 Feb CAHN
>D>	+ !	10MG	N207233 002 Oct 22, 2015 Jul CAHN
	+ !	10MG	N207233 002 Oct 22, 2015 Feb CAHN
>A>	+ ZYLA	5MG	N207233 001 Oct 22, 2015 Jul CAHN
>A>	+ !	10MG	N207233 002 Oct 22, 2015 Jul CAHN

SUSPENSION;ORAL

MOBIC

+ @ AVONDALE PHARMS

7.5MG/5ML

N021530 001 Jun 01, 2004 Jun CAHN

TABLET;ORAL

MELOXICAM

AB HERITAGE PHARMA

7.5MG

A077936 001 Jul 19, 2006 Feb CAHN

AB

15MG

A077936 002 Jul 19, 2006 Feb CAHN

MELPHALAN HYDROCHLORIDE

INJECTABLE;INJECTION

ALKERAN

AP + APOTEX INC

EQ 50MG BASE/VIAL

N020207 001 Nov 18, 1992 Feb CMFD

MELPHALAN HYDROCHLORIDE

AP ALVOGEN INC

EQ 50MG BASE/VIAL

A204817 001 May 17, 2019 May NEWA

AP GLAND PHARMA LTD

EQ 50MG BASE/VIAL

A209826 001 May 28, 2019 May NEWA

AP US WORLDMEDS LLC

EQ 50MG BASE/VIAL

A207032 001 May 03, 2019 Apr NEWA

POWDER;INTRAVENOUS

EVOMELA

+! ACROTECH

EQ 50MG BASE/VIAL

N207155 001 Mar 10, 2016 Mar CAHN

MEMANTINE HYDROCHLORIDE

SOLUTION;ORAL

MEMANTINE HYDROCHLORIDE

AA ! TTorrent

2MG/ML

A205446 001 Dec 07, 2015 Jan CAHN

TABLET;ORAL

MEMANTINE HYDROCHLORIDE

@ APOTEX INC

5MG

A090244 001 Jul 11, 2018 Jan DISC

@

10MG

A090244 002 Jul 11, 2018 Jan DISC

AB CADILA

5MG

A090961 001 Jul 10, 2017 Feb CAHN

AB

10MG

A090961 002 Jul 10, 2017 Feb CAHN

MEPERIDINE HYDROCHLORIDE; PROMETHAZINE HYDROCHLORIDE

INJECTABLE;INJECTION

MEPERGAN

@ HIKMA

25MG/ML;25MG/ML

N011730 001

Jun CAHN

MEQUINOL; TRETINOIN

SOLUTION;TOPICAL

SOLAGE

@ ALMIRALL

2%;0.01%

N020922 001 Dec 10, 1999 Feb CAHN

MESALAMINE

CAPSULE, DELAYED RELEASE;ORAL

DELZICOL

AB +! API

400MG

N204412 001 Feb 01, 2013 Apr CFTG

MESALAMINE

AB TEVA PHARMS USA

400MG

A207873 001 May 09, 2019 Apr NFTG

SUPPOSITORY;RECTAL

MESALAMINE

AB AMRING PHARMS

1GM

A208362 001 Jun 21, 2019 Jun NEWA

AB PHARM SOURCING

1GM

A207448 001 Apr 19, 2019 Apr NEWA

AB SANDOZ INC

1GM

A202065 001 Jun 12, 2019 May NEWA

TABLET, DELAYED RELEASE;ORAL

MESALAMINE

AB SUN PHARM

1.2GM

A211858 001 Jan 25, 2019 Jan NEWA

>D> MESTRANOL; NORETHINDRONE

>D> TABLET;ORAL-28

NORINYL 1+50 28-DAY

>D> +! ACTAVIS LABS UT INC

0.05MG;1MG

N016659 001

Jul DISC

>A>

+ @

0.05MG;1MG

N016659 001

Jul DISC

METAPROTERENOL SULFATE

TABLET;ORAL

METAPROTERENOL SULFATE

@ HERITAGE PHARMA

10MG

A072519 001 Mar 30, 1990 May CAHN

@

20MG

A072520 001 Mar 30, 1990 May CAHN

>D> PAR PHARM

10MG

A072024 001 Jun 28, 1988 Jul DISC

@

10MG

A072024 001 Jun 28, 1988 Jul DISC

>D> !

20MG

A072025 001 Jun 28, 1988 Jul DISC

>A>

@

20MG

A072025 001 Jun 28, 1988 Jul DISC

METAXALONE

TABLET;ORAL

METAXALONE

AB APPCO PHARMA LLC 800MG A208774 001 Sep 24, 2018 Feb CAHN

METFORMIN HYDROCHLORIDE

TABLET;ORAL

GLUCOPHAGE

>D> + @ BRISTOL MYERS SQUIBB 500MG N020357 001 Mar 03, 1995 Jul CAHN
+ @ 500MG N020357 001 Mar 03, 1995 Jun DISC

>D> + @ 625MG N020357 003 Nov 05, 1998 Jul CAHN

>D> + @ 750MG N020357 004 Nov 05, 1998 Jul CAHN

>D> + @ 850MG N020357 002 Mar 03, 1995 Jul CAHN

+ @ 850MG N020357 002 Mar 03, 1995 Jun DISC

>D> + @ 1GM N020357 005 Nov 05, 1998 Jul CAHN

+ @ 1GM N020357 005 Nov 05, 1998 Jun DISC

>A> + @ EMD SERONO INC 500MG N020357 001 Mar 03, 1995 Jul CAHN

>A> + @ 625MG N020357 003 Nov 05, 1998 Jul CAHN

>A> + @ 750MG N020357 004 Nov 05, 1998 Jul CAHN

>A> + @ 850MG N020357 002 Mar 03, 1995 Jul CAHN

>A> + @ 1GM N020357 005 Nov 05, 1998 Jul CAHN

METFORMIN HYDROCHLORIDE

AB ! GRANULES INDIA 1GM A090564 003 Apr 22, 2010 Jun CHRS

AB HERITAGE PHARMA 500MG A075978 001 Jan 25, 2002 Feb CAHN

AB 850MG A075978 002 Jan 25, 2002 Feb CAHN

AB 1GM A075978 003 Nov 05, 2002 Feb CAHN

@ SUNSHINE LAKE 500MG A208999 001 Oct 12, 2018 Apr DISC

@ 850MG A208999 002 Oct 12, 2018 Apr DISC

@ 1GM A208999 003 Oct 12, 2018 Apr DISC

TABLET, EXTENDED RELEASE;ORAL

GLUCOPHAGE XR

>D> + @ BRISTOL MYERS SQUIBB 500MG N021202 001 Oct 13, 2000 Jul CAHN

+ @ 500MG N021202 001 Oct 13, 2000 Jun DISC

>D> + @ 750MG N021202 004 Apr 11, 2003 Jul CAHN

+ @ 750MG N021202 004 Apr 11, 2003 Jun DISC

>A> + @ EMD SERONO INC 500MG N021202 001 Oct 13, 2000 Jul CAHN

>A> + @ 750MG N021202 004 Apr 11, 2003 Jul CAHN

METFORMIN HYDROCHLORIDE

AB ! AMNEAL PHARMS NY 750MG A078596 002 Jan 03, 2008 Jun CHRS

AB1 CADILA 500MG A077060 001 Apr 20, 2005 Feb CAHN

AB 750MG A077078 001 Apr 21, 2005 Feb CAHN

AB2 ! LUPIN LTD 1GM A090692 002 Jun 29, 2011 Apr CHRS

AB1 ! SUN PHARM INDS (IN) 500MG A077336 001 Feb 09, 2006 Jun CHRS

@ YICHANG HUMANWELL 500MG A211052 001 Sep 24, 2018 Mar DISC

@ 750MG A211052 002 Sep 24, 2018 Mar DISC

METFORMIN HYDROCHLORIDE; PIOGLITAZONE HYDROCHLORIDE

TABLET;ORAL

PIOGLITAZONE HYDROCHLORIDE AND METFORMIN HYDROCHLORIDE

>D> AB MYLAN 500MG;EQ 15MG BASE A090406 001 Feb 25, 2011 Jul DISC

>A> @ 500MG;EQ 15MG BASE A090406 001 Feb 25, 2011 Jul DISC

>D> AB 850MG;EQ 15MG BASE A090406 002 Feb 25, 2011 Jul DISC

>A> @ 850MG;EQ 15MG BASE A090406 002 Feb 25, 2011 Jul DISC

TABLET, EXTENDED RELEASE;ORAL

ACTOPLUS MET XR

+ @ TAKEDA PHARMS USA 1GM;EQ 15MG BASE N022024 001 May 12, 2009 Mar DISC

+ @ 1GM;EQ 30MG BASE N022024 002 May 12, 2009 Mar DISC

METHAZOLAMIDE

TABLET;ORAL

METHAZOLAMIDE

@ MICRO LABS 25MG A207438 001 Oct 05, 2018 Mar DISC

@ 50MG A207438 002 Oct 05, 2018 Mar DISC

METHENAMINE HIPPURATE

TABLET;ORAL

METHENAMINE HIPPURATE

>A> AB MICRO LABS 1GM A212172 001 Aug 01, 2019 Jul NEWA

METHOCARBAMOL

SOLUTION; IM-IV

METHOCARBAMOL

AP	SLATE	1GM/10ML (100MG/ML)	A208116	001	Jan 19, 2017	Feb CAHN
AP	ROBAXIN					
+!	HIKMA	1GM/10ML (100MG/ML)	N011790	001		Feb CAHN
	TABLET; ORAL					
	METHOCARBAMOL					
>D>	AA GRANULES INDIA LTD	500MG	A209312	001	May 07, 2018	Jul CHRS
>A>	AA !	500MG	A209312	001	May 07, 2018	Jul CHRS
>D>	ROBAXIN					
>D>	AA +! AUXILIUM PHARMS LLC	500MG	N011011	004		Jul DISC
>A>	+ @	500MG	N011011	004		Jul DISC

METHOTREXATE

SOLUTION; SUBCUTANEOUS

RASUVO

+!	MEDEXUS	7.5MG/0.15ML (7.5MG/0.15ML)	N205776	001	Jul 10, 2014	Apr CAHN
+!		10MG/0.20ML (10MG/0.20ML)	N205776	002	Jul 10, 2014	Apr CAHN
+!		12.5MG/0.25ML (12.5MG/0.25ML)	N205776	003	Jul 10, 2014	Apr CAHN
+!		15MG/0.30ML (15MG/0.30ML)	N205776	004	Jul 10, 2014	Apr CAHN
+!		17.5MG/0.35ML (17.5MG/0.35ML)	N205776	005	Jul 10, 2014	Apr CAHN
+!		20MG/0.4ML (20MG/0.4ML)	N205776	006	Jul 10, 2014	Apr CAHN
+!		22.5MG/0.45ML (22.5MG/0.45ML)	N205776	007	Jul 10, 2014	Apr CAHN
+!		25MG/0.5ML (25MG/0.5ML)	N205776	008	Jul 10, 2014	Apr CAHN
+ @		27.5MG/0.55ML (27.5MG/0.55ML)	N205776	009	Jul 10, 2014	Apr CAHN
+!		30MG/0.6ML (30MG/0.6ML)	N205776	010	Jul 10, 2014	Apr CAHN

METHSCOPOLAMINE BROMIDE

TABLET; ORAL

METHSCOPOLAMINE BROMIDE

@	BRECKENRIDGE PHARM	2.5MG	A040642	001	Dec 06, 2011	Jun DISC
@		5MG	A040642	002	Dec 06, 2011	Jun DISC

METHYLDOPA

TABLET; ORAL

METHYLDOPA

AB	HERITAGE PHARMA	250MG	A070098	001	Feb 20, 1986	Feb CAHN
AB		500MG	A070343	001	Feb 20, 1986	Feb CAHN

METHYLDOPATE HYDROCHLORIDE

INJECTABLE; INJECTION

METHYLDOPATE HYDROCHLORIDE

@	LUITPOLD	50MG/ML	A071279	001	Oct 02, 1987	Mar DISC
---	----------	---------	---------	-----	--------------	----------

METHYLERGONOVINE MALEATE

TABLET; ORAL

METHYLERGONOVINE MALEATE

AB	TEVA PHARMS USA	0.2MG	A211455	001	Mar 20, 2019	Mar NEWA
----	-----------------	-------	---------	-----	--------------	----------

METHYLPHENIDATE HYDROCHLORIDECAPSULE, EXTENDED RELEASE; ORAL
ADHANSIA XR

+	PURDUE PHARMA LP	25MG	N212038	001	Feb 27, 2019	Mar CRLD
		25MG	N212038	001	Feb 27, 2019	Feb NEWA
+		35MG	N212038	002	Feb 27, 2019	Feb NEWA
+		45MG	N212038	003	Feb 27, 2019	Feb NEWA
+		55MG	N212038	004	Feb 27, 2019	Feb NEWA
+		70MG	N212038	005	Feb 27, 2019	Feb NEWA
+		85MG	N212038	006	Feb 27, 2019	Feb NEWA

METHYLPHENIDATE HYDROCHLORIDE

AB1	GRANULES PHARMS	10MG	A211796	001	May 23, 2019	May NEWA
AB1		20MG	A211796	002	May 23, 2019	May NEWA
AB1		30MG	A211796	003	May 23, 2019	May NEWA
AB1		40MG	A211796	004	May 23, 2019	May NEWA
AB1		60MG	A211796	005	May 23, 2019	May NEWA

AB1	! MAYNE PHARMA	60MG	A078458	004	Jun 23, 2016	May CTEC
	FOR SUSPENSION, EXTENDED RELEASE; ORAL					

METHYLPHENIDATE HYDROCHLORIDE

@ ACTAVIS LABS FL INC 5MG/ML

A206049	001	May 17, 2018	Jan DISC
---------	-----	--------------	----------

FOR SUSPENSION, EXTENDED RELEASE;ORAL

QUILLIVANT XR

+! NEXTWAVE 5MG/ML

N202100 001 Sep 27, 2012 Feb CAHN

+! NEXTWAVE PHARMS 5MG/ML

N202100 001 Sep 27, 2012 Jan CTEC

TABLET;ORAL

METHYLPHENIDATE HYDROCHLORIDE

@ AUROLIFE PHARMA LLC 5MG

A209276 001 Oct 25, 2018 Apr DISC

@ 10MG

A209276 002 Oct 25, 2018 Apr DISC

@ 20MG

A209276 003 Oct 25, 2018 Apr DISC

@ LANNETT CO INC 5MG

A086429 001 Jan DISC

@ 10MG

A085799 001 Jan DISC

@ 20MG

A086428 001 Jan DISC

TABLET, EXTENDED RELEASE;ORAL

METADATE ER

@ LANNETT CO INC 20MG

A089601 001 Jun 01, 1988 Jan DISC

METHYLPHENIDATE HYDROCHLORIDE

AB	!	ABHAI LLC	20MG	A207488	002	Jun 09, 2015	Jan NEWA
AB		ANDOR PHARMS	18MG	A211918	001	Apr 24, 2019	Apr NEWA
AB			27MG	A211918	002	Apr 24, 2019	Apr NEWA
AB			36MG	A211918	003	Apr 24, 2019	Apr NEWA
AB			54MG	A211918	004	Apr 24, 2019	Apr NEWA
>A>	AB	@ HERITAGE PHARMA	20MG	A075450	001	Dec 21, 2001	May CAHN
>A>	AB	PAR PHARM	36MG	A204659	001	Jul 15, 2019	Jul NEWA
>A>	AB		54MG	A204659	002	Jul 15, 2019	Jul NEWA

METHYLPREDNISOLONE

TABLET;ORAL

MEDROL

AB	+	PHARMACIA AND UPJOHN	2MG	N011153	002		Mar CFTG
		METHYLPREDNISOLONE					
AB		LUPIN LTD	2MG	A209097	001	Feb 22, 2019	Mar NFTG
AB			2MG	A209097	001	Feb 22, 2019	Feb NEWA
AB			4MG	A209097	002	Feb 22, 2019	Feb NEWA
AB			8MG	A209097	003	Feb 22, 2019	Feb NEWA
AB			16MG	A209097	004	Feb 22, 2019	Feb NEWA
AB			32MG	A209097	005	Feb 22, 2019	Feb NEWA
AB		SUNGEN PHARMA	4MG	A212262	001	Jun 27, 2019	Jun NEWA
AB		TIANJIN TIANYAO	4MG	A204072	001	May 14, 2018	Apr CMFD

METHYLPREDNISOLONE ACETATE

INJECTABLE;INJECTION

METHYLPREDNISOLONE ACETATE

>D>	AB	AMNEAL PHARMS CO	40MG/ML	A210043	001	May 20, 2019	Jul DISC
>A>		@	40MG/ML	A210043	001	May 20, 2019	Jul DISC
AB			40MG/ML	A210043	001	May 20, 2019	May NEWA
>D>	AB		80MG/ML	A210043	002	May 20, 2019	Jul DISC
>A>		@	80MG/ML	A210043	002	May 20, 2019	Jul DISC
AB			80MG/ML	A210043	002	May 20, 2019	May NEWA

METHYLPREDNISOLONE SODIUM SUCCINATE

INJECTABLE;INJECTION

A-METHAPRED

@ HOSPIRA EQ 40MG BASE/VIAL

A040664 001 Dec 20, 2005 Mar DISC

@ EQ 125MG BASE/VIAL

A040665 001 Dec 20, 2005 Mar DISC

METHYLTESTOSTERONE

CAPSULE;ORAL

VIRILON

@ CHARTWELL 10MG

A087750 001 Nov 24, 1982 Jun CAHN

METIPRANOLOL HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC

METIPRANOLOL

@ SANDOZ INC 0.3%

A075720 001 Aug 06, 2001 May DISC

OPTIPRANOLOL

+! BAUSCH AND LOMB 0.3%

N019907 001 Dec 29, 1989 May CTEC

METOPROLOL SUCCINATE

TABLET, EXTENDED RELEASE;ORAL

TOPROL-XL

AB	+	TOPROL	EQ 25MG TARTRATE	N019962	004	Feb 05, 2001	Mar CAHN
AB	+!		EQ 50MG TARTRATE	N019962	001	Jan 10, 1992	Mar CAHN
AB	+		EQ 100MG TARTRATE	N019962	002	Jan 10, 1992	Mar CAHN
AB	+!		EQ 200MG TARTRATE	N019962	003	Jan 10, 1992	Mar CAHN

METOPROLOL TARTRATEINJECTABLE; INJECTION
LOPRESSOR+ @ NOVARTIS
METOPROLOL TARTRATE

AP	!	HOSPIRA	1MG/ML	N018704	001	Mar 30, 1984	Jun DISC
	@	LUITPOLD	1MG/ML	A078085	001	Apr 29, 2008	Jun CHRS
	@		1MG/ML	A090386	001	Sep 30, 2009	Mar DISC

TABLET;ORAL

METOPROLOL TARTRATE

AB		HERITAGE PHARMA	50MG	A074141	001	Jan 31, 1995	Apr CAHN
AB			100MG	A074141	002	Jan 31, 1995	Apr CAHN

METRONIDAZOLEGEL;VAGINAL
METROGEL-VAGINAL

AB	+!	BAUSCH	0.75%	N020208	001	Aug 17, 1992	Mar CAHN
>D>	AB	GAGE DEVELOPMENT	0.75%	A211786	001	Jul 02, 2019	Jul CAHN
AB			0.75%	A211786	001	Jul 02, 2019	Jun NEWA

>A>	AB	PERRIGO UK FINCO	0.75%	A211786	001	Jul 02, 2019	Jul CAHN
-----	----	------------------	-------	---------	-----	--------------	----------

INJECTABLE;INJECTION

METRONIDAZOLE IN PLASTIC CONTAINER

AP		INFORLIFE	500MG/100ML	A206191	001	Feb 25, 2019	Feb NEWA
----	--	-----------	-------------	---------	-----	--------------	----------

TABLET;ORAL
METRONIDAZOLE

AB		CADILA	250MG	A206560	001	Nov 16, 2016	Mar CAHN
AB			500MG	A206560	002	Nov 16, 2016	Mar CAHN
AB		STRIDES PHARMA	250MG	A070040	001	Jan 29, 1985	Apr CAHN
AB			500MG	A070039	001	Jan 29, 1985	Apr CAHN

METYROSINECAPSULE;ORAL
DEMSER

+! BAUSCH 250MG

N017871 001 Mar CAHN

MICAFUNGIN SODIUMINJECTABLE; INTRAVENOUS
MICAFUNGIN SODIUM

AP		FRESENIUS KABI USA	EQ 50MG BASE/VIAL	A207344	001	May 17, 2019	May NFTG
AP			EQ 100MG BASE/VIAL	A207344	002	May 17, 2019	May NFTG

MYCAMINE

AP	+!	ASTELLAS	EQ 50MG BASE/VIAL	N021506	002	Mar 16, 2005	May CFTG
AP	+!		EQ 100MG BASE/VIAL	N021506	003	Jun 27, 2006	May CDFR

MIDAZOLAM

SPRAY;NASAL

NAYZILAM

+! UCB INC 5MG/SPRAY

N211321 001 May 17, 2019 May NEWA

MIDAZOLAM HYDROCHLORIDE

INJECTABLE;INJECTION

MIDOZALAM HYDROCHLORIDE

AP		MYLAN ASI	EQ 1MG BASE/ML	A090316	001	May 04, 2011	Apr CAHN
AP			EQ 5MG BASE/ML	A090316	002	May 04, 2011	Apr CAHN

SYRUP;ORAL

MIDAZOLAM HYDROCHLORIDE

@ PD PARTNERS EQ 2MG BASE/ML

A077115 001 Sep 09, 2005 May CAHN

MONTELUKAST SODIUM

GRANULE;ORAL

MONTELUKAST SODIUM

AB	@ MYLAN PHARMS INC TORRENT	EQ 4MG BASE/PACKET EQ 4MG BASE/PACKET	A202776 001 Dec 18, 2012 Feb DISC A210431 001 Jul 31, 2018 Mar CAHN
AB	TABLET;ORAL		
	MONTELUKAST SODIUM		
AB	L PERRIGO CO	EQ 10MG BASE	A206112 001 Apr 26, 2017 May CAHN
>D> AB	MYLAN PHARMS INC	EQ 10MG BASE	A079103 001 Aug 03, 2012 Jul DISC
>A>	@	EQ 10MG BASE	A079103 001 Aug 03, 2012 Jul DISC
	@ VINTAGE PHARMS LLC	EQ 10MG BASE	A091576 001 Aug 03, 2012 Feb DISC
AB	TABLET, CHEWABLE;ORAL		
	MONTELUKAST SODIUM		
AB	@ MYLAN PHARMS INC	EQ 4MG BASE	A079142 001 Aug 03, 2012 Apr DISC
	@	EQ 5MG BASE	A079142 002 Aug 03, 2012 Apr DISC
	@ VINTAGE PHARMS LLC	EQ 4MG BASE	A091588 001 Aug 03, 2012 Feb DISC
	@	EQ 5MG BASE	A091588 002 Aug 03, 2012 Feb DISC

MORPHINE SULFATE

INJECTABLE;INJECTION

ASTRAMORPH PF

@ FRESENIUS KABI USA	0.5MG/ML	A071050 001 Oct 07, 1986 Mar DISC
@	0.5MG/ML	A071051 001 Oct 07, 1986 Mar DISC
@	1MG/ML	A071052 001 Oct 07, 1986 Mar DISC
@	1MG/ML	A071053 001 Oct 07, 1986 Mar DISC

SOLUTION;ORAL

MORPHINE SULFATE

@ LANNETT CO INC	10MG/5ML	A202309 001 Nov 25, 2015 Feb DISC
@	20MG/5ML	A202310 001 Oct 30, 2015 Jan DISC
@	100MG/5ML	N201517 001 Jun 23, 2011 Jan DISC
>D> AA VISTAPHARM	10MG/5ML	A201947 001 Jan 05, 2012 Jul DISC
>A>	@	A201947 001 Jan 05, 2012 Jul DISC

TABLET;ORAL

MORPHINE SULFATE

>D> + HIKMA	15MG	N022207 001 Mar 17, 2008 Jul CFTG
>A> AB +	15MG	N022207 001 Mar 17, 2008 Jul CFTG
	15MG	N022207 001 Mar 17, 2008 Jun CAHN
>D> +!	30MG	N022207 002 Mar 17, 2008 Jul CFTG
>A> AB +!	30MG	N022207 002 Mar 17, 2008 Jul CFTG
	30MG	N022207 002 Mar 17, 2008 Jun CAHN
>A> AB UPSHER SMITH LABS	15MG	A210610 001 Jul 22, 2019 Jul NFTG
>A> AB	30MG	A210610 002 Jul 22, 2019 Jul NFTG

TABLET, EXTENDED RELEASE;ORAL

ARYMO ER

>D> + @ EGALET	15MG	N208603 001 Jan 09, 2017 Jul CAHN
+ @	15MG	N208603 001 Jan 09, 2017 Mar CAHN
>D> + @	30MG	N208603 002 Jan 09, 2017 Jul CAHN
+ @	30MG	N208603 002 Jan 09, 2017 Mar CAHN
>D> + @	60MG	N208603 003 Jan 09, 2017 Jul CAHN
+ @	60MG	N208603 003 Jan 09, 2017 Mar CAHN
>A> + @ ZYLA	15MG	N208603 001 Jan 09, 2017 Jul CAHN
>A> + @	30MG	N208603 002 Jan 09, 2017 Jul CAHN
>A> + @	60MG	N208603 003 Jan 09, 2017 Jul CAHN

MORPHINE SULFATE

@ MYLAN PHARMS INC	200MG	A200824 005 Oct 18, 2011 Feb DISC
--------------------	-------	-----------------------------------

MOXIFLOXACIN HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC

MOXIFLOXACIN HYDROCHLORIDE

AT1 ALEMBIC PHARMS LTD	EQ 0.5% BASE	A209469 001 Feb 13, 2019 Jan NEWA
TABLET;ORAL		
MOXIFLOXACIN HYDROCHLORIDE		
@ SUNSHINE LAKE	EQ 400MG BASE	A206295 001 Sep 28, 2018 Mar DISC

MUPIROCIN

OINTMENT;TOPICAL

MUPIROCIN

AB ! PERRIGO ISRAEL	2%	A065123 001 Nov 07, 2003 May CAHN
---------------------	----	-----------------------------------

MYCOPHENOLATE MOFETIL

SUSPENSION;ORAL

MYCOPHENOLATE MOFETIL

AB VISTAPHARM 200MG/ML A210370 001 Feb 12, 2019 Jan NEWA

NADOLOL

TABLET;ORAL

NADOLOL

AB HERITAGE PHARMA	20MG	A074229	001	Aug 30, 1996	Apr CAHN
AB	40MG	A074229	002	Aug 30, 1996	Apr CAHN
AB	80MG	A074255	001	Jan 24, 1996	Apr CAHN
@	120MG	A074255	002	Jan 24, 1996	Apr CAHN
@	160MG	A074255	003	Jan 24, 1996	Apr CAHN

NAFTIFINE HYDROCHLORIDE

GEL;TOPICAL

NAFTIFINE HYDROCHLORIDE

AB @ TARO	2%	A208201	001	Apr 10, 2019	May DISC
AB	2%	A208201	001	Apr 10, 2019	Mar NFTG
AB TOLMAR	1%	A206165	001	Mar 20, 2019	Mar NFTG
AB +! SEBELA IRELAND LTD	1%	N019356	001	Jun 18, 1990	Mar CFTG
AB +!	2%	N204286	001	Jun 27, 2013	Mar CFTG

NALBUPHINE HYDROCHLORIDE

INJECTABLE;INJECTION

NALBUPHINE HYDROCHLORIDE

AP @ DR REDDYS	10MG/ML	A074471	001	Mar 19, 1998	May CAHN
AP @	20MG/ML	A074471	002	Mar 19, 1998	May CAHN
AP MYLAN LABS LTD	10MG/ML	A206506	001	Feb 06, 2019	Jan NEWA
AP	20MG/ML	A206506	002	Feb 06, 2019	Jan NEWA

NALDEMEDINE TOSYLATE

TABLET;ORAL

SYMPROIC

+! BDSI

EQ 0.2MG BASE

N208854 001 Mar 23, 2017 Apr CAHN

NALOXONE HYDROCHLORIDE

INJECTABLE;INJECTION

NALOXONE HYDROCHLORIDE

>D> AP RENAISSANCE SSA LLC	0.4MG/ML	A207846	001	Dec 17, 2018	Jul CAHN
>A> AP VIRTUS PHARMS	0.4MG/ML	A207846	001	Dec 17, 2018	Jul CAHN
SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS					
EVZIO (AUTOINJECTOR)					
+! KALEO INC	2MG/0.4ML (2MG/0.4ML)	N209862	001	Oct 19, 2016	Feb CTNA
SPRAY, METERED;NASAL					
NALOXONE HYDROCHLORIDE					
AB @ TEVA PHARMS USA	4MG/SPRAY	A209522	001	Apr 19, 2019	May DISC
	4MG/SPRAY	A209522	001	Apr 19, 2019	Apr NFTG
NARCAN					
+! ADAPT	4MG/SPRAY	N208411	001	Nov 18, 2015	May CTEC
AB +!	4MG/SPRAY	N208411	001	Nov 18, 2015	Apr CFTG

NALOXONE HYDROCHLORIDE; PENTAZOCINE HYDROCHLORIDE

TABLET;ORAL

NALOXONE HYDROCHLORIDE AND PENTAZOCINE HYDROCHLORIDE

AB LUPIN EQ 0.5MG BASE;EQ 50MG BASE A075735 001 Jul 11, 2001 Feb CAHN

NANDROLONE DECANOATE

INJECTABLE;INJECTION

NANDROLONE DECANOATE

@ LUITPOLD

200MG/ML

A091252 001 Aug 30, 2010 Feb DISC

NAPROXEN

SUSPENSION;ORAL

NAPROSYN

AB + ATNAHS PHARMA US	25MG/ML	N018965	001	Mar 23, 1987	Jun CHRS
AB ! WEST-WARD PHARMS INT	25MG/ML	A074190	001	Mar 30, 1994	Jun CHRS

TABLET;ORAL
NAPROXEN

AB	PERRIGO PHARMS CO	250MG	A077339	001	Apr 27, 2005	Apr CAHN
AB		375MG	A077339	002	Apr 27, 2005	Apr CAHN
AB		500MG	A077339	003	Apr 27, 2005	Apr CAHN

NAPROXEN SODIUM; SUMATRIPTAN SUCCINATE

TABLET;ORAL
TREXIMET

AB	+ @ CURRAX	60MG;EQ 10MG BASE	N021926	002	May 14, 2015	Apr CAHN
	+!	500MG;EQ 85MG BASE	N021926	001	Apr 15, 2008	Apr CAHN

NARATRIPTAN HYDROCHLORIDE

TABLET;ORAL
NARATRIPTAN

@ CASI PHARMS INC	EQ 1MG BASE	A090288	001	Jul 07, 2010	Jun DISC
@	EQ 2.5MG BASE	A090288	002	Jul 07, 2010	Jun DISC

NATEGLINIDE

TABLET;ORAL
NATEGLINIDE

AB	CADILA PHARMS LTD	60MG	A206432	001	Apr 19, 2019	Apr NEWA
AB		120MG	A206432	002	Apr 19, 2019	Apr NEWA
>D> AB	ZYDUS PHARMS	120MG	A205248	002	Jul 06, 2016	Jul CHRS
>A> AB	!	120MG	A205248	002	Jul 06, 2016	Jul CHRS
>D>	STARLIX					
>D> AB	+ NOVARTIS	60MG	N021204	001	Dec 22, 2000	Jul DISC
>A>	+ @	60MG	N021204	001	Dec 22, 2000	Jul DISC
>D> AB	+!	120MG	N021204	002	Dec 22, 2000	Jul DISC
>A>	+ @	120MG	N021204	002	Dec 22, 2000	Jul DISC

NEOMYCIN SULFATE

TABLET;ORAL
NEOMYCIN SULFATE

@ LANNETT CO INC	500MG	A204435	001	Jun 10, 2016	Jun DISC
------------------	-------	---------	-----	--------------	----------

NEOMYCIN SULFATE; POLYMYXIN B SULFATE

SOLUTION;IRRIGATION

NEOMYCIN AND POLYMYXIN B SULFATE

>D> AT	WATSON LABS	EQ 40MG BASE/ML;200,000 UNITS/ML	A062664	001	Apr 08, 1986	Jul DISC
>A>	@	EQ 40MG BASE/ML;200,000 UNITS/ML	A062664	001	Apr 08, 1986	Jul DISC

NEOSTIGMINE METHYLSULFATE

SOLUTION;INTRAVENOUS

NEOSTIGMINE METHYLSULFATE

AP	AMRING PHARMS	5MG/10ML (0.5MG/ML)	A210989	001	Aug 22, 2018	Jan CAHN
AP		10MG/10ML (1MG/ML)	A210989	002	Aug 22, 2018	Jan CAHN
AP	BE PHARMS	5MG/10ML (0.5MG/ML)	A212512	001	May 13, 2019	Apr NEWA
AP		10MG/10ML (1MG/ML)	A212512	002	May 13, 2019	Apr NEWA

NIACIN

TABLET, EXTENDED RELEASE;ORAL

NIACIN

@ JUBILANT GENERICS	500MG	A209156	001	May 14, 2018	Apr DISC	
@	750MG	A209156	002	May 14, 2018	Apr DISC	
@	1GM	A209156	003	May 14, 2018	Apr DISC	
AB	MYLAN	500MG	A203742	001	Feb 22, 2019	Feb NEWA
AB		750MG	A203742	002	Feb 22, 2019	Feb NEWA
AB		1GM	A203742	003	Feb 22, 2019	Feb NEWA
AB	YICHANG HUMANWELL	500MG	A212017	001	Jun 10, 2019	May NEWA
AB		750MG	A212017	002	Jun 10, 2019	May NEWA
AB		1GM	A212017	003	Jun 10, 2019	May NEWA

NIFEDIPINE

TABLET, EXTENDED RELEASE;ORAL

NIFEDIPINE

AB2	NOVAST LABS	30MG	A210614	001	Mar 12, 2019	Feb NEWA
AB2		60MG	A210614	002	Mar 12, 2019	Feb NEWA
AB2		90MG	A210614	003	Mar 12, 2019	Feb NEWA
AB2	OSMOTICA PHARM US	90MG	A077127	003	Oct 03, 2007	Apr CMS1
AB2	SPIL	30MG	A210838	001	Apr 16, 2019	Apr NEWA
AB2		60MG	A210838	002	Apr 16, 2019	Apr NEWA

TABLET, EXTENDED RELEASE;ORAL
NIFEDIPIINE

AB2 90MG A210838 003 Apr 16, 2019 Apr NEWA

NITROFURANTOIN, MACROCRYSTALLINE

CAPSULE;ORAL
NITROFURANTOIN

>D> AB	MYLAN	50MG	A074967	001	Jul 09, 1997	Jul DISC
>A>	@	50MG	A074967	001	Jul 09, 1997	Jul DISC
>D> AB		100MG	A077025	001	Aug 18, 2004	Jul DISC
>A>	@	100MG	A077025	001	Aug 18, 2004	Jul DISC

NITROGLYCERIN

AEROSOL, METERED;SUBLINGUAL
NITROMIST

+! EVUS 0.4MG/SPRAY

N021780 001 Nov 02, 2006 May CAHN

FILM, EXTENDED RELEASE;TRANSDERMAL

MINITRAN

@ MEDICIS	0.4MG/HR	A089773	001	Aug 30, 1996	May DISC
@ VALEANT PHARMS	0.1MG/HR	A089771	001	Aug 30, 1996	May DISC
@	0.6MG/HR	A089774	001	Aug 30, 1996	Jun DISC
@ VALEANT PHARMS NORTH	0.2MG/HR	A089772	001	Aug 30, 1996	May DISC

NITRO-DUR

+! USPHARMA	0.1MG/HR	N020145	001	Apr 04, 1995	May CTEC
-------------	----------	---------	-----	--------------	----------

+!	0.2MG/HR	N020145	002	Apr 04, 1995	May CTEC
----	----------	---------	-----	--------------	----------

+!	0.4MG/HR	N020145	004	Apr 04, 1995	May CTEC
----	----------	---------	-----	--------------	----------

+!	0.6MG/HR	N020145	005	Apr 04, 1995	Jun CTEC
----	----------	---------	-----	--------------	----------

NITROGLYCERIN

AB2 HERCON PHARM 0.1MG/HR

A089885 002 Oct 30, 2017 Feb NEWA

AB2 ! MYLAN TECHNOLOGIES 0.1MG/HR

A074559 004 Feb 06, 1998 Feb CTEC

TABLET;SUBLINGUAL

NITROGLYCERIN

AB ALVOGEN 0.3MG

A211604 001 Apr 30, 2019 Apr NEWA

AB 0.4MG

A211604 002 Apr 30, 2019 Apr NEWA

AB 0.6MG

A211604 003 Apr 30, 2019 Apr NEWA

NORETHINDRONE

TABLET;ORAL-28

MICRONOR

+ @ JANSSEN PHARMS	0.35MG	N016954	001		Mar DISC
--------------------	--------	---------	-----	--	----------

NORETHINDRONE

AB2 ! MYLAN LABS LTD 0.35MG

A200980 001 Jun 12, 2013 Mar CHRS

NORETHINDRONE ACETATE

TABLET;ORAL

NORETHINDRONE ACETATE

AB RISING 5MG

A206490 001 Nov 05, 2018 May CAHN

NYSTATIN

CREAM;TOPICAL

NYSTATIN

>A> AT TORRENT 100,000 UNITS/GM

A212557 001 Jul 24, 2019 Jul NEWA

OINTMENT;TOPICAL

NYSTATIN

AT TORRENT 100,000 UNITS/GM

A211838 001 Jan 28, 2019 Jan NEWA

POWDER;TOPICAL

NYSTATIN

AT LUPIN 100,000 UNITS/GM

A065138 001 Jul 23, 2004 Feb CAHN

TABLET;ORAL

NYSTATIN

>A> @ UPSHER SMITH LABS 500,000 UNITS

A062524 001 Nov 26, 1985 Jul CAHN

>D> @ USL PHARMA 500,000 UNITS

A062524 001 Nov 26, 1985 Jul CAHN

NYSTATIN; TRIAMCINOLONE ACETONIDE

OINTMENT;TOPICAL

NYSTATIN AND TRIAMCINOLONE ACETONIDE

@ ZYDUS PHARMS	100,000 UNITS/GM;0.1%	A207764	001	Nov 08, 2018	Mar DISC
----------------	-----------------------	---------	-----	--------------	----------

OCTREOTIDE ACETATE

INJECTABLE; INJECTION

OCTREOTIDE ACETATE

AP	HERITAGE PHARMS INC	EQ 0.05MG BASE/ML	A204669	001	Dec 27, 2018	Apr CAHN
AP		EQ 0.1MG BASE/ML	A204669	002	Dec 27, 2018	Apr CAHN
	@	EQ 0.2MG BASE/ML	A203765	001	Sep 07, 2018	Mar DISC
AP		EQ 0.2MG BASE/ML	A203765	001	Sep 07, 2018	Jan CAHN
AP		EQ 0.5MG BASE/ML	A204669	003	Dec 27, 2018	Apr CAHN
	@	EQ 1MG BASE/ML	A203765	002	Sep 07, 2018	Mar DISC
AP		EQ 1MG BASE/ML	A203765	002	Sep 07, 2018	Jan CAHN
>D> AP	SUN PHARM INDNS	EQ 0.05MG BASE/ML	A077372	001	Aug 14, 2007	Jul DISC
>A>	@	EQ 0.05MG BASE/ML	A077372	001	Aug 14, 2007	Jul DISC
>D> AP		EQ 0.1MG BASE/ML	A077372	002	Aug 14, 2007	Jul DISC
>A>	@	EQ 0.1MG BASE/ML	A077372	002	Aug 14, 2007	Jul DISC
>D> AP		EQ 0.2MG BASE/ML	A077373	001	Aug 14, 2007	Jul DISC
>A>	@	EQ 0.2MG BASE/ML	A077373	001	Aug 14, 2007	Jul DISC
>D> AP		EQ 0.5MG BASE/ML	A077372	003	Aug 14, 2007	Jul DISC
>A>	@	EQ 0.5MG BASE/ML	A077372	003	Aug 14, 2007	Jul DISC
>D> AP		EQ 1MG BASE/ML	A077373	002	Aug 14, 2007	Jul DISC
>A>	@	EQ 1MG BASE/ML	A077373	002	Aug 14, 2007	Jul DISC

OFLOXACIN

SOLUTION/DROPS;OPHTHALMIC

OFLOXACIN

AT	APOTEX INC	0.3%	A076513	001	May 14, 2004	Feb CMFD
	@ SANDOZ INC	0.3%	A076231	001	May 14, 2004	Mar DISC
	SOLUTION/DROPS;OTIC					
	OFLOXACIN					

@ SANDOZ INC

0.3%

A078222 001 Mar 17, 2008 Mar DISC

OLANZAPINE

TABLET;ORAL

OLANZAPINE

@ SUNSHINE LAKE

2.5MG

A206238 001 Nov 19, 2018 Apr DISC

@

5MG

A206238 002 Nov 19, 2018 Apr DISC

@

7.5MG

A206238 003 Nov 19, 2018 Apr DISC

@

10MG

A206238 004 Nov 19, 2018 Apr DISC

@

15MG

A206238 005 Nov 19, 2018 Apr DISC

@

20MG

A206238 006 Nov 19, 2018 Apr DISC

TABLET, ORALLY DISINTEGRATING;ORAL

OLANZAPINE

@ HEC PHARM

5MG

A208146 001 Jul 02, 2018 Feb DISC

@

10MG

A208146 002 Jul 02, 2018 Feb DISC

@

15MG

A208146 003 Jul 02, 2018 Feb DISC

@

20MG

A208146 004 Jul 02, 2018 Feb DISC

OLIVE OIL; SOYBEAN OIL

EMULSION;INTRAVENOUS

CLINOLIPID 20%

+ @	BAXTER HLTHCARE CORP	16%(160GM/1000ML);4% (40GM/1000ML)	N204508	001	Oct 03, 2013	Jun CDFR
-----	----------------------	---------------------------------------	---------	-----	--------------	----------

OLMESARTAN MEDOXOMIL

TABLET;ORAL

OLMESARTAN MEDOXOMIL

AB	SUNSHINE LAKE	5MG	A211049	001	Feb 22, 2019	Feb NEWA
AB		20MG	A211049	002	Feb 22, 2019	Feb NEWA
AB		40MG	A211049	003	Feb 22, 2019	Feb NEWA
>A> AB	UMEDICA LABS PVT LTD	5MG	A207135	001	Jul 18, 2019	Jul NEWA
>A> AB		20MG	A207135	002	Jul 18, 2019	Jul NEWA
>A> AB		40MG	A207135	003	Jul 18, 2019	Jul NEWA

OLOPATADINE HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC

OLOPATADINE HYDROCHLORIDE

AT	ALEMBIC PHARMS LTD	EQ 0.2% BASE	A209420	001	Apr 29, 2019	Apr NEWA
AT	AUROBINDO PHARMA LTD	EQ 0.2% BASE	A209995	001	Apr 04, 2019	Mar NEWA
>A> AT	GLAND PHARMA LTD	EQ 0.1% BASE	A209619	001	Aug 02, 2019	Jul NEWA
AT	USV	EQ 0.1% BASE	A203152	001	Dec 07, 2015	Jun CAHN

OMBITASVIR; PARITAPREVIR; RITONAVIR

TABLET;ORAL
TECHNIVIE
+ @ ABBVIE INC 12.5MG;75MG;50MG N207931 001 Jul 24, 2015 Apr DISC

OMEGA-3-ACID ETHYL ESTERS

CAPSULE;ORAL
OMEGA-3-ACID ETHYL ESTERS

AB	ASCENT PHARMS INC	1GM CONTAINS AT LEAST 900MG OF THE ETHYL ESTERS OF OMEGA-3 FATTY ACIDS	A207420	001	Feb 25, 2019	Feb NEWA
>A> AB	BIONPHARMA INC	1GM CONTAINS AT LEAST 900MG OF THE ETHYL ESTERS OF OMEGA-3 FATTY ACIDS	A206455	001	Aug 07, 2019	Jul NEWA
	@ PAR PHARM INC	1GM CONTAINS AT LEAST 900MG OF THE ETHYL ESTERS OF OMEGA-3 FATTY ACIDS	A091018	001	Jun 24, 2014	Jun DISC
AB	SOFGEN PHARMS	1GM CONTAINS AT LEAST 900MG OF THE ETHYL ESTERS OF OMEGA-3 FATTY ACIDS	A211355	001	Jul 10, 2019	Jun NEWA
AB	ZYDUS	1GM CONTAINS AT LEAST 900MG OF THE ETHYL ESTERS OF OMEGA-3 FATTY ACIDS	A210107	001	Jun 14, 2019	Jun NEWA

OMEPRAZOLE

CAPSULE, DELAYED REL PELLETS;ORAL
OMEPRAZOLE
@ MYLAN 10MG A075876 001 May 29, 2003 Jun DISC

OMEPRAZOLE; SODIUM BICARBONATE

FOR SUSPENSION;ORAL
ZEGERID

AB	+ SALIX	20MG/PACKET;1.68GM/PACKET	N021636	001	Jun 15, 2004	Apr CAHN
AB	+!	40MG/PACKET;1.68GM/PACKET	N021636	002	Dec 21, 2004	Apr CAHN

ONDANSETRON HYDROCHLORIDE

INJECTABLE;INJECTION
ONDANSETRON HYDROCHLORIDE

@ LUITPOLD	EQ 2MG BASE/ML	A079039	001	Nov 18, 2008	Feb DISC
ONDANSETRON HYDROCHLORIDE PRESERVATIVE FREE					
@ HIKMA FARMACEUTICA	EQ 2MG BASE/ML	A076780	001	Dec 26, 2006	Feb DISC
@ LUITPOLD	EQ 2MG BASE/ML	A079032	001	Nov 18, 2008	Feb DISC

SOLUTION;ORAL
ONDANSETRON HYDROCHLORIDE

AA	PD PARTNERS	EQ 4MG BASE/5ML	A078127	001	Jun 25, 2007	May CAHN
----	-------------	-----------------	---------	-----	--------------	----------

TABLET;ORAL
ONDANSETRON HYDROCHLORIDE

	@ MYLAN	EQ 24MG BASE	A076930	004	Jun 25, 2007	Feb DISC
--	---------	--------------	---------	-----	--------------	----------

ORPHENADRINE CITRATE

INJECTABLE;INJECTION
NORFLEX

+ @ TELIGENT	30MG/ML	N013055	001		Jan CRLD
--------------	---------	---------	-----	--	----------

TABLET, EXTENDED RELEASE;ORAL
ORPHENADRINE CITRATE

AB	LUPIN	100MG	A040284	001	Jun 19, 1998	Feb CAHN
----	-------	-------	---------	-----	--------------	----------

OSELTAMIVIR PHOSPHATE

CAPSULE;ORAL
OSELTAMIVIR PHOSPHATE

AB	ALEMBIC PHARMS LTD	EQ 30MG BASE	A211823	001	Jun 24, 2019	Jun NEWA
AB		EQ 45MG BASE	A211823	002	Jun 24, 2019	Jun NEWA
AB		EQ 75MG BASE	A211823	003	Jun 24, 2019	Jun NEWA

FOR SUSPENSION;ORAL
OSELTAMIVIR PHOSPHATE

AB	TEVA PHARMS USA	EQ 6MG BASE/ML	A211125	001	Feb 27, 2019	Feb NEWA
----	-----------------	----------------	---------	-----	--------------	----------

OXACILLIN SODIUM

INJECTABLE; INJECTION

OXACILLIN SODIUM

>A> AP	PIRAMAL CRITICAL	EQ 1GM BASE/VIAL	A206681	001	Sep 11, 2017	Jul CAHN
>A> AP		EQ 2GM BASE/VIAL	A206681	002	Sep 11, 2017	Jul CAHN
>A> AP		EQ 10GM BASE/VIAL	A206760	001	Oct 26, 2017	Jul CAHN
>D> AP	RENAISSANCE SSA LLC	EQ 1GM BASE/VIAL	A206681	001	Sep 11, 2017	Jul CAHN
>D> AP		EQ 2GM BASE/VIAL	A206681	002	Sep 11, 2017	Jul CAHN
>D> AP		EQ 10GM BASE/VIAL	A206760	001	Oct 26, 2017	Jul CAHN

OXALIPLATIN

INJECTABLE; INTRAVENOUS

ELOXATIN

+ @ AP	SANOFI AVENTIS US	50MG/VIAL	N021492	001	Aug 09, 2002	Feb CDFR
AP	+!	50MG/10ML (5MG/ML)	N021759	001	Jan 31, 2005	Feb CDFR
	+ @	100MG/VIAL	N021492	002	Aug 09, 2002	Feb CDFR
AP	+!	100MG/20ML (5MG/ML)	N021759	002	Jan 31, 2005	Feb CDFR
	+ @	200MG/40ML (5MG/ML)	N021759	003	Nov 17, 2006	Feb CDFR
	OXALIPLATIN					
AP	ACCORD HLTHCARE	50MG/10ML (5MG/ML)	A207474	001	Mar 21, 2017	Feb CDFR
AP		100MG/20ML (5MG/ML)	A207474	002	Mar 21, 2017	Feb CDFR
AP		200MG/40ML (5MG/ML)	A207474	003	Mar 21, 2017	Feb CDFR
AP	ACTAVIS LLC	50MG/10ML (5MG/ML)	A204880	001	Mar 05, 2018	Feb CDFR
AP		100MG/20ML (5MG/ML)	A204880	002	Mar 05, 2018	Feb CDFR
>D> AP	ACTAVIS TOTOWA	50MG/VIAL	A078803	001	Aug 08, 2012	Jul CHRS
>A> AP	!	50MG/VIAL	A078803	001	Aug 08, 2012	Jul CHRS
AP		50MG/VIAL	A078803	001	Aug 08, 2012	Feb CDFR
>D> AP		100MG/VIAL	A078803	002	Aug 08, 2012	Jul CHRS
>A> AP	!	100MG/VIAL	A078803	002	Aug 08, 2012	Jul CHRS
AP		100MG/VIAL	A078803	002	Aug 08, 2012	Feb CDFR
AP	CIPLA	50MG/10ML (5MG/ML)	A208523	001	Feb 10, 2017	Feb CDFR
AP		100MG/20ML (5MG/ML)	A208523	002	Feb 10, 2017	Feb CDFR
AP	EUGIA PHARMA	50MG/10ML (5MG/ML)	A205529	001	Sep 06, 2017	Feb CDFR
AP		100MG/20ML (5MG/ML)	A205529	002	Sep 06, 2017	Feb CDFR
AP	FRESENIUS KABI USA	50MG/10ML (5MG/ML)	A078811	001	Jun 10, 2010	Feb CDFR
AP		100MG/20ML (5MG/ML)	A078811	002	Jun 10, 2010	Feb CDFR
AP		50MG/VIAL	A078819	001	Jun 02, 2010	Feb CDFR
AP		50MG/10ML (5MG/ML)	A090030	001	Jan 31, 2017	Feb CDFR
AP		100MG/VIAL	A078819	002	Jun 02, 2010	Feb CDFR
AP		100MG/20ML (5MG/ML)	A090030	002	Jan 31, 2017	Feb CDFR
AP		200MG/40ML (5MG/ML)	A090030	003	Jan 31, 2017	Feb CDFR
AP	GLAND PHARMA LTD	50MG/10ML (5MG/ML)	A207325	001	Feb 10, 2017	Feb CDFR
AP		50MG/VIAL	A207385	001	May 23, 2017	Feb CDFR
AP		100MG/20ML (5MG/ML)	A207325	002	Feb 10, 2017	Feb CDFR
AP		100MG/VIAL	A207385	002	May 23, 2017	Feb CDFR
AP		200MG/40ML (5MG/ML)	A207325	003	Oct 18, 2017	Feb CDFR
AP	@ HOSPIRA INC	50MG/VIAL	A078815	001	Sep 30, 2009	Apr DISC
AP		50MG/VIAL	A078815	001	Sep 30, 2009	Feb CDFR
	@	100MG/VIAL	A078815	002	Sep 30, 2009	Apr DISC
AP		100MG/VIAL	A078815	002	Sep 30, 2009	Feb CDFR
AP	HOSPIRA WORLDWIDE	50MG/10ML (5MG/ML)	A078813	001	Aug 07, 2009	Feb CDFR
AP		100MG/20ML (5MG/ML)	A078813	002	Aug 07, 2009	Feb CDFR
AP	INGENUS PHARMS LLC	50MG/10ML (5MG/ML)	A207562	001	Oct 16, 2018	Feb CDFR
AP		100MG/20ML (5MG/ML)	A207562	002	Oct 16, 2018	Feb CDFR
AP	JIANGSU HENGRIU MED	50MG/10ML (5MG/ML)	A203869	001	Jun 18, 2014	Feb CDFR
AP		100MG/20ML (5MG/ML)	A203869	002	Jun 18, 2014	Feb CDFR
AP	MYLAN LABS LTD	50MG/10ML (5MG/ML)	A091358	001	Aug 07, 2012	Feb CDFR
AP		50MG/VIAL	A200979	001	Aug 08, 2012	Feb CDFR
AP		100MG/20ML (5MG/ML)	A091358	002	Aug 07, 2012	Feb CDFR
AP		100MG/VIAL	A200979	002	Aug 08, 2012	Feb CDFR
AP		200MG/40ML (5MG/ML)	A091358	003	Nov 14, 2017	Feb CDFR
AP	QILU PHARM CO LTD	50MG/10ML (5MG/ML)	A204368	001	Jun 07, 2016	Feb CDFR
AP		50MG/VIAL	A204616	001	May 11, 2016	Feb CDFR
AP		100MG/20ML (5MG/ML)	A204368	002	Jun 07, 2016	Feb CDFR
AP		100MG/VIAL	A204616	002	May 11, 2016	Feb CDFR
AP	!	200MG/40ML (5MG/ML)	A204368	003	Jun 07, 2016	Feb CDFR
AP	SANDOZ	50MG/10ML (5MG/ML)	A078817	001	Jan 24, 2011	Feb CDFR
	@	50MG/VIAL	A090849	001	Apr 28, 2011	Feb CDFR
AP		100MG/20ML (5MG/ML)	A078817	002	Jan 24, 2011	Feb CDFR
	@	100MG/VIAL	A090849	002	Apr 28, 2011	Feb CDFR
	@ SANDOZ INC	50MG/10ML (5MG/ML)	A078812	001	Aug 07, 2009	Feb CDFR
	@	100MG/20ML (5MG/ML)	A078812	002	Aug 07, 2009	Feb CDFR
>D> AP	! SUN PHARM	50MG/VIAL	A078818	001	Aug 07, 2009	Jul DISC

INJECTABLE; INTRAVENOUSOXALIPLATIN

>A>	@	50MG/VIAL	A078818	001	Aug 07, 2009	Jul DISC	
>D> AP		50MG/10ML (5MG/ML)	A202922	001	Apr 08, 2014	Jul DISC	
>A>	@	50MG/10ML (5MG/ML)	A202922	001	Apr 08, 2014	Jul DISC	
>D> AP	!	100MG/VIAL	A078818	002	Aug 07, 2009	Jul DISC	
>A>	@	100MG/VIAL	A078818	002	Aug 07, 2009	Jul DISC	
>D> AP		100MG/20ML (5MG/ML)	A202922	002	Apr 08, 2014	Jul DISC	
>A>	@	100MG/20ML (5MG/ML)	A202922	002	Apr 08, 2014	Jul DISC	
>D> AP		200MG/40ML (5MG/ML)	A202922	003	Feb 15, 2019	Jul DISC	
>A>	@	200MG/40ML (5MG/ML)	A202922	003	Feb 15, 2019	Jul DISC	
AP		200MG/40ML (5MG/ML)	A202922	003	Feb 15, 2019	Apr CDFR	
AP	!	SUN PHARMA GLOBAL	A078818	001	Aug 07, 2009	Feb CDFR	
AP		50MG/VIAL	A202922	001	Apr 08, 2014	Feb CDFR	
AP	!	50MG/10ML (5MG/ML)	A078818	002	Aug 07, 2009	Feb CDFR	
AP		100MG/VIAL	A202922	002	Apr 08, 2014	Feb CDFR	
AP		100MG/20ML (5MG/ML)	A202922	002	Apr 08, 2014	Feb CDFR	
AP	+	TEVA PHARMS	50MG/10ML (5MG/ML)	N022160	001	Aug 07, 2009	Feb CDFR
AP	+		100MG/20ML (5MG/ML)	N022160	002	Aug 07, 2009	Feb CDFR
<u>INJECTABLE; IV (INFUSION)</u>							
<u>OXALIPLATIN</u>							
AP		SUN PHARMA GLOBAL	200MG/40ML (5MG/ML)	A202922	003	Feb 15, 2019	Feb NEWA

OXAPROZINTABLET; ORALOXAPROZIN

@ BEXIMCO PHARMS USA

600MG

A075842 001 Apr 12, 2001 Mar CAHN

OXYBUTYNIN CHLORIDESYRUP; ORALOXYBUTYNIN CHLORIDE

@ PD PARTNERS

5MG/5ML

A074997 001 Oct 15, 1997 May CAHN

TABLET; ORALOXYBUTYNIN CHLORIDE

AB EMCURE PHARMS LTD

5MG

A211682 001 May 10, 2019 Apr NEWA

AB INVATECH PHARMA

5MG

A211062 001 Feb 06, 2019 Jan NEWA

TABLET, EXTENDED RELEASE; ORALOXYBUTYNIN CHLORIDE

AB AJANTA PHARMA LTD

5MG

A211655 001 Feb 28, 2019 Feb NEWA

AB

10MG

A211655 002 Feb 28, 2019 Feb NEWA

AB

15MG

A211655 003 Feb 28, 2019 Feb NEWA

OXYCODONE HYDROCHLORIDESOLUTION; ORALOXYCODONE HYDROCHLORIDE

AA ALKEM LABS LTD

5MG/5ML

A211748 001 Feb 07, 2019 Feb NEWA

AA

100MG/5ML

A211749 001 Feb 04, 2019 Jan NEWA

@ LANNETT CO INC

100MG/5ML

A204085 001 Sep 09, 2014 Jan DISC

AA PHARM ASSOC

5MG/5ML

A206914 001 Feb 01, 2019 May CPOT

AA

5MG/ML

A206914 001 Feb 01, 2019 Jan NEWA

TABLET; ORALOXAYDO

>D> EGALET

5MG

N202080 001 Jun 17, 2011 Jul CAHN

>D>

7.5MG

N202080 002 Jun 17, 2011 Jul CAHN

>A> ZYLA

5MG

N202080 001 Jun 17, 2011 Jul CAHN

>A>

7.5MG

N202080 002 Jun 17, 2011 Jul CAHN

OXYCODONE HYDROCHLORIDE

@ VINTAGE PHARMS

5MG

A077712 003 Mar 02, 2009 Apr DISC

@

10MG

A077712 004 Apr 13, 2015 Apr DISC

@

15MG

A077712 001 Jan 31, 2007 Apr DISC

@

20MG

A077712 005 Apr 13, 2015 Apr DISC

@

30MG

A077712 002 Jan 31, 2007 Apr DISC

OXYTOCININJECTABLE; INJECTIONOXYTOCIN

@ DR REDDYS

10USP UNITS/ML (10USP UNITS/ML)

A077453 001 Jan 24, 2008 May CAHN

@

100USP UNITS/10ML (10USP UNITS/ML)

A077453 002 Jan 24, 2008 May CAHN

PACLITAXEL

INJECTABLE; INJECTION

PACLITAXEL

@ ACCORD HLTHCARE

6MG/ML

A205720 001 Aug 17, 2018 Mar DISC

PALIPIPERIDONE

TABLET, EXTENDED RELEASE; ORAL

PALIPIPERIDONE

AB	INVENTIA HLTHCARE	1.5MG
AB		3MG
AB		6MG
AB		9MG

A204452 001 Jun 12, 2019 May NEWA
A204452 002 Jun 12, 2019 May NEWA
A204452 003 Jun 12, 2019 May NEWA
A204452 004 Jun 12, 2019 May NEWAPALONOSETRON HYDROCHLORIDE

INJECTABLE; INTRAVENOUS

PALONOSETRON HYDROCHLORIDE

@ DR REDDYS LABS LTD EQ 0.075MG BASE/1.5ML (EQ 0.05MG BASE/ML)

A201533 001 Apr 21, 2016 Mar DISC

SOLUTION; INTRAVENOUS

PALONOSETRON HYDROCHLORIDE

>D>	EXELA PHARMA SCIENCE	EQ 0.25MG BASE/2ML (EQ 0.125MG BASE/ML)
>A>	HIKMA	EQ 0.25MG BASE/2ML (EQ 0.125MG BASE/ML)

N207963 001 Aug 22, 2016 Jul CAHN
N207963 001 Aug 22, 2016 Jul CAHNPAMIDRONATE DISODIUM

INJECTABLE; INJECTION

PAMIDRONATE DISODIUM

AP	DR REDDYS	30MG/10ML (3MG/ML)
AP		60MG/10ML (6MG/ML)
AP		90MG/10ML (9MG/ML)
@	LUITPOLD	30MG/10ML (3MG/ML)
@		90MG/10ML (9MG/ML)

A078156 001 Aug 19, 2008 May CAHN
A078156 002 Aug 19, 2008 May CAHN
A078156 003 Aug 19, 2008 May CAHN
A078942 001 Jul 25, 2008 Mar DISC
A078942 002 Jul 25, 2008 Mar DISCPANCURONIUM BROMIDE

INJECTABLE; INJECTION

PANCURONIUM BROMIDE

AP	! DR REDDYS	1MG/ML
!		2MG/ML

A072759 001 Jul 31, 1990 May CAHN
A072760 001 Jul 31, 1990 May CAHNPANOBINOSTAT LACTATE

CAPSULE; ORAL

FARYDAK

+	SECURA	EQ 10MG BASE
+		EQ 15MG BASE
+!		EQ 20MG BASE

N205353 001 Feb 23, 2015 Jun CAHN
N205353 002 Feb 23, 2015 Jun CAHN
N205353 003 Feb 23, 2015 Jun CAHNPANTOPRAZOLE SODIUM

POWDER; IV (INFUSION)

PANTOPRAZOLE SODIUM

>D>	EXELA PHARMA SCS LLC	EQ 40MG BASE/VIAL
>A>	HIKMA	EQ 40MG BASE/VIAL

N209463 001 Jun 30, 2017 Jul CAHN
N209463 001 Jun 30, 2017 Jul CAHN

TABLET, DELAYED RELEASE; ORAL

PANTOPRAZOLE SODIUM

AB	INGENUS PHARMS LLC	EQ 40MG BASE
AB	L PERRIGO CO	EQ 20MG BASE

A211368 001 Mar 01, 2019 Feb NEWA
A203024 001 May 07, 2014 May CAHNPENICILLAMINE

CAPSULE; ORAL

CUPRIMINE

AB	@ VALEANT PHARMS INTL	125MG
AB	+!	250MG
AB	+!	250MG
	PENICILLAMINE	

N019853 002 Jan CAHN
N019853 001 Apr CFTG
N019853 001 Jan CAHN
A209921 001 May 07, 2019 Apr NFTG
A210976 001 Jun 24, 2019 Jun NEWA

AB	AMERIGEN PHARMS LTD	250MG
AB	WATSON LABS INC	250MG

PENTAMIDINE ISETHIONATE

FOR SOLUTION; INHALATION
NEBUPENT

AN	+! FRESENIUS KABI USA	300MG/VIAL	N019887	001	Jun 15, 1989	Apr CFTG
AN	SETON PHARMS	300MG/VIAL	A206667	001	Apr 24, 2019	Apr NFTG

PENTOSTATIN

INJECTABLE; INJECTION
PENTOSTATIN
@ MYLAN INSTITUTIONAL 10MG/VIAL

A203554 001 Sep 19, 2014 Mar DISC

PENTOXIFYLLINE

TABLET, EXTENDED RELEASE; ORAL
PENTOXIFYLLINE

@ ANI PHARMS INC	400MG	A074878	001	Jul 09, 1997	May CAHN
@ MYLAN	400MG	A074425	001	Jul 08, 1997	Jun DISC

PERMETHRIN

CREAM; TOPICAL
PERMETHRIN

AB	ENCUBE ETHICALS	5%	A211303	001	Apr 03, 2019	Mar NEWA
AB	PERRIGO ISRAEL	5%	A076369	001	Apr 21, 2003	May CAHN

PHENDIMETRAZINE TARTRATE

TABLET; ORAL
PHENDIMETRAZINE TARTRATE

>A>	@ UPSHER SMITH LABS	35MG	A084399	001	Jul CAHN
>D>	@ USL PHARMA	35MG	A084399	001	Jul CAHN

PHENYLEPHRINE HYDROCHLORIDE

SOLUTION; INTRAVENOUS
PHENYLEPHRINE HYDROCHLORIDE

AP	FRESENIUS KABI USA	10MG/ML (10MG/ML)	A210665	001	Jan 29, 2019	Jan NEWA
AP		50MG/5ML (10MG/ML)	A210666	001	Jan 30, 2019	Jan NEWA
AP		100MG/10ML (10MG/ML)	A210666	002	Jan 30, 2019	Jan NEWA
AP	MEITHEAL	10MG/ML (10MG/ML)	A210334	001	Apr 27, 2018	Jun CAHN
AP		50MG/5ML (10MG/ML)	A210333	001	Apr 27, 2018	Jun CAHN
AP		100MG/10ML (10MG/ML)	A210333	002	Apr 27, 2018	Jun CAHN
AP	SANDOZ INC	10MG/ML (10MG/ML)	A208905	001	Jan 31, 2019	Jan NEWA
AP		50MG/5ML (10MG/ML)	A208905	002	Jan 31, 2019	Jan NEWA
AP		100MG/10ML (10MG/ML)	A208905	003	Jan 31, 2019	Jan NEWA

SOLUTION/DROPS; OPHTHALMIC
PHENYLEPHRINE HYDROCHLORIDE

AT	+! AKORN INC	2.5%	N207926	001	Jan 15, 2015	Jan CTEC
AT	+!	10%	N207926	002	Jan 15, 2015	Jan CTEC
AT	+! PARAGON BIOTECK	2.5%	N203510	001	Mar 21, 2013	Jan CTEC
AT	+!	10%	N203510	002	Mar 21, 2013	Jan CTEC

PHENYTOIN SODIUM

CAPSULE; ORAL
EXTENDED PHENYTOIN SODIUM

>D> AB	SUN PHARM INDNS (IN)	100MG EXTENDED	A040621	001	Dec 11, 2006	Jul DISC
>A>	@	100MG EXTENDED	A040621	001	Dec 11, 2006	Jul DISC

INJECTABLE; INJECTION
PHENYTOIN SODIUM

@ LUITPOLD 50MG/ML

A040781 001 Dec 04, 2007 Feb DISC

PHYTONADIONE

INJECTABLE; INJECTION
PHYTONADIONE

AB	DR REDDYS LABS LTD	10MG/ML	A207719	001	May 22, 2019	May NEWA
AB	VITAMIN K1					
AB	! HOSPIRA	10MG/ML	A087955	001	Jul 25, 1983	May CTEC
	TABLET; ORAL					
	MEPHYTON					
AB	+! BAUSCH	5MG	N010104	003		Feb CAHN
AB	+! VALEANT PHARMS INTL	5MG	N010104	003		Jan CAHN
	PHYTONADIONE					
AB	ZYDUS	5MG	A210189	001	Feb 20, 2019	Feb NEWA

PILOCARPINE HYDROCHLORIDE

TABLET;ORAL

PILOCARPINE HYDROCHLORIDE

>A> AB	AUROBINDO PHARMA LTD	5MG	A212377	001	Aug 13, 2019	Jul NEWA
>A> AB		7.5MG	A212377	002	Aug 13, 2019	Jul NEWA
	SALAGEN					
>A> AB	+ CONCORDIA	5MG	N020237	001	Mar 22, 1994	Jul CAHN
>A> AB	+!	7.5MG	N020237	002	Apr 18, 2003	Jul CAHN
>D> AB	+ EISAI INC	5MG	N020237	001	Mar 22, 1994	Jul CAHN
>D> AB	+!	7.5MG	N020237	002	Apr 18, 2003	Jul CAHN

PIMAVANSERIN TARTRATE

TABLET;ORAL

NUPLAZID

+ @ ACADIA PHARMS INC

EQ 17MG BASE

N207318 001 Apr 29, 2016 Jan DISC

PINDOLOL

TABLET;ORAL

PINDOLOL

>A> AB	BAYSHORE PHARMS LLC	5MG	A211712	001	Aug 01, 2019	Jul NEWA
>A> AB		10MG	A211712	002	Aug 01, 2019	Jul NEWA
	@ ZYDUS PHARMS	5MG	A209866	001	Aug 18, 2017	Jun DISC
	@	10MG	A209866	002	Aug 18, 2017	Jun DISC

PIPERACILLIN SODIUM; TAZOBACTAM SODIUM

INJECTABLE;INJECTION

PIPERACILLIN AND TAZOBACTAM

>A> AP	ASTRAL	EQ 2GM BASE/VIAL;EQ 250MG BASE/VIAL	A212287	001	Jul 29, 2019	Jul NEWA
>A> AP		EQ 3GM BASE/VIAL;EQ 375MG BASE/VIAL	A212287	002	Jul 29, 2019	Jul NEWA
>A> AP		EQ 4GM BASE/VIAL;EQ 500MG BASE/VIAL	A212287	003	Jul 29, 2019	Jul NEWA

PIROXICAM

CAPSULE;ORAL

PIROXICAM

AB	CADILA	10MG	A205585	001	Jul 17, 2018	Feb CAHN
AB		20MG	A205585	002	Jul 17, 2018	Feb CAHN

PITAVASTATIN CALCIUM

TABLET;ORAL

PITAVASTATIN CALCIUM

@ MYLAN		EQ 1MG BASE	A206070	001	Apr 04, 2019	Apr DISC
@		EQ 2MG BASE	A206070	002	Apr 04, 2019	Apr DISC
@		EQ 4MG BASE	A206070	003	Apr 04, 2019	Apr DISC
AB	MYLAN PHARMS INC	EQ 1MG BASE	A206070	001	Apr 04, 2019	Mar NEWA
AB		EQ 2MG BASE	A206070	002	Apr 04, 2019	Mar NEWA
AB		EQ 4MG BASE	A206070	003	Apr 04, 2019	Mar NEWA

PLAZOMICIN SULFATE

SOLUTION;INTRAVENOUS

ZEMDR

>D>	+! ACHAOPEN INC	EQ 500MG BASE/10ML (EQ 50MG BASE/ML)	N210303	001	Jun 25, 2018	Jul CAHN
>A>	+! CIPLA USA	EQ 500MG BASE/10ML (EQ 50MG BASE/ML)	N210303	001	Jun 25, 2018	Jul CAHN

PLECANATIDE

TABLET;ORAL

TRULANCE

+! BAUSCH

+! SALIX

3MG

3MG

N208745 001 Jan 19, 2017 Mar CAHN

N208745 001 Jan 19, 2017 Apr CAHN

POLYETHYLENE GLYCOL 3350

FOR SOLUTION;ORAL

GLYCOLAX

@ LANNETT CO INC

17GM/SCOOPFUL

POLYETHYLENE GLYCOL 3350

@ NEXGEN PHARMA INC

17GM/SCOOPFUL

@ PADDICK LLC

17GM/SCOOPFUL

A076652 001 Jul 02, 2004 May DISC

A077706 001 Sep 27, 2006 May DISC

A077893 001 May 26, 2006 May DISC

POTASSIUM CHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL

POTASSIUM CHLORIDE

AB	PRINSTON INC	8MEQ	A209026	001	Jun 11, 2019	May NEWA
AB		10MEQ	A209026	002	Jun 11, 2019	May NEWA
AB	ZYDUS PHARMS	8MEQ	A208445	001	Mar 11, 2019	Feb NEWA
AB		10MEQ	A208445	002	Mar 11, 2019	Feb NEWA
	FOR SOLUTION;ORAL					
	POTASSIUM CHLORIDE					
AA	AMNEAL PHARMS LLC	20MEQ	A210902	001	May 23, 2019	May NEWA
AA	BELCHER PHARMS LLC	20MEQ	A212183	001	May 06, 2019	Apr NEWA
	SOLUTION;ORAL					
	POTASSIUM CHLORIDE					
AA	PHARM ASSOC	20MEQ/15ML	A210766	001	Mar 29, 2019	Mar NEWA
AA		40MEQ/15ML	A210766	002	Mar 29, 2019	Mar NEWA
	TABLET, EXTENDED RELEASE;ORAL					
	KLOR-CON M15					
AB1	UPSHER SMITH LABS	15MEQ	A074726	003	Jun 06, 2003	Mar CTEC
	POTASSIUM CHLORIDE					
AB1	ADARE PHARMS INC	10MEQ	A076368	002	Jun 05, 2019	Jun NEWA
>D> AB2	PII	8MEQ	A206881	001	Jan 22, 2019	Jul DISC
>A>	@	8MEQ	A206881	001	Jan 22, 2019	Jul DISC
AB2		8MEQ	A206881	001	Jan 22, 2019	Jan NEWA
AB1		10MEQ	A206630	001	Mar 29, 2019	Mar NEWA
>D> AB2		10MEQ	A206881	002	Jan 22, 2019	Jul DISC
>A>	@	10MEQ	A206881	002	Jan 22, 2019	Jul DISC
AB2		10MEQ	A206881	002	Jan 22, 2019	Jan NEWA
AB3		10MEQ	A210097	001	Jun 17, 2019	Jun NEWA
AB1		15MEQ	A206630	002	Mar 29, 2019	Mar NEWA
AB1		20MEQ	A206630	003	Mar 29, 2019	Mar NEWA
AB2		20MEQ	A210098	001	Apr 26, 2019	Apr NEWA
AB1	PRINSTON INC	10MEQ	A209922	001	Apr 30, 2019	Apr NEWA
AB1		15MEQ	A209922	002	Apr 30, 2019	Apr NEWA
AB1		20MEQ	A209922	003	Apr 30, 2019	Apr NEWA

PRALATREXATESOLUTION;INTRAVENOUS
FOLOTYN

+ ACROTECH	20MG/ML (20MG/ML)	N 022468	001	Sep 24, 2009	Mar CAHN
+!	40MG/2ML (20MG/ML)	N 022468	002	Sep 24, 2009	Mar CAHN

PRAMIPEXOLE DIHYDROCHLORIDE

TABLET;ORAL

PRAMIPEXOLE DIHYDROCHLORIDE

AB	HERITAGE PHARMA	0.125MG	A077724	001	Feb 19, 2008	May CAHN
	@	0.125MG	A091254	001	Nov 30, 2010	May CAHN
AB		0.25MG	A077724	002	Feb 19, 2008	May CAHN
	@	0.25MG	A091254	002	Nov 30, 2010	May CAHN
AB		0.5MG	A077724	003	Feb 19, 2008	May CAHN
	@	0.5MG	A091254	003	Nov 30, 2010	May CAHN
AB		0.75MG	A091254	004	Nov 30, 2010	May CAHN
AB		1MG	A077724	004	Feb 19, 2008	May CAHN
	@	1MG	A091254	005	Nov 30, 2010	May CAHN
AB		1.5MG	A077724	005	Feb 19, 2008	May CAHN
	@	1.5MG	A091254	006	Nov 30, 2010	May CAHN

PRAVASTATIN SODIUM

TABLET;ORAL

PRAVASTATIN SODIUM

AB	APNAR PHARMA LP	10MG	A076397	003	Oct 23, 2006	Jun CAHN
AB		20MG	A076397	002	Oct 23, 2006	Jun CAHN
AB		40MG	A076397	001	Oct 23, 2006	Jun CAHN
AB		80MG	A077491	001	Feb 11, 2008	Jun CAHN

PREDNISOLONE

SYRUP;ORAL

PREDNISOLONE

@ PD PARTNERS	5MG/5ML	A 040570	001	Aug 25, 2005	May CAHN
@	15MG/5ML	A 040571	001	Aug 25, 2005	May CAHN

PREDNISOLONE ACETATE

SUSPENSION/DROPS; OPHTHALMIC

ECONOPRED

@ EYEVANCE

0.125%

N017468 001

May CAHN

PREDNISOLONE SODIUM PHOSPHATE; SULFACETAMIDE SODIUM

SOLUTION/DROPS; OPHTHALMIC

SULFACETAMIDE SODIUM AND PREDNISOLONE SODIUM PHOSPHATE

! BAUSCH AND LOMB EQ 0.23% PHOSPHATE; 10%

@ SANDOZ INC EQ 0.23% PHOSPHATE; 10%

A074449 001 Dec 29, 1995 May CTEC

A073630 001 May 27, 1993 May DISC

PREDNISONE

TABLET; ORAL

PREDNISONE

>D>	@ GENEYORK PHARMS	1MG	A211496	001	Dec 28, 2018	Jul CMFD
>A> AB		1MG	A211496	001	Dec 28, 2018	Jul CMFD
	@	1MG	A211496	001	Dec 28, 2018	May DISC
>D>	@	2.5MG	A211495	001	Dec 07, 2018	Jul CMFD
>A> AB		2.5MG	A211495	001	Dec 07, 2018	Jul CMFD
	@	2.5MG	A211495	001	Dec 07, 2018	May DISC
>D>	@	5MG	A211495	002	Dec 07, 2018	Jul CMFD
>A> AB		5MG	A211495	002	Dec 07, 2018	Jul CMFD
	@	5MG	A211495	002	Dec 07, 2018	May DISC
>D>	@	10MG	A210525	001	Dec 04, 2018	Jul CMFD
>A> AB		10MG	A210525	001	Dec 04, 2018	Jul CMFD
	@	10MG	A210525	001	Dec 04, 2018	May DISC
>D>	@	20MG	A210525	002	Dec 04, 2018	Jul CMFD
>A> AB		20MG	A210525	002	Dec 04, 2018	Jul CMFD
	@	20MG	A210525	002	Dec 04, 2018	May DISC
>D>	@	50MG	A210525	003	Dec 04, 2018	Jul CMFD
>A> AB		50MG	A210525	003	Dec 04, 2018	Jul CMFD
	@	50MG	A210525	003	Dec 04, 2018	May DISC
AB	SUN PHARM INDUSTRIES	5MG	A089247	002	Dec 04, 1985	Jan CMS1
AB		10MG	A089247	003	Dec 04, 1985	Jan CMS1

PREGABALIN

CAPSULE; ORAL

LYRICA

>D>	+	PF PRISM CV	25MG	N021446	001	Dec 30, 2004	Jul CFTG
>A> AB	+		25MG	N021446	001	Dec 30, 2004	Jul CFTG
>D>	+		50MG	N021446	002	Dec 30, 2004	Jul CFTG
>A> AB	+		50MG	N021446	002	Dec 30, 2004	Jul CFTG
>D>	+		75MG	N021446	003	Dec 30, 2004	Jul CFTG
>A> AB	+		75MG	N021446	003	Dec 30, 2004	Jul CFTG
>D>	+		100MG	N021446	004	Dec 30, 2004	Jul CFTG
>A> AB	+		100MG	N021446	004	Dec 30, 2004	Jul CFTG
>D>	+		150MG	N021446	005	Dec 30, 2004	Jul CFTG
>A> AB	+		150MG	N021446	005	Dec 30, 2004	Jul CFTG
>D>	+		200MG	N021446	006	Dec 30, 2004	Jul CFTG
>A> AB	+		200MG	N021446	006	Dec 30, 2004	Jul CFTG
>D>	+		225MG	N021446	007	Dec 30, 2004	Jul CFTG
>A> AB	+		225MG	N021446	007	Dec 30, 2004	Jul CFTG
>D>	+!		300MG	N021446	008	Dec 30, 2004	Jul CFTG
>A> AB	+!		300MG	N021446	008	Dec 30, 2004	Jul CFTG
>A>	PREGABALIN						
>A> AB	ALEMBIC PHARMS LTD		25MG	A203459	001	Jul 19, 2019	Jul NFTG
>A> AB			50MG	A203459	002	Jul 19, 2019	Jul NFTG
>A> AB			75MG	A203459	003	Jul 19, 2019	Jul NFTG
>A> AB			100MG	A203459	004	Jul 19, 2019	Jul NFTG
>A> AB			150MG	A203459	005	Jul 19, 2019	Jul NFTG
>A> AB			200MG	A203459	006	Jul 19, 2019	Jul NFTG
>A> AB			225MG	A203459	007	Jul 19, 2019	Jul NFTG
>A> AB			300MG	A203459	008	Jul 19, 2019	Jul NFTG
>A> AB	ALKEM LABS LTD		75MG	A207799	001	Jul 19, 2019	Jul NFTG
>A> AB			100MG	A207799	002	Jul 19, 2019	Jul NFTG
>A> AB			150MG	A207799	003	Jul 19, 2019	Jul NFTG
>A> AB			200MG	A207799	004	Jul 19, 2019	Jul NFTG
>A> AB			225MG	A207799	005	Jul 19, 2019	Jul NFTG
>A> AB			300MG	A207799	006	Jul 19, 2019	Jul NFTG
>A> AB	AMNEAL PHARMS CO		25MG	A209743	001	Jul 19, 2019	Jul NFTG
>A> AB			50MG	A209743	002	Jul 19, 2019	Jul NFTG
>A> AB			75MG	A209743	003	Jul 19, 2019	Jul NFTG

>A>	CAPSULE;ORAL PREGABALIN						
>A> AB		100MG	A209743	004	Jul 19, 2019	Jul NFTG	
>A> AB		150MG	A209743	005	Jul 19, 2019	Jul NFTG	
>A> AB		200MG	A209743	006	Jul 19, 2019	Jul NFTG	
>A> AB		225MG	A209743	007	Jul 19, 2019	Jul NFTG	
>A> AB		300MG	A209743	008	Jul 19, 2019	Jul NFTG	
>A> AB	DR REDDYS	25MG	A209664	001	Jul 19, 2019	Jul NFTG	
>A> AB		50MG	A209664	002	Jul 19, 2019	Jul NFTG	
>A> AB		75MG	A209664	003	Jul 19, 2019	Jul NFTG	
>A> AB		100MG	A209664	004	Jul 19, 2019	Jul NFTG	
>A> AB		150MG	A209664	005	Jul 19, 2019	Jul NFTG	
>A> AB		200MG	A209664	006	Jul 19, 2019	Jul NFTG	
>A> AB		225MG	A209664	007	Jul 19, 2019	Jul NFTG	
>A> AB		300MG	A209664	008	Jul 19, 2019	Jul NFTG	
>A> AB	INVAGEN PHARMS	25MG	A211384	001	Jul 19, 2019	Jul NFTG	
>A> AB		50MG	A211384	002	Jul 19, 2019	Jul NFTG	
>A> AB		75MG	A211384	003	Jul 19, 2019	Jul NFTG	
>A> AB		100MG	A211384	004	Jul 19, 2019	Jul NFTG	
>A> AB		150MG	A211384	005	Jul 19, 2019	Jul NFTG	
>A> AB		200MG	A211384	006	Jul 19, 2019	Jul NFTG	
>A> AB		225MG	A211384	007	Jul 19, 2019	Jul NFTG	
>A> AB		300MG	A211384	008	Jul 19, 2019	Jul NFTG	
>A> AB	MSN LABS PVT LTD	25MG	A209357	001	Jul 19, 2019	Jul NFTG	
>A> AB		50MG	A209357	002	Jul 19, 2019	Jul NFTG	
>A> AB		75MG	A209357	003	Jul 19, 2019	Jul NFTG	
>A> AB		100MG	A209357	004	Jul 19, 2019	Jul NFTG	
>A> AB		150MG	A209357	005	Jul 19, 2019	Jul NFTG	
>A> AB		200MG	A209357	006	Jul 19, 2019	Jul NFTG	
>A> AB		225MG	A209357	007	Jul 19, 2019	Jul NFTG	
>A> AB		300MG	A209357	008	Jul 19, 2019	Jul NFTG	
>A> AB	RISING	25MG	A210432	001	Jul 19, 2019	Jul NFTG	
>A> AB		50MG	A210432	002	Jul 19, 2019	Jul NFTG	
>A> AB		75MG	A210432	003	Jul 19, 2019	Jul NFTG	
>A> AB		100MG	A210432	004	Jul 19, 2019	Jul NFTG	
>A> AB		150MG	A210432	005	Jul 19, 2019	Jul NFTG	
>A> AB		200MG	A210432	006	Jul 19, 2019	Jul NFTG	
>A> AB		225MG	A210432	007	Jul 19, 2019	Jul NFTG	
>A> AB		300MG	A210432	008	Jul 19, 2019	Jul NFTG	
>A> AB	SCIEGEN PHARMS INC	25MG	A208677	001	Jul 19, 2019	Jul NFTG	
>A> AB		50MG	A208677	002	Jul 19, 2019	Jul NFTG	
>A> AB		75MG	A208677	003	Jul 19, 2019	Jul NFTG	
>A> AB		100MG	A208677	004	Jul 19, 2019	Jul NFTG	
>A> AB		150MG	A208677	005	Jul 19, 2019	Jul NFTG	
>A> AB		200MG	A208677	006	Jul 19, 2019	Jul NFTG	
>A> AB		225MG	A208677	007	Jul 19, 2019	Jul NFTG	
>A> AB		300MG	A208677	008	Jul 19, 2019	Jul NFTG	
>D> AB	TEVA PHARMS	25MG	A091219	001	Jul 03, 2012	Jul NFTG	
>A> AB		25MG	A091219	001	Jul 19, 2019	Jul NFTG	
>D> AB		50MG	A091219	002	Jul 03, 2012	Jul NFTG	
>A> AB		50MG	A091219	002	Jul 19, 2019	Jul NFTG	
>D> AB		75MG	A091224	001	Jul 03, 2012	Jul NFTG	
>A> AB		75MG	A091224	001	Jul 19, 2019	Jul NFTG	
>D> AB		100MG	A091224	002	Jul 03, 2012	Jul NFTG	
>A> AB		100MG	A091224	002	Jul 19, 2019	Jul NFTG	
>D> AB		150MG	A091224	003	Jul 03, 2012	Jul NFTG	
>A> AB		150MG	A091224	003	Jul 19, 2019	Jul NFTG	
>D> AB		200MG	A091224	004	Jul 03, 2012	Jul NFTG	
>A> AB		200MG	A091224	004	Jul 19, 2019	Jul NFTG	
>D> AB		225MG	A091224	005	Jul 03, 2012	Jul NFTG	
>A> AB		225MG	A091224	005	Jul 19, 2019	Jul NFTG	
>D> AB		300MG	A091224	006	Jul 03, 2012	Jul NFTG	
>A> AB		300MG	A091224	006	Jul 19, 2019	Jul NFTG	
SOLUTION;ORAL LYRICA							
>D>	+! PF PRISM CV	20MG/ML	N022488	001	Jan 04, 2010	Jul CFTG	
>A> AA	+!	20MG/ML	N022488	001	Jan 04, 2010	Jul CFTG	
>A>	PREGABALIN						
>A> AA	ALKEM LABS LTD	20MG/ML	A207623	001	Jul 19, 2019	Jul NFTG	

PROCHLORPERAZINE EDISYLATE

INJECTABLE; INJECTION

PROCHLORPERAZINE EDISYLATE

AP NEXUS PHARMS EQ 5MG BASE/ML A204860 001 Feb 15, 2019 Feb NEWA

PROCHLORPERAZINE MALEATE

TABLET; ORAL

PROCHLORPERAZINE MALEATE

>D> AB TEVA PHARMS EQ 5MG BASE A040120 001 Jul 11, 1996 Jul DISC
>A> @ EQ 5MG BASE A040120 001 Jul 11, 1996 Jul DISC
>D> AB EQ 10MG BASE A040120 002 Jul 11, 1996 Jul DISC
>A> @ EQ 10MG BASE A040120 002 Jul 11, 1996 Jul DISCPROGESTERONE

INJECTABLE; INJECTION

PROGESTERONE

@ LUITPOLD 50MG/ML A090845 001 Jun 22, 2009 Mar DISC

PROMETHAZINE HYDROCHLORIDE

SUPPOSITORY; RECTAL

PROMETHAZINE HYDROCHLORIDE

AB PERRIGO ISRAEL 12.5MG A040500 001 Jun 30, 2003 May CAHN
AB 25MG A040500 002 Jun 30, 2003 May CAHN
TABLET; ORAL
PROMETHAZINE HYDROCHLORIDE
@ IMPAX LABS 12.5MG A040791 002 Feb 12, 2008 Mar DISC
@ 25MG A040791 003 Feb 12, 2008 Mar DISCPROPRANOLOL HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

INNOPRAN XL

>D> BX ANI PHARMS INC 80MG N021438 001 Mar 12, 2003 Jul CRLD
>A> BX + 80MG N021438 001 Mar 12, 2003 Jul CRLD
>D> BX 120MG N021438 002 Mar 12, 2003 Jul CRLD
>A> BX +! 120MG N021438 002 Mar 12, 2003 Jul CHRS
>A> BX + 120MG N021438 002 Mar 12, 2003 Jul CRLD
TABLET; ORAL
PROPRANOLOL HYDROCHLORIDE
@ INNOGENIX 10MG A070322 002 Oct 22, 1985 May CMS1
@ 20MG A070322 003 Oct 22, 1985 May CMS1
@ 40MG A070322 004 Oct 22, 1985 May CMS1
@ 60MG A070322 005 Sep 24, 1986 May CMS1
@ 80MG A070322 001 Aug 04, 1986 Mar CAHNPROTRIPTYLINE HYDROCHLORIDE

TABLET; ORAL

VIVACTIL

AB HERITAGE PHARMA 5MG A073644 001 Aug 24, 1995 May CAHN
AB ! 10MG A073645 001 Aug 24, 1995 May CAHNPYRIDOSTIGMINE BROMIDE

INJECTABLE; INJECTION

MESTINON

AP +! BAUSCH 5MG/ML N009830 001 Feb CAHN

SYRUP; ORAL

MESTINON

AA +! BAUSCH 60MG/5ML N015193 001 Feb CFTG
+! 60MG/5ML N015193 001 Feb CAHN

PYRIDOSTIGMINE BROMIDE

AA NOVITIUM PHARMA 60MG/5ML A211694 001 Mar 08, 2019 Feb NFTG

TABLET; ORAL

MESTINON

AB +! BAUSCH 60MG N009829 002 Feb CAHN

PYRIDOSTIGMINE BROMIDE

APNAR PHARMA LP 30MG A211181 002 May 14, 2019 May NEWA

TABLET, EXTENDED RELEASE; ORAL

MESTINON

AB +! BAUSCH 180MG N011665 001 Feb CAHN

PYRIDOXINE HYDROCHLORIDE

INJECTABLE; INJECTION

PYRIDOXINE HYDROCHLORIDE

@ DR REDDYS

100MG/ML

A080572 001

May CAHN

QUETIAPINE FUMARATE

TABLET, EXTENDED RELEASE; ORAL

QUETIAPINE FUMARATE

@ AMNEAL PHARMS

EQ 400MG BASE

A211405 001 Oct 26, 2018 Apr DISC

QUININE SULFATE

CAPSULE; ORAL

QUININE SULFATE

@ MYLAN PHARMS INC

324MG

A202581 001 Dec 14, 2012 Mar DISC

RABEPRAZOLE SODIUM

TABLET, DELAYED RELEASE; ORAL

RABEPRAZOLE SODIUM

>D> AB

MYLAN

20MG

A076885 001 Nov 08, 2013 Jul DISC

>A>

@

20MG

A076885 001 Nov 08, 2013 Jul DISC

AB RUBICON 20MG

A204237 001 Nov 18, 2015 Feb CAHN

RAMELTEON

TABLET; ORAL

RAMELTEON

>A> AB

ZYDUS PHARMS

8MG

A211567 001 Jul 22, 2019 Jul NEWA

RANITIDINE HYDROCHLORIDE

CAPSULE; ORAL

RANITIDINE HYDROCHLORIDE

AB

APPCO PHARMA LLC

EQ 150MG BASE

A211893 001 Apr 05, 2019 Mar NEWA

AB

EQ 300MG BASE

A211893 002 Apr 05, 2019 Mar NEWA

SYRUP; ORAL

RANITIDINE HYDROCHLORIDE

>D> AA

TORRENT

EQ 15MG BASE/ML

A090102 001 May 26, 2009 Jul DISC

>A>

@

EQ 15MG BASE/ML

A090102 001 May 26, 2009 Jul DISC

AA

EQ 15MG BASE/ML

A090102 001 May 26, 2009 Jan CAHN

TABLET; ORAL

RANITIDINE HYDROCHLORIDE

AB

HERITAGE PHARMA

EQ 150MG BASE

A075165 001 Sep 30, 1998 Feb CAHN

AB

EQ 300MG BASE

A075165 002 Sep 30, 1998 Feb CAHN

AB

STRIDES PHARMA

EQ 150MG BASE

A210010 001 Aug 01, 2018 Apr CAHN

AB

EQ 300MG BASE

A210010 002 Aug 01, 2018 Apr CAHN

AB

VKT PHARMA PVT LTD

EQ 150MG BASE

A211289 001 Jan 31, 2019 Jan NEWA

AB

EQ 300MG BASE

A211289 002 Jan 31, 2019 Jan NEWA

RANOLAZINE

TABLET, EXTENDED RELEASE; ORAL

RANEXA

AB

+ GILEAD

500MG

N021526 002 Jan 27, 2006 Feb CTEC

AB

+!

1GM

N021526 001 Feb 12, 2007 Feb CTEC

RANOLAZINE

AB

ACTAVIS ELIZABETH

500MG

A208862 001 May 28, 2019 May NEWA

AB

1GM

A208862 002 May 28, 2019 May NEWA

AB

AJANTA PHARMA LTD

500MG

A210054 001 May 28, 2019 May NEWA

AB

1GM

A210054 002 May 28, 2019 May NEWA

AB

CIPLA

500MG

A211291 001 May 28, 2019 May NEWA

AB

1GM

A211291 002 May 28, 2019 May NEWA

AB

GLENMARK PHARMS LTD

500MG

A211082 001 Jul 05, 2019 Jun NEWA

AB

1GM

A211082 002 Jul 05, 2019 Jun NEWA

AB

LUPIN LTD

500MG

A201046 001 Jul 29, 2013 Feb CMFD

AB

1GM

A201046 002 Jul 29, 2013 Feb CMFD

AB

SCIEGEN PHARMS INC

500MG

A211829 001 Jun 04, 2019 May NEWA

AB

1GM

A211829 002 Jun 04, 2019 May NEWA

AB

SUN PHARM

500MG

A211707 001 May 28, 2019 May NEWA

AB

1GM

A211707 002 May 28, 2019 May NEWA

RASAGILINE MESYLATE

TABLET;ORAL

RASAGILINE MESYLATE

AB	MICRO LABS	EQ 0.5MG BASE	A207004	001	Mar 29, 2019	Mar NEWA
AB		EQ 1MG BASE	A207004	002	Mar 29, 2019	Mar NEWA

REPAGLINIDE

TABLET;ORAL

PRANDIN

+ @ GEMINI LABS LLC	0.5MG	N020741	001	Dec 22, 1997	Mar DISC
+ @	1MG	N020741	002	Dec 22, 1997	Mar DISC
+ @	2MG	N020741	003	Dec 22, 1997	Mar DISC

REPAGLINIDE

AB	! AUROBINDO PHARMA LTD	2MG	A203820	003	Jan 22, 2014	Mar CHRS
	@ MYLAN	0.5MG	A090252	001	Aug 23, 2013	Feb DISC
>D> AB		1MG	A090252	002	Jan 22, 2014	Jul DISC
>A>	@	1MG	A090252	002	Jan 22, 2014	Jul DISC
>D> AB		2MG	A090252	003	Jan 22, 2014	Jul DISC
>A>	@	2MG	A090252	003	Jan 22, 2014	Jul DISC

RETAPAMULIN

OINTMENT;TOPICAL

ALTABAX

+ ! ALMIRALL	1%	N022055	001	Apr 12, 2007	Mar CAHN
--------------	----	---------	-----	--------------	----------

RIBAVIRIN

CAPSULE;ORAL

RIBAVIRIN

@ CASI PHARMS INC	200MG	A076192	001	Apr 06, 2004	Jun DISC
-------------------	-------	---------	-----	--------------	----------

SOLUTION;ORAL

REBETOL

+ @ SCHERING	40MG/ML	N021546	001	Jul 29, 2003	Jun DISC
--------------	---------	---------	-----	--------------	----------

TABLET;ORAL

RIBAVIRIN

AB	BEXIMCO PHARMS USA	200MG	A202546	001	Aug 12, 2014	Feb CAHN
AB		400MG	A202546	002	Aug 12, 2014	Feb CAHN
AB		500MG	A202546	003	Aug 12, 2014	Feb CAHN
AB		600MG	A202546	004	Aug 12, 2014	Feb CAHN
AB	HERITAGE PHARMA	200MG	A077053	001	Dec 05, 2005	May CAHN

RILUZOLE

TABLET;ORAL

RILUZOLE

@ DAITO PHARMS CO LTD	50MG	A204430	001	Oct 16, 2018	Mar DISC
-----------------------	------	---------	-----	--------------	----------

RIMANTADINE HYDROCHLORIDE

TABLET;ORAL

RIMANTADINE HYDROCHLORIDE

@ HERITAGE PHARMA	100MG	A076375	001	Jan 14, 2003	May CAHN
-------------------	-------	---------	-----	--------------	----------

RIMEXOLONE

SUSPENSION/DROPS;OPHTHALMIC

VEXOL

@ EYEVANCE	1%	N020474	001	Dec 30, 1994	May CAHN
------------	----	---------	-----	--------------	----------

RISEDRONATE SODIUM

TABLET;ORAL

RISEDRONATE SODIUM

@ MYLAN	5MG	A200477	001	Nov 30, 2015	May DISC	
@	30MG	A200477	002	Nov 30, 2015	May DISC	
@	35MG	A200477	003	Nov 30, 2015	May DISC	
@	75MG	A200477	004	Jun 10, 2014	May DISC	
@	150MG	A200477	005	Jun 10, 2014	May DISC	
AB	ORCHID HLTHCARE	30MG	A205280	001	May 13, 2019	Apr NEWA
AB		35MG	A205280	002	May 13, 2019	Apr NEWA

TABLET, DELAYED RELEASE;ORAL

RISEDRONATE SODIUM

AB	SUN PHARM	35MG	A203925	001	Jul 09, 2019	Jun NEWA
	@ ZYDUS PHARMS	35MG	A203822	001	Sep 11, 2018	Feb DISC

RISPERIDONE

	SOLUTION;ORAL RISPERIDONE						
AA	TORRENT	1MG/ML		A078909	001	Jul 29, 2009	Jan CAHN
	TABLET;ORAL RISPERIDONE						
AB	HERITAGE PHARMA	0.25MG		A076228	001	Jun 30, 2008	May CAHN
AB		0.25MG		A077769	001	Oct 16, 2008	May CAHN
AB		0.5MG		A076228	002	Jun 30, 2008	May CAHN
AB		0.5MG		A077769	002	Oct 16, 2008	May CAHN
AB		1MG		A076228	003	Jun 30, 2008	May CAHN
AB		1MG		A077769	003	Oct 16, 2008	May CAHN
AB		2MG		A076228	004	Jun 30, 2008	May CAHN
AB		2MG		A077769	004	Oct 16, 2008	May CAHN
AB		3MG		A076228	005	Jun 30, 2008	May CAHN
AB		3MG		A077769	005	Oct 16, 2008	May CAHN
AB		4MG		A076228	006	Jun 30, 2008	May CAHN
AB		4MG		A077769	006	Oct 16, 2008	May CAHN
	TABLET, ORALLY DISINTEGRATING;ORAL RISPERIDONE						
AB	HERITAGE PHARMA	0.5MG		A076908	001	Mar 12, 2012	May CAHN
AB		1MG		A076908	002	Mar 12, 2012	May CAHN
AB		2MG		A076908	003	Mar 12, 2012	May CAHN

RIVASTIGMINE

	FILM, EXTENDED RELEASE;TRANSDERMAL RIVASTIGMINE						
AB	ZYDUS NOVELTECH INC	4.6MG/24HR		A206318	001	Mar 04, 2019	Feb NEWA
AB		9.5MG/24HR		A206318	002	Mar 04, 2019	Feb NEWA
AB		13.3MG/24HR		A206318	003	Mar 04, 2019	Feb NEWA

ROCURONIUM BROMIDE

	INJECTABLE;INJECTION ROCURONIUM BROMIDE						
>A> AP	CAMARGO PHARM	50MG/5ML (10MG/ML)		A210437	001	Aug 13, 2019	Jul NEWA
>A> AP		100MG/10ML (10MG/ML)		A210437	002	Aug 13, 2019	Jul NEWA

ROFLUMILAST

	TABLET;ORAL ROFLUMILAST						
AB	MICRO LABS	500MCG		A208180	001	Mar 22, 2019	Mar NEWA

ROPINIROLE HYDROCHLORIDE

	TABLET;ORAL ROPINIROLE HYDROCHLORIDE						
AB	CADILA	EQ 0.25MG BASE		A090411	001	Jun 01, 2009	Feb CAHN
AB		EQ 0.5MG BASE		A090411	002	Jun 01, 2009	Feb CAHN
AB		EQ 1MG BASE		A090411	003	Jun 01, 2009	Feb CAHN
AB		EQ 2MG BASE		A090411	004	Jun 01, 2009	Feb CAHN
AB		EQ 3MG BASE		A090411	005	Jun 01, 2009	Feb CAHN
AB		EQ 4MG BASE		A090411	006	Jun 01, 2009	Feb CAHN
AB		EQ 5MG BASE		A090411	007	Jun 01, 2009	Feb CAHN
>A> AB	CELLTRION	EQ 0.25MG BASE		A079050	001	May 29, 2008	Jul CAHN
>A> AB		EQ 0.5MG BASE		A079050	002	May 29, 2008	Jul CAHN
>A> AB		EQ 1MG BASE		A079050	003	May 29, 2008	Jul CAHN
>A> AB		EQ 2MG BASE		A079050	004	May 29, 2008	Jul CAHN
>A> AB		EQ 3MG BASE		A079050	005	May 29, 2008	Jul CAHN
>A> AB		EQ 4MG BASE		A079050	006	May 29, 2008	Jul CAHN
>A> AB		EQ 5MG BASE		A079050	007	May 29, 2008	Jul CAHN
AB	LAX	EQ 0.25MG BASE		A079165	001	Feb 07, 2012	Mar CAHN
AB		EQ 0.5MG BASE		A079165	002	Feb 07, 2012	Mar CAHN
AB		EQ 1MG BASE		A079165	003	Feb 07, 2012	Mar CAHN
AB		EQ 2MG BASE		A079165	004	Feb 07, 2012	Mar CAHN
AB		EQ 3MG BASE		A079165	005	Feb 07, 2012	Mar CAHN
AB		EQ 4MG BASE		A079165	006	Feb 07, 2012	Mar CAHN
AB		EQ 5MG BASE		A079165	007	Feb 07, 2012	Mar CAHN
>D> AB	WOCKHARDT	EQ 0.25MG BASE		A079050	001	May 29, 2008	Jul CAHN
>D> AB		EQ 0.5MG BASE		A079050	002	May 29, 2008	Jul CAHN
>D> AB		EQ 1MG BASE		A079050	003	May 29, 2008	Jul CAHN
>D> AB		EQ 2MG BASE		A079050	004	May 29, 2008	Jul CAHN
>D> AB		EQ 3MG BASE		A079050	005	May 29, 2008	Jul CAHN
>D> AB		EQ 4MG BASE		A079050	006	May 29, 2008	Jul CAHN

TABLET;ORAL
ROPINIROLE HYDROCHLORIDE

>D> AB EQ 5MG BASE A079050 007 May 29, 2008 Jul CAHN

ROSUVASTATIN CALCIUM

TABLET;ORAL	ROSUVASTATIN CALCIUM						
@ AMNEAL PHARMS CO	5MG	A208850	001	Oct 16, 2018	Apr DISC		
@	10MG	A208850	002	Oct 16, 2018	Apr DISC		
@	20MG	A208850	003	Oct 16, 2018	Apr DISC		
@	40MG	A208850	004	Oct 16, 2018	Apr DISC		
>D> AB MYLAN	5MG	A079161	001	Jul 19, 2016	Jul DISC		
>A> @	5MG	A079161	001	Jul 19, 2016	Jul DISC		
>D> AB	10MG	A079161	002	Jul 19, 2016	Jul DISC		
>A> @	10MG	A079161	002	Jul 19, 2016	Jul DISC		
>D> AB	20MG	A079161	003	Jul 19, 2016	Jul DISC		
>A> @	20MG	A079161	003	Jul 19, 2016	Jul DISC		
>D> AB	40MG	A079161	004	Jul 19, 2016	Jul DISC		
>A> @	40MG	A079161	004	Jul 19, 2016	Jul DISC		
AB SCIEGEN PHARMS INC	5MG	A206381	001	Apr 24, 2019	Apr NEWA		
AB	10MG	A206381	002	Apr 24, 2019	Apr NEWA		
AB	20MG	A206381	003	Apr 24, 2019	Apr NEWA		
AB	40MG	A206381	004	Apr 24, 2019	Apr NEWA		
AB SHANDONG	5MG	A207375	001	May 07, 2019	Apr NEWA		
AB	10MG	A207375	002	May 07, 2019	Apr NEWA		
AB	20MG	A207375	003	May 07, 2019	Apr NEWA		
AB	40MG	A207375	004	May 07, 2019	Apr NEWA		
>D> AB TEVA PHARMS USA	5MG	A079166	001	Jul 19, 2016	Jul DISC		
>A> @	5MG	A079166	001	Jul 19, 2016	Jul DISC		
>D> AB	10MG	A079166	002	Jul 19, 2016	Jul DISC		
>A> @	10MG	A079166	002	Jul 19, 2016	Jul DISC		
>D> AB	20MG	A079166	003	Jul 19, 2016	Jul DISC		
>A> @	20MG	A079166	003	Jul 19, 2016	Jul DISC		
>D> AB	40MG	A079166	004	Jul 19, 2016	Jul DISC		
>A> @	40MG	A079166	004	Jul 19, 2016	Jul DISC		
AB UMEDICA LABS PVT LTD	5MG	A207626	001	Apr 09, 2019	Mar NEWA		
AB	10MG	A207626	002	Apr 09, 2019	Mar NEWA		
AB	20MG	A207626	003	Apr 09, 2019	Mar NEWA		
AB	40MG	A207626	004	Apr 09, 2019	Mar NEWA		

RUFINAMIDE

SUSPENSION;ORAL	BANZEL						
AB +! EISAI INC	40MG/ML	N201367	001	Mar 03, 2011	Apr CFTG		
RUFINAMIDE							
AB BIONPHARMA INC	40MG/ML	A211388	001	Apr 23, 2019	Apr NFTG		
AB HIKMA	40MG/ML	A207363	001	Apr 23, 2019	Apr NFTG		
TABLET;ORAL							
RUFINAMIDE							
AB @ MYLAN	200MG	A205095	001	May 16, 2016	Feb DISC		
AB @	400MG	A205095	002	May 16, 2016	Feb DISC		

SAPROPTERIN DIHYDROCHLORIDE

TABLET;ORAL	KUVAN						
AB +! BIOMARIN PHARM	100MG	N022181	001	Dec 13, 2007	May CTEC		
+!	100MG	N022181	001	Dec 13, 2007	Apr CFTG		
SAPROPTERIN DIHYDROCHLORIDE							
AB @ PAR PHARM INC	100MG	A207200	001	May 10, 2019	May DISC		
AB	100MG	A207200	001	May 10, 2019	Apr NFTG		

SCOPOLAMINE

FILM, EXTENDED RELEASE;TRANSDERMAL	SCOPOLAMINE						
AB MYLAN TECHNOLOGIES	1MG/72HR	A203753	001	Jun 19, 2019	Jun NEWA		

SELEGILINE HYDROCHLORIDE

TABLET;ORAL	SELEGILINE HYDROCHLORIDE						
AB BOSCOGEN	5MG	A074912	001	Apr 30, 1998	Jun CAHN		
AB KENTON	5MG	A074912	001	Apr 30, 1998	Mar CAHN		

TABLET, ORALLY DISINTEGRATING;ORAL

ZELAPAR

+! BAUSCH

1.25MG

N021479 001 Jun 14, 2006 Mar CAHN

SELENIOS ACID

SOLUTION;INTRAVENOUS

SELENIOS ACID

+! AM REGENT

EQ 600MCG BASE/10ML (EQ 60MCG
BASE/ML)

N209379 001 Apr 30, 2019 Apr NEWA

>A> SELINEXOR

>A> TABLET;ORAL

>A> XPOVIO

>A> +! KARYOPHARM THERAPS 20MG

N212306 001 Jul 03, 2019 Jul NEWA

SERTACONAZOLE NITRATE

CREAM;TOPICAL

ERTACZO

+! BAUSCH

2%

N021385 001 Dec 10, 2003 Jun CAHN

SERTRALINE HYDROCHLORIDE

TABLET;ORAL

SERTRALINE HYDROCHLORIDE

AB	@ CADILA	EQ 25MG BASE	A077106 001 Feb 06, 2007	Jun DISC
AB	@	EQ 25MG BASE	A077106 001 Feb 06, 2007	Feb CAHN
AB	@	EQ 50MG BASE	A077106 002 Feb 06, 2007	Jun DISC
AB	@	EQ 50MG BASE	A077106 002 Feb 06, 2007	Feb CAHN
AB		EQ 100MG BASE	A077106 003 Feb 06, 2007	Jun DISC
AB		EQ 100MG BASE	A077106 003 Feb 06, 2007	Feb CAHN
AB	HERITAGE PHARMA	EQ 25MG BASE	A076465 001 Aug 11, 2006	May CAHN
AB	@	EQ 25MG BASE	A077299 001 Feb 06, 2007	May CAHN
AB	@	EQ 25MG BASE	A077345 001 Feb 06, 2007	May CAHN
AB	@	EQ 50MG BASE	A076465 002 Aug 11, 2006	May CAHN
AB	@	EQ 50MG BASE	A077299 002 Feb 06, 2007	May CAHN
AB	@	EQ 50MG BASE	A077345 002 Feb 06, 2007	May CAHN
AB		EQ 100MG BASE	A076465 003 Aug 11, 2006	May CAHN
AB	@	EQ 100MG BASE	A077299 003 Feb 06, 2007	May CAHN
AB	@	EQ 100MG BASE	A077345 003 Feb 06, 2007	May CAHN
AB	@ MYLAN PHARMS INC	EQ 25MG BASE	A078626 001 Jan 31, 2008	May DISC
AB	@	EQ 50MG BASE	A078626 002 Jan 31, 2008	May DISC

SEVELAMER HYDROCHLORIDE

TABLET;ORAL

RENAGEL

AB	+ GENZYME	400MG	N021179 001 Jul 12, 2000	Feb CFTG
AB	+!	800MG	N021179 002 Jul 12, 2000	Feb CFTG
AB	SEVELAMER HYDROCHLORIDE			
AB	GLENMARK PHARMS LTD	400MG	A204724 001 Feb 08, 2019	Feb NFTG
AB		800MG	A204724 002 Feb 08, 2019	Feb NFTG

SILDENAFIL CITRATE

FOR SUSPENSION;ORAL

REVATIO

AB	+! PFIZER	EQ 10MG BASE/ML	N203109 001 Aug 30, 2012	May CFTG
AB	NOVITIUM PHARMA	EQ 10MG BASE/ML	A212260 001 May 31, 2019	May NFTG
AB	TABLET;ORAL			
AB	SILDENAFIL CITRATE			
AB	LUPIN LTD	EQ 25MG BASE	A212051 001 Mar 22, 2019	Mar NEWA
AB		EQ 50MG BASE	A212051 002 Mar 22, 2019	Mar NEWA
AB		EQ 100MG BASE	A212051 003 Mar 22, 2019	Mar NEWA
AB	MYLAN	EQ 25MG BASE	A201171 001 Mar 25, 2019	Mar NEWA
AB		EQ 50MG BASE	A201171 002 Mar 25, 2019	Mar NEWA
AB		EQ 100MG BASE	A201171 003 Mar 25, 2019	Mar NEWA

SIMVASTATIN

TABLET;ORAL

SIMVASTATIN

AB	MICRO LABS	5MG	A090383 001 Sep 16, 2011	Mar CAHN
AB		10MG	A090383 002 Sep 16, 2011	Mar CAHN
AB		20MG	A090383 003 Sep 16, 2011	Mar CAHN
AB		40MG	A090383 004 Sep 16, 2011	Mar CAHN

	TABLET;ORAL SIMVASTATIN	80MG	A 090383 005 Sep 16, 2011	Mar CAHN
<u>SIPONIMOD</u>				
	TABLET;ORAL MAYZENT		N 209884 001 Mar 26, 2019	Mar NEWA
	+ NOVARTIS PHARMS CORP	0.25MG	N 209884 002 Mar 26, 2019	Mar NEWA
	+!	2MG		
<u>SIPONIMOD FUMARIC ACID</u>				
	TABLET;ORAL MAYZENT		N 209884 001 Mar 26, 2019	Apr CAIN
	+ NOVARTIS PHARMS CORP	EQ 0.25MG BASE	N 209884 002 Mar 26, 2019	Apr CAIN
	+!	EQ 2MG BASE		
<u>SIROLIMUS</u>				
	SOLUTION;ORAL RAPAMUNE			
AA	+! PF PRISM CV	1MG/ML	N 021083 001 Sep 15, 1999	Jan CFTG
	SIROLIMUS			
AA	NOVITIUM PHARMA	1MG/ML	A 211040 001 Jan 28, 2019	Jan NFTG
<u>SODIUM BICARBONATE</u>				
	INJECTABLE;INJECTION SODIUM BICARBONATE			
	EXELA PHARMA SCS LLC	0.5MEQ/ML	A 211091 001 Jun 20, 2019	Jun NEWA
AP		0.9MEQ/ML	A 211091 002 Jun 20, 2019	Jun NEWA
AP		1MEQ/ML	A 211091 003 Jun 20, 2019	Jun NEWA
<u>SODIUM CHLORIDE</u>				
	INJECTABLE;INJECTION SODIUM CHLORIDE 3% IN PLASTIC CONTAINER			
AP	FRESENIUS KABI USA	3GM/100ML	A 209476 001 Mar 13, 2019	Feb NEWA
<u>SODIUM CHROMATE CR-51</u>				
	INJECTABLE;INJECTION SODIUM CHROMATE CR 51			
	@ CURIUM	100uCi/ML	N 016708 001	Jan CAHN
<u>SODIUM FLUORIDE F-18</u>				
	INJECTABLE;INTRAVENOUS SODIUM FLUORIDE F-18			
AP	DECATUR	10-200mCi/ML	A 204464 001 Oct 21, 2014	Apr CAHN
<u>SODIUM IODIDE I-131</u>				
	CAPSULE;ORAL SODIUM IODIDE I 131			
	@ CURIUM	0.8-100mCi	N 016515 002	Jan CAHN
	+ @	0.8-100mCi	N 016517 001	Jan CAHN
	@	15-100uCi	N 016517 002	Jan CAHN
	SOLUTION;ORAL SODIUM IODIDE I 131			
	+ @ CURIUM	3.5-150mCi/VIAL	N 016515 001	Jan CAHN
<u>SODIUM NITROPRUSSIDE</u>				
	INJECTABLE;INJECTION SODIUM NITROPRUSSIDE			
AP	DR REDDYS LABS LTD	25MG/ML	A 210114 001 Apr 10, 2019	Mar NEWA
>D> AP	RENAISSANCE SSA LLC	25MG/ML	A 209834 001 Jun 26, 2018	Jul CAHN
>D> AP	SUN PHARM	25MG/ML	A 210467 001 Nov 26, 2018	Jul DISC
>A>	@	25MG/ML	A 210467 001 Nov 26, 2018	Jul DISC
>A> AP	VIRTUS PHARM	25MG/ML	A 209834 001 Jun 26, 2018	Jul CAHN
	SOLUTION;INTRAVENOUS NIPRIDE RTU IN SODIUM CHLORIDE 0.9%			
>D>	+! EXELA PHARMA SCS LLC	10MG/50ML (0.2MG/ML)	N 209387 002 Dec 07, 2017	Jul DISC
>A>	+ @	10MG/50ML (0.2MG/ML)	N 209387 002 Dec 07, 2017	Jul DISC

SODIUM PHENYLBUTYRATE

POWDER;ORAL
BUPHENYL
AB +! HORIZON THERAP 3GM/TEASPOONFUL N020573 001 Apr 30, 1996 Feb CAHN
TABLET;ORAL
BUPHENYL
AB +! HORIZON THERAP 500MG N020572 001 May 13, 1996 Feb CAHN

SOLIFENACIN SUCCINATE

TABLET;ORAL
SOLIFENACIN SUCCINATE
AB AJANTA PHARMA LTD 5MG A205483 001 May 20, 2019 May NEWA
AB 10MG A205483 002 May 20, 2019 May NEWA
AB ALEMBIC PHARMS LTD 5MG A205575 001 May 20, 2019 May NEWA
AB 10MG A205575 002 May 20, 2019 May NEWA
AB ALKEM LABS LTD 5MG A210224 001 May 20, 2019 May NEWA
AB 10MG A210224 002 May 20, 2019 May NEWA
AB AMNEAL PHARMS CO 5MG A209719 001 May 20, 2019 May NEWA
AB 10MG A209719 002 May 20, 2019 May NEWA
AB BRECKENRIDGE PHARM 5MG A209818 001 May 20, 2019 May NEWA
AB 10MG A209818 002 May 20, 2019 May NEWA
AB CELLTRION 5MG A210582 001 May 20, 2019 May NEWA
AB 10MG A210582 002 May 20, 2019 May NEWA
AB CIPLA 5MG A209839 001 May 20, 2019 May NEWA
AB 10MG A209839 002 May 20, 2019 May NEWA
AB GLENMARK PHARMS INC 5MG A209239 001 May 20, 2019 May NEWA
AB 10MG A209239 002 May 20, 2019 May NEWA
AB JIANGXI BOYA SEEHOT 5MG A210281 001 May 20, 2019 May NEWA
AB 10MG A210281 002 May 20, 2019 May NEWA
AB MSN LABS PVT LTD 5MG A210688 001 May 20, 2019 May NEWA
AB 10MG A210688 002 May 20, 2019 May NEWA
AB QILU PHARM CO LTD 5MG A209333 001 May 20, 2019 May NEWA
AB 10MG A209333 002 May 20, 2019 May NEWA
AB SCIEGEN PHARMS INC 5MG A211657 001 May 20, 2019 May NEWA
AB 10MG A211657 002 May 20, 2019 May NEWA
AB WATSON LABS INC 5MG A202551 001 May 20, 2019 May NEWA
AB 10MG A202551 002 May 20, 2019 May NEWA

SOLRIAMFETOL

TABLET;ORAL
SUNOSI
+ JAZZ 75MG N211230 001 Jun 17, 2019 Jun NEWA
+ 150MG N211230 002 Jun 17, 2019 Jun NEWA

SOTALOL HYDROCHLORIDE

TABLET;ORAL
BETAPACE
AB + COVIS PHARMA BV 80MG N019865 001 Oct 30, 1992 May CTEC
AB + 120MG N019865 005 Apr 20, 1994 May CTEC
AB +! 160MG N019865 002 Oct 30, 1992 May CTEC
AB + 240MG N019865 003 Oct 30, 1992 May CTEC
BETAPACE AF
AB + COVIS PHARMA BV 80MG N021151 001 Feb 22, 2000 May CTEC
AB + 120MG N021151 002 Feb 22, 2000 May CTEC
AB +! 160MG N021151 003 Feb 22, 2000 May CTEC
SORINE
AB UPSHER SMITH LABS 80MG A075500 001 Apr 27, 2001 May CTEC
AB 120MG A075500 004 Apr 27, 2001 May CTEC
AB 160MG A075500 002 Apr 27, 2001 May CTEC
AB 240MG A075500 003 Apr 27, 2001 May CTEC
SOTALOL HYDROCHLORIDE
AB APOTEX 80MG A076214 001 Aug 27, 2003 May CTEC
AB 120MG A076214 002 Aug 27, 2003 May CTEC
AB 160MG A076214 003 Aug 27, 2003 May CTEC
AB APOTEX INC 80MG A076140 001 Sep 26, 2002 May CTEC
AB 120MG A076140 002 Sep 26, 2002 May CTEC
AB 160MG A076140 003 Sep 26, 2002 May CTEC
AB 240MG A076140 004 Sep 26, 2002 May CTEC
AB BEXIMCO PHARMS USA 80MG A207428 001 Oct 21, 2016 May CTEC
AB 80MG A207429 001 Nov 02, 2018 May CTEC
AB 120MG A207428 002 Oct 21, 2016 May CTEC
AB 120MG A207429 002 Nov 02, 2018 May CTEC

TABLET;ORAL
SOTALOL HYDROCHLORIDE

AB		160MG	A207428	003	Oct 21, 2016	May CTEC
AB		160MG	A207429	003	Nov 02, 2018	May CTEC
AB	EPIC PHARMA INC	80MG	A077070	001	Nov 04, 2005	May CTEC
AB		120MG	A077070	002	Nov 04, 2005	May CTEC
AB		160MG	A077070	003	Nov 04, 2005	May CTEC
AB	MYLAN	80MG	A077616	001	Feb 07, 2007	May CTEC
AB		120MG	A077616	002	Feb 07, 2007	May CTEC
AB		160MG	A077616	003	Feb 07, 2007	May CTEC
AB	OXFORD PHARMS	80MG	A075563	001	Nov 07, 2003	May CTEC
AB		120MG	A075563	002	Nov 07, 2003	May CTEC
AB		160MG	A075563	003	Nov 07, 2003	May CTEC
AB		240MG	A075563	004	Nov 07, 2003	May CTEC
AB	TEVA	80MG	A075429	001	May 01, 2000	May CTEC
AB		120MG	A075429	002	May 01, 2000	May CTEC
AB		160MG	A075429	003	May 01, 2000	May CTEC
AB		240MG	A075429	004	May 01, 2000	May CTEC
	@ UPSHER SMITH LABS	80MG	A075366	001	May 01, 2000	Jun DISC
AB		80MG	A075366	001	May 01, 2000	May CTEC
	@	120MG	A075366	002	May 01, 2000	Jun DISC
AB		120MG	A075366	002	May 01, 2000	May CTEC
	@	160MG	A075366	003	May 01, 2000	Jun DISC
AB		160MG	A075366	003	May 01, 2000	May CTEC
	@	240MG	A075366	004	May 01, 2000	Jun DISC
AB		240MG	A075366	004	May 01, 2000	May CTEC

SPIRONOLACTONE

TABLET;ORAL
SPIRONOLACTONE

@ ACTAVIS ELIZABETH	25MG	A040353	003	Mar 15, 2006	Jun DISC
@	50MG	A040353	001	Jul 29, 1999	Jun DISC
@	100MG	A040353	002	Jul 29, 1999	Jun DISC
@ CASI PHARMS INC	25MG	A086809	001		Jun DISC

STAVUDINE

FOR SOLUTION;ORAL
ZERIT

+ @ BRISTOL-MYERS SQUIBB	1MG/ML	N020413	001	Sep 06, 1996	Mar DISC
--------------------------	--------	---------	-----	--------------	----------

STRONTIUM CHLORIDE SR-89

INJECTABLE;INJECTION
METASTRON

AP	+! Q BIOMED	1mCi/ML	N020134	001	Jun 18, 1993	Jan CAHN
----	-------------	---------	---------	-----	--------------	----------

SUCCINYLCHOLINE CHLORIDE

INJECTABLE;INJECTION
SUCCINYLCHOLINE CHLORIDE

AP	AMRING PHARMS	20MG/ML	A210231	001	Jun 04, 2018	Jan CAHN
>A>	DR REDDYS	20MG/ML	A210698	001	Aug 02, 2019	Jul NEWA

SULFAMETHOXAZOLE; TRIMETHOPRIM

INJECTABLE;INJECTION
SULFAMETHOXAZOLE AND TRIMETHOPRIM

AP	SOMERSET THERAPS LLC	80MG/ML;16MG/ML	A212231	001	Jun 26, 2019	Jun NEWA
----	----------------------	-----------------	---------	-----	--------------	----------

TABLET;ORAL

AB	SULFAMETHOXAZOLE AND TRIMETHOPRIM DOUBLE STRENGTH		A070037	001	Jun 02, 1987	May CAHN
----	---	--	---------	-----	--------------	----------

SULFAMETHOXAZOLE AND TRIMETHOPRIM SINGLE STRENGTH

AB	HERITAGE PHARMA	400MG;80MG	A070030	001	Jun 02, 1987	May CAHN
----	-----------------	------------	---------	-----	--------------	----------

SUMATRIPTAN

SPRAY;NASAL
TOSYMRA

>D>	+! DR REDDYS LABS LTD	10MG/SPRAY	N210884	001	Jan 25, 2019	Jul CAHN
>A>	+! UPSHER SMITH LABS	10MG/SPRAY	N210884	001	Jan 25, 2019	Jan NEWA

		N210884	001	Jan 25, 2019	Jul CAHN
--	--	---------	-----	--------------	----------

SUMATRIPTAN SUCCINATE

	INJECTABLE;SUBCUTANEOUS SUMATRIPTAN SUCCINATE						
	@ PAR STERILE PRODUCTS	EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)	A077871	001	Jul 09, 2009	Apr	DISC
	@ ZYDUS	EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)	A090310	001	Aug 11, 2010	Apr	CAHN
	SOLUTION;SUBCUTANEOUS ZEMBRACE SYMTOUCH						
>D>	+ DR REDDYS	EQ 3MG BASE/0.5ML (EQ 3MG BASE/0.5ML)	N208223	001	Jan 28, 2016	Jul	CAHN
>A>	+ UPSHER SMITH LABS	EQ 3MG BASE/0.5ML (EQ 3MG BASE/0.5ML)	N208223	001	Jan 28, 2016	Jul	CAHN

TACROLIMUSOINTMENT;TOPICAL
TACROLIMUS

AB	ACCORD HLTHCARE	0.03%	A211688	001	Jan 31, 2019	Jan	NEWA
AB		0.1%	A211688	002	Jan 31, 2019	Jan	NEWA

TADALAFILTABLET;ORAL
ALYQ

AB2	TEVA PHARMS USA TADALAFIL	20MG	A209942	001	Feb 05, 2019	Jan	NEWA
AB	ACCORD HLTHCARE	2.5MG	A209167	001	Mar 26, 2019	Mar	NEWA
AB		5MG	A209167	002	Mar 26, 2019	Mar	NEWA
AB1		20MG	A209167	004	Mar 26, 2019	Mar	NEWA
AB	AJANTA PHARMA LTD	2.5MG	A209654	001	Mar 26, 2019	Mar	NEWA
AB		5MG	A209654	002	Mar 26, 2019	Mar	NEWA
AB		10MG	A209654	003	Mar 26, 2019	Mar	NEWA
AB1		20MG	A209654	004	Mar 26, 2019	Mar	NEWA
AB2		20MG	A210392	001	Feb 05, 2019	Jan	NEWA
AB	ALEMBIC PHARMS LTD	2.5MG	A204809	001	Mar 26, 2019	Mar	NEWA
AB		5MG	A204809	002	Mar 26, 2019	Mar	NEWA
AB		10MG	A204809	003	Mar 26, 2019	Mar	NEWA
AB1		20MG	A204809	004	Mar 26, 2019	Mar	NEWA
AB	AMNEAL PHARMS CO	2.5MG	A209744	001	Mar 26, 2019	Mar	NEWA
AB		5MG	A209744	002	Mar 26, 2019	Mar	NEWA
AB		10MG	A209744	003	Mar 26, 2019	Mar	NEWA
AB1		20MG	A209744	004	Mar 26, 2019	Mar	NEWA
AB	AUROBINDO PHARMA LTD	2.5MG	A206285	001	Mar 26, 2019	Mar	NEWA
AB		5MG	A206285	002	Mar 26, 2019	Mar	NEWA
AB		10MG	A206285	003	Mar 26, 2019	Mar	NEWA
AB1		20MG	A206285	004	Mar 26, 2019	Mar	NEWA
AB2		20MG	A206286	001	Feb 05, 2019	Jan	NEWA
AB	CIPLA	2.5MG	A209539	001	Mar 26, 2019	Mar	NEWA
AB		5MG	A209539	002	Mar 26, 2019	Mar	NEWA
AB		10MG	A209539	003	Mar 26, 2019	Mar	NEWA
AB1		20MG	A209539	004	Mar 26, 2019	Mar	NEWA
AB2		20MG	A210255	001	Feb 05, 2019	Jan	NEWA
AB	DR REDDYS LABS LTD	2.5MG	A210069	001	Mar 26, 2019	Mar	NEWA
AB		5MG	A210069	002	Mar 26, 2019	Mar	NEWA
AB		10MG	A210069	003	Mar 26, 2019	Mar	NEWA
AB1		20MG	A210069	004	Mar 26, 2019	Mar	NEWA
AB2		20MG	A210145	001	Feb 05, 2019	Jan	NEWA
AB	HETERO LABS LTD III	2.5MG	A209908	001	Mar 26, 2019	Mar	NEWA
AB		5MG	A209908	002	Mar 26, 2019	Mar	NEWA
AB		10MG	A209908	003	Mar 26, 2019	Mar	NEWA
AB2		20MG	A209907	001	Feb 05, 2019	Jan	NEWA
AB1		20MG	A209908	004	Mar 26, 2019	Mar	NEWA
AB	LUPIN LTD	2.5MG	A210567	001	Mar 26, 2019	Mar	NEWA
AB		5MG	A210567	002	Mar 26, 2019	Mar	NEWA
AB		10MG	A210567	003	Mar 26, 2019	Mar	NEWA
AB1		20MG	A210567	004	Mar 26, 2019	Mar	NEWA
AB2		20MG	A210572	001	Feb 05, 2019	Jan	NEWA
AB	MYLAN	2.5MG	A206956	001	Apr 29, 2019	Apr	NEWA
AB		5MG	A206957	001	Apr 29, 2019	Apr	NEWA
AB		10MG	A206956	002	Apr 29, 2019	Apr	NEWA
AB1		20MG	A206956	003	Apr 29, 2019	Apr	NEWA
AB2		20MG	A210420	001	Mar 26, 2019	Mar	NEWA
AB	QILU PHARM CO LTD	2.5MG	A210420	002	Mar 26, 2019	Mar	NEWA
AB		5MG	A210420	003	Mar 26, 2019	Mar	NEWA
AB		10MG	A210420	003	Mar 26, 2019	Mar	NEWA

TABLET;ORAL
TADALAFIL

AB1		20MG	A210420	004	Mar 26, 2019	Mar NEWA
AB	SUN PHARM	2.5MG	A208934	001	Mar 26, 2019	Mar NEWA
AB		5MG	A208934	002	Mar 26, 2019	Mar NEWA
AB		10MG	A208934	003	Mar 26, 2019	Mar NEWA
AB1		20MG	A208934	004	Mar 26, 2019	Mar NEWA
AB	SUNSHINE LAKE	2.5MG	A211335	001	Mar 26, 2019	Mar NEWA
AB		5MG	A211335	002	Mar 26, 2019	Mar NEWA
AB		10MG	A211335	003	Mar 26, 2019	Mar NEWA
AB1		20MG	A211335	004	Mar 26, 2019	Mar NEWA
AB	TORRENT	2.5MG	A211839	001	Mar 26, 2019	Mar NEWA
AB		5MG	A211839	002	Mar 26, 2019	Mar NEWA
AB		10MG	A211839	003	Mar 26, 2019	Mar NEWA
AB1		20MG	A211839	004	Mar 26, 2019	Mar NEWA
AB2		20MG	A212062	001	Mar 26, 2019	Mar NEWA
AB	UNICHEM LABS LTD	2.5MG	A209250	001	Mar 26, 2019	Mar NEWA
AB		5MG	A209250	002	Mar 26, 2019	Mar NEWA
AB		10MG	A209250	003	Mar 26, 2019	Mar NEWA
AB1		20MG	A209250	004	Mar 26, 2019	Mar NEWA
AB	WATSON LABS INC	2.5MG	A205885	001	Mar 29, 2019	Mar NEWA
AB		5MG	A205885	002	Mar 29, 2019	Mar NEWA
AB		10MG	A205885	003	Mar 29, 2019	Mar NEWA
AB1		20MG	A205885	004	Mar 29, 2019	Mar NEWA
AB	ZYDUS PHARMS	2.5MG	A206693	001	Mar 26, 2019	Mar NEWA
AB		5MG	A206693	002	Mar 26, 2019	Mar NEWA
AB		10MG	A206693	003	Mar 26, 2019	Mar NEWA
AB1		20MG	A206693	004	Mar 26, 2019	Mar NEWA

TAFAMIDIS

CAPSULE;ORAL						
VYNDAMAX						
+!	FOLDRX PHARMS	61MG	N212161	001	May 03, 2019	May NEWA

TAFAMIDIS MEGLUMINE

CAPSULE;ORAL						
VYNDAQEL						
+!	FOLDRX PHARMS	20MG	N211996	001	May 03, 2019	May NEWA

TECHNETIUM TC-99M MERTIATIDE KIT

INJECTABLE;INJECTION							
TECHNESCAN MAG3							
>D>	+!	CURIUM	N/A	N019882	001	Jun 15, 1990	Jul CFTG
>A> AP	+!		N/A	N019882	001	Jun 15, 1990	Jul CFTG
	+!		N/A	N019882	001	Jun 15, 1990	Jan CAHN
>A>		TECHNETIUM TC99M MERTIATIDE KIT					
>A> AP		PHARMALUCENCE	N/A	A208994	001	Jul 12, 2019	Jul NFTG

TECHNETIUM TC-99M OXIDRONATE KIT

INJECTABLE;INJECTION						
TECHNESCAN						
+!	CURIUM	N/A	N018321	001		Jan CAHN

TECHNETIUM TC-99M PYROPHOSPHATE KIT

INJECTABLE;INJECTION						
TECHNESCAN PYP KIT						
AP	CURIUM	N/A	N017538	001		Jan CAHN

TECHNETIUM TC-99M RED BLOOD CELL KIT

INJECTABLE;INJECTION						
ULTRATAG						
+!	CURIUM	N/A	N019981	001	Jun 10, 1991	Jan CAHN

TECHNETIUM TC-99M SODIUM PERTECHNETATE GENERATOR

SOLUTION;INTRAVENOUS						
ULTRA-TECHNEKOW FM						
+!	CURIUM	1-19 CI/GENERATOR	N017243	003	Feb 18, 2014	Jan CAHN
@		0.25-3 CI/GENERATOR	N017243	002		Jan CAHN
SOLUTION;INTRAVENOUS, ORAL						
TECHNETIUM TC 99M GENERATOR						
+ @ GE HEALTHCARE		68-2703mCi/GENERATOR	N017693	002	Dec 13, 2013	Feb DISC

TEGASEROD MALEATE

TABLET;ORAL

ZELNORM

>D>	@ US WORLDMEDS LLC	EQ 2MG BASE	N021200	001	Jul 24, 2002	Jul CRLD
>A>	+ @	EQ 2MG BASE	N021200	001	Jul 24, 2002	Jul CRLD
>D>	@	EQ 6MG BASE	N021200	002	Jul 24, 2002	Jul CRLD
>A>	+ @	EQ 6MG BASE	N021200	002	Jul 24, 2002	Jul CRLD

TELMISARTAN

TABLET;ORAL

TELMISARTAN

AB	@ CIPLA	20MG	A078710	001	Jan 08, 2014	Jun DISC
		20MG	A078710	001	Jan 08, 2014	Feb CAHN
	@	40MG	A078710	002	Jan 08, 2014	Feb CAHN
	@	80MG	A078710	003	Jan 08, 2014	Feb CAHN
AB	HISUN PHARM HANGZHOU	20MG	A207843	001	Feb 19, 2019	Feb NEWA
AB		40MG	A207843	002	Feb 19, 2019	Feb NEWA
AB		80MG	A207843	003	Feb 19, 2019	Feb NEWA
	@ MICRO LABS	20MG	A207016	001	Oct 03, 2017	Mar DISC
	@	40MG	A207016	002	Oct 03, 2017	Mar DISC
	@	80MG	A207016	003	Oct 03, 2017	Mar DISC
	@ WATSON LABS	80MG	A078710	003	Jan 08, 2014	Feb DISC

TEMOZOLOMIDE

CAPSULE;ORAL

TEMOZOLOMIDE

AB	@ APOTEX INC	5MG	A204159	001	Jul 05, 2018	Jan DISC
	@	20MG	A204159	002	Jul 05, 2018	Jan DISC
	@	100MG	A204159	003	Jul 05, 2018	Jan DISC
	@	140MG	A204159	004	Jul 05, 2018	Jan DISC
	@	180MG	A204159	005	Jul 05, 2018	Jan DISC
	@	250MG	A204159	006	Jul 05, 2018	Jan DISC

TENOFOVIR DISOPROXIL FUMARATE

TABLET;ORAL

TENOFOVIR DISOPROXIL FUMARATE

	@ APOTEX INC	300MG	A206481	001	Jul 26, 2018	Jan DISC
--	--------------	-------	---------	-----	--------------	----------

TERAZOSIN HYDROCHLORIDE

CAPSULE;ORAL

TERAZOSIN HYDROCHLORIDE

AB	APNAR PHARMA LP	EQ 1MG BASE	A074823	001	Mar 30, 1998	Jun CAHN
AB	!	EQ 2MG BASE	A074823	002	Mar 30, 1998	Jun CAHN
AB		EQ 5MG BASE	A074823	003	Mar 30, 1998	Jun CAHN
AB		EQ 10MG BASE	A074823	004	Mar 30, 1998	Jun CAHN
	@ BEXIMCO PHARMS USA	EQ 1MG BASE	A075667	001	Jul 28, 2000	Feb CAHN
	@	EQ 2MG BASE	A075667	002	Jul 28, 2000	Feb CAHN
	@	EQ 5MG BASE	A075667	003	Jul 28, 2000	Feb CAHN
	@	EQ 10MG BASE	A075667	004	Jul 28, 2000	Feb CAHN
AB	HERITAGE PHARMA	EQ 1MG BASE	A075614	002	Jan 30, 2001	Mar CAHN
AB		EQ 2MG BASE	A075614	001	Jan 30, 2001	Mar CAHN
AB		EQ 5MG BASE	A075614	003	Jan 30, 2001	Mar CAHN
AB		EQ 10MG BASE	A075614	004	Jan 30, 2001	Mar CAHN
AB	HIKMA	EQ 1MG BASE	A075498	001	Apr 12, 2001	Jun CAHN
AB		EQ 2MG BASE	A075498	002	Apr 12, 2001	Jun CAHN
AB		EQ 5MG BASE	A075498	003	Apr 12, 2001	Jun CAHN
AB		EQ 10MG BASE	A075498	004	Apr 12, 2001	Jun CAHN

TERBINAFINE HYDROCHLORIDE

TABLET;ORAL

TERBINAFINE HYDROCHLORIDE

AB	HERITAGE PHARMA	EQ 250MG BASE	A076377	001	Jul 02, 2007	May CAHN
----	-----------------	---------------	---------	-----	--------------	----------

TERBUTALINE SULFATE

INJECTABLE;INJECTION

TERBUTALINE SULFATE

	@ DR REDDYS	1MG/ML	A076853	001	Jul 20, 2004	May CAHN
--	-------------	--------	---------	-----	--------------	----------

TERCONAZOLE

CREAM;VAGINAL	TERCONAZOLE					
BX	+! FOUGERA PHARMS INC	0.8%	N021735	001	Oct 01, 2004	May CAHN
	SUPPOSITORY;VAGINAL	TERCONAZOLE				
AB	! PERRIGO ISRAEL	80MG	A077149	001	Mar 17, 2006	May CAHN

TERIFLUONIMIDE

TABLET;ORAL	TERIFLUONIMIDE					
AB	ALEMBIC PHARMS LTD	7MG	A209572	001	Apr 19, 2019	Apr NEWA
AB		14MG	A209572	002	Apr 19, 2019	Apr NEWA
	@ AMNEAL PHARMS CO	7MG	A209613	001	Sep 28, 2018	Feb DISC
	@	14MG	A209613	002	Sep 28, 2018	Feb DISC
	@ APOTEX INC	7MG	A209601	001	Nov 02, 2018	Jan DISC
	@	14MG	A209601	002	Nov 02, 2018	Jan DISC
	@ AUROBINDO PHARMA LTD	7MG	A209638	001	Oct 26, 2018	Feb DISC
	@	14MG	A209638	002	Oct 26, 2018	Feb DISC
AB	MSN LABS PVT LTD	7MG	A209623	001	Apr 24, 2019	Apr NEWA
AB		14MG	A209623	002	Apr 24, 2019	Apr NEWA
	@ TEVA PHARMS USA	7MG	A209700	001	Sep 04, 2018	Mar DISC
	@	14MG	A209700	002	Sep 04, 2018	Mar DISC
	@ WATSON LABS TEVA	7MG	A209549	001	Jul 27, 2018	Feb DISC
	@	14MG	A209549	002	Jul 27, 2018	Feb DISC
	@ ZYDUS PHARMS	7MG	A209668	001	Nov 30, 2018	May DISC
	@	14MG	A209668	002	Nov 30, 2018	May DISC

TESTOSTERONE

GEL;TRANSDERMAL	TESTOSTERONE					
	@ PAR PHARM	25MG/2.5GM PACKET	A076744	001	May 23, 2007	Mar DISC
GEL, METERED;TRANSDERMAL	TESTOSTERONE					
AB	ACTAVIS LABS UT INC	1.62% (20.25MG/1.25GM ACTUATION)	A204570	001	Apr 10, 2019	Mar NEWA
AB	AMNEAL PHARMS LLC	1.62% (20.25MG/1.25GM ACTUATION)	A207373	001	Apr 10, 2019	Mar NEWA
AB	DR REDDYS	1.62% (20.25MG/1.25GM ACTUATION)	A208620	001	Apr 10, 2019	Mar NEWA
AB	LUPIN ATLANTIS	1.62% (20.25MG/1.25GM ACTUATION)	A208560	001	Apr 10, 2019	Mar NEWA
>D>	TABLET, EXTENDED RELEASE;BUCCAL					
>D>	STRIANT					
>D>	+! AUXILIUM PHARMS LLC	30MG	N021543	001	Jun 19, 2003	Jul DISC
>A>	+ @	30MG	N021543	001	Jun 19, 2003	Jul DISC

TESTOSTERONE CYPIONATE

INJECTABLE;INJECTION	TESTOSTERONE CYPIONATE					
	@ MYLAN INSTITUTIONAL	200MG/ML	A040652	001	Dec 11, 2006	Mar DISC
AO	WILSHIRE PHARMS INC	200MG/ML	A206368	001	Apr 24, 2019	Apr NEWA

TESTOSTERONE UNDECANOATE

CAPSULE;ORAL	JATENZO					
	+ CLARUS	158MG	N206089	001	Mar 27, 2019	Mar NEWA
	+	198MG	N206089	002	Mar 27, 2019	Mar NEWA
	+!	237MG	N206089	003	Mar 27, 2019	Mar NEWA

TETRABENAZINE

TABLET;ORAL	TETRABENAZINE					
>D> AB	APICORE US	12.5MG	A207682	001	Jan 31, 2017	Jul CAHN
>D> AB		25MG	A207682	002	Jan 31, 2017	Jul CAHN
	@ LUPIN LTD	12.5MG	A210544	001	Apr 20, 2018	Feb DISC
	@	25MG	A210544	002	Apr 20, 2018	Feb DISC
>A> AB	MYLAN	12.5MG	A207682	001	Jan 31, 2017	Jul CAHN
>A> AB		25MG	A207682	002	Jan 31, 2017	Jul CAHN
AB	WEST-WARD PHARMS INT	12.5MG	A209739	001	Apr 08, 2019	Mar NEWA
AB		25MG	A209739	002	Apr 08, 2019	Mar NEWA

TETRACAININE HYDROCHLORIDE

SOLUTION;OPHTHALMIC
TETRACAININE HYDROCHLORIDE
BAUSCH 0.5%
VALEANT PHARMS 0.5%

N210821 001 Mar 12, 2019 Apr CAHN
N210821 001 Mar 12, 2019 Mar NEWA

THALLOUS CHLORIDE TL-201

INJECTABLE;INJECTION
THALLOUS CHLORIDE TL 201
AP +! CURIUM 1mCi/ML

N018150 001 Jan CAHN

THEOPHYLLINE

TABLET, EXTENDED RELEASE;ORAL
THEOPHYLLINE
AB ! HERITAGE PHARMA 100MG
AB ! 200MG
AB 300MG
AB @ 450MG

A089807 001 Apr 30, 1990 Feb CAHN
A089808 001 Apr 30, 1990 Feb CAHN
A089763 001 Apr 30, 1990 Feb CAHN
A081236 001 Nov 09, 1992 Feb CAHN

THIOTHIXENE

CAPSULE;ORAL
THIOTHIXENE
AB MYLAN 1MG
AB 2MG
>D> AB ! 5MG
>A> AB 5MG
AB ! 5MG
AB 10MG
AB NOVITIUM PHARMA 1MG
AB 2MG
>D> AB 5MG
>A> AB ! 5MG
AB 5MG
AB 10MG

A071093 002 Jun 23, 1987 Mar CTEC
A071093 003 Jun 23, 1987 Mar CTEC
A071093 004 Jun 23, 1987 Jul CHRS
A071093 004 Jun 23, 1987 Jul CHRS
A071093 004 Jun 23, 1987 Mar CTEC
A071093 001 Jun 23, 1987 Mar CTEC
A211642 001 Apr 05, 2019 Mar NEWA
A211642 002 Apr 05, 2019 Mar NEWA
A211642 003 Apr 05, 2019 Jul CHRS
A211642 003 Apr 05, 2019 Jul CHRS
A211642 003 Apr 05, 2019 Mar NEWA
A211642 004 Apr 05, 2019 Mar NEWA

TICAGRELOR

TABLET;ORAL
BRILINTA
+ ASTRAZENECA PHARMS 60MG
TICAGRELOR
@ AMNEAL PHARMS CO 90MG
AB 90MG
AB HISUN PHARM HANGZHOU 90MG
@ WATSON LABS INC 60MG
@ 90MG

N022433 002 Sep 03, 2015 Jun CTEC
A208531 001 Jan 23, 2019 Jun DISC
A208531 001 Jan 23, 2019 Jan NEWA
A208575 001 Jan 23, 2019 Jan NEWA
A208390 001 Sep 04, 2018 Feb DISC
A208390 002 Sep 04, 2018 Feb DISC

TIGECYCLINE

POWDER;INTRAVENOUS
TIGECYCLINE
>D> @ AMNEAL PHARMS LLC 50MG/VIAL
>A> AP 50MG/VIAL
AP @ 50MG/VIAL
AP AUROBINDO PHARMA LTD 50MG/VIAL

N211158 001 Aug 02, 2018 Jul CMFD
N211158 001 Aug 02, 2018 Jul CMFD
N211158 001 Aug 02, 2018 Feb DISC
A206335 001 Jun 11, 2019 May NEWA

TIMOLOL MALEATE

SOLUTION/DROPS;OPHTHALMIC
TIMOPTIC
AT + VALEANT PHARMS INTL EQ 0.25% BASE
AT1 + EQ 0.5% BASE
TIMOPTIC IN OCUDOSE
+! VALEANT PHARMS INTL EQ 0.25% BASE
+! EQ 0.5% BASE
TABLET;ORAL
BLOCADREN
+ @ MERCK 5MG
+ @ 10MG
+ @ 20MG
TIMOLOL MALEATE
AB INVATECH PHARMA 5MG
AB 10MG
AB 20MG

N018086 001 Jan CAHN
N018086 002 Jan CAHN
N019463 001 Nov 05, 1986 Jan CAHN
N019463 002 Nov 05, 1986 Jan CAHN
N018017 001 Apr CRLD
N018017 002 Apr CRLD
N018017 004 Apr CRLD
A207556 001 May 02, 2019 Apr NEWA
A207556 002 May 02, 2019 Apr NEWA
A207556 003 May 02, 2019 Apr NEWA

TABLET;ORAL

TIMOLOL MALEATE

AB	MYLAN	5MG	A072668	002	Jun 08, 1990	Apr CTEC
AB		10MG	A072668	003	Jun 08, 1990	Apr CTEC
AB	!	20MG	A072668	001	Jun 08, 1990	Apr CTEC

TIOPRONIN

TABLET, DELAYED RELEASE;ORAL

THIOLA EC

+ !	MISSION PHARMACAL CO	100MG	N211843	001	Jun 28, 2019	Jun NEWA
+ !		300MG	N211843	002	Jun 28, 2019	Jun NEWA

TIZANIDINE HYDROCHLORIDE

CAPSULE;ORAL

TIZANIDINE HYDROCHLORIDE

AB	ALKEM LABS LTD	EQ 2MG BASE	A212196	001	Mar 27, 2019	Mar NEWA
AB		EQ 4MG BASE	A212196	002	Mar 27, 2019	Mar NEWA
AB		EQ 6MG BASE	A212196	003	Mar 27, 2019	Mar NEWA
AB	CADILA PHARMS LTD	EQ 2MG BASE	A210021	001	Mar 26, 2019	Mar NEWA
AB		EQ 4MG BASE	A210021	002	Mar 26, 2019	Mar NEWA
AB		EQ 6MG BASE	A210021	003	Mar 26, 2019	Mar NEWA
AB	RICONPHARMA LLC	EQ 2MG BASE	A210267	001	Mar 12, 2019	Feb NEWA
AB		EQ 4MG BASE	A210267	002	Mar 12, 2019	Feb NEWA
AB		EQ 6MG BASE	A210267	003	Mar 12, 2019	Feb NEWA

TABLET;ORAL

TIZANIDINE HYDROCHLORIDE

AB	ALKEM LABS LTD	EQ 2MG BASE	A211798	001	Jan 25, 2019	Jan NEWA
AB		EQ 4MG BASE	A211798	002	Jan 25, 2019	Jan NEWA
@	ANI PHARMS INC	EQ 2MG BASE	A076283	001	Jul 12, 2002	May CAHN
@		EQ 2MG BASE	A076371	001	Apr 09, 2003	May CAHN
@		EQ 4MG BASE	A076283	002	Jul 12, 2002	May CAHN
@		EQ 4MG BASE	A076371	002	Apr 09, 2003	May CAHN
@	PAR PHARM INC	EQ 2MG BASE	A207170	001	Jan 26, 2017	Mar DISC
@		EQ 4MG BASE	A207170	002	Jan 26, 2017	Mar DISC

TOBRAMYCIN

SOLUTION;INHALATION

BETHKIS

>D>	AN	+ ! CHIESI USA INC	300MG/4ML	N201820	001	Oct 12, 2012	Jul CTEC
>A>		+ !	300MG/4ML	N201820	001	Oct 12, 2012	Jul CTEC
	AN	+ !	300MG/4ML	N201820	001	Oct 12, 2012	Jun CFTG
		TOBRAMYCIN					
	AN	DR REDDYS LABS SA	300MG/5ML	A207080	001	Jul 09, 2018	Mar CMFD
		@	300MG/5ML	A207080	001	Jul 09, 2018	Jan DISC
>D>	AN	TEVA PHARMS USA	300MG/4ML	A210915	001	Jun 26, 2019	Jul DISC
>A>		@	300MG/4ML	A210915	001	Jun 26, 2019	Jul DISC
	AN		300MG/4ML	A210915	001	Jun 26, 2019	Jun NFTG

SOLUTION/DROPS;OPHTHALMIC

TOBRAMYCIN

AT	ALEMBIC PHARMS LTD	0.3%	A211847	001	Apr 19, 2019	Apr NEWA
----	--------------------	------	---------	-----	--------------	----------

TOFACITINIB CITRATE

TABLET;ORAL

XELJANZ

+ !	PF PRISM CV	EQ 5MG BASE	N203214	001	Nov 06, 2012	May CHRS
-----	-------------	-------------	---------	-----	--------------	----------

TOLAZAMIDE

TABLET;ORAL

TOLAZAMIDE

@	COSETTE	100MG	N018894	001	Nov 02, 1984	Jun CAHN
@		250MG	N018894	002	Nov 02, 1984	Jun CAHN
@		500MG	N018894	003	Nov 02, 1984	Jun CAHN

TOLCAPONE

TABLET;ORAL

TASMAR

AB	+ ! BAUSCH	100MG	N020697	001	Jan 29, 1998	Mar CAHN	
	@	200MG	N020697	002	Jan 29, 1998	Mar CAHN	
	TOLCAPONE						
>A>	AB	KINEDEXE UK	100MG	A210095	001	Aug 01, 2019	Jul NEWA

TOLMETIN SODIUM

CAPSULE;ORAL TOLMETIN SODIUM © ANI PHARMS INC	EQ 400MG BASE	A073308 001 Jan 24, 1992	May CAHN
TABLET;ORAL TOLMETIN SODIUM © ANI PHARMS INC	EQ 600MG BASE	A073527 001 Jun 30, 1992	May CAHN

TOLVAPTAN

TABLET;ORAL JYNARQUE +! OTSUKA PHARM CO LTD	45MG	N204441 003 Apr 23, 2018	Jun CHRS
+!	90MG	N204441 005 Apr 23, 2018	Jun CHRS

TOPIRAMATE

CAPSULE, EXTENDED RELEASE;ORAL QUDEXY XR			
BC + UPSHER SMITH LABS	25MG	N205122 001 Mar 11, 2014	Feb CTEC
BC +	50MG	N205122 002 Mar 11, 2014	Feb CTEC
BC +	100MG	N205122 003 Mar 11, 2014	Feb CTEC
BC +!	200MG	N205122 005 Mar 11, 2014	Feb CTEC
TROKENDI XR			
BC +! SUPERNUS PHARMS	200MG	N201635 004 Aug 16, 2013	Apr CTEC

TRAMADOL HYDROCHLORIDE

TABLET;ORAL TRAMADOL HYDROCHLORIDE			
AB POLYGEN PHARMS	50MG	A206706 001 Jul 02, 2019	Jun NEWA
AB RUBICON	50MG	A208708 001 Jun 28, 2019	Jun NEWA
AB	100MG	A208708 002 Jun 28, 2019	Jun NEWA
>A> AB UNICHEM LABS LTD	50MG	A211825 001 Aug 09, 2019	Jul NEWA

TRANEXAMIC ACID

INJECTABLE; INJECTION TRANEXAMIC ACID			
AP ACIC PHARMS	100MG/ML	A209326 001 Feb 22, 2019	Feb NEWA
>A> AP APOLLO PHARMS INC	100MG/ML	A212676 001 Jul 17, 2019	Jul NEWA
>A> AP CAPLIN	100MG/ML	A212360 001 Jul 17, 2019	Jul NEWA
+! EXELA PHARMA SCS LLC	10MG/ML	N212020 001 Apr 15, 2019	Apr NEWA
AP MICRO LABS	100MG/ML	A206713 001 Jun 27, 2017	Mar CAHN
SOLUTION; INTRAVENOUS TRANEXAMIC ACID			
+! EXELA PHARMA SCS LLC	1GM/100ML (10MG/ML)	N212020 001 Apr 15, 2019	May CPOT

TREPROSTINIL DIOLAMINE

TABLET, EXTENDED RELEASE;ORAL ORENITRAM			
+! UNITED THERAP	EQ 1MG BASE	N203496 003 Dec 20, 2013	Feb CHRS
+	EQ 2.5MG BASE	N203496 004 Dec 20, 2013	Feb CHRS

TRETINOIN

CREAM;TOPICAL TRETINOIN			
AB1 TARO PHARMS	0.05%	A211644 001 Jan 25, 2019	Jan NEWA
AB	0.1%	A211645 001 Jan 22, 2019	Jan NEWA

TRIAMCINOLONE ACETONIDE

CREAM;TOPICAL TRIAMCINOLONE ACETONIDE			
AT SAPTALIS PHARMS	0.025%	A040671 001 Jun 09, 2006	May CAHN
AT	0.1%	A040671 002 Jun 09, 2006	May CAHN
AT STRIDES PHARMA	0.025%	A210346 001 Feb 11, 2019	Jan NEWA
AT	0.1%	A210346 002 Feb 11, 2019	Jan NEWA
AT	0.5%	A210346 003 Feb 11, 2019	Jan NEWA
INJECTABLE; INJECTION KENALOG-80			
+! APOTHECON	80MG/ML	N014901 002 Apr 12, 2019	Apr NEWA
TRIAMCINOLONE ACETONIDE			
>D> © TEVA PHARMS USA	40MG/ML	A209852 001 Oct 05, 2018	Jul CMFD
>A> AB	40MG/ML	A209852 001 Oct 05, 2018	Jul CMFD
©	40MG/ML	A209852 001 Oct 05, 2018	Mar DISC

LOTION;TOPICAL

TRIAMCINOLONE ACETONIDE

AT SAPTALIS PHARMS 0.1% A040672 002 Dec 13, 2006 May CAHN

TRICLABENDAZOLE

TABLET;ORAL

EGATEN

+! NOVARTIS PHARMS CORP 250MG N208711 001 Feb 13, 2019 Feb NEWA

TRIENTINE HYDROCHLORIDE

CAPSULE;ORAL

TRIENTINE HYDROCHLORIDE

AB AMNEAL PHARMS LLC 250MG A210619 001 Feb 08, 2019 Feb NEWA
AB DR REDDYS LABS LTD 250MG A211076 001 Jul 03, 2019 Jun NEWA
AB MSN LABS PVT LTD 250MG A211134 001 May 22, 2019 May NEWA
AB ZYDUS PHARMS 250MG A211554 001 Apr 26, 2019 Apr NEWA>D> TRIMETHADIONE

>D> TABLET;ORAL

>D> TRIDIONE

>D> +! ABBVIE 150MG N005856 009 Jul DISC

>A> + @ 150MG N005856 009 Jul DISC

TRIMETHOBENZAMIDE HYDROCHLORIDE

CAPSULE;ORAL

TRIMETHOBENZAMIDE HYDROCHLORIDE

AB LUPIN 300MG A076546 001 Aug 20, 2003 Feb CAHN
INJECTABLE;INJECTION
TIGAN
+! PAR STERILE PRODUCTS 100MG/ML N017530 001 May CTECTRIMIPRAMINE MALEATE

CAPSULE;ORAL

SURMONTIL

>D> AB + ODYSSEY PHARMS EQ 25MG BASE N016792 001 Jul DISC
>A> + @ EQ 25MG BASE N016792 001 Jul DISC
>D> AB +! EQ 50MG BASE N016792 002 Jul DISC
>A> + @ EQ 50MG BASE N016792 002 Jul DISC
>D> AB + EQ 100MG BASE N016792 003 Sep 15, 1982 Jul DISC
>A> + @ EQ 100MG BASE N016792 003 Sep 15, 1982 Jul DISC
TRIMIPRAMINE MALEATE
>D> AB CROSSMEDIKA SA EQ 50MG BASE A208127 002 Apr 15, 2016 Jul CHRS
>A> AB ! EQ 50MG BASE A208127 002 Apr 15, 2016 Jul CHRSURSODIOL

CAPSULE;ORAL

URSODIOL

AB AMNEAL PHARMS CO 300MG A211301 001 Oct 16, 2018 Jun CMFD
@ 300MG A211301 001 Oct 16, 2018 Apr DISCVALACYCLOVIR HYDROCHLORIDE

TABLET;ORAL

VALACYCLOVIR HYDROCHLORIDE

@ WATSON LABS INC EQ 500MG BASE A090370 001 Mar 16, 2011 Apr DISC
@ EQ 1GM BASE A090370 002 Mar 16, 2011 Apr DISCVALPROATE SODIUM

INJECTABLE;INJECTION

DEPACON

+ @ ABBVIE EQ 100MG BASE/ML N020593 001 Dec 30, 1996 Apr DISC
VALPROATE SODIUM
AP ! HIKMA FARMACEUTICA EQ 100MG BASE/ML A078523 001 Feb 17, 2010 Apr CHRSVALPROIC ACID

CAPSULE;ORAL

VALPROIC ACID

>A> AB NOVELGENIX THERAPS 250MG A207611 001 Aug 05, 2019 Jul NEWA
>A> @ UPSHER SMITH LABS 250MG A070631 001 Jun 11, 1987 Jul CAHN
>D> @ USL PHARMA 250MG A070631 001 Jun 11, 1987 Jul CAHN

	SYRUP;ORAL VALPROIC ACID @ PD PARTNERS	250MG/5ML	A 077105 001 Jul 29, 2005	May CAHN
<u>VALRUBICIN</u>				
	SOLUTION;INTRAVESICAL VALRUBICIN			
AO	CUSTOPHARM INC	40MG/ML	A 206430 001 Apr 19, 2019	Apr NFTG
	VALSTAR PRESERVATIVE FREE			
AO	+! ENDO PHARM	40MG/ML	N 020892 001 Sep 25, 1998	Apr CFTG
<u>VALSARTAN</u>				
	TABLET;ORAL VALSARTAN			
AB	ALKEM LABS LTD	40MG	A 205536 001 Mar 12, 2019	Feb NEWA
AB		80MG	A 205536 002 Mar 12, 2019	Feb NEWA
AB		160MG	A 205536 003 Mar 12, 2019	Feb NEWA
AB		320MG	A 205536 004 Mar 12, 2019	Feb NEWA
<u>VANCOMYCIN HYDROCHLORIDE</u>				
	CAPSULE;ORAL VANCOMYCIN HYDROCHLORIDE			
AB	ORIENT PHARMA CO LTD	EQ 125MG BASE	A 210729 001 Apr 29, 2019	Apr NEWA
AB		EQ 250MG BASE	A 210729 002 Apr 29, 2019	Apr NEWA
	FOR SOLUTION;ORAL VANCOCIN HYDROCHLORIDE			
>D>	@ ANI PHARMS INC	EQ 250MG BASE/5ML	A 061667 002 Jul 13, 1983	Jul CMFD
>A>		EQ 250MG BASE/5ML	A 061667 002 Jul 13, 1983	Jul CMFD
	INJECTABLE;INJECTION VANCOMYCIN HYDROCHLORIDE			
AP	HAINAN POLY PHARM	EQ 500MG BASE/VIAL	A 212332 001 Jun 12, 2019	May NEWA
AP		EQ 1GM BASE/VIAL	A 212332 002 Jun 12, 2019	May NEWA
	SOLUTION;INTRAVENOUS VANCOMYCIN HYDROCHLORIDE			
+!	XELLIA PHARMS APS	EQ 500MG BASE/100ML	N 211962 001 Feb 15, 2019	Feb NEWA
+!		EQ 1GM BASE/200ML	N 211962 002 Feb 15, 2019	Feb NEWA
+!		EQ 1.5GM BASE/300ML	N 211962 003 Feb 15, 2019	Feb NEWA
+!		EQ 2GM BASE/400ML	N 211962 004 Feb 15, 2019	Feb NEWA
<u>VARDENAFIL HYDROCHLORIDE</u>				
	TABLET;ORAL VARDENAFIL HYDROCHLORIDE			
	@ AMNEAL PHARMS CO	5MG	A 210738 001 Oct 31, 2018	Apr DISC
	@	10MG	A 210738 002 Oct 31, 2018	Apr DISC
	@	20MG	A 210738 003 Oct 31, 2018	Apr DISC
<u>VASOPRESSIN</u>				
	SOLUTION;INTRAVENOUS VASOSTRICT			
+!	PAR STERILE PRODUCTS	20UNITS/ML (20UNITS/ML)	N 204485 001 Apr 17, 2014	Mar CDFR
+!		200UNITS/10ML (20UNITS/ML)	N 204485 002 Dec 17, 2016	Mar CDFR
<u>VECURONIUM BROMIDE</u>				
	INJECTABLE;INJECTION VECURONIUM BROMIDE			
>A> AP	HIKMA	10MG/VIAL	A 203725 001 Jul 30, 2019	Jul NEWA
>A> AP		20MG/VIAL	A 203725 002 Jul 30, 2019	Jul NEWA
<u>VENLAFAKINE HYDROCHLORIDE</u>				
	CAPSULE, EXTENDED RELEASE;ORAL VENLAFAKINE HYDROCHLORIDE			
AB	ANNORA PHARMA	EQ 37.5MG BASE	A 212277 001 Jul 08, 2019	Jun NEWA
AB		EQ 75MG BASE	A 212277 002 Jul 08, 2019	Jun NEWA
AB		EQ 150MG BASE	A 212277 003 Jul 08, 2019	Jun NEWA
<u>VERAPAMIL HYDROCHLORIDE</u>				
	CAPSULE, EXTENDED RELEASE;ORAL VERAPAMIL HYDROCHLORIDE			
	@ MYLAN	300MG	A 078306 003 Aug 09, 2007	May DISC
	VERELAN PM			
+!	RECRO GAINESVILLE	300MG	N 020943 003 Nov 25, 1998	May CTEC

	TABLET;ORAL CALAN						
AB	+ @ GD SEARLE LLC	80MG	N 018817	001	Sep 10, 1984	May DISC	
	+	120MG	N 018817	002	Sep 10, 1984	May CHRS	
AB	VERAPAMIL HYDROCHLORIDE						
	! HERITAGE PHARMS INC	120MG	A 071881	001	Apr 05, 1988	May CHRS	
	<u>VIGABATRIN</u>						
	FOR SOLUTION;ORAL VIGADRONE						
AA	AUCTA	500MG/PACKET	A 210196	001	Jun 21, 2018	Jun CAHN	
AA	SHANGHAI	500MG/PACKET	A 210196	001	Jun 21, 2018	Mar CAHN	
	<u>VINCRISTINE SULFATE</u>						
	INJECTABLE, LIPOSOMAL; INTRAVENOUS MARQIBO KIT						
	+ ! AROTECH	5MG/5ML (1MG/ML)	N 202497	001	Aug 09, 2012	Mar CAHN	
	<u>VINORELBINE TARTRATE</u>						
	INJECTABLE; INJECTION NAVELBINE						
	+ @ PIERRE FABRE	EQ 10MG BASE/ML	N 020388	001	Dec 23, 1994	Jun DISC	
	VINORELBINE TARTRATE						
>A> AP	INGENUS PHARMS LLC	EQ 10MG BASE/ML	A 208997	001	Aug 05, 2019	Jul NEWA	
	<u>VORAPAXAR SULFATE</u>						
	TABLET;ORAL ZONTIVITY						
	+ ! TOPROL	EQ 2.08MG BASE	N 204886	001	May 08, 2014	May CAHN	
	<u>VORICONAZOLE</u>						
	INJECTABLE; INTRAVENOUS VFEND						
AP	+ ! PF PRISM CV	200MG/VIAL	N 021267	001	May 24, 2002	May CDFR	
	VORICONAZOLE						
AP	ALVOGEN INC	200MG/VIAL	A 206398	001	Mar 23, 2016	May CDFR	
AP	HAINAN POLY PHARM	200MG/VIAL	A 211661	001	Nov 30, 2018	May CDFR	
AP	SANDOZ INC	200MG/VIAL	A 090862	001	May 30, 2012	May CDFR	
AP	ZYDUS PHARMS	200MG/VIAL	A 208983	001	Jul 16, 2018	May CDFR	
	POWDER; INTRAVENOUS VORICONAZOLE						
AP	XELLIA PHARMS APS	200MG/VIAL	N 208562	001	Mar 09, 2017	May CDFR	
	POWDER; IV (INFUSION) VORICONAZOLE						
AP	XELLIA PHARMS APS	200MG/VIAL	N 208562	001	Mar 09, 2017	Feb CTEC	
	TABLET;ORAL VORICONAZOLE						
AB	APPCO PHARMA LLC	50MG	A 206762	001	May 24, 2016	Feb CAHN	
AB		200MG	A 206762	002	May 24, 2016	Feb CAHN	
AB	CADILA	50MG	A 206747	001	May 24, 2016	Apr CAHN	
AB		200MG	A 206747	002	May 24, 2016	Apr CAHN	
	<u>WARFARIN SODIUM</u>						
	TABLET;ORAL JANTOVEN						
>A> AB	UPSHER SMITH LABS	1MG	A 040416	001	Oct 02, 2003	Jul CAHN	
>A> AB		2MG	A 040416	002	Oct 02, 2003	Jul CAHN	
>A> AB		2.5MG	A 040416	003	Oct 02, 2003	Jul CAHN	
>A> AB		3MG	A 040416	004	Oct 02, 2003	Jul CAHN	
>A> AB		4MG	A 040416	005	Oct 02, 2003	Jul CAHN	
>A> AB		5MG	A 040416	006	Oct 02, 2003	Jul CAHN	
>A> AB		6MG	A 040416	007	Oct 02, 2003	Jul CAHN	
>A> AB		7.5MG	A 040416	008	Oct 02, 2003	Jul CAHN	
>A> AB		10MG	A 040416	009	Oct 02, 2003	Jul CAHN	
>D> AB	USL PHARMA	1MG	A 040416	001	Oct 02, 2003	Jul CAHN	
>D> AB		2MG	A 040416	002	Oct 02, 2003	Jul CAHN	
>D> AB		2.5MG	A 040416	003	Oct 02, 2003	Jul CAHN	
>D> AB		3MG	A 040416	004	Oct 02, 2003	Jul CAHN	
>D> AB		4MG	A 040416	005	Oct 02, 2003	Jul CAHN	
>D> AB		5MG	A 040416	006	Oct 02, 2003	Jul CAHN	
>D> AB		6MG	A 040416	007	Oct 02, 2003	Jul CAHN	
>D> AB		7.5MG	A 040416	008	Oct 02, 2003	Jul CAHN	

TABLET;ORAL
JANTOVEN

>D> AB 10MG A040416 009 Oct 02, 2003 Jul CAHN

XENON XE-133

GAS; INHALATION
XENON XE 133

CURIUM 10mCi/VIAL N018327 001 Mar 09, 1982 May CAHN
20mCi/VIAL N018327 002 Mar 09, 1982 May CAHN

ZIDOVUDINE

INJECTABLE; INJECTION
ZIDOVUDINE
@ LUITPOLD

10MG/ML A091457 001 May 06, 2010 Feb DISC

ZINC SULFATE

SOLUTION; INTRAVENOUS
ZINC SULFATE

>A> +! AM REGENT EQ 25MG BASE/5ML (EQ 5 BASE/ML) N209377 002 Jul 18, 2019 Jul NEWA
>A> +! EQ 30MG BASE/10ML (EQ 3MG BASE/ML) N209377 001 Jul 18, 2019 Jul NEWA

ZIPRASIDONE HYDROCHLORIDE

CAPSULE; ORAL
ZIPRASIDONE HYDROCHLORIDE

AB	@ CADILA	EQ 20MG BASE	A208988 001 Aug 22, 2017 Jun DISC
		EQ 20MG BASE	A208988 001 Aug 22, 2017 Feb CAHN
AB	@	EQ 40MG BASE	A208988 002 Aug 22, 2017 Jun DISC
		EQ 40MG BASE	A208988 002 Aug 22, 2017 Feb CAHN
AB	@	EQ 60MG BASE	A208988 003 Aug 22, 2017 Jun DISC
		EQ 60MG BASE	A208988 003 Aug 22, 2017 Feb CAHN
AB	@	EQ 80MG BASE	A208988 004 Aug 22, 2017 Jun DISC
		EQ 80MG BASE	A208988 004 Aug 22, 2017 Feb CAHN

ZOLEDRONIC ACID

INJECTABLE; INTRAVENOUS
RECLAST

AP	+! NOVARTIS	EQ 5MG BASE/100ML	N021817 001 Apr 16, 2007 Mar CDFR
AP	ZOLEDRONIC GLAND PHARMA LTD	EQ 4MG BASE/100ML	A205749 001 Jun 29, 2018 Mar CDFR
AP	ZOLEDRONIC ACID ACCORD HLTHCARE	EQ 4MG BASE/5ML	A205279 001 Nov 28, 2016 Mar CDFR
>D> AP	ACTAVIS INC	EQ 4MG BASE/5ML	A202472 001 Mar 04, 2013 Jul DISC
>A>	@	EQ 4MG BASE/5ML	A202472 001 Mar 04, 2013 Jul DISC
AP		EQ 4MG BASE/5ML	A202472 001 Mar 04, 2013 Mar CDFR
AP	AKORN	EQ 5MG BASE/100ML	A200918 001 Aug 21, 2014 Mar CDFR
AP	AKORN INC	EQ 4MG BASE/5ML	A202548 001 May 22, 2014 Mar CDFR
AP	APOTEX INC	EQ 5MG BASE/100ML	A204367 001 Dec 24, 2015 Mar CDFR
AP	AUROBINDO PHARMA LTD	EQ 4MG BASE/5ML	A207751 001 Sep 26, 2016 Mar CDFR
AP		EQ 5MG BASE/100ML	A209125 001 Dec 08, 2017 Mar CDFR
AP	BPI LABS LLC	EQ 4MG BASE/5ML	A207341 001 Dec 29, 2017 Mar CDFR
AP	BRECKENRIDGE PHARM	EQ 4MG BASE/5ML	A091170 001 Mar 04, 2013 Mar CDFR
AP		EQ 4MG BASE/5ML	A202571 001 May 07, 2013 Mar CDFR
AP		EQ 5MG BASE/100ML	A202163 001 Aug 05, 2013 Mar CDFR
AP	CIPLA	EQ 4MG BASE/100ML	A210174 001 Oct 27, 2017 Mar CDFR
AP	DR REDDYS LABS LTD	EQ 4MG BASE/5ML	A091186 001 Mar 04, 2013 May CDFR
AP		EQ 5MG BASE/100ML	A091363 001 Mar 29, 2013 Mar CDFR
AP	EMCURE PHARMS LTD	EQ 4MG BASE/5ML	A201783 001 Mar 12, 2013 Mar CDFR
AP		EQ 5MG BASE/100ML	A201801 001 Mar 29, 2013 Mar CDFR
AP	FRESENIUS KABI USA	EQ 4MG BASE/5ML	A091516 001 Apr 23, 2015 Mar CDFR
AP	GLAND PHARMA LTD	EQ 4MG BASE/5ML	A202930 001 Aug 05, 2013 Mar CDFR
AP		EQ 5MG BASE/100ML	A204217 001 Aug 18, 2016 Mar CDFR
>A> AP		EQ 5MG BASE/100ML	A209578 001 Aug 08, 2019 Jul NEWA
AP	HIKMA FARMACEUTICA	EQ 4MG BASE/5ML	A202182 001 Jun 03, 2013 Mar CDFR
AP	HOSPIRA INC	EQ 4MG BASE/5ML	A090621 001 Mar 19, 2015 Mar CDFR
AP		EQ 5MG BASE/100ML	A202837 001 Apr 05, 2013 Mar CDFR
AP	INFORLIFE	EQ 4MG BASE/100ML	N203231 001 Aug 02, 2013 Mar CDFR
AP		EQ 5MG BASE/100ML	A202828 001 Sep 23, 2013 Mar CDFR
AP	MYLAN LABS LTD	EQ 4MG BASE/5ML	A202650 001 Mar 04, 2013 Mar CDFR
AP		EQ 5MG BASE/100ML	A203841 001 Feb 14, 2017 Mar CDFR
AP		EQ 5MG BASE/100ML	A205254 001 Oct 27, 2017 Mar CDFR
AP	SAGENT PHARMS	EQ 4MG BASE/5ML	A091493 001 Nov 24, 2014 Mar CDFR
AP	SHILPA MEDICARE LTD	EQ 4MG BASE/5ML	A208513 001 May 15, 2019 Apr NEWA
@	SUN PHARMA GLOBAL	EQ 4MG BASE/VIAL	A090018 001 Mar 04, 2013 Mar CDFR

INJECTABLE; INTRAVENOUS

ZOLEDRONIC ACID

AP	@ USV	EQ 4MG BASE/5ML	A202746	001	Mar 04, 2013	Mar CDFR
AP	USV NORTH AMERICA	EQ 4MG BASE/5ML	A202923	001	Sep 04, 2014	Jun CAHN
	ZOMETA		A202923	001	Sep 04, 2014	Mar CDFR
AP	+ @ NOVARTIS	EQ 4MG BASE/VIAL	N021223	001	Aug 20, 2001	Mar CDFR
AP	+!	EQ 4MG BASE/5ML	N021223	002	Mar 07, 2003	Mar CDFR
AP	+!	EQ 4MG BASE/100ML	N021223	003	Jun 17, 2011	Mar CDFR
	INJECTABLE; IV (INFUSION)					
	ZOLEDRONIC ACID					
AP	DR REDDYS LABS LTD	EQ 4MG BASE/5ML	A091186	001	Mar 04, 2013	Mar CDFR
	SOLUTION; INTRAVENOUS					
	ZOLEDRONIC ACID					
	HOSPIRA INC	EQ 4MG BASE/100ML (EQ 0.04MG BASE/ML)	N204016	001	Dec 28, 2015	Mar CDFR

ZOLPIDEM TARTRATESPRAY, METERED; ORAL
ZOLPIMIST

+	AYTU	5MG/SPRAY	N022196	001	Dec 19, 2008	Feb CAHN
	TABLET; ORAL					
	ZOLPIDEM TARTRATE					
+	STRIDES PHARMA	5MG	A076062	001	Apr 23, 2007	Apr CAHN
+	@	10MG	A076062	002	Apr 23, 2007	Apr CAHN
	TABLET; SUBLINGUAL					
	INTERMEZZO					
+	@ PURDUE PHARMA	1.75MG	N022328	001	Nov 23, 2011	Mar DISC
+	@	3.5MG	N022328	002	Nov 23, 2011	Mar DISC
	ZOLPIDEM TARTRATE					
AB	! NOVEL LABS INC	3.5MG	A204299	002	Jun 03, 2015	Mar CHRS

ZONISAMIDECAPSULE; ORAL
ZONISAMIDE

AB	BIONPHARMA INC	25MG	A077813	001	Aug 16, 2006	Apr CAHN
AB		50MG	A077813	002	Aug 16, 2006	Apr CAHN
AB		100MG	A077813	003	Aug 16, 2006	Apr CAHN

ACETAMINOPHEN

SUPPOSITORIY;RECTAL					
ACEPHEN					
ACP NIMBLE	120MG	N 018060	001	Feb CAHN	
@	325MG	N 018060	003	Dec 18, 1986	Feb CAHN
@	650MG	N 018060	002		Feb CAHN
TABLET, EXTENDED RELEASE;ORAL					
ACETAMINOPHEN					
GRANULES INDIA LTD	650MG	A 211544	001	Apr 16, 2019	Apr NEWA
@ HERITAGE PHARMA	650MG	A 207035	001	May 31, 2018	Mar DISC

ADAPALENE

GEL;TOPICAL					
ADAPALENE					
>A>	GLENMARK GENERICS	0.1%	A 091314	002	Jul 09, 2019 Jul NEWA

CETIRIZINE HYDROCHLORIDE

SOLUTION;ORAL					
CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY					
QUAGEN	5MG/5ML	A 212266	001	May 16, 2019	May NEWA
SYRUP;ORAL					
CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY					
HETERO LABS LTD III	5MG/5ML	A 210622	001	Mar 13, 2019	Feb NEWA
@ PD PARTNERS	5MG/5ML	A 090188	002	Apr 22, 2008	May CAHN
TORRENT	5MG/5ML	A 090474	002	Mar 30, 2009	Jan CAHN
CHILDREN'S CETIRIZINE HYDROCHLORIDE HIVES RELIEF					
@ PD PARTNERS	5MG/5ML	A 090188	001	Apr 22, 2008	May CAHN
TORRENT	5MG/5ML	A 090474	001	Mar 30, 2009	Jan CAHN
TABLET;ORAL					
CETIRIZINE HYDROCHLORIDE ALLERGY					
@ HERITAGE PHARMA	5MG	A 078615	003	Dec 28, 2007	May CAHN
@	10MG	A 078615	004	Dec 28, 2007	May CAHN

CETIRIZINE HYDROCHLORIDE; PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL					
CETIRIZINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE					
@ PERRIGO R AND D	5MG;120MG	A 210719	001	Nov 16, 2018	May DISC

CHLORHEXIDINE GLUCONATE

SOLUTION;TOPICAL					
CHLORHEXIDINE GLUCONATE					
BAJAJ	0.75%	N 020111	001	Sep 11, 1997	Apr CTNA
	0.75%	N 020111	001	Sep 11, 1997	Jan CMFD

CHLORPHENIRAMINE MALEATE

TABLET, EXTENDED RELEASE;ORAL					
CHLORPHENIRAMINE MALEATE					
! AVANTHI INC	12MG	A 040829	001	May 13, 2009	Jan CHRS

DIPHENHYDRAMINE HYDROCHLORIDE; IBUPROFEN

CAPSULE;ORAL					
DIPHENHYDRAMINE HYDROCHLORIDE					
AUROBINDO PHARMA LTD	25MG;EQ 200MG FREE ACID AND POTASSIUM SALT	A 210676	001	Feb 14, 2019	Jan NEWA

DIPHENHYDRAMINE HYDROCHLORIDE; NAPROXEN SODIUM

TABLET;ORAL					
NAPROXEN SODIUM AND DIPHENHYDRAMINE HYDROCHLORIDE					
>D>	ACTAVIS ELIZABETH	25MG;220MG	A 207597	001	Jan 25, 2019 Jul DISC
>A>	@	25MG;220MG	A 207597	001	Jan 25, 2019 Jul DISC
		25MG;220MG	A 207597	001	Jan 25, 2019 Jan NEWA
	PERRIGO R AND D	25MG;220MG	A 208499	001	May 10, 2019 Apr NEWA

ESOMEPRAZOLE MAGNESIUM

CAPSULE, DELAYED RELEASE;ORAL					
ESOMEPRAZOLE MAGNESIUM					
AMNEAL PHARMS NY	EQ 20MG BASE	A 209716	001	Jun 05, 2019	May NEWA

TABLET, DELAYED RELEASE;ORAL
ESOMEPRAZOLE MAGNESIUM

@ ACTAVIS ELIZABETH	EQ 20MG BASE	A209202 001 Mar 05, 2019	Apr DISC
	EQ 20MG BASE	A209202 001 Mar 05, 2019	Feb NEWA

FEXOFENADINE HYDROCHLORIDE

TABLET;ORAL

CHILDREN'S FEXOFENADINE HYDROCHLORIDE ALLERGY

>D>	MYLAN	30MG	A077081 004 Jul 21, 2011	Jul DISC
-----	-------	------	--------------------------	----------

>A>	@	30MG	A077081 004 Jul 21, 2011	Jul DISC
-----	---	------	--------------------------	----------

CHILDREN'S FEXOFENADINE HYDROCHLORIDE HIVES

>D>	MYLAN	30MG	A077081 005 Jul 21, 2011	Jul DISC
-----	-------	------	--------------------------	----------

>A>	@	30MG	A077081 005 Jul 21, 2011	Jul DISC
-----	---	------	--------------------------	----------

FLUTICASONE PROPIONATE

SPRAY, METERED;NASAL

FLUTICASONE PROPIONATE

HI TECH 0.05MG/SPRAY

A208024 001 Apr 17, 2019

Apr NEWA

GUAIFENESIN

TABLET, EXTENDED RELEASE;ORAL

GUAIFENESIN

@ OHM LABS INC 600MG

A209254 001 Jul 16, 2018

Mar DISC

@ 1.2GM

A209254 002 Jul 16, 2018

Mar DISC

IBUPROFEN

SUSPENSION;ORAL

IBUPROFEN

@ GUARDIAN DRUG 100MG/5ML

A210149 001 Aug 17, 2018

Feb DISC

TABLET;ORAL

IBUPROFEN

! PERRIGO R AND D 200MG

A077349 001 Jun 21, 2005

Jun CHRS

MOTRIN IB

+ J AND J CONSUMER INC 200MG

N019012 003 Dec 17, 1990

May CHRS

ISOPROPYL ALCOHOL

SOLUTION;TOPICAL

ZURAGARD

+! ZUREX PHARMA 70% (10.5ML)

N210872 001 Apr 26, 2019

May CMS2

KETOCONAZOLE

SHAMPOO;TOPICAL

NIZORAL A-D

+! KRAMER 1%

N020310 001 Oct 10, 1997

Jan CAHN

KETOTIFEN FUMARATE

SOLUTION/DROPS;OPHTHALMIC

ZADITOR

! ALCON PHARMS LTD EQ 0.025% BASE

A077200 001 Sep 02, 2008

Feb CTNA

LEVOCEFTIRIZINE DIHYDROCHLORIDE

TABLET;ORAL

LEVOCEFTIRIZINE DIHYDROCHLORIDE

>D>	PERRIGO R AND D	5MG	A211983 001 Mar 26, 2019	Jul CMS1
>A>		5MG	A211983 001 Mar 28, 2019	Jul CMS1
		5MG	A211983 001 Mar 26, 2019	Mar NEWA

LEVONORGESTREL

TABLET;ORAL

LEVONORGESTREL

>A> ACCORD HLTHCARE 1.5MG

A207660 001 May 02, 2019

Apr NEWA

ALVOGEN 1.5MG

A202246 001 Jun 05, 2015

Jul CAHN

@ APOTEX INC 1.5MG

A205329 001 Sep 18, 2018

Jan DISC

@ FDN CONSUMER 1.5MG

A200670 001 Jul 12, 2012

Jun DISC

! L PERRIGO CO 0.75MG

A090740 001 Dec 30, 2010

May CAHN

>D> RECKITT BENCKISER 1.5MG

A202246 001 Jun 05, 2015

Jul CAHN

LORATADINE

CAPSULE;ORAL LORATADINE @ BIONPHARMA INC	10MG	A202538	001	Dec 21, 2018	Mar DISC
SYRUP;ORAL LORATADINE @ PD PARTNERS	1MG/ML	A075565	001	Oct 05, 2004	May CAHN
TABLET;ORAL LORATADINE GUARDIAN DRUG	10MG	A207569	001	Mar 12, 2019	Mar CAHN
NEWGEN PHARMS LLC	10MG	A207569	001	Mar 12, 2019	Feb NEWA
TABLET, CHEWABLE;ORAL LORATADINE PERRIGO PHARMA INTL	5MG	A210033	001	Jun 12, 2019	May NEWA
SUN PHARM	5MG	A210088	001	Apr 16, 2018	Mar CAHN

LORATADINE; PSEUDOEPHEDRINE SULFATE

TABLET, EXTENDED RELEASE;ORAL LORATADINE AND PSEUDOEPHEDRINE SULFATE @ HERITAGE PHARMA	5MG;120MG	A076208	001	Jan 28, 2004	May CAHN
--	-----------	---------	-----	--------------	----------

MINOXIDIL

AEROSOL, FOAM;TOPICAL MINOXIDIL (FOR WOMEN) TARO PHARM	5%	A209074	002	Apr 22, 2019	Apr NEWA
--	----	---------	-----	--------------	----------

NAPROXEN SODIUM

CAPSULE;ORAL NAPROXEN SODIUM >D> >A>	EQ 200MG BASE EQ 200MG BASE	A202807	001	Jan 04, 2019	Jul DISC
		A202807	001	Jan 04, 2019	Jul DISC

NAPROXEN SODIUM; PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL ALEVE-D SINUS & COLD +! BAYER	EQ 200MG BASE;120MG	N021076	001	Nov 29, 1999	Mar CPOT
---	---------------------	---------	-----	--------------	----------

NICOTINE POLACRILEX

TROCHE/LOZENGE;ORAL NICOTINE POLACRILEX >A>	EQ 2MG BASE	A212056	001	Jul 26, 2019	Jul CAHN	
	EQ 4MG BASE	A212056	002	Jul 26, 2019	Jul CAHN	
PLD ACQUISITIONS	EQ 2MG BASE	A207868	001	Feb 07, 2019	Feb NEWA	
	EQ 4MG BASE	A207868	002	Feb 07, 2019	Feb NEWA	
>A>	TEVA PHARMS USA INC	EQ 2MG BASE	A212056	001	Jul 26, 2019	Jul NEWA
>A>		EQ 4MG BASE	A212056	002	Jul 26, 2019	Jul NEWA
@ WATSON LABS INC	EQ 2MG BASE	A209206	001	Jun 26, 2018	Feb DISC	
@	EQ 4MG BASE	A209206	002	Jun 26, 2018	Feb DISC	
@ WATSON LABS TEVA	EQ 2MG BASE	A209519	001	Jul 02, 2018	Feb DISC	
@	EQ 4MG BASE	A209519	002	Jul 02, 2018	Feb DISC	

POLYETHYLENE GLYCOL 3350

FOR SOLUTION;ORAL GLYCOLAX @ LANNETT CO INC	17GM/PACKET 17GM/SCOOPFUL	A090600	001	Oct 06, 2009	Jun DISC
		A090600	002	Oct 06, 2009	Jun DISC

RANITIDINE HYDROCHLORIDE

TABLET;ORAL RANITIDINE HYDROCHLORIDE STRIDES PHARMA	EQ 75MG BASE EQ 150MG BASE	A209160	001	Mar 05, 2018	Apr CAHN
		A209161	001	Feb 22, 2018	Apr CAHN

SODIUM FLUORIDE; TRICLOSAN

PASTE;DENTAL COLGATE TOTAL + @ COLGATE PALMOLIVE	0.24%;0.3%	N020231	001	Jul 11, 1997	Mar DISC
--	------------	---------	-----	--------------	----------

**DRUG PRODUCTS WITH APPROVAL UNDER SECTION 505 OF THE ACT
ADMINISTERED BY THE CENTER FOR BIOLOGICS EVALUATION AND RESEARCH LIST**

CUMULATIVE SUPPLEMENT NUMBER 07 JULY 2019

NO JULY 2019 APPROVALS

ORPHAN PRODUCT DESIGNATIONS AND APPROVALS LIST

The list of Orphan Designations and Approvals is available at:

<https://www.fda.gov/industry/developing-products-rare-diseases-conditions/designating-orphan-product-drugs-and-biological-products>.

**DRUG PRODUCTS WHICH MUST DEMONSTRATE *IN VIVO* BIOAVAILABILITY
ONLY IF PRODUCT FAILS TO ACHIEVE ADEQUATE DISSOLUTION**

NO JULY 2019 ADDITIONS

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ABIRATERONE ACETATE - ABIRATERONE ACETATE</u>						
A 208327 001					PC	Apr 29, 2019
<u>ABIRATERONE ACETATE - YONSA</u>						
N 210308 001	10292990	May 20, 2034	U-2535			
<u>ACALABRUTINIB - CALQUENCE</u>						
N 210259 001	10167291	Jul 01, 2036	DP U-2145			
	10272083	Jan 21, 2035	U-2519			
<u>ACETAMINOPHEN; BENZHYDROCODONE HYDROCHLORIDE - APADAZ</u>						
N 208653 002	8461137	Feb 22, 2031	DS DP			
	8748413	Jul 10, 2030	DS DP			
	8828978	Jul 01, 2030	DP			
	9132125	Jul 01, 2030	DS DP U-2249			
	9549923	Jul 01, 2030	DS DP			
<u>ACETAMINOPHEN; BENZHYDROCODONE HYDROCHLORIDE - APADAZ</u>						
N 208653 003	8461137	Feb 22, 2031	DS DP			
	8748413	Jul 10, 2030	DS DP			
	8828978	Jul 01, 2030	DP			
	9132125	Jul 01, 2030	DS DP U-2249			
	9549923	Jul 01, 2030	DS DP			
<u>ACLIDINIUM BROMIDE - TUDORZA PRESSAIR</u>						
N 202450 001	10034867	Jul 07, 2020	DP U-2513			
	10034867	Jul 07, 2020	DP U-2514			
	10085974	Mar 13, 2029	DP U-2513			
	7078412	Jul 07, 2020	DS DP U-2513			
	9056100	Jul 07, 2020	DP U-2513			
	9333195	Jul 07, 2020	DP U-2513			
	RE46417	Feb 10, 2025	DS DP U-2513			
<u>ACLIDINIUM BROMIDE; FORMOTEROL FUMARATE - DUAKLIR PRESSAIR</u>						
N 210595 001	10034867	Jul 07, 2020	DP U-2513		NC	Mar 29, 2022
	10034867	Jul 07, 2020	DP U-2514			
	10085974	Mar 13, 2029	DP U-2513			
	6681768	Aug 07, 2022	DP			
	7078412	Jul 07, 2020	DS DP U-2513			
	7750023	Jul 07, 2020	DP U-2513			
	8051851	Apr 22, 2027	DP			
	8129405	Jul 07, 2020	DP U-2513			
	9056100	Jul 07, 2020	DP U-2513			
	9333195	Jul 07, 2020	DP U-2513			
	RE46417	Feb 10, 2025	DS DP U-2513			
<u>ACYCLOVIR - AVACLYR</u>						
N 202408 001				ODE-235		Mar 29, 2026
<u>AFATINIB DIMALEATE - GILOTRIE</u>						
N 201292 001				ODE-230		Jan 12, 2025
<u>AFATINIB DIMALEATE - GILOTRIE</u>						
N 201292 002				ODE-230		Jan 12, 2025
<u>AFATINIB DIMALEATE - GILOTRIE</u>						
N 201292 003				ODE-230		Jan 12, 2025
<u>ALBUTEROL SULFATE - PROAIR RESPICLICK</u>						
N 205636 001	10124131	May 18, 2031	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ALBUTEROL SULFATE - PROAIR DIGITALER</u>						
N 205636 002	10022510	May 18, 2031	DP			
	10124131	May 18, 2031	DP			
	6701917	Jun 23, 2021	DP			
	6718972	Jun 23, 2021	DP			
	6748947	Jun 23, 2021	DP			
	6871646	Jun 23, 2021	DP			
	7540282	May 06, 2023	DP			
	8006690	Jun 23, 2021	DP			
	8651103	Mar 26, 2028	DP			
	8978966	Jan 13, 2032	DP			
	9216260	Jun 28, 2031	DP			
	9463288	May 19, 2025	DP			
	9731087	May 18, 2031	DP			
	9782550	Aug 28, 2035	DP			
	9782551	Aug 28, 2035	DP			
<u>ALLOPURINOL; LESINURAD - DUZALLO</u>						
N 209203 001	10183012	Nov 26, 2028	U-2104			
<u>ALLOPURINOL; LESINURAD - DUZALLO</u>						
N 209203 002	10183012	Nov 26, 2028	U-2104			
<u>ALPELISIB - PIQRAY</u>						
N 212526 001	8227462	Sep 28, 2030	DS DP U-2539		NCE	May 24, 2024
	8476268	Sep 10, 2029	DS DP			
<u>ALPELISIB - PIQRAY</u>						
N 212526 002	8227462	Sep 28, 2030	DS DP U-2539		NCE	May 24, 2024
	8476268	Sep 10, 2029	DS DP			
<u>ALPELISIB - PIQRAY</u>						
N 212526 003	8227462	Sep 28, 2030	DS DP U-2539		NCE	May 24, 2024
	8476268	Sep 10, 2029	DS DP			
<u>AMANTADINE HYDROCHLORIDE - OSMOLEX ER</u>						
N 209410 001	10213393	Feb 15, 2038	U-20			
	10213394	Feb 15, 2038	U-2497			
<u>AMANTADINE HYDROCHLORIDE - OSMOLEX ER</u>						
N 209410 002	10213393	Feb 15, 2038	U-20			
	10213394	Feb 15, 2038	U-2497			
<u>AMANTADINE HYDROCHLORIDE - OSMOLEX ER</u>						
N 209410 003	10213393	Feb 15, 2038	U-20			
	10213394	Feb 15, 2038	U-2497			
<u>AMIFAMPRIDINE - Ruzurgi</u>						
N 209321 001				ODE-244		May 06, 2026
<u>AMIKACIN SULFATE - ARIKAYCE KIT</u>						
N 207356 001	10251900	May 15, 2035	U-2414		>A> ODE-214	Sep 28, 2025
					>A> GAIN	Sep 28, 2030
<u>AMINOLEVULINIC ACID HYDROCHLORIDE - LEVULAN</u>						
N 020965 001	>A> 10357567	Jan 12, 2038	U-804			
<u>AMPHENETAMINE SULFATE - EVEKEO ODT</u>						
N 209905 001	10130580	Apr 19, 2024	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>AMPHETAMINE SULFATE - EVEKEO ODT</u> N 209905 002	10130580	Apr 19, 2024	DP			
<u>AMPHETAMINE SULFATE - EVEKEO ODT</u> N 209905 003	10130580	Apr 19, 2024	DP			
<u>AMPHETAMINE SULFATE - EVEKEO ODT</u> N 209905 004	10130580	Apr 19, 2024	DP			
<u>ANGIOTENSIN II ACETATE - GIAPREZA</u> N 209360 001	>A> 10335451 >A> 9572856	Dec 16, 2029 Nov 20, 2030	U-2581 U-2221			
<u>ANGIOTENSIN II ACETATE - GIAPREZA</u> N 209360 002	>A> 10335451 >A> 9572856	Dec 16, 2029 Nov 20, 2030	U-2581 U-2221			
<u>APREMILAST - OTEZLA</u> N 205437 001				>A> I-803		Jul 19, 2022
<u>APREMILAST - OTEZLA</u> N 205437 002				>A> I-803		Jul 19, 2022
<u>APREMILAST - OTEZLA</u> N 205437 003				>A> I-803		Jul 19, 2022
<u>ARIPIPRAZOLE LAUROXIL - ARISTADA</u> N 207533 001	10226458 10238651	Nov 07, 2032 Mar 19, 2035	U-543 U-2402			
<u>ARIPIPRAZOLE LAUROXIL - ARISTADA</u> N 207533 002	10226458 10238651	Nov 07, 2032 Mar 19, 2035	U-543 U-2402			
<u>ARIPIPRAZOLE LAUROXIL - ARISTADA</u> N 207533 003	10226458 10238651	Nov 07, 2032 Mar 19, 2035	U-543 U-2402			
<u>ARIPIPRAZOLE LAUROXIL - ARISTADA</u> N 207533 004	10226458 10238651	Nov 07, 2032 Mar 19, 2035	U-543 U-2402			
<u>AVATROMBOPAG MALEATE - DOPTELET</u> N 210238 001	>A> 8338429 >A> 8765764 >A> 8765764	Jun 30, 2023 Jan 15, 2023 Jan 15, 2023	U-2577 U-2314 U-2578	>A> I-802 >A> ODE-246		Jun 26, 2022 Jun 26, 2026
<u>AVIBACTAM SODIUM; CEFTAZIDIME - AVYCAZ</u> N 206494 001	7112592 7112592 7112592 8178554 8178554 8178554	Feb 24, 2022 Feb 24, 2022 Feb 24, 2022 Jul 24, 2021 Jul 24, 2021 Jul 24, 2021	DS DP U-2244 DS DP U-2508 DS DP U-282 DS DP U-2245 DS DP U-2509 DS DP U-282			
<u>AZELAIC ACID - FINACEA</u> N 207071 001	10322085	Oct 24, 2023	DP			
<u>BALOXAVIR MARBOXIL - XOFLUZA</u> N 210854 001				NCE		Oct 24, 2023

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>BALOXAVIR MARBOXIL - XOFLUZA</u>						
N 210854 002					NCE	Oct 24, 2023
<u>BAZEDOXIFENE ACETATE; ESTROGENS, CONJUGATED - DUAVEE</u>						
N 022247 001	6479535	May 06, 2024	DP U-594			
	6479535	May 06, 2024	DP U-904			
<u>BECLOMETHASONE DIPROPIONATE - QNASL</u>						
N 202813 001	10188811	Oct 21, 2031	DP			
<u>BECLOMETHASONE DIPROPIONATE - QNASL</u>						
N 202813 002	10188811	Oct 21, 2031	DP			
<u>BENZOYL PEROXIDE; CLINDAMYCIN PHOSPHATE - CLINDAMYCIN PHOSPHATE AND BENZOYL PEROXIDE</u>						
A 205128 001					PC	Aug 18, 2019
<u>BENZOYL PEROXIDE; CLINDAMYCIN PHOSPHATE - ACANYA</u>						
N 050819 001	10220049	Jun 03, 2029	DP U-916			
<u>BENZOYL PEROXIDE; CLINDAMYCIN PHOSPHATE - ONEXTON</u>						
N 050819 002	10220049	Jun 03, 2029	DP U-916			
<u>BETAMETHASONE DIPROPIONATE - SERNIVO</u>						
N 208079 001	10179137	Aug 31, 2030	DP U-1858			
<u>BETAMETHASONE DIPROPIONATE; CALCIPOTRIENE - TACLONEX</u>						
N 022185 001					>A> NPP	Jul 25, 2022
					>A> PED	Jan 25, 2023
<u>BETAMETHASONE DIPROPIONATE; CALCIPOTRIENE - ENSTILAR</u>						
N 207589 001	>A> 10130640	Jun 10, 2031	DP		>A> NPP	Jul 30, 2022
	>A> 10130640*PED	Dec 10, 2031			>A> PED	Jan 30, 2023
	>A> 9119781	Jun 10, 2031	DP U-1761			
	>A> 9119781*PED	Dec 10, 2031				
<u>BICTEGRAVIR SODIUM; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE - BIKTARVY</u>						
N 210251 001					NPP	Jun 18, 2022
<u>BOSUTINIB MONOHYDRATE - BOSULIF</u>						
N 203341 003	7417148	Dec 11, 2025	U-1283			
<u>BREMELANOTIDE ACETATE - VYLEESI (AUTOINJECTOR)</u>						
N 210557 001	10286034	Nov 05, 2033	U-2568		NCE	Jun 21, 2024
	6579968	Jun 28, 2020	DS DP			
	6794489	Jun 28, 2020	DS DP			
	9352013	Nov 05, 2033	U-2568			
	9700592	Nov 05, 2033	U-2568			
<u>BREXANOLONE - ZULRESSO</u>						
N 211371 001	10117951	Mar 13, 2029	DP		NCE	Jun 17, 2024
	10251894	Nov 27, 2033	U-2552			
	10322139	Jan 23, 2033	DP			
	7635773	Mar 13, 2029	DP			
	8410077	Mar 13, 2029	DP			
	9200088	Mar 13, 2029	DP			
	9750822	Mar 13, 2029	DP			
<u>BREXIPIRAZOLE - REXULTI</u>						
N 205422 001	10307419	Oct 12, 2032	DP			
	>A> 7888362	Apr 12, 2026	DS			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>BREXPIPRAZOLE - REXULTI</u>						
N 205422 002	10307419 >A> 7888362	Oct 12, 2032 Apr 12, 2026	DP DS			
<u>BREXPIPRAZOLE - REXULTI</u>						
N 205422 003	10307419 >A> 7888362	Oct 12, 2032 Apr 12, 2026	DP DS			
<u>BREXPIPRAZOLE - REXULTI</u>						
N 205422 004	10307419 >A> 7888362	Oct 12, 2032 Apr 12, 2026	DP DS			
<u>BREXPIPRAZOLE - REXULTI</u>						
N 205422 005	10307419 >A> 7888362	Oct 12, 2032 Apr 12, 2026	DP DS			
<u>BRIGATINIB - ALUNBRIG</u>						
N 208772 001	9012462	Jul 31, 2030	DS			
<u>BRIGATINIB - ALUNBRIG</u>						
N 208772 002	9012462	Jul 31, 2030	DS			
<u>BRIGATINIB - ALUNBRIG</u>						
N 208772 003	9012462	Jul 31, 2030	DS			
<u>BRIMONIDINE TARTRATE - ALPHAGAN P</u>						
N 021770 001	10307368	Jul 10, 2021	DP			
<u>BRIMONIDINE TARTRATE - MIRVASO</u>						
N 204708 001	10201517	Jun 13, 2031	DP			
<u>BUDESONIDE - UCERIS</u>						
N 203634 001	10307375	Sep 07, 2031	DP			
<u>BUDESONIDE - ORTIKOS</u>						
N 211929 001	10172802 9707182	Sep 09, 2036 Sep 09, 2036	U-2554 DP U-2554			
<u>BUDESONIDE - ORTIKOS</u>						
N 211929 002	10172802 9707182	Sep 09, 2036 Sep 09, 2036	U-2554 DP U-2554			
<u>BUPRENORPHINE - SUBLOCADE</u>						
N 209819 001	10198218	Jun 06, 2031	U-2489			
<u>BUPRENORPHINE - SUBLOCADE</u>						
N 209819 002	10198218	Jun 06, 2031	U-2489			
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - SUBOXONE</u>						
N 022410 001	10285910	Oct 11, 2022	DP			
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - SUBOXONE</u>						
N 022410 002	10285910	Oct 11, 2022	DP			
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - SUBOXONE</u>						
N 022410 003	10285910	Oct 11, 2022	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - SUBOXONE</u>						
N 022410 004	10285910	Oct 11, 2022	DP			
<u>BUPROPION HYDROCHLORIDE; NALTREXONE HYDROCHLORIDE - CONTRAVE</u>						
N 200063 001	10231964	Jul 02, 2034	U-1583			
	10307376	Nov 08, 2027	U-1585			
<u>CABAZITAXEL - JEVVTANA KIT</u>						
N 201023 001	8927592	Oct 27, 2030	U-1630			
	8927592*PED	Apr 27, 2031				
<u>CABOZANTINIB S-MALATE - CABOMETYX</u>						
N 208692 001	10034873	Jul 18, 2031	U-2488	I-792	Jan 14, 2022	
	8497284	Sep 24, 2024	U-1220	ODE-227	Jan 14, 2026	
	8497284	Sep 24, 2024	U-1480			
	8497284	Sep 24, 2024	U-2488			
<u>CABOZANTINIB S-MALATE - CABOMETYX</u>						
N 208692 002	10034873	Jul 18, 2031	U-2488	I-792	Jan 14, 2022	
	8497284	Sep 24, 2024	U-1220	ODE-227	Jan 14, 2026	
	8497284	Sep 24, 2024	U-1480			
	8497284	Sep 24, 2024	U-2488			
<u>CABOZANTINIB S-MALATE - CABOMETYX</u>						
N 208692 003	10034873	Jul 18, 2031	U-2488	I-792	Jan 14, 2022	
	8497284	Sep 24, 2024	U-1220	ODE-227	Jan 14, 2026	
	8497284	Sep 24, 2024	U-1480			
	8497284	Sep 24, 2024	U-2488			
<u>CALCIFEDIOL - RAYALDEE</u>						
N 208010 001	10213442	Feb 02, 2027	DP			
	10300078	Mar 14, 2034	DP			
>A>	10357502	Mar 14, 2034	DP			
<u>CALCIUM GLUCONATE - CALCIUM GLUCONATE IN SODIUM CHLORIDE</u>						
N 210906 001	>A> 10130646	Jul 25, 2037	DP			
	>A> 10342813	Jul 25, 2037	DP			
<u>CALCIUM GLUCONATE - CALCIUM GLUCONATE IN SODIUM CHLORIDE</u>						
N 210906 002	>A> 10130646	Jul 25, 2037	DP			
	>A> 10342813	Jul 25, 2037	DP			
<u>CANNABIDIOL - EPIDIOLEX</u>						
N 210365 001	>A> 10195159	May 07, 2022	DS			
<u>CARBOPROST TROMETHAMINE - CARBOPROST TROMETHAMINE</u>						
A 211941 001				CGT	Dec 29, 2019	
<u>CARIPRAZINE HYDROCHLORIDE - VRAYLAR</u>						
N 204370 001	7737142	Mar 27, 2027	DS DP U-1750	I-798	May 24, 2022	
	7737142	Mar 27, 2027	DS DP U-2543			
	7737142	Mar 27, 2027	DS DP U-2544			
	7737142	Mar 27, 2027	DS DP U-2545			
	RE47350	Jul 16, 2029	U-1750			
	RE47350	Jul 16, 2029	U-2543			
	RE47350	Jul 16, 2029	U-2544			
	RE47350	Jul 16, 2029	U-2545			
<u>CARIPRAZINE HYDROCHLORIDE - VRAYLAR</u>						
N 204370 002	7737142	Mar 27, 2027	DS DP U-1750	I-798	May 24, 2022	
	7737142	Mar 27, 2027	DS DP U-2543			
	7737142	Mar 27, 2027	DS DP U-2544			
	7737142	Mar 27, 2027	DS DP U-2545			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>CARIPRAZINE HYDROCHLORIDE - VRAYLAR</u>						
N 204370 002	7737142	Mar 27, 2027	DS DP U-1750		I-798	May 24, 2022
	7737142	Mar 27, 2027	DS DP U-2543			
	7737142	Mar 27, 2027	DS DP U-2544			
	7737142	Mar 27, 2027	DS DP U-2545			
<u>CARIPRAZINE HYDROCHLORIDE - VRAYLAR</u>						
N 204370 003	7737142	Mar 27, 2027	DS DP U-1750		I-798	May 24, 2022
	7737142	Mar 27, 2027	DS DP U-2543			
	7737142	Mar 27, 2027	DS DP U-2544			
<u>CARIPRAZINE HYDROCHLORIDE - VRAYLAR</u>						
N 204370 004	7737142	Mar 27, 2027	DS DP U-1750		I-798	May 24, 2022
	7737142	Mar 27, 2027	DS DP U-2543			
	7737142	Mar 27, 2027	DS DP U-2544			
<u>CEFTOLOZANE SULFATE; TAZOBACTAM SODIUM - ZERBAXA</u>						
N 206829 001	10028963	Sep 07, 2032	U-2565			
	10028963	Sep 07, 2032	U-2566			
	9724353	Sep 07, 2032	U-2565			
	9724353	Sep 07, 2032	U-2566			
<u>CERITINIB - ZYKADIA</u>						
N 211225 001	>A> 7153964	Feb 26, 2021	DS DP		NCE	Apr 29, 2019
	>A> 7893074	Apr 25, 2026	DS DP			
	>A> 7964592	Jan 13, 2027	DS DP			
	>A> 8039479	Jun 29, 2030	DS DP			
	>A> 8188276	Jan 31, 2023	DS DP			
	>A> 8377921	Nov 20, 2027	U-1179			
	>A> 8399450	Nov 20, 2027	DS DP			
	>A> 8703787	Feb 02, 2032	U-1179			
	>A> 8835430	Jan 31, 2023	DS DP			
	>A> 9018204	Jan 31, 2023	DS DP			
	>A> 9309229	Jan 18, 2032	DS DP			
	>A> 9416112	Jan 31, 2023	DS DP			
<u>CHLORPHENIRAMINE MALEATE; IBUPROFEN; PSEUDOEPHEDRINE HYDROCHLORIDE - CHILDREN'S ADVIL ALLERGY SINUS</u>						
N 021587 001	10238640	May 25, 2024	DP			
<u>CILASTATIN SODIUM; IMIPENEM; RELEBACTAM - RECARBRIQ</u>						
N 212819 001	>A> 8487093	Nov 19, 2029	DS DP U-2586			
	>A> 8487093	Nov 19, 2029	DS DP U-2587			
<u>CITRIC ACID; MAGNESIUM OXIDE; SODIUM PICOSULFATE - CLENPIO</u>						
N 209589 001	>A> 9827231	Jun 26, 2034	DP U-2162			
<u>CLADRBINE - MAVENCLAD</u>						
N 022561 001	7713947	Oct 16, 2026	U-2520		NP	Mar 29, 2022
	7888328	Apr 11, 2024	DP U-2521			
	8377903	May 31, 2026	U-2522			
	8785415	Apr 11, 2024	DP U-2523			
<u>COCAINE HYDROCHLORIDE - GOPRELTO</u>						
N 209963 001	10231961	Feb 07, 2037	DP			
<u>COLCHICINE - GLOPERBA</u>						
N 210942 001	10226423	Dec 20, 2037	DP			
	9907751	Nov 22, 2036	DP			
<u>COLESEVELAM HYDROCHLORIDE - WELCHOL</u>						
N 210895 001	7229613	Apr 17, 2022	U-2516			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>CROFELEMER - MYTESI</u>						
N 202292 001	7341744 9585868	Jun 02, 2022 Oct 31, 2031	DP U-1319 U-1319			
<u>CYSTEAMINE BITARTRATE - PROCYSBI</u>						
N 203389 001	>A> 10328037	Aug 16, 2036	U-1399			
<u>CYSTEAMINE BITARTRATE - PROCYSBI</u>						
N 203389 002	>A> 10328037	Aug 16, 2036	U-1399			
<u>CYTARABINE; DAUNORUBICIN - VYXEOS</u>						
N 209401 001	10166184	Oct 15, 2032	DP U-2341			
<u>DALFAMPRIDINE - DALFAMPRIDINE</u>						
A 206863 001				PC		Mar 09, 2019
<u>DALTEPARIN SODIUM - FRAGMIN</u>						
N 020287 001				NPP		May 16, 2022
<u>DALTEPARIN SODIUM - FRAGMIN</u>						
N 020287 002				NPP		May 16, 2022
<u>DALTEPARIN SODIUM - FRAGMIN</u>						
N 020287 003				NPP		May 16, 2022
<u>DALTEPARIN SODIUM - FRAGMIN</u>						
N 020287 004				NPP		May 16, 2022
<u>DALTEPARIN SODIUM - FRAGMIN</u>						
N 020287 005				NPP		May 16, 2022
<u>DALTEPARIN SODIUM - FRAGMIN</u>						
N 020287 006				NPP		May 16, 2022
<u>DALTEPARIN SODIUM - FRAGMIN</u>						
N 020287 007			>A> NPP			May 16, 2022
<u>DALTEPARIN SODIUM - FRAGMIN</u>						
N 020287 008			>A> NPP			May 16, 2022
<u>DALTEPARIN SODIUM - FRAGMIN</u>						
N 020287 009			>A> NPP			May 16, 2022
<u>DALTEPARIN SODIUM - FRAGMIN</u>						
N 020287 010			>A> NPP			May 16, 2022
<u>DALTEPARIN SODIUM - FRAGMIN</u>						
N 020287 011			>A> NPP			May 16, 2022
<u>DAPAGLIFLOZIN - FARXIGA</u>						
N 202293 001				M-238		Feb 22, 2022
<u>DAPAGLIFLOZIN - FARXIGA</u>						
N 202293 002				M-238		Feb 22, 2022
<u>DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE; SAXagliptin Hydrochloride - OTERNMET XR</u>						
N 210874 001	6414126 6515117 6936590 7919598	Oct 04, 2020 Oct 04, 2020 Oct 04, 2020 Dec 16, 2029	DS DP U-493 DS DP U-493 U-493 DS	>A> NP		May 02, 2022

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE; SAXagliptin HYDROCHLORIDE - QTERNMET XR</u>						
N 210874 001	8501698	Jun 20, 2027	DP U-493			
	8628799	Jul 13, 2025	DP			
	8716251	Mar 21, 2028	DP			
	9198925	Oct 04, 2020	U-493			
	9616028	Nov 12, 2030	DP			
	RE44186	Jul 31, 2023	DS DP U-493			
<u>DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE; SAXagliptin HYDROCHLORIDE - QTERNMET XR</u>						
N 210874 002	6414126	Oct 04, 2020	DS DP U-493	>A> NP		May 02, 2022
	6515117	Oct 04, 2020	DS DP U-493			
	6936590	Oct 04, 2020	U-493			
	7919598	Dec 16, 2029	DS			
	8501698	Jun 20, 2027	DP U-493			
	8628799	Jul 13, 2025	DP			
	8716251	Mar 21, 2028	DP			
	9198925	Oct 04, 2020	U-493			
	9616028	Nov 12, 2030	DP			
	RE44186	Jul 31, 2023	DS DP U-493			
<u>DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE; SAXagliptin HYDROCHLORIDE - QTERNMET XR</u>						
N 210874 003	6414126	Oct 04, 2020	DS DP U-493	>A> NP		May 02, 2022
	6515117	Oct 04, 2020	DS DP U-493			
	6936590	Oct 04, 2020	U-493			
	7919598	Dec 16, 2029	DS			
	8501698	Jun 20, 2027	DP U-493			
	8628799	Jul 13, 2025	DP			
	8716251	Mar 21, 2028	DP			
	9198925	Oct 04, 2020	U-493			
	9616028	Nov 12, 2030	DP			
	RE44186	Jul 31, 2023	DS DP U-493			
<u>DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE; SAXagliptin HYDROCHLORIDE - QTERNMET XR</u>						
N 210874 004	6414126	Oct 04, 2020	DS DP U-493	>A> NP		May 02, 2022
	6515117	Oct 04, 2020	DS DP U-493			
	6936590	Oct 04, 2020	U-493			
	7919598	Dec 16, 2029	DS			
	8501698	Jun 20, 2027	DP U-493			
	8628799	Jul 13, 2025	DP			
	8716251	Mar 21, 2028	DP			
	9198925	Oct 04, 2020	U-493			
	9616028	Nov 12, 2030	DP			
	RE44186	Jul 31, 2023	DS DP U-493			
<u>DAPAGLIFLOZIN; SAXagliptin HYDROCHLORIDE - QTERN</u>						
N 209091 001	>A> 6414126	Oct 04, 2020	DS DP U-493	>A> I-804		May 02, 2022
	>A> 6515117	Oct 04, 2020	DS DP U-493			
	6936590	Oct 04, 2020	U-1976			
	6936590	Oct 04, 2020	U-1977			
	6936590	Oct 04, 2020	U-493			
	8361972	Mar 21, 2028	U-1976			
	8361972	Mar 21, 2028	U-1977			
	8361972	Mar 21, 2028	U-493			
	8501698	Jun 20, 2027	DP U-1976			
	8501698	Jun 20, 2027	DP U-1977			
	8501698	Jun 20, 2027	DP U-493			
	9198925	Oct 04, 2020	U-1976			
	9198925	Oct 04, 2020	U-1977			
	9198925	Oct 04, 2020	U-493			
	>A> RE44186	Jul 31, 2023	DS DP U-493			
<u>DAPAGLIFLOZIN; SAXagliptin HYDROCHLORIDE - QTERN</u>						
N 209091 002	6414126	Oct 04, 2020	DS DP U-493	>A> NS		May 02, 2022
	6515117	Oct 04, 2020	DS DP U-493			
	6936590	Oct 04, 2020	U-493			
	7919598	Dec 16, 2029	DS			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>DAPAGLIFLOZIN; SAXAGLIPTIN HYDROCHLORIDE - QTERN</u>						
N 209091 002	8221786	Mar 21, 2028	DP			
	8361972	Mar 21, 2028		U-493		
	8501698	Jun 20, 2027		DP U-493		
	8628799	Jul 13, 2025		DP		
	8716251	Mar 21, 2028		DP		
	9198925	Oct 04, 2020		U-493		
	RE44186	Jul 31, 2023	DS DP	U-493		
<u>DAPTOMYCIN - DAPTOMYCIN</u>						
A 212667 001					>A> CGT	Jan 12, 2020
<u>DAROLUTAMIDE - NUBEQA</u>						
N 212099 001					>A> NCE	Jul 30, 2024
<u>DARUNAVIR ETHANOLATE - PREZISTA</u>						
N 021976 002	9889115	Jun 23, 2019		U-1305		
	9889115*PED	Dec 23, 2019				
<u>DARUNAVIR ETHANOLATE - PREZISTA</u>						
N 021976 004	9889115	Jun 23, 2019		U-1305		
	9889115*PED	Dec 23, 2019				
<u>DARUNAVIR ETHANOLATE - PREZISTA</u>						
N 021976 005	9889115	Jun 23, 2019		U-1305		
	9889115*PED	Dec 23, 2019				
<u>DARUNAVIR ETHANOLATE - PREZISTA</u>						
N 021976 006	9889115	Jun 23, 2019		U-1305		
	9889115*PED	Dec 23, 2019				
<u>DARUNAVIR ETHANOLATE - PREZISTA</u>						
N 202895 001	9889115	Jun 23, 2019		U-1305		
	9889115*PED	Dec 23, 2019				
<u>DASABUVIR SODIUM ; OMBITASVIR; PARITAPREVIR; RITONAVIR - VIEKIRA PAK (COPACKAGED)</u>						
N 206619 001	10201542	Oct 18, 2033	DP	U-1753		
<u>DASABUVIR SODIUM; OMBITASVIR; PARITAPREVIR; RITONAVIR - VIEKIRA XR</u>						
N 208624 001	10201541	May 17, 2032	DP			
	10201584	May 17, 2032		U-1889		
<u>DASATINIB - SPRYCEL</u>						
N 021986 001					ODE-225	Dec 21, 2025
					PED	Jun 21, 2026
<u>DASATINIB - SPRYCEL</u>						
N 021986 002					ODE-225	Dec 21, 2025
					PED	Jun 21, 2026
<u>DASATINIB - SPRYCEL</u>						
N 021986 003					ODE-225	Dec 21, 2025
					PED	Jun 21, 2026
<u>DASATINIB - SPRYCEL</u>						
N 021986 004					ODE-225	Dec 21, 2025
					PED	Jun 21, 2026
<u>DASATINIB - SPRYCEL</u>						
N 021986 005					ODE-225	Dec 21, 2025
					PED	Jun 21, 2026

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>DASATINIB - SPRYCEL</u>						
N 021986 006				ODE-225 PED		Dec 21, 2025 Jun 21, 2026
<u>DEFERASIROX - DEFERASIROX</u>						
A 203560 001				PC		Apr 05, 2019
<u>DEFERASIROX - DEFERASIROX</u>						
A 203560 002				PC		Apr 05, 2019
<u>DEFERASIROX - DEFERASIROX</u>						
A 203560 003				PC		Apr 05, 2019
<u>DEFERASIROX - EXJADE</u>						
N 021882 001				M-239 >A> M-241		Dec 12, 2021 Jul 24, 2022
<u>DEFERASIROX - EXJADE</u>						
N 021882 002				M-239 >A> M-241		Dec 12, 2021 Jul 24, 2022
<u>DEFERASIROX - EXJADE</u>						
N 021882 003				M-239 >A> M-241		Dec 12, 2021 Jul 24, 2022
<u>DEFERASIROX - JADENU</u>						
N 206910 001				M-239 >A> M-241		Dec 12, 2021 Jul 24, 2022
<u>DEFERASIROX - JADENU</u>						
N 206910 002				M-239 >A> M-241		Dec 12, 2021 Jul 24, 2022
<u>DEFERASIROX - JADENU</u>						
N 206910 003				M-239 >A> M-241		Dec 12, 2021 Jul 24, 2022
<u>DEFERASIROX - JADENU SPRINKLE</u>						
N 207968 001				M-239 >A> M-241		Dec 12, 2021 Jul 24, 2022
<u>DEFERASIROX - JADENU SPRINKLE</u>						
N 207968 002				M-239 >A> M-241		Dec 12, 2021 Jul 24, 2022
<u>DEFERASIROX - JADENU SPRINKLE</u>						
N 207968 003				M-239 >A> M-241		Dec 12, 2021 Jul 24, 2022
<u>DEFERIPRONE - FERRIPROX</u>						
N 208030 002	7049328 8703156	Jun 28, 2021 Oct 29, 2029		U-735 DP U-735		
<u>DESMOPRESSIN ACETATE - NOCDURNA</u>						
N 022517 001	>A> 10307459	May 07, 2023		DP		
<u>DESMOPRESSIN ACETATE - NOCDURNA</u>						
N 022517 002	>A> 10307459	May 07, 2023		DP		

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>DESONIDE - VERDESO</u>						
N 021978 001	8460641	Aug 13, 2027	DP U-1412			
<u>DEXAMETHASONE - DEXTENZA</u>						
N 208742 001	8409606	May 14, 2030	DP	I-800	Jun 20, 2022	
	8563027	Feb 12, 2030	U-2487	NP	Nov 30, 2021	
	9254267	Sep 11, 2024	DP			
<u>DEXAMETHASONE - DEXYCU KIT</u>						
N 208912 001	10159683	May 23, 2034	DP			
<u>DEXMEDETOMIDINE HYDROCHLORIDE - DEXMEDETOMIDINE HYDROCHLORIDE</u>						
A 208129 001				PC	Nov 30, 2019	
<u>DOCETAXEL - DOCETAXEL</u>						
N 205934 001	9763880	Sep 30, 2033	U-2558			
	9763880	Sep 30, 2033	U-2559			
	9763880	Sep 30, 2033	U-2560			
	9763880	Sep 30, 2033	U-2561			
	9763880	Sep 30, 2033	U-2562			
	9763880	Sep 30, 2033	U-2563			
	9763880	Sep 30, 2033	U-2564			
<u>DOCETAXEL - DOCETAXEL</u>						
N 205934 002	9763880	Sep 30, 2033	U-2558			
	9763880	Sep 30, 2033	U-2559			
	9763880	Sep 30, 2033	U-2560			
	9763880	Sep 30, 2033	U-2561			
	9763880	Sep 30, 2033	U-2562			
	9763880	Sep 30, 2033	U-2563			
	9763880	Sep 30, 2033	U-2564			
<u>DOCETAXEL - DOCETAXEL</u>						
N 205934 003	9763880	Sep 30, 2033	U-2558			
	9763880	Sep 30, 2033	U-2559			
	9763880	Sep 30, 2033	U-2560			
	9763880	Sep 30, 2033	U-2561			
	9763880	Sep 30, 2033	U-2562			
	9763880	Sep 30, 2033	U-2563			
	9763880	Sep 30, 2033	U-2564			
<u>DOLUTEGRAVIR SODIUM; LAMIVUDINE - DOVATO</u>						
N 211994 001	8129385	Oct 05, 2027	DS DP	NC	Apr 08, 2022	
	9242986	Dec 08, 2029	DS DP			
<u>DOXE PIN HYDROCHLORIDE - SILENOR</u>						
N 022036 001	10238620	May 18, 2027	U-620			
<u>DOXE PIN HYDROCHLORIDE - SILENOR</u>						
N 022036 002	10238620	May 18, 2027	U-620			
<u>DOXYCYCLINE - ORACEA</u>						
N 050805 001	10058564	Apr 05, 2022	U-1063			
<u>DRONABINOL - SYNDROS</u>						
N 205525 001	10265293	Aug 06, 2028	DS DP			
<u>DROSPIRENONONE - SLYND</u>						
N 211367 001	>A> 10179140	Jun 28, 2031	U-2547	NP	May 23, 2022	
	>A> 10179140	Jun 28, 2031	U-2553			
	>A> 9603860	Jun 28, 2031	U-2553			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>DULOXETINE HYDROCHLORIDE - DRIZALMA SPRINKLE</u>						
N 212516 001 >A> 9839626		Apr 13, 2037		DP		
<u>DULOXETINE HYDROCHLORIDE - DRIZALMA SPRINKLE</u>						
N 212516 002 >A> 9839626		Apr 13, 2037		DP		
<u>DULOXETINE HYDROCHLORIDE - DRIZALMA SPRINKLE</u>						
N 212516 003 >A> 9839626		Apr 13, 2037		DP		
<u>DULOXETINE HYDROCHLORIDE - DRIZALMA SPRINKLE</u>						
N 212516 004 >A> 9839626		Apr 13, 2037		DP		
<u>ELTROMBOPAG OLAMINE - PROMACTA</u>						
N 022291 001	7160870	Nov 20, 2022	DS DP U-1306			
	7160870	Nov 20, 2022	DS DP U-2451			
	7160870*PED	May 20, 2023				
	7332481	May 24, 2021	U-1306			
	7332481	May 24, 2021	U-2451			
	7332481*PED	Nov 24, 2021				
	7452874	May 24, 2021	DS DP			
	7452874*PED	Nov 24, 2021				
	7473686	May 24, 2021	DS DP U-1306			
	7473686	May 24, 2021	DS DP U-2451			
	7473686*PED	Nov 24, 2021				
	7547719	Jul 13, 2025	DS DP U-1306			
	7547719	Jul 13, 2025	DS DP U-1575			
	7547719	Jul 13, 2025	DS DP U-2451			
	7547719	Jul 13, 2025	DS DP U-2452			
	7547719*PED	Jan 13, 2026				
	7790704	May 24, 2021	U-1306			
	7790704	May 24, 2021	U-2451			
	7790704*PED	Nov 24, 2021				
	7795293	May 21, 2023	U-1306			
	7795293	May 21, 2023	U-2451			
	7795293*PED	Nov 21, 2023				
	8052993	Aug 01, 2027	DP U-1306			
	8052993	Aug 01, 2027	DP U-1575			
	8052993	Aug 01, 2027	DP U-2451			
	8052993	Aug 01, 2027	DP U-930			
	8052993*PED	Feb 01, 2028				
	8828430	Aug 01, 2027	DP U-1306			
	8828430	Aug 01, 2027	DP U-2451			
	8828430*PED	Feb 01, 2028				
<u>ELTROMBOPAG OLAMINE - PROMACTA</u>						
N 022291 002	7160870	Nov 20, 2022	DS DP U-1306			
	7160870	Nov 20, 2022	DS DP U-2451			
	7160870*PED	May 20, 2023				
	7332481	May 24, 2021	U-1306			
	7332481	May 24, 2021	U-2451			
	7332481*PED	Nov 24, 2021				
	7452874	May 24, 2021	DS DP			
	7452874*PED	Nov 24, 2021				
	7473686	May 24, 2021	DS DP U-1306			
	7473686	May 24, 2021	DS DP U-2451			
	7473686*PED	Nov 24, 2021				
	7547719	Jul 13, 2025	DS DP U-1306			
	7547719	Jul 13, 2025	DS DP U-1575			
	7547719	Jul 13, 2025	DS DP U-2451			
	7547719	Jul 13, 2025	DS DP U-2452			
	7547719	Jul 13, 2025	DS DP U-930			
	7547719*PED	Jan 13, 2026				
	7790704	May 24, 2021	U-1306			
	7790704	May 24, 2021	U-2451			
	7790704*PED	Nov 24, 2021				
	7795293	May 21, 2023	U-1306			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ELTROMBOPAG OLAMINE - PROMACTA</u>						
N 022291 002	7795293	May 21, 2023	U-2451			
	7795293	May 21, 2023	U-930			
	7795293*PED	Nov 21, 2023				
	8052994	Aug 01, 2027	DP U-1306			
	8052994	Aug 01, 2027	DP U-2451			
	8052994	Aug 01, 2027	DP U-930			
	8052994*PED	Feb 01, 2028				
	8828430	Aug 01, 2027	DP U-1306			
	8828430	Aug 01, 2027	DP U-2451			
	8828430*PED	Feb 01, 2028				
<u>ELTROMBOPAG OLAMINE - PROMACTA</u>						
N 022291 003	7160870	Nov 20, 2022	DS DP U-1306			
	7160870	Nov 20, 2022	DS DP U-2451			
	7160870*PED	May 20, 2023				
	7332481	May 24, 2021	U-1306			
	7332481	May 24, 2021	U-2451			
	7332481*PED	Nov 24, 2021				
	7452874	May 24, 2021	DS DP			
	7452874*PED	Nov 24, 2021				
	7473686	May 24, 2021	DS DP U-1306			
	7473686	May 24, 2021	DS DP U-2451			
	7473686*PED	Nov 24, 2021				
	7547719	Jul 13, 2025	DS DP U-1306			
	7547719	Jul 13, 2025	DS DP U-1575			
	7547719	Jul 13, 2025	DS DP U-2451			
	7547719	Jul 13, 2025	DS DP U-2452			
	7547719	Jul 13, 2025	DS DP U-930			
	7547719*PED	Jan 13, 2026				
	7790704	May 24, 2021	U-1306			
	7790704	May 24, 2021	U-2451			
	7790704*PED	Nov 24, 2021				
	7795293	May 21, 2023	U-1306			
	7795293	May 21, 2023	U-2451			
	7795293	May 21, 2023	U-930			
	7795293*PED	Nov 21, 2023				
	8062665	Aug 01, 2027	DP U-1306			
	8062665	Aug 01, 2027	DP U-2451			
	8062665	Aug 01, 2027	DP U-930			
	8062665*PED	Feb 01, 2028				
	8828430	Aug 01, 2027	DP U-1306			
	8828430	Aug 01, 2027	DP U-2451			
	8828430*PED	Feb 01, 2028				
<u>ELTROMBOPAG OLAMINE - PROMACTA</u>						
N 022291 004	7160870	Nov 20, 2022	DS DP U-1306			
	7160870	Nov 20, 2022	DS DP U-2451			
	7160870*PED	May 20, 2023				
	7332481	May 24, 2021	U-1306			
	7332481	May 24, 2021	U-2451			
	7332481*PED	Nov 24, 2021				
	7452874	May 24, 2021	DS DP			
	7452874*PED	Nov 24, 2021				
	7473686	May 24, 2021	DS DP U-1306			
	7473686	May 24, 2021	DS DP U-2451			
	7473686*PED	Nov 24, 2021				
	7547719	Jul 13, 2025	DS DP U-1306			
	7547719	Jul 13, 2025	DS DP U-1575			
	7547719	Jul 13, 2025	DS DP U-2451			
	7547719	Jul 13, 2025	DS DP U-2452			
	7547719*PED	Jan 13, 2026				
	7790704	May 24, 2021	U-1306			
	7790704	May 24, 2021	U-2451			
	7790704*PED	Nov 24, 2021				
	7795293	May 21, 2023	U-1306			
	7795293	May 21, 2023	U-2451			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ELTROMBOPAG OLAMINE - PROMACTA</u>						
N 022291 004	7795293*PED	Nov 21, 2023				
	8071129	Aug 01, 2027	DP U-1306			
	8071129	Aug 01, 2027	DP U-2451			
	8071129	Aug 01, 2027	DP U-930			
	8071129*PED	Feb 01, 2028				
	8828430	Aug 01, 2027	DP U-1306			
	8828430	Aug 01, 2027	DP U-2451			
	8828430*PED	Feb 01, 2028				
<u>ELTROMBOPAG OLAMINE - PROMACTA KIT</u>						
N 207027 001	7160870	Nov 20, 2022	DS DP U-1306			
	7160870	Nov 20, 2022	DS DP U-1736			
	7160870*PED	May 20, 2023				
	7332481	May 24, 2021	U-1306			
	7332481	May 24, 2021	U-1736			
	7332481*PED	Nov 24, 2021				
	7473686	May 24, 2021	DS DP U-1306			
	7473686	May 24, 2021	DS DP U-1736			
	7473686*PED	Nov 24, 2021				
	7547719	Jul 13, 2025	DS DP U-1306			
	7547719	Jul 13, 2025	DS DP U-1575			
	7547719	Jul 13, 2025	DS DP U-1736			
	7547719	Jul 13, 2025	DS DP U-2452			
	7547719*PED	Jan 13, 2026				
	7790704	May 24, 2021	U-1306			
	7790704	May 24, 2021	U-1736			
	7790704*PED	Nov 24, 2021				
	7795293	May 21, 2023	U-1306			
	7795293	May 21, 2023	U-1736			
	7795293*PED	Nov 24, 2023				
<u>ELTROMBOPAG OLAMINE - PROMACTA KIT</u>						
N 207027 002	7160870	Nov 20, 2022	DS DP U-1306			
	7160870	Nov 20, 2022	DS DP U-1736			
	7160870*PED	May 20, 2023				
	7332481	May 24, 2021	U-1306			
	7332481	May 24, 2021	U-1736			
	7332481*PED	Nov 24, 2021				
	7452874	May 24, 2021	DS DP			
	7452874*PED	Nov 24, 2021				
	7473686	May 24, 2021	DS DP U-1306			
	7473686	May 24, 2021	DS DP U-1736			
	7473686*PED	Nov 24, 2021				
	7547719	Jul 13, 2025	DS DP U-1306			
	7547719	Jul 13, 2025	DS DP U-1575			
	7547719	Jul 13, 2025	DS DP U-1736			
	7547719	Jul 13, 2025	DS DP U-2452			
	7547719*PED	Jan 13, 2026				
	7790704	May 24, 2021	U-1306			
	7790704	May 24, 2021	U-1736			
	7790704*PED	Nov 24, 2021				
	7795293	May 21, 2023	U-1306			
	7795293	May 21, 2023	U-1736			
	7795293*PED	Nov 21, 2023				
<u>ELUXADOLINE - VIBERZI</u>						
N 206940 001	10188632	Mar 14, 2033	DP			
	10213415	Mar 14, 2025	DS U-2152			
<u>ELUXADOLINE - VIBERZI</u>						
N 206940 002	10188632	Mar 14, 2033	DP			
	10213415	Mar 14, 2025	DS U-2152			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>EMPAGLIFLOZIN - JARDIANCE</u> N 204629 001	10258637	Apr 03, 2034	U-2290			
<u>EMPAGLIFLOZIN - JARDIANCE</u> N 204629 002	10258637	Apr 03, 2034	U-2290			
<u>EMPAGLIFLOZIN; LINAGLIPTIN - GLYXAMBI</u> N 206073 001	10258637	Apr 03, 2034	U-2290			
<u>EMPAGLIFLOZIN; LINAGLIPTIN - GLYXAMBI</u> N 206073 002	10258637	Apr 03, 2034	U-2290			
<u>EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY</u> N 206111 001	10258637	Apr 03, 2034	U-2290			
<u>EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY</u> N 206111 002	10258637	Apr 03, 2034	U-2290			
<u>EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY</u> N 206111 003	10258637	Apr 03, 2034	U-2290			
<u>EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY</u> N 206111 004	10258637	Apr 03, 2034	U-2290			
<u>EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY XR</u> N 208658 001	10258637	Apr 03, 2034	U-2290			
<u>EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY XR</u> N 208658 002	10258637	Apr 03, 2034	U-2290			
<u>EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY XR</u> N 208658 003	10258637	Apr 03, 2034	U-2290			
<u>EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY XR</u> N 208658 004	10258637	Apr 03, 2034	U-2290			
<u>ENASIDENIB MESYLATE - IDHIFA</u> N 209606 001	10294215	Jan 07, 2033	DP U-2087			
<u>ENASIDENIB MESYLATE - IDHIFA</u> N 209606 002	10294215	Jan 07, 2033	DP U-2087			
<u>EPINEPHRINE - AUVI-Q</u> N 201739 001	10314977 10335549	Nov 23, 2024 Apr 30, 2025	DP DP			
<u>EPINEPHRINE - AUVI-Q</u> N 201739 002	10314977 10335549	Nov 23, 2024 Apr 30, 2025	DP DP			
<u>EPINEPHRINE - AUVI-Q</u> N 201739 003	10314977 10335549	Nov 23, 2024 Apr 30, 2025	DP DP			
<u>ERAVACYCLINE DIHYDROCHLORIDE - XERAVA</u> N 211109 001	8796245 8906887	Aug 07, 2029 Dec 28, 2030	U-2380 DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ERDAFITINIB - BALVERSA</u>						
N 212018 001	8895601	May 22, 2031	DS DP		NCE	Apr 12, 2024
	9464071	Apr 28, 2031		U-2518		
	9902714	Mar 26, 2035	DP			
<u>ERDAFITINIB - BALVERSA</u>						
N 212018 002	8895601	May 22, 2031	DS DP		NCE	Apr 12, 2024
	9464071	Apr 28, 2031		U-2518		
	9902714	Mar 26, 2035	DP			
<u>ERDAFITINIB - BALVERSA</u>						
N 212018 003	8895601	May 22, 2031	DS DP		NCE	Apr 12, 2024
	9464071	Apr 28, 2031		U-2518		
	9902714	Mar 26, 2035	DP			
<u>ERLOTINIB HYDROCHLORIDE - ERLOTINIB HYDROCHLORIDE</u>						
A 091002 001					PC	Nov 05, 2019
<u>ERLOTINIB HYDROCHLORIDE - ERLOTINIB HYDROCHLORIDE</u>						
A 091002 002					PC	Nov 05, 2019
<u>ERLOTINIB HYDROCHLORIDE - ERLOTINIB HYDROCHLORIDE</u>						
A 091002 003					PC	Nov 05, 2019
<u>ESKETAMINE HYDROCHLORIDE - SPRAVATO</u>						
N 211243 001	8785500	Jul 09, 2031		U-2502	NCE*	Mar 05, 2024
	9592207	Mar 20, 2027		U-2502		
<u>ESTRADIOL - IMVEXXY</u>						
N 208564 001	10258630	Dec 20, 2033		U-2316		
	10258630	Dec 20, 2033		U-2317		
<u>ESTRADIOL - IMVEXXY</u>						
N 208564 002	10258630	Dec 20, 2033		U-2316		
	10258630	Dec 20, 2033		U-2317		
<u>ESTRADIOL; PROGESTERONE - BIJUVA</u>						
N 210132 001	10206932	Nov 21, 2032		U-2439		
<u>ETELCALCETIDE - PARSABIV</u>						
N 208325 001 >A> 10344765		Jun 27, 2034	DP			
<u>ETELCALCETIDE - PARSABIV</u>						
N 208325 002 >A> 10344765		Jun 27, 2034	DP			
<u>ETELCALCETIDE - PARSABIV</u>						
N 208325 003 >A> 10344765		Jun 27, 2034	DP			
<u>FERRIC CARBOXYMALTOSE - INJECTAFER</u>						
N 203565 001	7754702	Feb 15, 2028	DP	U-1432		
	7754702	Feb 15, 2028	DP	U-2555		
	7754702	Feb 15, 2028	DP	U-2556		
	7754702	Feb 15, 2028	DP	U-2557		
<u>FERRIC CITRATE - AURYXIA</u>						
N 205874 001	10300039	Jul 21, 2030		U-2549	I-790	Nov 06, 2020
	5753706	Feb 03, 2020	DP	U-1577		
<u>FERRIC MALTOL - ACCRUFER</u>						
N 212320 001			>A>	NCE		Jul 25, 2024

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>FERRIC PYROPHOSPHATE CITRATE - TRIFERIC</u>						
N 208551 001	7816404	Apr 17, 2029		U-1656		
	7857977	Sep 08, 2027		U-1656		
<u>FEXOFENADINE HYDROCHLORIDE - CHILDREN'S ALLEGRA ALLERGY</u>						
N 201373 001	8933097	Aug 02, 2030	DP			
<u>FISH OIL TRIGLYCERIDES - OMEGAVEN</u>						
N 210589 001	>A> 9566260	Jul 11, 2025		DP U-2366		
	>A> 9629821	Jul 11, 2025		DP U-2367		
<u>FISH OIL TRIGLYCERIDES - OMEGAVEN</u>						
N 210589 002	>A> 10350186	Nov 05, 2024		U-2585		
	>A> 9566260	Jul 11, 2025		DP U-2366		
	>A> 9629821	Jul 11, 2025		DP U-2367		
<u>FLUTICASONE PROPIONATE - ARMONAIR RESPICLICK</u>						
N 208798 001	10195375	Feb 14, 2031	DP			
<u>FLUTICASONE PROPIONATE - ARMONAIR RESPICLICK</u>						
N 208798 002	10195375	Feb 14, 2031	DP			
<u>FLUTICASONE PROPIONATE - ARMONAIR RESPICLICK</u>						
N 208798 003	10195375	Feb 14, 2031	DP			
<u>FLUTICASONE PROPIONATE - XHANCE</u>						
N 209022 001	10179216	Jul 08, 2033		DP U-2133		
	10252010	Feb 07, 2031		DP		
	10300229	Jul 07, 2035		DP U-2133		
<u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - AIRDUO RESPICLICK</u>						
N 208799 001	10195375	Feb 14, 2031	DP			
<u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - AIRDUO RESPICLICK</u>						
N 208799 002	10195375	Feb 14, 2031	DP			
<u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - AIRDUO RESPICLICK</u>						
N 208799 003	10195375	Feb 14, 2031	DP			
<u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - AIRDUO DIGITALIZER</u>						
N 208799 004	>A> 10022510	May 18, 2031	DP			
	>A> 10124131	May 18, 2031	DP			
	>A> 10195375	Feb 14, 2031	DP			
	>A> 6701917	Jun 23, 2021	DP			
	>A> 6718972	Jun 23, 2021	DP			
	>A> 6748947	Jun 23, 2021	DP			
	>A> 6871646	Jun 23, 2021	DP			
	>A> 7540282	May 06, 2023	DP			
	>A> 8006690	Jun 23, 2021	DP			
	>A> 8651103	Mar 26, 2028	DP			
	>A> 8714149	Feb 25, 2032	DP			
	>A> 8978966	Jan 13, 2032	DP			
	>A> 9066957	Oct 06, 2034	DP U-645			
	>A> 9216260	Jun 28, 2031	DP			
	>A> 9415008	Oct 06, 2034	DP U-645			
	>A> 9463288	May 19, 2025	DP			
	>A> 9616024	Sep 01, 2024	DP			
	>A> 9731087	May 18, 2031	DP			
	>A> 9782550	Aug 28, 2035	DP			
	>A> 9782551	Aug 28, 2035	DP			
	>A> 9987229	Sep 01, 2024	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - AIRDUO DIGITALHALER</u>						
N 208799 005	>A> 10022510	May 18, 2031	DP			
	>A> 10124131	May 18, 2031	DP			
	>A> 10195375	Feb 14, 2031	DP			
	>A> 6701917	Jun 23, 2021	DP			
	>A> 6718972	Jun 23, 2021	DP			
	>A> 6748947	Jun 23, 2021	DP			
	>A> 6871646	Jun 23, 2021	DP			
	>A> 7540282	May 06, 2023	DP			
	>A> 8006690	Jun 23, 2021	DP			
	>A> 8651103	Mar 26, 2028	DP			
	>A> 8714149	Feb 25, 2032	DP			
	>A> 8978966	Jan 13, 2032	DP			
	>A> 9066957	Oct 06, 2034	DP U-645			
	>A> 9216260	Jun 28, 2031	DP			
	>A> 9463288	May 19, 2025	DP			
	>A> 9616024	Sep 01, 2024	DP			
	>A> 9731087	May 18, 2031	DP			
	>A> 9782550	Aug 28, 2035	DP			
	>A> 9782551	Aug 28, 2035	DP			
	>A> 9987229	Sep 01, 2024	DP			
<u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - AIRDUO DIGITALHALER</u>						
N 208799 006	>A> 10022510	May 18, 2031	DP			
	>A> 10124131	May 18, 2031	DP			
	>A> 10195375	Feb 14, 2031	DP			
	>A> 6701917	Jun 23, 2021	DP			
	>A> 6718972	Jun 23, 2021	DP			
	>A> 6748947	Jun 23, 2021	DP			
	>A> 6871646	Jun 23, 2021	DP			
	>A> 7540282	May 06, 2023	DP			
	>A> 8006690	Jun 23, 2021	DP			
	>A> 8651103	Mar 26, 2028	DP			
	>A> 8714149	Feb 25, 2032	DP			
	>A> 8978966	Jan 13, 2032	DP			
	>A> 9066957	Oct 06, 2034	DP U-645			
	>A> 9216260	Jun 28, 2031	DP			
	>A> 9463288	May 19, 2025	DP			
	>A> 9616024	Sep 01, 2024	DP			
	>A> 9731087	May 18, 2031	DP			
	>A> 9782550	Aug 28, 2035	DP			
	>A> 9782551	Aug 28, 2035	DP			
	>A> 9987229	Sep 01, 2024	DP			
<u>FORMOTEROL FUMARATE; GLYCOPYRROLATE - BEVESPI AEROSPHERE</u>						
N 208294 001	8324266	May 28, 2030	U-2546			
	8703806	May 28, 2030	U-2546			
	8808713	May 28, 2030	DP U-2546			
	8815258	Mar 17, 2031	U-2546			
	9415009	May 28, 2030	U-2546			
	9463161	May 28, 2030	DP U-2546			
<u>FORMOTEROL FUMARATE; MOMETASONE FUROATE - DULERA</u>						
N 022518 001	7067502	May 21, 2020	DP U-1068	M-214	Dec 20, 2020	
	7067502*PED	Nov 21, 2020		PED	Jun 20, 2021	
	7566705	May 21, 2020	DP U-1068			
	7566705*PED	Nov 21, 2020				
<u>FORMOTEROL FUMARATE; MOMETASONE FUROATE - DULERA</u>						
N 022518 002	7067502	May 21, 2020	DP U-1068	M-214	Dec 20, 2020	
	7067502*PED	Nov 21, 2020		PED	Jun 20, 2021	
	7566705	May 21, 2020	DP U-1068			
	7566705*PED	Nov 21, 2020				

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>FOSNETUPITANT CHLORIDE HYDROCHLORIDE; PALONOSETRON HYDROCHLORIDE - AKYNZEO</u>						
N 210493 001	10208073	May 23, 2032	U-2301			
<u>FULVESTRANT - FASLODEX</u>						
N 021344 001	6774122	Jan 09, 2021	U-1826			
	6774122	Jan 09, 2021	U-2108			
	6774122	Jan 09, 2021	U-2163			
	6774122	Jan 09, 2021	U-2504			
	6774122	Jan 09, 2021	U-596			
	6774122*PED	Jul 09, 2021				
	7456160	Jan 09, 2021	U-1826			
	7456160	Jan 09, 2021	U-2108			
	7456160	Jan 09, 2021	U-2163			
	7456160	Jan 09, 2021	U-2504			
	7456160	Jan 09, 2021	U-596			
	7456160*PED	Jul 09, 2021				
	8329680	Jan 09, 2021	U-1826			
	8329680	Jan 09, 2021	U-2108			
	8329680	Jan 09, 2021	U-2163			
	8329680	Jan 09, 2021	U-2504			
	8329680	Jan 09, 2021	U-596			
	8329680*PED	Jul 09, 2021				
	8466139	Jan 09, 2021	U-1826			
	8466139	Jan 09, 2021	U-2108			
	8466139	Jan 09, 2021	U-2163			
	8466139	Jan 09, 2021	U-2504			
	8466139	Jan 09, 2021	U-596			
	8466139*PED	Jul 09, 2021				
<u>FULVESTRANT - FULVESTRANT</u>						
N 210326 001	10188663	Feb 14, 2034	DP U-2540			
	9271990	May 17, 2034	DP U-2540			
	9833459	Feb 14, 2034	DP U-2540			
<u>GABAPENTIN ENACARBIL - HORIZANT</u>						
N 022399 001 >A> 6818787		Apr 06, 2025	DS DP			
<u>GABAPENTIN ENACARBIL - HORIZANT</u>						
N 022399 002 >A> 6818787		Apr 06, 2025	DS DP			
<u>GADOBUTROL - GADAVIST</u>						
N 201277 001				>A> I-801		Jul 12, 2022
<u>GADOBUTROL - GADAVIST</u>						
N 201277 002				>A> I-801		Jul 12, 2022
<u>GADOBUTROL - GADAVIST</u>						
N 201277 003				>A> I-801		Jul 12, 2022
<u>GADOBUTROL - GADAVIST</u>						
N 201277 004				>A> I-801		Jul 12, 2022
<u>GADOBUTROL - GADAVIST</u>						
N 201277 005				>A> I-801		Jul 12, 2022
<u>GADOBUTROL - GADAVIST</u>						
N 201277 006				>A> I-801		Jul 12, 2022
<u>GILTERITINIB FUMARATE - XOSPATA</u>						
N 211349 001				NCE		Nov 28, 2023

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>GLECAPREVIR; PIBRENTASVIR - MAVYRET</u>						
N 209394 001	10028937	Jun 10, 2030	U-2141		NPP	Apr 30, 2022
	10028937	Jun 10, 2030	U-2532	ODE-232	ODE-232	Apr 30, 2026
	10039754	Jun 10, 2030	U-2141	ODE-233	ODE-233	Apr 30, 2026
	10039754	Jun 10, 2030	U-2532			
	10286029	Mar 14, 2034	U-2532			
	8648037	Jan 19, 2032	DS DP U-2141			
	8648037	Jan 19, 2032	DS DP U-2532			
	9586978	Jun 10, 2030	U-2141			
	9586978	Jun 10, 2030	U-2532			
<u>GLUCAGON - BAOSIMI</u>						
N 210134 001				>A> NP		Jul 24, 2022
<u>GLYCEROL PHENYLBUTYRATE - RAVICTI</u>						
N 203284 001	10183002	Sep 22, 2030	U-1816			
	10183003	Sep 22, 2030	U-1816			
	10183004	Sep 22, 2030	U-1816			
	10183005	Sep 22, 2030	U-1816			
	10183006	Sep 22, 2030	U-1816			
<u>GRANISETRON - SUSTOIL</u>						
N 022445 001	>A> 10357570	Sep 28, 2024	U-2253			
<u>HALOBETASOL PROPIONATE - BRYHALI</u>						
N 209355 001	6517847	Aug 03, 2020	DP			
	8809307	Nov 02, 2031	DP			
<u>HALOBETASOL PROPIONATE; TAZAROTENE - DUOBRII</u>						
N 209354 001	10251895	Jun 06, 2036	DP		NP	Apr 25, 2022
	6517847	Aug 03, 2020	DP			
	8809307	Nov 02, 2031	DP			
<u>HYDROCODONE BITARTRATE - ZOHYDRO ER</u>						
N 202880 001	>A> 10322120	Jul 25, 2033	DP			
<u>HYDROCODONE BITARTRATE - ZOHYDRO ER</u>						
N 202880 002	>A> 10322120	Jul 25, 2033	DP			
<u>HYDROCODONE BITARTRATE - ZOHYDRO ER</u>						
N 202880 003	>A> 10322120	Jul 25, 2033	DP			
<u>HYDROCODONE BITARTRATE - ZOHYDRO ER</u>						
N 202880 004	>A> 10322120	Jul 25, 2033	DP			
<u>HYDROCODONE BITARTRATE - ZOHYDRO ER</u>						
N 202880 005	>A> 10322120	Jul 25, 2033	DP			
<u>HYDROCODONE BITARTRATE - ZOHYDRO ER</u>						
N 202880 006	>A> 10322120	Jul 25, 2033	DP			
<u>HYDROCODONE BITARTRATE - HYSINGLA ER</u>						
N 206627 001	>A> 10369109	Jun 16, 2023	DP			
<u>HYDROCODONE BITARTRATE - HYSINGLA ER</u>						
N 206627 002	>A> 10369109	Jun 16, 2023	DP			
<u>HYDROCODONE BITARTRATE - HYSINGLA ER</u>						
N 206627 003	>A> 10369109	Jun 16, 2023	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>HYDROCODONE BITARTRATE - HYSINGLA ER</u>						
N 206627 004 >A> 10369109		Jun 16, 2023	DP			
<u>HYDROCODONE BITARTRATE - HYSINGLA ER</u>						
N 206627 005 >A> 10369109		Jun 16, 2023	DP			
<u>HYDROCODONE BITARTRATE - HYSINGLA ER</u>						
N 206627 006 >A> 10369109		Jun 16, 2023	DP			
<u>HYDROCORTISONE VALERATE - HYDROCORTISONE VALERATE</u>						
A 211750 001				CGT		Jul 16, 2019
<u>IBRUTINIB - IMBRUVICA</u>						
N 205552 001 10294231		Jun 03, 2033	DP		M-236	Jan 25, 2022
	10294232	Jun 03, 2033	DP			
<u>IBRUTINIB - IMBRUVICA</u>						
N 205552 002 10294231		Jun 03, 2033	DP		M-236	Jan 25, 2022
	10294232	Jun 03, 2033	DP			
<u>IBRUTINIB - IMBRUVICA</u>						
N 210563 001 10213386		Mar 03, 2036	DP		M-236	Jan 25, 2022
<u>IBRUTINIB - IMBRUVICA</u>						
N 210563 002 10213386		Mar 03, 2036	DP		M-236	Jan 25, 2022
<u>IBRUTINIB - IMBRUVICA</u>						
N 210563 003 10213386		Mar 03, 2036	DP		M-236	Jan 25, 2022
<u>IBRUTINIB - IMBRUVICA</u>						
N 210563 004 10213386		Mar 03, 2036	DP		M-236	Jan 25, 2022
<u>IBUPROFEN - CHILDREN'S ADVIL-FLAVORED</u>						
N 020589 002 10238640		May 25, 2024	DP			
<u>IMIQUIMOD - ZYCLARA</u>						
N 022483 001 10238644		Dec 11, 2029	U-68			
	10238645	Aug 18, 2029	U-1455			
	10238645	Aug 18, 2029	U-172			
<u>INSULIN ASPART - FIASP FLEXTOUCH</u>						
N 208751 002 10220155		Jul 17, 2026	DP			
>A> 10357616		Jan 20, 2026	DP			
7762994		May 23, 2024	DP			
8579869		Jun 30, 2023	DP			
RE46363		Aug 03, 2026	DP			
<u>INSULIN ASPART PROTAMINE RECOMBINANT; INSULIN ASPART RECOMBINANT - NOVOLOG MIX 70/30 FLEXPEN</u>						
N 021172 004 7762994		May 23, 2024	DP			
	8579869	Jun 30, 2023	DP			
<u>INSULIN ASPART RECOMBINANT - NOVOLOG PENFILL</u>						
N 020986 002 7762994		May 23, 2024	DP			
	8579869	Jun 30, 2023	DP			
<u>INSULIN ASPART RECOMBINANT - NOVOLOG FLEXPEN</u>						
N 020986 003 7762994		May 23, 2024	DP			
	8579869	Jun 30, 2023	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>INSULIN ASPART RECOMBINANT - NOVOLOG FLEXPEN</u>						
N 020986 003	7762994	May 23, 2024	DP			
	8579869	Jun 30, 2023	DP			
<u>INSULIN ASPART RECOMBINANT - NOVOLOG FLEXTOUCH</u>						
N 020986 005	10220155	Jul 17, 2026	DP			
	7762994	May 23, 2024	DP			
	8579869	Jun 30, 2023	DP			
<u>INSULIN ASPART: INSULIN DEGLUDEC - RYZODEG 70/30</u>						
N 203313 001	10220155	Jul 17, 2026	DP			
>A>	10357616	Jan 20, 2026	DP			
	7762994	May 23, 2024	DP			
	8579869	Jun 30, 2023	DP			
<u>INSULIN DEGLUDEC - TRESIBA</u>						
N 203314 001	10220155	Jul 17, 2026	DP			
	7762994	May 23, 2024	DP			
	8579869	Jun 30, 2023	DP			
<u>INSULIN DEGLUDEC - TRESIBA</u>						
N 203314 002	10220155	Jul 17, 2026	DP			
	7762994	May 23, 2024	DP			
	8579869	Jun 30, 2023	DP			
<u>INSULIN DEGLUDEC; LIRAGLUTIDE - XULTOPHY 100/3.6</u>						
N 208583 001	10220155	Jul 17, 2026	DP			
>A>	10357616	Jan 20, 2026	DP			
	6268343	Aug 22, 2022	DS DP			
	6268343*PED	Feb 22, 2023				
	6899699	Jan 02, 2022	DP			
	7615532	Jun 28, 2029	DS DP			
	7762994	May 23, 2024	DP			
	7762994*PED	Nov 23, 2024				
	8579869	Jun 30, 2023	DP			
	8579869*PED	Dec 30, 2023				
	8672898	Jan 02, 2022	DP			
	8684969	Oct 20, 2025	DP			
	8846618	Jun 27, 2022	DS DP			
	8846618*PED	Dec 27, 2022				
	8920383	Jul 17, 2026	DP			
	8937042	May 05, 2029	DP			
	9108002	Jan 20, 2026	DP			
	9132239	Feb 01, 2032	DP			
	9457154	Sep 27, 2027	DP			
	9486588	Jan 02, 2022	DP			
	9616180	Jan 20, 2026	DP			
	9687611	Feb 27, 2027	DP			
	9775953	Jul 17, 2026	DP			
	9861757	Jan 20, 2026	DP			
	RE46363	Aug 03, 2026	DP			
<u>INSULIN DETEMIR RECOMBINANT - LEVEMIR FLEXTOUCH</u>						
N 021536 005	10220155	Jul 17, 2026	DP			
>A>	10357616	Jan 20, 2026	DP			
	7762994	May 23, 2024	DP			
	8579869	Jun 30, 2023	DP			
<u>INSULIN GLARGINE; LIXISENATIDE - SOLIQUA 100/33</u>						
N 208673 001	9011391	Mar 26, 2024	U-1923			
	9011391	Mar 26, 2024	U-2496			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>INSULIN RECOMBINANT HUMAN - AFREZZA</u>						
N 022472 001	10201672 >A> 10342938	Aug 02, 2030 Jun 12, 2029	DP			
<u>INSULIN RECOMBINANT HUMAN - AFREZZA</u>						
N 022472 002	10201672 >A> 10342938	Aug 02, 2030 Jun 12, 2029	DP			
<u>INSULIN RECOMBINANT HUMAN - AFREZZA</u>						
N 022472 003	10201672 >A> 10342938	Aug 02, 2030 Jun 12, 2029	DP			
<u>ISOPROPYL ALCOHOL - ZURAGARD</u>						
N 210872 001					NP	Apr 26, 2022
<u>IVABRADINE - CORLANOR</u>						
N 209964 001	7361649 7361650 7867996 7879842	Feb 22, 2026 Feb 22, 2026 Feb 22, 2026 Feb 22, 2026	DS DP U-1694 DS DP U-1694 DS DP U-1694 DS DP U-1694		NCE NP ODE-234 PED PED PED	Apr 15, 2020 Apr 22, 2022 Apr 22, 2026 Oct 15, 2020 Oct 22, 2022 Oct 22, 2026
<u>IVABRADINE HYDROCHLORIDE - CORLANOR</u>						
N 206143 001	7361649 7361649*PED 7361650 7361650*PED 7867996 7867996*PED 7879842 7879842*PED	Feb 22, 2026 Aug 22, 2026 Feb 22, 2026 Aug 22, 2026 Feb 22, 2026 Aug 22, 2026 Feb 22, 2026 Aug 22, 2026	DS DP U-1694 DS DP U-1694		NCE PED	Apr 15, 2020 Oct 15, 2020
<u>IVABRADINE HYDROCHLORIDE - CORLANOR</u>						
N 206143 002	7361649 7361649*PED 7361650 7361650*PED 7867996 7867996*PED 7879842 7879842*PED	Feb 22, 2026 Aug 22, 2026 Feb 22, 2026 Aug 22, 2026 Feb 22, 2026 Aug 22, 2026 Feb 22, 2026 Aug 22, 2026	DS DP U-1694 DS DP U-1694		NCE PED	Apr 15, 2020 Oct 15, 2020
<u>IVACAFTOR - KALYDECO</u>						
N 203188 002					NPP ODE-186 ODE-187 ODE-189 ODE-190 ODE-199	Jul 31, 2020 Feb 21, 2021 Dec 29, 2021 Jul 31, 2024 May 17, 2024 Aug 15, 2025
<u>IVACAFTOR - KALYDECO</u>						
N 207925 001	10272046 8324242 8324242 8324242 8354427 8354427 8354427 8629162 8629162 9670163 9670163	Feb 27, 2033 Aug 05, 2027 Aug 05, 2027 Aug 05, 2027 Jul 06, 2026 Jul 06, 2026 Jul 06, 2026 Jun 24, 2025 Jun 24, 2025 Dec 28, 2026 Dec 28, 2026	DP U-2531 U-1311 U-1906 U-2527 U-1311 U-1905 U-2528 U-2234 U-2529 DP U-1311 DP U-2530	>A>	NPP ODE-236	Apr 29, 2022 Apr 29, 2026

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>IVACAFTOR - KALYDECO</u>						
N 207925 002	10272046	Feb 27, 2033	DP U-2531	>A> NPP	Apr 29, 2022	
	8324242	Aug 05, 2027	U-1311	ODE-236	Apr 29, 2026	
	8324242	Aug 05, 2027	U-1906			
	8324242	Aug 05, 2027	U-2527			
	8354427	Jul 06, 2026	U-1311			
	8354427	Jul 06, 2026	U-1905			
	8354427	Jul 06, 2026	U-2528			
	8629162	Jun 24, 2025	U-2234			
	8629162	Jun 24, 2025	U-2529			
	9670163	Dec 28, 2026	DP U-1311			
	9670163	Dec 28, 2026	DP U-2530			
<u>IVACAFTOR - KALYDECO</u>						
N 207925 003	10272046	Feb 27, 2033	DP U-2531	NPP	Jul 31, 2020	
	7495103	May 20, 2027	DS DP	>A> NPP	Apr 29, 2022	
	8324242	Aug 05, 2027	U-1311	>A> ODE-188	Mar 17, 2022	
	8324242	Aug 05, 2027	U-1906	>A> ODE-189	Jul 31, 2024	
	8324242	Aug 05, 2027	U-2527	>A> ODE-190	May 17, 2024	
	8354427	Jul 06, 2026	U-1311	>A> ODE-199	Aug 15, 2025	
	8354427	Jul 06, 2026	U-1905	ODE-236	Apr 29, 2026	
	8354427	Jul 06, 2026	U-2528			
	8410274	Dec 28, 2026	DP			
	8629162	Jun 24, 2025	U-2234			
	8629162	Jun 24, 2025	U-2529			
	8754224	Dec 28, 2026	DS DP			
	8883206	Feb 27, 2033	DP			
	9670163	Dec 28, 2026	DP U-1311			
	9670163	Dec 28, 2026	DP U-2530			
<u>IVACAFTOR; IVACAFTOR, TEZACAFTOR - SYMDEKO (COPACKAGED)</u>						
N 210491 001	>A> 10022352	Apr 09, 2027	DP U-2343	>A> NPP	Jun 21, 2022	
	>A> 10022352	Apr 09, 2027	DP U-2573	>A> ODE-247	Jun 21, 2026	
	>A> 10058546	Jul 15, 2033	U-2399			
	>A> 10058546	Jul 15, 2033	U-2572			
	>A> 10081621	Mar 25, 2031	DP U-2420			
	>A> 10081621	Mar 25, 2031	DP U-2571			
	>A> 10206877	Apr 14, 2035	DP U-2498			
	>A> 10206877	Apr 14, 2035	DP U-2570			
	>A> 10239867	Apr 09, 2027	DS DP U-2512			
	>A> 10239867	Apr 09, 2027	DS DP U-2569			
	>A> 9931334	Dec 28, 2026	DP U-2275			
	>A> 9931334	Dec 28, 2026	DP U-2575			
	>A> 9974781	Apr 09, 2027	DP U-2318			
	>A> 9974781	Apr 09, 2027	DP U-2574			
<u>IVACAFTOR; IVACAFTOR, TEZACAFTOR - SYMDEKO (COPACKAGED)</u>						
N 210491 002	>A> 10022352	Apr 09, 2027	DP U-2343	>A> NCE	Feb 12, 2023	
	>A> 10022352	Apr 09, 2027	DP U-2573	>A> NPP	Jun 21, 2022	
	>A> 10058546	Jul 15, 2033	U-2399	>A> ODE-173	Feb 12, 2025	
	>A> 10058546	Jul 15, 2033	U-2572	>A> ODE-247	Jun 21, 2026	
	>A> 10081621	Mar 25, 2031	DP U-2420			
	>A> 10081621	Mar 25, 2031	DP U-2571			
	>A> 10206877	Apr 14, 2035	DP U-2498			
	>A> 10206877	Apr 14, 2035	DP U-2570			
	>A> 10239867	Apr 09, 2027	DS DP U-2512			
	>A> 10239867	Apr 09, 2027	DS DP U-2569			
	>A> 7495103	May 20, 2027	DS DP			
	>A> 7645789	May 01, 2027	DS DP			
	>A> 7776905	Jun 03, 2027	DS DP			
	>A> 8324242	Aug 05, 2027	U-2246			
	>A> 8410274	Dec 28, 2026	DP			
	>A> 8415387	Nov 12, 2027	U-2246			
	>A> 8598181	May 01, 2027	U-2246			
	>A> 8623905	May 01, 2027	DS DP			
	>A> 8629162	Jun 24, 2025	U-2247			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>IVACAFTOR; IVACAFTOR, TEZACAFATOR - SYMDEKO (COPACKAGED)</u>						
N 210491 002	>A> 8754224	Dec 28, 2026	DS DP			
	>A> 9012496	Jul 15, 2033		U-2248		
	>A> 9670163	Dec 28, 2026		DP U-2246		
	>A> 9931334	Dec 28, 2026		DP U-2275		
	>A> 9931334	Dec 28, 2026		DP U-2575		
	>A> 9974781	Apr 09, 2027		DP U-2318		
	>A> 9974781	Apr 09, 2027		DP U-2574		
<u>IVERMECTIN - SOOLANTRA</u>						
N 206255 001	10206939	Mar 13, 2034		U-1631		
<u>IVOSIDENIB - TIBSOVO</u>						
N 211192 001	9474779	Aug 19, 2033	DS DP	U-2350	ODE-242	May 02, 2026
	9474779	Aug 19, 2033	DS DP	U-2533		
	9474779	Aug 19, 2033	DS DP	U-2534		
	9850277	Jan 18, 2033	DS DP	U-2350		
	9850277	Jan 18, 2033	DS DP	U-2533		
	9850277	Jan 18, 2033	DS DP	U-2534		
	9968595	Mar 13, 2035		DP U-2351		
	9968595	Mar 13, 2035		DP U-2533		
	9968595	Mar 13, 2035		DP U-2534		
<u>LAROTRECTINIB SULFATE - VITRAKVI</u>						
N 210861 001	10172861	Nov 16, 2035	DS DP		NCE	Nov 26, 2023
	10285993	Nov 16, 2035		U-2470		
<u>LAROTRECTINIB SULFATE - VITRAKVI</u>						
N 210861 002	10172861	Nov 16, 2035	DS DP		NCE	Nov 26, 2023
	10285993	Nov 16, 2035		U-2470		
<u>LAROTRECTINIB SULFATE - VITRAKVI</u>						
N 211710 001	10172861	Nov 16, 2035	DS		NCE	Nov 26, 2023
<u>LATANOPROST - XELPROS</u>						
N 206185 001	9539262	Oct 15, 2028		U-2400		
<u>LATANOPROST; NETARSUDIL DIMESYLATE - ROCKLATAN</u>						
N 208259 001	10174017	Jan 27, 2030	DS DP	U-1524	NC	Mar 12, 2022
	8394826	Nov 10, 2030	DS DP	U-1524	NCE	Dec 18, 2022
	8450344	Jul 11, 2026	DS DP	U-1524		
	9096569	Jul 11, 2026	DS DP	U-1524		
	9415043	Mar 14, 2034		DS		
	9931336	Mar 14, 2034	DS DP	U-1524		
	9993470	Mar 14, 2034	DS DP	U-1524		
<u>LEDIPASVIR; SOFOBEUVIR - HARVONI</u>						
N 205834 001	>A> 10039779	Jan 30, 2034	DS DP	U-2369	>A> ODE-136	Apr 07, 2024
	>A> 10039779	Jan 30, 2034	DS DP	U-2370	>A> PED	Oct 07, 2024
	>A> 10039779*PED	Jul 30, 2034				
	>A> 7964580	Mar 26, 2029	DS DP	U-1470		
	>A> 7964580*PED	Sep 26, 2029				
	>A> 8088368	May 12, 2030	DS DP			
	>A> 8088368*PED	Nov 12, 2030				
	>A> 8273341	May 12, 2030		U-1470		
	>A> 8273341*PED	Nov 12, 2030				
	>A> 8334270	Mar 21, 2028	DS DP	U-1470		
	>A> 8334270*PED	Sep 21, 2028				
	>A> 8580765	Mar 21, 2028	DS DP	U-1470		
	>A> 8580765*PED	Sep 21, 2028				
	>A> 8618076	Dec 11, 2030	DS DP	U-1470		
	>A> 8618076*PED	Jun 11, 2031				
	>A> 8633309	Mar 26, 2029	DS DP	U-1470		
	>A> 8633309*PED	Sep 26, 2029				

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>LEDIPASVIR; SOFOBUVIR - HARVONI</u>						
N 205834 001	>A> 8735372	Mar 21, 2028	U-1470			
	>A> 8735372*PED	Sep 21, 2028				
	>A> 8822430	May 12, 2030	DS DP U-1470			
	>A> 8822430*PED	Nov 12, 2030				
	>A> 8841278	May 12, 2030	DP U-1470			
	>A> 8841278*PED	Nov 12, 2030				
	>A> 8889159	Mar 26, 2029	DP U-1470			
	>A> 8889159*PED	Sep 26, 2029				
	>A> 9085573	Mar 21, 2028	DS DP U-1470			
	>A> 9085573*PED	Sep 21, 2028				
	>A> 9284342	Sep 13, 2030	DS DP U-1470			
	>A> 9284342*PED	Mar 13, 2031				
	>A> 9393256	Sep 14, 2032	U-1470			
	>A> 9393256*PED	Mar 14, 2033				
	>A> 9511056	May 12, 2030	DP U-1470			
	>A> 9511056*PED	Nov 12, 2030				
<u>LENALIDOMIDE - REVLIMID</u>						
N 021880 001	7189740	Apr 11, 2023	U-1982	I-796	May 28, 2022	
	7468363	Oct 07, 2023	U-1983	I-797	May 28, 2022	
	7468363	Oct 07, 2023	U-2550	ODE-241	May 28, 2026	
	7468363	Oct 07, 2023	U-2551	ODE-245	May 28, 2026	
	7968569	Oct 07, 2023	U-1984			
	8404717	Apr 11, 2023	U-1982			
	8492406	Oct 07, 2023	U-2550			
	8530498	May 15, 2023	U-1984			
	8648095	May 15, 2023	U-1984			
	8741929	Mar 08, 2028	U-1983			
	9056120	Apr 11, 2023	U-1982			
	9101621	May 15, 2023	U-1985			
	9101622	May 15, 2023	U-1986			
	9155730	May 15, 2023	U-2550			
	9393238	May 15, 2023	U-2550			
<u>LENALIDOMIDE - REVLIMID</u>						
N 021880 002	7189740	Apr 11, 2023	U-1982	I-796	May 28, 2022	
	7468363	Oct 07, 2023	U-1983	I-797	May 28, 2022	
	7468363	Oct 07, 2023	U-2550	ODE-241	May 28, 2026	
	7468363	Oct 07, 2023	U-2551	ODE-245	May 28, 2026	
	7968569	Oct 07, 2023	U-1984			
	8404717	Apr 11, 2023	U-1982			
	8492406	Oct 07, 2023	U-2550			
	8530498	May 15, 2023	U-1984			
	8648095	May 15, 2023	U-1984			
	8741929	Mar 08, 2028	U-1983			
	9056120	Apr 11, 2023	U-1982			
	9101621	May 15, 2023	U-1985			
	9101622	May 15, 2023	U-1986			
	9155730	May 15, 2023	U-2550			
	9393238	May 15, 2023	U-2550			
<u>LENALIDOMIDE - REVLIMID</u>						
N 021880 003	7189740	Apr 11, 2023	U-1982	I-796	May 28, 2022	
	7468363	Oct 07, 2023	U-1983	I-797	May 28, 2022	
	7468363	Oct 07, 2023	U-2550	ODE-241	May 28, 2026	
	7468363	Oct 07, 2023	U-2551	ODE-245	May 28, 2026	
	7968569	Oct 07, 2023	U-1984			
	8404717	Apr 11, 2023	U-1982			
	8492406	Oct 07, 2023	U-2550			
	8530498	May 15, 2023	U-1984			
	8648095	May 15, 2023	U-1984			
	8741929	Mar 08, 2028	U-1983			
	9056120	Apr 11, 2023	U-1982			
	9101621	May 15, 2023	U-1985			
	9101622	May 15, 2023	U-1986			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LENALIDOMIDE - REVLIMID</u>						
N 021880 003	9155730	May 15, 2023	U-2550			
	9393238	May 15, 2023	U-2550			
<u>LENALIDOMIDE - REVLIMID</u>						
N 021880 004	7189740	Apr 11, 2023	U-1982	I-796	May 28, 2022	
	7468363	Oct 07, 2023	U-1983	I-797	May 28, 2022	
	7468363	Oct 07, 2023	U-2550	ODE-241	May 28, 2026	
	7468363	Oct 07, 2023	U-2551	ODE-245	May 28, 2026	
	7968569	Oct 07, 2023	U-1984			
	8404717	Apr 11, 2023	U-1982			
	8492406	Oct 07, 2023	U-2550			
	8530498	May 15, 2023	U-1984			
	8648095	May 15, 2023	U-1984			
	8741929	Mar 08, 2028	U-1983			
	9056120	Apr 11, 2023	U-1982			
	9101621	May 15, 2023	U-1985			
	9101622	May 15, 2023	U-1986			
	9155730	May 15, 2023	U-2550			
	9393238	May 15, 2023	U-2550			
<u>LENALIDOMIDE - REVLIMID</u>						
N 021880 005	7189740	Apr 11, 2023	U-1982	I-796	May 28, 2022	
	7468363	Oct 07, 2023	U-1983	I-797	May 28, 2022	
	7468363	Oct 07, 2023	U-2550	ODE-241	May 28, 2026	
	7468363	Oct 07, 2023	U-2551	ODE-245	May 28, 2026	
	7968569	Oct 07, 2023	U-1984			
	8404717	Apr 11, 2023	U-1982			
	8492406	Oct 07, 2023	U-2550			
	8530498	May 15, 2023	U-1984			
	8648095	May 15, 2023	U-1984			
	8741929	Mar 08, 2028	U-1983			
	9056120	Apr 11, 2023	U-1982			
	9101621	May 15, 2023	U-1985			
	9101622	May 15, 2023	U-1986			
	9155730	May 15, 2023	U-2550			
	9393238	May 15, 2023	U-2550			
<u>LENALIDOMIDE - REVLIMID</u>						
N 021880 006	7189740	Apr 11, 2023	U-1982	I-796	May 28, 2022	
	7468363	Oct 07, 2023	U-1983	I-797	May 28, 2022	
	7468363	Oct 07, 2023	U-2550	ODE-241	May 28, 2026	
	7468363	Oct 07, 2023	U-2551	ODE-245	May 28, 2026	
	7968569	Oct 07, 2023	U-1984			
	8404717	Apr 11, 2023	U-1982			
	8492406	Oct 07, 2023	U-2550			
	8530498	May 15, 2023	U-1984			
	8648095	May 15, 2023	U-1984			
	8741929	Mar 08, 2028	U-1983			
	9056120	Apr 11, 2023	U-1982			
	9101621	May 15, 2023	U-1985			
	9101622	May 15, 2023	U-1986			
	9155730	May 15, 2023	U-2550			
	9393238	May 15, 2023	U-2550			
<u>LENVATINIB MESYLATE - LENVIMA</u>						
N 206947 001	10259791	Aug 26, 2035	DS			
<u>LENVATINIB MESYLATE - LENVIMA</u>						
N 206947 002	10259791	Aug 26, 2035	DS			
<u>LESINURAD - ZURAMPIC</u>						
N 207988 001	10183012	Nov 26, 2028	U-2311			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>LETROZOLE; RIBOCICLIB SUCCINATE - KISQALI FEMARA CO-PACK (COPACKAGED)</u>						
N 209935 001	8962630	Dec 09, 2029	U-2505			
	9416136	Aug 20, 2029	U-2505			
	9868739	Nov 09, 2031	U-2505			
<u>LEVETIRACETAM - ELEPSIA XR</u>						
N 204417 001	8470367	Oct 31, 2027	DP			
<u>LEVETIRACETAM - ELEPSIA XR</u>						
N 204417 002	8470367	Oct 31, 2027	DP			
<u>LEVODOPA - INBRIJA</u>						
N 209184 001	6514482	Sep 19, 2020	DP U-2484		NP	Dec 21, 2021
	6613308	Sep 19, 2020	U-2484			
	6858199	Nov 04, 2021	U-2485			
	6921528	Jun 19, 2020	U-2485			
	6979437	Sep 19, 2020	U-2484			
	7146978	Apr 16, 2021	U-2486			
	7182961	Feb 22, 2024	DP			
	7384649	Nov 20, 2022	DP			
	7556798	Nov 04, 2021	U-2485			
	8404276	Mar 19, 2023	U-2484			
	8545878	Nov 16, 2032	DP			
	8586093	Mar 19, 2023	U-2484			
	8628754	Jun 19, 2020	U-2485			
	8685442	Nov 16, 2032	DP			
	8945612	Nov 16, 2032	DP			
	9155699	Mar 19, 2023	DP			
	9393210	Nov 16, 2032	DP			
	RE43711	Feb 03, 2029	U-2484			
<u>LEVOTHYROXINE SODIUM - LEVOTHYROXINE SODIUM</u>						
N 210632 001	9782376	Dec 01, 2036	DP			
<u>LEVOTHYROXINE SODIUM - LEVOTHYROXINE SODIUM</u>						
N 210632 002	9782376	Dec 01, 2036	DP			
<u>LEVOTHYROXINE SODIUM - LEVOTHYROXINE SODIUM</u>						
N 210632 003	9782376	Dec 01, 2036	DP			
<u>LINACLOTIDE - LINZESS</u>						
N 202811 001	8802628	Oct 30, 2031	DP			
<u>LINACLOTIDE - LINZESS</u>						
N 202811 002	8802628	Oct 30, 2031	DP			
<u>LIRAGLUTIDE RECOMBINANT - VICTOZA</u>						
N 022341 001	6268343	Aug 22, 2022	DS DP U-968		NPP	Jun 17, 2022
	6268343*PED	Feb 22, 2023			PED	Dec 17, 2022
	7762994	May 23, 2024	DP			
	7762994*PED	Nov 23, 2024				
	8114833	Aug 13, 2025	DS DP			
	8114833*PED	Feb 13, 2026				
	8579869	Jun 30, 2023	DP			
	8579869*PED	Dec 30, 2023				
	8846618	Jun 27, 2022	DP			
	8846618*PED	Dec 27, 2022				
	9265893	Sep 23, 2032	DP			
	9265893*PED	Mar 23, 2033				
	9968659	Jan 09, 2037	U-2313			
	9968659*PED	Jul 09, 2037				
	RE41956	Jan 21, 2021	DP			
	RE41956*PED	Jul 21, 2021				

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>LIRAGLUTIDE RECOMBINANT - SAXENDA</u>						
N 206321 001	10220155	Jul 17, 2026	DP			
	10220155*PED	Jan 17, 2027				
>A>	10357616	Jan 20, 2026	DP			
	6268343	Aug 22, 2022	DS DP U-1255			
	6268343*PED	Feb 22, 2023				
	6899699	Jan 01, 2022	DP			
	6899699*PED	Jul 01, 2022				
	7762994	May 23, 2024	DP			
	7762994*PED	Nov 23, 2024				
	8114833	Aug 13, 2025	DP			
	8114833*PED	Feb 13, 2026				
	8579869	Jun 30, 2023	DP			
	8579869*PED	Dec 30, 2023				
	8672898	Jan 02, 2022	DP			
	8672898*PED	Jul 02, 2022				
	8684969	Oct 20, 2025	DP			
	8684969*PED	Apr 20, 2026				
	8846618	Jun 27, 2022	DP			
	8846618*PED	Dec 27, 2022				
	8920383	Jul 17, 2026	DP			
	8920383*PED	Jan 17, 2027				
	9108002	Jan 26, 2026	DP			
	9108002*PED	Jul 26, 2026				
	9132239	Feb 01, 2032	DP			
	9132239*PED	Aug 01, 2032				
	9457154	Sep 27, 2027	DP			
	9457154*PED	Mar 27, 2028				
	9486588	Jan 02, 2022	DP			
	9486588*PED	Jul 02, 2022				
	9616180	Jan 20, 2026	DP			
	9616180*PED	Jul 20, 2026				
	9687611	Feb 27, 2027	DP			
	9687611*PED	Aug 27, 2027				
	9775953	Jul 17, 2026	DP			
	9775953*PED	Jan 17, 2027				
	9861757	Jan 20, 2026	DP			
	9861757*PED	Jul 20, 2026				
	9968659	Jan 09, 2037	U-2438			
	9968659*PED	Jul 09, 2037				
	RE46363	Aug 03, 2026	DP			
	RE46363*PED	Feb 03, 2027				
<u>LISINOPRIL - OBRELIS</u>						
N 208401 001	10265370	Nov 06, 2035	DP			
<u>LIXISENATIDE - ADLYXIN</u>						
N 208471 001	10201663	Mar 10, 2034	DP			
<u>LIXISENATIDE - ADLYXIN</u>						
N 208471 002	10201663	Mar 10, 2034	DP			
<u>LORCASERIN HYDROCHLORIDE - BELVIQ XR</u>						
N 208524 001	10226471	Aug 31, 2031	DP			
<u>LOTEPREDNOL ETABONATE - LOTEMAX SM</u>						
N 208219 001					NS	Feb 22, 2022
<u>LOTEPREDNOL ETABONATE - INVELTYS</u>						
N 210565 001	10058511	May 03, 2033	DP U-2492			
	9056057	May 03, 2033	DP U-2491			
	9393213	May 03, 2033	DP			
	9532955	May 03, 2033	U-2491			
	9737491	May 03, 2033	U-2492			
	9827191	May 03, 2033	DP U-2493			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>LOTEPREDNOL ETABONATE - INVELTYS</u>						
N 210565 001	10058511	May 03, 2033	DP U-2492			
	9056057	May 03, 2033	DP U-2491			
	9393213	May 03, 2033	DP			
	9532955	May 03, 2033	U-2491			
	9737491	May 03, 2033	U-2492			
	9827191	May 03, 2033	DP U-2493			
<u>LUBIPROSTONE - AMITIZA</u>						
N 021908 001	8779187	Jan 23, 2027	DP			
<u>MEROPENEM; VABORBACTAM - VABOMERE</u>						
N 209776 001	10172874	Aug 08, 2031	DP			
	10183034	Aug 08, 2031	U-2490			
<u>METFORMIN HYDROCHLORIDE - RIOMET</u>						
N 021591 001	6890957	Aug 07, 2021	DP			
<u>METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE - KOMBIGLYZE XR</u>						
N 200678 002	8628799	Jul 13, 2025	DP			
<u>METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE - KOMBIGLYZE XR</u>						
N 200678 003	8628799	Jul 13, 2025	DP			
<u>METHOTREXATE SODIUM - XATMEP</u>						
N 208400 001	10231927	Jan 02, 2033	U-1349			
	10231927	Jan 02, 2033	U-1699			
<u>METHYLNALTREXONE BROMIDE - RELISTOR</u>						
N 208271 001	10307417	Mar 10, 2031	DP			
<u>METHYLPHENIDATE HYDROCHLORIDE - APTENSIO XR</u>						
N 205831 001	10039719	Dec 16, 2019	U-2357			
	10039719*PED	Jun 16, 2020				
	6419960	Dec 16, 2019	DP			
	6419960*PED	Jun 16, 2020				
	7083808	Dec 16, 2019	DP			
	7083808*PED	Jun 16, 2020				
	7247318	Dec 16, 2019	DP			
	7247318*PED	Jun 16, 2020				
	7438930	Dec 16, 2019	DP		Y	
	7438930*PED	Jun 16, 2020				
	8580310	Dec 16, 2019	DP			
	8580310*PED	Jun 16, 2020				
	9066869	Dec 16, 2019	DP			
	9066869*PED	Jun 16, 2020				
	9801823	Dec 16, 2019	DP			
	9801823*PED	Jun 16, 2020				
<u>METHYLPHENIDATE HYDROCHLORIDE - APTENSIO XR</u>						
N 205831 002	10039719	Dec 16, 2019	U-2357			
	10039719*PED	Jun 16, 2020				
	6419960	Dec 16, 2019	DP			
	6419960*PED	Jun 16, 2020				
	7083808	Dec 16, 2019	DP			
	7083808*PED	Jun 16, 2020				
	7247318	Dec 16, 2019	DP			
	7247318*PED	Jun 16, 2020				
	7438930	Dec 16, 2019	DP		Y	
	7438930*PED	Jun 16, 2020				
	8580310	Dec 16, 2019	DP			
	8580310*PED	Jun 16, 2020				
	9066869	Dec 16, 2019	DP			
	9066869*PED	Jun 16, 2020				

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>METHYLPHENIDATE HYDROCHLORIDE - APTENSIO XR</u>						
N 205831 002	9801823	Dec 16, 2019		DP		
	9801823*PED	Jun 16, 2020				
<u>METHYLPHENIDATE HYDROCHLORIDE - APTENSIO XR</u>						
N 205831 003	10039719	Dec 16, 2019		U-2357		
	10039719*PED	Jun 16, 2020				
	6419960	Dec 16, 2019		DP		
	6419960*PED	Jun 16, 2020				
	7083808	Dec 16, 2019		DP		
	7083808*PED	Jun 16, 2020				
	7247318	Dec 16, 2019		DP		
	7247318*PED	Jun 16, 2020				
	7438930	Dec 16, 2019		DP	Y	
	7438930*PED	Jun 16, 2020				
	8580310	Dec 16, 2019		DP		
	8580310*PED	Jun 16, 2020				
	9066869	Dec 16, 2019		DP		
	9066869*PED	Jun 16, 2020				
	9801823	Dec 16, 2019		DP		
	9801823*PED	Jun 16, 2020				
<u>METHYLPHENIDATE HYDROCHLORIDE - APTENSIO XR</u>						
N 205831 004	10039719	Dec 16, 2019		U-2357		
	10039719*PED	Jun 16, 2020				
	6419960	Dec 16, 2019		DP		
	6419960*PED	Jun 16, 2020				
	7083808	Dec 16, 2019		DP		
	7083808*PED	Jun 16, 2020				
	7247318	Dec 16, 2019		DP		
	7247318*PED	Jun 16, 2020				
	7438930	Dec 16, 2019		DP	Y	
	7438930*PED	Jun 16, 2020				
	8580310	Dec 16, 2019		DP		
	8580310*PED	Jun 16, 2020				
	9066869	Dec 16, 2019		DP		
	9066869*PED	Jun 16, 2020				
	9801823	Dec 16, 2019		DP		
	9801823*PED	Jun 16, 2020				
<u>METHYLPHENIDATE HYDROCHLORIDE - APTENSIO XR</u>						
N 205831 005	10039719	Dec 16, 2019		U-2357		
	10039719*PED	Jun 16, 2020				
	6419960	Dec 16, 2019		DP		
	6419960*PED	Jun 16, 2020				
	7083808	Dec 16, 2019		DP		
	7083808*PED	Jun 16, 2020				
	7247318	Dec 16, 2019		DP		
	7247318*PED	Jun 16, 2020				
	7438930	Dec 16, 2019		DP	Y	
	7438930*PED	Jun 16, 2020				
	8580310	Dec 16, 2019		DP		
	8580310*PED	Jun 16, 2020				
	9066869	Dec 16, 2019		DP		
	9066869*PED	Jun 16, 2020				
	9801823	Dec 16, 2019		DP		
	9801823*PED	Jun 16, 2020				
<u>METHYLPHENIDATE HYDROCHLORIDE - APTENSIO XR</u>						
N 205831 006	10039719	Dec 16, 2019		U-2357		
	10039719*PED	Jun 16, 2020				
	6419960	Dec 16, 2019		DP		
	6419960*PED	Jun 16, 2020				
	7083808	Dec 16, 2019		DP		
	7083808*PED	Jun 16, 2020				
	7247318	Dec 16, 2019		DP		

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>METHYLPHENIDATE HYDROCHLORIDE - APTENSIO XR</u>						
N 205831 006	7247318*PED	Jun 16, 2020				
	7438930	Dec 16, 2019	DP		Y	
	7438930*PED	Jun 16, 2020				
	8580310	Dec 16, 2019	DP			
	8580310*PED	Jun 16, 2020				
	9066869	Dec 16, 2019	DP			
	9066869*PED	Jun 16, 2020				
	9801823	Dec 16, 2019	DP			
	9801823*PED	Jun 16, 2020				
<u>METHYLPHENIDATE HYDROCHLORIDE - APTENSIO XR</u>						
N 205831 007	10039719	Dec 16, 2019		U-2357		
	10039719*PED	Jun 16, 2020				
	6419960	Dec 16, 2019	DP			
	6419960*PED	Jun 16, 2020				
	7083808	Dec 16, 2019	DP			
	7083808*PED	Jun 16, 2020				
	7247318	Dec 16, 2019	DP			
	7247318*PED	Jun 16, 2020				
	7438930	Dec 16, 2019	DP		Y	
	7438930*PED	Jun 16, 2020				
	8580310	Dec 16, 2019	DP			
	8580310*PED	Jun 16, 2020				
	9066869	Dec 16, 2019	DP			
	9066869*PED	Jun 16, 2020				
	9801823	Dec 16, 2019	DP			
	9801823*PED	Jun 16, 2020				
<u>METHYLPHENIDATE HYDROCHLORIDE - JORNAY PM</u>						
N 209311 001	10182995	Mar 23, 2032	DP			
	10292937	Mar 23, 2032		U-2357		
<u>METHYLPHENIDATE HYDROCHLORIDE - JORNAY PM</u>						
N 209311 002	10182995	Mar 23, 2032	DP			
	10292937	Mar 23, 2032		U-2357		
<u>METHYLPHENIDATE HYDROCHLORIDE - JORNAY PM</u>						
N 209311 003	10182995	Mar 23, 2032	DP			
	10292937	Mar 23, 2032		U-2357		
<u>METHYLPHENIDATE HYDROCHLORIDE - JORNAY PM</u>						
N 209311 004	10182995	Mar 23, 2032	DP			
	10292937	Mar 23, 2032		U-2357		
<u>METHYLPHENIDATE HYDROCHLORIDE - JORNAY PM</u>						
N 209311 005	10182995	Mar 23, 2032	DP			
	10292937	Mar 23, 2032		U-2357		
<u>METHYLPHENIDATE HYDROCHLORIDE - ADHANSIA XR</u>						
N 212038 001	10111839	Oct 30, 2035		U-2357		
	10292938	Oct 30, 2035	DP		NP	Feb 27, 2022
	10292939	Oct 30, 2035	DP	U-2357		
	9974752	Oct 30, 2035	DP			
<u>METHYLPHENIDATE HYDROCHLORIDE - ADHANSIA XR</u>						
N 212038 002	10111839	Oct 30, 2035		U-2357		
	10292938	Oct 30, 2035	DP		NP	Feb 27, 2022
	10292939	Oct 30, 2035	DP	U-2357		
	9974752	Oct 30, 2035	DP			
<u>METHYLPHENIDATE HYDROCHLORIDE - ADHANSIA XR</u>						
N 212038 003	10111839	Oct 30, 2035		U-2357		
	10292938	Oct 30, 2035	DP		NP	Feb 27, 2022

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>METHYLPHENIDATE HYDROCHLORIDE - ADHANSIA XR</u>						
N 212038 003	10292939	Oct 30, 2035	DP U-2357			
	9974752	Oct 30, 2035	DP			
<u>METHYLPHENIDATE HYDROCHLORIDE - ADHANSIA XR</u>						
N 212038 004	10111839	Oct 30, 2035	U-2357		NP	Feb 27, 2022
	10292938	Oct 30, 2035	DP			
	10292939	Oct 30, 2035	DP U-2357			
	9974752	Oct 30, 2035	DP			
<u>METHYLPHENIDATE HYDROCHLORIDE - ADHANSIA XR</u>						
N 212038 005	10111839	Oct 30, 2035	U-2357		NP	Feb 27, 2022
	10292938	Oct 30, 2035	DP			
	10292939	Oct 30, 2035	DP U-2357			
	9974752	Oct 30, 2035	DP			
<u>METHYLPHENIDATE HYDROCHLORIDE - ADHANSIA XR</u>						
N 212038 006	10111839	Oct 30, 2035	U-2357		NP	Feb 27, 2022
	10292938	Oct 30, 2035	DP			
	10292939	Oct 30, 2035	DP U-2357			
	9974752	Oct 30, 2035	DP			
<u>METRONIDAZOLE - NUVESSA</u>						
N 205223 001	10238634	Jun 28, 2032	DP			
<u>MIDAZOLAM - NAYZILAM</u>						
N 211321 001	8217033	Jan 18, 2028	DP U-2526		NP	May 21, 2022
	8809322	Jan 18, 2028	DP		ODE-243	May 17, 2026
	9289432	Jan 18, 2028	DP U-2526			
	9687495	Jan 18, 2028	DP U-2526			
<u>MIFEPRISTONE - KORLYM</u>						
N 202107 001	10195214	Jun 19, 2037	U-1643			
	10231983	Aug 22, 2038	U-1643			
	10314850	Aug 22, 2038	U-1643			
<u>MIGALASTAT HYDROCHLORIDE - GALAFOLD</u>						
N 208623 001	10251873	May 30, 2038	U-2371			
<u>MINOCYCLINE HYDROCHLORIDE - MINOCYCLINE HYDROCHLORIDE</u>						
A 091424 002					PC	Aug 21, 2019
<u>MORPHINE SULFATE - MORPHABOND ER</u>						
N 206544 001	10314788	Aug 12, 2028	DP			
<u>MORPHINE SULFATE - MORPHABOND ER</u>						
N 206544 002	10314788	Aug 12, 2028	DP			
<u>MORPHINE SULFATE - MORPHABOND ER</u>						
N 206544 003	10314788	Aug 12, 2028	DP			
<u>MORPHINE SULFATE - MORPHABOND ER</u>						
N 206544 004	10314788	Aug 12, 2028	DP			
<u>NAFTIFINE HYDROCHLORIDE - NAFTIN</u>						
N 204286 001	10166205	Jan 31, 2033	DP			
	10166206	Jan 31, 2033	DP			
<u>NALOXONE HYDROCHLORIDE - EVZIO</u>						
N 205787 001	10220158	Mar 20, 2035	DP U-2500			
	10314977	Nov 23, 2024	DP			
	10322239	Feb 28, 2031	U-1907			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>NALOXONE HYDROCHLORIDE - EVZIO</u>						
N 205787 001	10335549	Apr 30, 2025	DP			
<u>NALOXONE HYDROCHLORIDE - EVZIO (AUTOINJECTOR)</u>						
N 209862 001	10143792	May 24, 2031	U-2476			
	10220158	Mar 20, 2035	DP U-2500			
	10314977	Nov 23, 2024	DP			
	10322239	Feb 28, 2031	U-1907			
	10335549	Apr 30, 2025	DP			
<u>NETARSUDIL DIMESYLATE - RHOPRESSA</u>						
N 208254 001	10174017	Jan 27, 2030	DS DP U-1524			
<u>NETUPITANT; PALONOSETRON HYDROCHLORIDE - AKYNZEO</u>						
N 205718 001	10233154	Sep 25, 2035	DS			
<u>NITISINONE - NITYR</u>						
N 209449 001 >A>	10328029	Jan 05, 2035	DP U-1836			
<u>NITISINONE - NITYR</u>						
N 209449 002 >A>	10328029	Jan 05, 2035	DP U-1836			
<u>NITISINONE - NITYR</u>						
N 209449 003 >A>	10328029	Jan 05, 2035	DP U-1836			
<u>NUSINERSEN SODIUM - SPINRAZA</u>						
N 209531 001 >A>	10266822	Dec 05, 2025	DP U-1942			
>A>	10266822	Dec 05, 2025	DP U-1943			
>A>	10266822	Dec 05, 2025	DP U-1944			
<u>OLAPARIB - LYNPARZA</u>						
N 208558 001	8143241	Aug 12, 2027	U-2101		ODE-226	Dec 19, 2025
	8143241	Aug 12, 2027	U-2103			
	8143241	Aug 12, 2027	U-2480			
	8143241	Aug 12, 2027	U-2481			
	8143241	Aug 12, 2027	U-2482			
	8143241	Aug 12, 2027	U-2483			
	8859562	Aug 04, 2031	U-2101			
	8859562	Aug 04, 2031	U-2480			
	8859562	Aug 04, 2031	U-2481			
	8859562	Aug 04, 2031	U-2482			
	8859562	Aug 04, 2031	U-2483			
	8912187	Mar 12, 2024	U-2101			
	8912187	Mar 12, 2024	U-2480			
	8912187	Mar 12, 2024	U-2481			
	8912187	Mar 12, 2024	U-2482			
	8912187	Mar 12, 2024	U-2483			
<u>OLAPARIB - LYNPARZA</u>						
N 208558 002	8143241	Aug 12, 2027	U-2101		ODE-226	Dec 19, 2025
	8143241	Aug 12, 2027	U-2103			
	8143241	Aug 12, 2027	U-2480			
	8143241	Aug 12, 2027	U-2481			
	8143241	Aug 12, 2027	U-2482			
	8143241	Aug 12, 2027	U-2483			
	8859562	Aug 04, 2031	U-2101			
	8859562	Aug 04, 2031	U-2480			
	8859562	Aug 04, 2031	U-2481			
	8859562	Aug 04, 2031	U-2482			
	8859562	Aug 04, 2031	U-2483			
	8912187	Mar 12, 2024	U-2101			
	8912187	Mar 12, 2024	U-2480			
	8912187	Mar 12, 2024	U-2481			
	8912187	Mar 12, 2024	U-2482			
	8912187	Mar 12, 2024	U-2483			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>OLAPARIB - LYNPARZA</u>						
N 208558 002	8912187	Mar 12, 2024		U-2483		
<u>OMADACYCLINE TOSYLATE - NUZYRA</u>						
N 209816 001	>A> 7326696	Sep 24, 2023	DS			
	>A> 7553828	Jun 02, 2023	DS			
	>A> 8383610	Sep 23, 2030	DS			
	>A> 9265740	Mar 05, 2029		U-1569		
	>A> 9314475	Mar 18, 2031	DP			
	>A> 9365500	Jun 29, 2021		U-1569		
	>A> 9365500	Jun 29, 2021		U-2576		
	>A> 9724358	Mar 05, 2029		U-1569		
<u>OMADACYCLINE TOSYLATE - NUZYRA</u>						
N 209817 001	>A> 7326696	Sep 24, 2023	DS			
	>A> 7553828	Jun 02, 2023	DS			
	>A> 9265740	Mar 05, 2029	DP			
	>A> 9365500	Jun 29, 2021		U-1569		
	>A> 9365500	Jun 29, 2021		U-2576		
	>A> 9724358	Mar 05, 2029		U-1569		
<u>OMEGA-3-CARBOXYLIC ACIDS - EPANOVA</u>						
N 205060 001	5792795	May 13, 2020	DP			
	5948818	May 13, 2020	DP			
<u>OSIMERTINIB MESYLATE - TAGRISSO</u>						
N 208065 001	10183020	Jan 02, 2035	DP	U-1777		
	10183020	Jan 02, 2035	DP	U-2289		
<u>OSIMERTINIB MESYLATE - TAGRISSO</u>						
N 208065 002	10183020	Jan 02, 2035	DP	U-1777		
	10183020	Jan 02, 2035	DP	U-2289		
<u>OSPEMIFENE - OSPHENIA</u>						
N 203505 001	6245819	Jul 21, 2025	U-1370		I-793	Jan 25, 2022
	6245819	Jul 21, 2025	U-905			
	8236861	Aug 11, 2026	U-1369			
	8236861	Aug 11, 2026	U-1370			
	8236861	Aug 11, 2026	U-905			
	8470890	Feb 13, 2024	U-1369			
	8470890	Feb 13, 2024	U-1370			
	8470890	Feb 13, 2024	U-905			
	8772353	Feb 13, 2024	U-1369			
	8772353	Feb 13, 2024	U-1370			
	8772353	Feb 13, 2024	U-905			
	9241915	Feb 13, 2024	U-1369			
	9241915	Feb 13, 2024	U-1370			
	9241915	Feb 13, 2024	U-905			
	9855224	Feb 13, 2024	U-1369			
	9855224	Feb 13, 2024	U-1370			
	9855224	Feb 13, 2024	U-905			
<u>OXCARBAZEPINE - OXTELLAR XR</u>						
N 202810 001	10220042	Apr 13, 2027	U-2501			
	7910131	Apr 13, 2027	U-2041			
	9119791	Apr 13, 2027	U-2041			
<u>OXCARBAZEPINE - OXTELLAR XR</u>						
N 202810 002	10220042	Apr 13, 2027	U-2501			
	7910131	Apr 13, 2027	U-2041			
	9119791	Apr 13, 2027	U-2041			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>OXCARBAZEPINE - OXTELLAR XR</u>						
N 202810 003	10220042	Apr 13, 2027	U-2501			
	7910131	Apr 13, 2027	U-2041			
	9119791	Apr 13, 2027	U-2041			
<u>OXYBUTYNIN CHLORIDE - GELNIQUE</u>						
N 022204 001	10272061	Apr 26, 2020	U-2525			
<u>OXYCODONE - XTAMPZA ER</u>						
N 208090 001	10188644	Sep 02, 2036	DP U-1556			
<u>OXYCODONE - XTAMPZA ER</u>						
N 208090 002	10188644	Sep 02, 2036	DP U-1556			
<u>OXYCODONE - XTAMPZA ER</u>						
N 208090 003	10188644	Sep 02, 2036	DP U-1556			
<u>OXYCODONE - XTAMPZA ER</u>						
N 208090 004	10188644	Sep 02, 2036	DP U-1556			
<u>OXYCODONE - XTAMPZA ER</u>						
N 208090 005	10188644	Sep 02, 2036	DP U-1556			
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N 022272 001 >A> 10369109		Jun 16, 2023	DP			
	9060976	Aug 06, 2022	DP		Y	
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N 022272 002 >A> 10369109		Jun 16, 2023	DP			
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N 022272 003 >A> 10369109		Jun 16, 2023	DP			
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N 022272 004 >A> 10369109		Jun 16, 2023	DP			
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N 022272 005 >A> 10369109		Jun 16, 2023	DP			
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N 022272 006 >A> 10369109		Jun 16, 2023	DP			
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N 022272 007 >A> 10369109		Jun 16, 2023	DP			
<u>OXYCODONE HYDROCHLORIDE - ROXBOND</u>						
N 209777 001	10314788	Aug 12, 2028	DP			
<u>OXYCODONE HYDROCHLORIDE - ROXBOND</u>						
N 209777 002	10314788	Aug 12, 2028	DP			
<u>OXYCODONE HYDROCHLORIDE - ROXBOND</u>						
N 209777 003	10314788	Aug 12, 2028	DP			
<u>OXYMETAZOLINE HYDROCHLORIDE - RHOFADE</u>						
N 208552 001	10335391	Jun 11, 2035	U-2567			
<u>OZENOXACIN - XEPI</u>						
N 208945 001	6335447	Apr 06, 2020	DS			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>PALBOCICLIB - IBRANCE</u>						
N 207103 001	7456168	Jan 16, 2023	U-1998			
	7456168	Jan 16, 2023	U-2515			
<u>PALBOCICLIB - IBRANCE</u>						
N 207103 002	7456168	Jan 16, 2023	U-1998			
	7456168	Jan 16, 2023	U-2515			
<u>PALBOCICLIB - IBRANCE</u>						
N 207103 003	7456168	Jan 16, 2023	U-1998			
	7456168	Jan 16, 2023	U-2515			
<u>PENICILLAMINE - PENICILLAMINE</u>						
A 210976 001					CGT	Dec 22, 2019
<u>PIMAVANSERIN TARTRATE - NUPLAZID</u>						
N 207318 002					NCE	Apr 29, 2021
<u>PIRFENIDONE - ESBRIET</u>						
N 208780 001	10188637	Mar 28, 2037	DP			
<u>PIRFENIDONE - ESBRIET</u>						
N 208780 002	10188637	Mar 28, 2037	DP			
<u>PIRFENIDONE - ESBRIET</u>						
N 208780 003	10188637	Mar 28, 2037	DP			
<u>PITAVASTATIN CALCIUM - LIVALO</u>						
N 022363 001	5856336	Dec 25, 2020	DS	U-998	NPP	May 16, 2022
	5856336*PED	Jun 25, 2021			PED	Nov 16, 2022
	7022713	Feb 19, 2024		U-998		
	7022713*PED	Aug 19, 2024				
	8557993	Feb 02, 2024	DP			
	8557993*PED	Aug 02, 2024				
<u>PITAVASTATIN CALCIUM - LIVALO</u>						
N 022363 002	5856336	Dec 25, 2020	DS	U-998	NPP	May 16, 2022
	5856336*PED	Jun 25, 2021			PED	Nov 16, 2022
	7022713	Feb 19, 2024		U-998		
	7022713*PED	Aug 19, 2024				
	8557993	Feb 02, 2024	DP			
	8557993*PED	Aug 02, 2024				
<u>PITAVASTATIN CALCIUM - LIVALO</u>						
N 022363 003	5856336	Dec 25, 2020	DS	U-998	NPP	May 16, 2022
	5856336*PED	Jun 25, 2021			PED	Nov 16, 2022
	7022713	Feb 19, 2024		U-998		
	7022713*PED	Aug 19, 2024				
	8557993	Feb 02, 2024	DP			
	8557993*PED	Aug 02, 2024				
<u>PREGABALIN - LYRICA</u>						
N 021446 001					NPP	May 23, 2022
					PED	Nov 23, 2022
<u>PREGABALIN - LYRICA</u>						
N 021446 002					NPP	May 23, 2022
					PED	Nov 23, 2022
<u>PREGABALIN - LYRICA</u>						
N 021446 003					NPP	May 23, 2022
					PED	Nov 23, 2022

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>PREGABALIN - LYRICA</u>						
N 021446 003				NPP PED	May 23, 2022 Nov 23, 2022	
<u>PREGABALIN - LYRICA</u>						
N 021446 004				NPP PED	May 23, 2022 Nov 23, 2022	
<u>PREGABALIN - LYRICA</u>						
N 021446 005				NPP PED	May 23, 2022 Nov 23, 2022	
<u>PREGABALIN - LYRICA</u>						
N 021446 006				NPP PED	May 23, 2022 Nov 23, 2022	
<u>PREGABALIN - LYRICA</u>						
N 021446 007				NPP PED	May 23, 2022 Nov 23, 2022	
<u>PREGABALIN - LYRICA</u>						
N 021446 008				NPP PED	May 23, 2022 Nov 23, 2022	
<u>PROPRANOLOL HYDROCHLORIDE - HEMANGEOL</u>						
N 205410 001	8987262	Oct 16, 2028		U-1988		
<u>PYRIDOSTIGMINE BROMIDE - PYRIDOSTIGMINE BROMIDE</u>						
A 211694 001					CGT	Sep 04, 2019
<u>RANOLAZINE - RANOLAZINE</u>						
A 201046 001					PC	May 27, 2019
<u>RANOLAZINE - RANOLAZINE</u>						
A 201046 002					PC	May 27, 2019
<u>REGADENOSON - LEXISCAN</u>						
N 022161 001	RE47301 RE47351	Feb 02, 2027 Jun 22, 2019	DP DS DP U-869			
<u>REVEFENACIN - YUPELRI</u>						
N 210598 001	>A> 10343995 8541451 9765028	Mar 10, 2025 Aug 25, 2031 Jul 14, 2030	DS DS	U-2440		
<u>RIFAXIMIN - XIFAXAN</u>						
N 021361 001	10314828	Oct 02, 2029		U-1481		
<u>RIFAXIMIN - XIFAXAN</u>						
N 022554 001	>A> 10314828 >A> 10335397	Oct 02, 2029 Oct 02, 2029		U-1481 U-2579		
<u>ROTIGOTINE - NEUPRO</u>						
N 021829 001	>A> 10350174	Dec 22, 2030	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ROTIGOTINE - NEUPRO</u>						
N 021829 002 >A> 10350174		Dec 22, 2030	DP			
<u>ROTIGOTINE - NEUPRO</u>						
N 021829 003 >A> 10350174		Dec 22, 2030	DP			
<u>ROTIGOTINE - NEUPRO</u>						
N 021829 004 >A> 10350174		Dec 22, 2030	DP			
<u>ROTIGOTINE - NEUPRO</u>						
N 021829 005 >A> 10350174		Dec 22, 2030	DP			
<u>RUCAPARIB CAMSYLATE - RUBRACA</u>						
N 209115 001 10278974		Feb 10, 2031	DP			
<u>RUCAPARIB CAMSYLATE - RUBRACA</u>						
N 209115 002 10278974		Feb 10, 2031	DP			
<u>RUCAPARIB CAMSYLATE - RUBRACA</u>						
N 209115 003 10278974		Feb 10, 2031	DP			
<u>RUXOLITINIB PHOSPHATE - JAKAFI</u>						
N 202192 001 10016429 9814722		Jun 12, 2028 Dec 12, 2026	U-2536 U-2536	I-799 ODE-238	May 24, 2022 May 24, 2026	
<u>RUXOLITINIB PHOSPHATE - JAKAFI</u>						
N 202192 002 10016429 9814722		Jun 12, 2028 Dec 12, 2026	U-2536 U-2536	I-799 ODE-238	May 24, 2022 May 24, 2026	
<u>RUXOLITINIB PHOSPHATE - JAKAFI</u>						
N 202192 003 10016429 9814722		Jun 12, 2028 Dec 12, 2026	U-2536 U-2536	I-799 ODE-238	May 24, 2022 May 24, 2026	
<u>RUXOLITINIB PHOSPHATE - JAKAFI</u>						
N 202192 004 10016429 9814722		Jun 12, 2028 Dec 12, 2026	U-2536 U-2536	I-799 ODE-238	May 24, 2022 May 24, 2026	
<u>RUXOLITINIB PHOSPHATE - JAKAFI</u>						
N 202192 005 10016429 9814722		Jun 12, 2028 Dec 12, 2026	U-2536 U-2536	I-799 ODE-238	May 24, 2022 May 24, 2026	
<u>SECNIDAZOLE - SOLOSEC</u>						
N 209363 001 >A> 10335390		Sep 04, 2035	U-2583			
<u>SELENIOUS ACID - SELENIOUS ACID</u>						
N 209379 001				NCE	Apr 30, 2024	
<u>SELINEXOR - XPOVIO</u>						
N 212306 001 >A> 8999996 >A> 9079865 >A> 9714226		Sep 15, 2032 Jul 26, 2032 Jul 26, 2032	DS DP U-2584 DS DP	>A> NCE	Jul 03, 2024	
<u>SEMAGLUTIDE - OZEMPI</u>						
N 209637 001 10220155 >A> 10335462 >A> 10357616		Jul 17, 2026 Jun 21, 2033 Jan 20, 2026	DP U-2580 DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2019

See List footnote for information regarding List content

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>SOFOSBUVIR; VELPATASVIR; VOXILAPREVIR - VOSEVI</u>						
N 209195 001	>A> 7964580*PED	Sep 26, 2029				
	>A> 8334270	Mar 21, 2028	DS DP U-2039			
	>A> 8334270	Mar 21, 2028	DS DP U-2040			
	>A> 8334270*PED	Sep 21, 2028				
	>A> 8580765	Mar 21, 2028	DS DP U-2039			
	>A> 8580765	Mar 21, 2028	DS DP U-2040			
	>A> 8580765*PED	Sep 21, 2028				
	>A> 8618076	Dec 11, 2030	DS DP U-2039			
	>A> 8618076	Dec 11, 2030	DS DP U-2040			
	>A> 8618076*PED	Jun 11, 2031				
	>A> 8633309	Mar 26, 2029	DS DP U-2039			
	>A> 8633309	Mar 26, 2029	DS DP U-2040			
	>A> 8633309*PED	Sep 26, 2029				
	>A> 8889159	Mar 26, 2029	DS DP U-2039			
	>A> 8889159	Mar 26, 2029	DS DP U-2040			
	>A> 8889159*PED	Sep 26, 2029				
	>A> 9085573	Mar 21, 2028	DS DP U-2039			
	>A> 9085573	Mar 21, 2028	DS DP U-2040			
	>A> 9085573*PED	Sep 21, 2028				
	>A> 9284342	Sep 13, 2030	DS DP U-2039			
	>A> 9284342	Sep 13, 2030	DS DP U-2040			
	>A> 9284342*PED	Mar 13, 2031				
<u>SOLRIAMFETOL - SUNOSI</u>						
N 211230 001	10195151	Sep 05, 2037	DP		NCE	
	8440715	Aug 25, 2027	U-2548			
	8877806	Jun 07, 2026	U-2548			
	9604917	Jun 07, 2026	U-2548			
<u>SOLRIAMFETOL - SUNOSI</u>						
N 211230 002	10195151	Sep 05, 2037	DP		NCE	
	8440715	Aug 25, 2027	U-2548			
	8877806	Jun 07, 2026	U-2548			
	9604917	Jun 07, 2026	U-2548			
<u>SOMATROPIN RECOMBINANT - NORDITROPIN FLEXPRO</u>						
N 021148 008	10220155	Jul 17, 2026	DP			
	>A> 10357616	Jan 20, 2026	DP			
	7762994	May 23, 2024	DP			
	8579869	Jun 30, 2023	DP			
<u>SOMATROPIN RECOMBINANT - NORDITROPIN FLEXPRO</u>						
N 021148 009	10220155	Jul 17, 2026	DP			
	>A> 10357616	Jan 20, 2026	DP			
	7762994	May 23, 2024	DP			
	8579869	Jun 30, 2023	DP			
<u>SOMATROPIN RECOMBINANT - NORDITROPIN FLEXPRO</u>						
N 021148 010	10220155	Jul 17, 2026	DP			
	>A> 10357616	Jan 20, 2026	DP			
	7762994	May 23, 2024	DP			
	8579869	Jun 30, 2023	DP			
<u>SOMATROPIN RECOMBINANT - NORDITROPIN FLEXPRO</u>						
N 021148 011	10220155	Jul 17, 2026	DP			
	>A> 10357616	Jan 20, 2026	DP			
	7762994	May 23, 2024	DP			
	8579869	Jun 30, 2023	DP			
<u>SOTALOL HYDROCHLORIDE - SOTYLIZE</u>						
N 205108 001	10206895	Apr 01, 2034	DP U-2096			
	10206895	Apr 01, 2034	DP U-2494			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>SUFENTANIL CITRATE - DSUVIA</u>						
N 209128 001	10245228	Jan 05, 2027	DP U-1351			
	>A> 10342762	Jan 05, 2027	DP			
<u>SULFUR HEXAFLUORIDE LIPID-TYPE A MICROSPHERES - LUMASON</u>						
N 203684 001	10232061	Jul 06, 2038	DP			
	>A> 10335502	Jul 06, 2038	DP			
<u>SUMATRIPTAN - TOSYMRRA</u>						
N 210884 001	8268791	May 09, 2026	DP			
	8440631	May 09, 2026	DP U-1719			
	9211282	Jul 19, 2031	DP U-1719			
	9283280	Jul 01, 2025	DP			
	9610280	Jun 16, 2030	DP U-1719			
	9974770	Jun 16, 2030	DP U-1719			
<u>SUNITINIB MALATE - SUTENT</u>						
N 021938 001	6573293	Feb 15, 2021	DS DP U-1154		I-755	Nov 16, 2020
	6573293	Feb 15, 2021	DS DP U-2171		PED	May 16, 2021
	6573293*PED	Aug 15, 2021				
	7125905	Feb 15, 2021	DS DP			
	7125905*PED	Aug 15, 2021				
	7211600	Dec 22, 2020		U-883		
	7211600*PED	Jun 22, 2021				
<u>SUNITINIB MALATE - SUTENT</u>						
N 021938 002	6573293	Feb 15, 2021	DS DP U-1154		I-755	Nov 16, 2020
	6573293	Feb 15, 2021	DS DP U-2171		PED	May 16, 2021
	6573293*PED	Aug 15, 2021				
	7125905	Feb 15, 2021	DS DP			
	7125905*PED	Aug 15, 2021				
	7211600	Dec 22, 2020		U-883		
	7211600*PED	Jun 22, 2021				
<u>SUNITINIB MALATE - SUTENT</u>						
N 021938 003	6573293	Feb 15, 2021	DS DP U-1154		I-755	Nov 16, 2020
	6573293	Feb 15, 2021	DS DP U-2171		PED	May 16, 2021
	6573293*PED	Aug 15, 2021				
	7125905	Feb 15, 2021	DS DP			
	7125905*PED	Aug 15, 2021				
	7211600	Dec 22, 2020		U-883		
	7211600*PED	Jun 22, 2021				
<u>SUNITINIB MALATE - SUTENT</u>						
N 021938 004	6573293	Feb 15, 2021	DS DP U-1154		I-755	Nov 16, 2020
	6573293	Feb 15, 2021	DS DP U-2171		PED	May 16, 2021
	6573293*PED	Aug 15, 2021				
	7125905	Feb 15, 2021	DS DP			
	7125905*PED	Aug 15, 2021				
	7211600	Dec 22, 2020		U-883		
	7211600*PED	Jun 22, 2021				
<u>TACROLIMUS - ENVARSUS XR</u>						
N 206406 001	10166190	May 30, 2028	DP			
<u>TACROLIMUS - ENVARSUS XR</u>						
N 206406 002	10166190	May 30, 2028	DP			
<u>TACROLIMUS - ENVARSUS XR</u>						
N 206406 003	10166190	May 30, 2028	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
TADALAFIL - CIALIS						
N 021368 003	7182958	Apr 26, 2020	DP U-155	Y		
	7182958*PED	Oct 26, 2020				
TADALAFIL - CIALIS						
N 021368 004	7182958	Apr 26, 2020	DP U-155	Y		
	7182958*PED	Oct 26, 2020				
TAFAMIDIS - VYNDAMAX						
N 212161 001	7214695	Apr 27, 2024	DS DP		NCE	May 03, 2024
	7214696	Dec 19, 2023	U-2524		ODE-237	May 03, 2026
	9770441	Aug 31, 2035	DS DP U-2524			
TAFAMIDIS MEGLUMINE - VYNDAQEL						
N 211996 001	7214695	Apr 27, 2024	DS DP		NCE	May 03, 2024
	7214696	Dec 19, 2023	U-2524		ODE-237	May 03, 2026
	8168663	Dec 19, 2023	DS DP			
	8653119	Jan 28, 2024	U-2524			
TAFENOQUINE SUCCINATE - ARAKODA						
N 210607 001 >A> 10342791		Dec 02, 2035	U-2582			
TALAZOPARIB TOSYLATE - TALZENNA						
N 211651 001	10189837	Oct 20, 2031	DS DP		>A> NCE	Oct 16, 2023
TALAZOPARIB TOSYLATE - TALZENNA						
N 211651 002	10189837	Oct 20, 2031	DS DP		>A> NCE	Oct 16, 2023
TAVABOROLE - KERYDIN						
N 204427 001					NCE	Jul 07, 2019
					PED	Jan 07, 2020
TEDIZOLID PHOSPHATE - SIVEXTRO						
N 205435 001	10065947	Feb 03, 2030	DP			
	9624250	Feb 03, 2030	DS DP U-2507			
	9988406	Feb 03, 2030	DP			
TEDIZOLID PHOSPHATE - SIVEXTRO						
N 205436 001	10065947	Feb 03, 2030	DP			
	9624250	Feb 03, 2030	DS DP U-2507			
	9988406	Feb 03, 2030	DP			
TEDUGLUTIDE RECOMBINANT - GATTEX KIT						
N 203441 001	5789379	Apr 14, 2020	DS DP U-1320		ODE-240	May 16, 2026
	5789379*PED	Oct 14, 2020			ODE-37	Dec 21, 2019
	7056886	Sep 18, 2022	DP U-1320		PED	Jun 21, 2020
	7056886*PED	Mar 18, 2023				
	7847061	Nov 01, 2025	U-1320			
	7847061*PED	May 01, 2026				
	9060992	Nov 01, 2025	U-1320			
	9060992*PED	May 01, 2026				
	9539310	Nov 01, 2025	U-1320			
	9539310*PED	May 01, 2026				
	9545434	Nov 01, 2025	U-1320			
	9545434*PED	May 01, 2026				
	9545435	Nov 01, 2025	U-1320			
	9545435*PED	May 01, 2026				
	9555079	Nov 01, 2025	U-1320			
	9555079*PED	May 01, 2026				
	9572867	Nov 01, 2025	U-1320			
	9572867*PED	May 01, 2026				
	9592273	Nov 01, 2025	U-1320			
	9592273*PED	May 01, 2026				
	9592274	Nov 01, 2025	U-1320			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>TEDUGLUTIDE RECOMBINANT - GATTEX KIT</u>						
N 203441 001	9592274*PED	May 01, 2026				
	9968655	Nov 01, 2025	U-2308			
	9968655*PED	May 01, 2026				
	9968656	Nov 01, 2025	U-2308			
	9968656*PED	May 01, 2026				
	9968658	Nov 01, 2025	U-1320			
	9968658*PED	May 01, 2026				
	9974835	Nov 01, 2025	U-1320			
	9974835*PED	May 01, 2026				
	9974837	Nov 01, 2025	U-1320			
	9974837*PED	May 01, 2026				
	9981014	Nov 01, 2025	U-1320			
	9981014*PED	May 01, 2026				
	9981016	Nov 01, 2025	U-1320			
	9981016*PED	May 01, 2026				
	9987334	Nov 01, 2025	U-1320			
	9987334*PED	May 01, 2026				
	9987335	Nov 01, 2025	U-1320			
	9987335*PED	May 01, 2026				
	9993528	Nov 01, 2025	U-1320			
	9993528*PED	May 01, 2026				
<u>TESTOSTERONE UNDECANOATE - JATENZO</u>						
N 206089 001	8241664	Mar 29, 2029	DP U-2506	>A> NP		Mar 27, 2022
	8492369	Dec 20, 2030	DP U-2506			
	8778916	Apr 12, 2030	DP			
<u>TESTOSTERONE UNDECANOATE - JATENZO</u>						
N 206089 002	8241664	Mar 29, 2029	DP U-2506	>A> NP		Mar 27, 2022
	8492369	Dec 20, 2030	DP U-2506			
	8778916	Apr 12, 2030	DP			
<u>TESTOSTERONE UNDECANOATE - JATENZO</u>						
N 206089 003	8241664	Mar 29, 2029	DP U-2506	>A> NP		Mar 27, 2022
	8492369	Dec 20, 2030	DP U-2506			
	8778916	Apr 12, 2030	DP			
<u>THIOTHIXENE - THIOTHIXENE</u>						
A 211642 001				CGT		Oct 02, 2019
<u>THIOTHIXENE - THIOTHIXENE</u>						
A 211642 002				CGT		Oct 02, 2019
<u>THIOTHIXENE - THIOTHIXENE</u>						
A 211642 003				CGT		Oct 02, 2019
<u>THIOTHIXENE - THIOTHIXENE</u>						
A 211642 004				CGT		Oct 02, 2019
<u>TICAGRELOR - BRILINTA</u>						
N 022433 001	10300065	Jan 27, 2036	U-2541			
	10300065	Jan 27, 2036	U-2542			
<u>TICAGRELOR - BRILINTA</u>						
N 022433 002	10300065	Jan 27, 2036	U-2541			
	10300065	Jan 27, 2036	U-2542			
<u>TIPIRACIL HYDROCHLORIDE; TRIFLURIDINE - LONSURF</u>						
N 207981 001	RE46284	Dec 16, 2026	U-1751	>A> I-794		Feb 22, 2022
	RE46284	Dec 16, 2026	U-2503	ODE-229		Feb 22, 2026

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>TIPIRACIL HYDROCHLORIDE; TRIFLURIDINE - LONSURF</u>						
N 207981 002	RE46284	Dec 16, 2026	U-1751	>A> I-794		Feb 22, 2022
	RE46284	Dec 16, 2026	U-2503		ODE-229	Feb 22, 2026
<u>TOBRAMYCIN - TOBI PODHALER</u>						
N 201688 001	>A> 10207066	Nov 04, 2030	DP U-909			
	>A> 8664187	Jun 20, 2025	U-909			
	>A> 8869794	Sep 12, 2028	DP U-909			
	>A> 9421166	Dec 19, 2022	DP U-909			
<u>TOPIRAMATE - TROKENDI XR</u>						
N 201635 001	10314790	Nov 16, 2027	DP U-1675			
	10314790	Nov 16, 2027	DP U-1992			
<u>TOPIRAMATE - TROKENDI XR</u>						
N 201635 002	10314790	Nov 16, 2027	DP U-1675			
	10314790	Nov 16, 2027	DP U-1992			
<u>TOPIRAMATE - TROKENDI XR</u>						
N 201635 003	10314790	Nov 16, 2027	DP U-1675			
	10314790	Nov 16, 2027	DP U-1992			
<u>TOPIRAMATE - TROKENDI XR</u>						
N 201635 004	10314790	Nov 16, 2027	DP U-1675			
	10314790	Nov 16, 2027	DP U-1992			
<u>TOPIRAMATE - OUDEXY XR</u>						
N 205122 001	>A> 10363224	Mar 19, 2033	U-766			
<u>TOPIRAMATE - OUDEXY XR</u>						
N 205122 002	>A> 10363224	Mar 19, 2033	U-766			
<u>TOPIRAMATE - OUDEXY XR</u>						
N 205122 003	>A> 10363224	Mar 19, 2033	U-766			
<u>TOPIRAMATE - OUDEXY XR</u>						
N 205122 004	>A> 10363224	Mar 19, 2033	U-766			
<u>TOPIRAMATE - OUDEXY XR</u>						
N 205122 005	>A> 10363224	Mar 19, 2033	U-766			
<u>TRAMETINIB DIMETHYL SULFOXIDE - MEKINIST</u>						
N 204114 001	8703781	Oct 15, 2030	DS DP U-1712			
	8703781	Oct 15, 2030	DS DP U-2020			
	8703781	Oct 15, 2030	DS DP U-2037			
	8703781	Oct 15, 2030	DS DP U-2302			
	8703781	Oct 15, 2030	DS DP U-2305			
<u>TRAMETINIB DIMETHYL SULFOXIDE - MEKINIST</u>						
N 204114 002	8703781	Oct 15, 2030	DS DP U-1712			
	8703781	Oct 15, 2030	DS DP U-2020			
	8703781	Oct 15, 2030	DS DP U-2037			
	8703781	Oct 15, 2030	DS DP U-2302			
	8703781	Oct 15, 2030	DS DP U-2305			
<u>TRAMETINIB DIMETHYL SULFOXIDE - MEKINIST</u>						
N 204114 003	8703781	Oct 15, 2030	DS DP U-1712			
	8703781	Oct 15, 2030	DS DP U-2020			
	8703781	Oct 15, 2030	DS DP U-2037			
	8703781	Oct 15, 2030	DS DP U-2302			
	8703781	Oct 15, 2030	DS DP U-2305			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>TREPROSTINIL - TREPROSTINIL</u>						
A 203649 001				PC		Sep 21, 2019
<u>TREPROSTINIL - TREPROSTINIL</u>						
A 203649 002				PC		Sep 21, 2019
<u>TREPROSTINIL - TREPROSTINIL</u>						
A 203649 003				PC		Sep 21, 2019
<u>TREPROSTINIL - TREPROSTINIL</u>						
A 203649 004				PC		Sep 21, 2019
<u>TRETINOIN - ALTRENO</u>						
N 209353 001	6517847	Aug 03, 2020	DP U-2368			
<u>TRICLABENDAZOLE - EGATEN</u>						
N 208711 001				NCE ODE-228	Feb 13, 2024 Feb 13, 2026	
<u>TRIPTORELIN PAMOATE - TRELSTAR</u>						
N 022437 001	10166181	Feb 10, 2029	DP			
<u>TRIPTORELIN PAMOATE - TRIPTODUR KIT</u>						
N 208956 001	10166181	Feb 10, 2029	DP			
<u>ULIPRISTAL ACETATE - ELLA</u>						
N 022474 001	10159681 9844510	Apr 13, 2030 Dec 08, 2028	U-2510 DP			
<u>URIDINE TRIACETATE - VISTOGARD</u>						
N 208159 001	6258795	Jul 10, 2023	DP			
<u>URIDINE TRIACETATE - XURIDEN</u>						
N 208169 001	6258795	Jul 10, 2023	DP			
<u>VANCOMYCIN HYDROCHLORIDE - VANCOMYCIN HYDROCHLORIDE</u>						
N 211962 001	10039804 10188697	Nov 06, 2035 Nov 06, 2035	DP U-282 DP U-282			
<u>VANCOMYCIN HYDROCHLORIDE - VANCOMYCIN HYDROCHLORIDE</u>						
N 211962 002	10039804 10188697	Nov 06, 2035 Nov 06, 2035	DP U-282 DP U-282			
<u>VANCOMYCIN HYDROCHLORIDE - VANCOMYCIN HYDROCHLORIDE</u>						
N 211962 003	10039804 10188697	Nov 06, 2035 Nov 06, 2035	DP U-282 DP U-282			
<u>VANCOMYCIN HYDROCHLORIDE - VANCOMYCIN HYDROCHLORIDE</u>						
N 211962 004	10039804 10188697	Nov 06, 2035 Nov 06, 2035	DP U-282 DP U-282			
<u>VARENICLINE TARTRATE - CHANTIX</u>						
N 021928 001				M-237 PED	Feb 22, 2022 Aug 22, 2022	
<u>VARENICLINE TARTRATE - CHANTIX</u>						
N 021928 002				M-237 PED	Feb 22, 2022 Aug 22, 2022	

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>VENETOCLAX - VENCLEXTA</u>						
N 208573 001	>A> 9174982	May 26, 2030	U-2323	I-795	May 15, 2022	
	>A> 9174982	May 26, 2030	U-2445	ODE-239	May 15, 2026	
	>A> 9174982	May 26, 2030	U-2446			
	>A> 9174982	May 26, 2030	U-2537			
	9539251	Sep 06, 2033	U-2538			
<u>VENETOCLAX - VENCLEXTA</u>						
N 208573 002	>A> 9174982	May 26, 2030	U-2323	I-795	May 15, 2022	
	>A> 9174982	May 26, 2030	U-2445	ODE-239	May 15, 2026	
	>A> 9174982	May 26, 2030	U-2446			
	>A> 9174982	May 26, 2030	U-2537			
	9539251	Sep 06, 2033	U-2538			
<u>VENETOCLAX - VENCLEXTA</u>						
N 208573 003	>A> 9174982	May 26, 2030	U-2323	I-795	May 15, 2022	
	>A> 9174982	May 26, 2030	U-2445	ODE-239	May 15, 2026	
	>A> 9174982	May 26, 2030	U-2446			
	>A> 9174982	May 26, 2030	U-2537			
	9539251	Sep 06, 2033	U-2538			
<u>VORICONAZOLE - VFEND</u>						
N 021266 001				NPP	Jan 29, 2022	
<u>VORICONAZOLE - VFEND</u>						
N 021266 002				NPP	Jan 29, 2022	
<u>VORICONAZOLE - VFEND</u>						
N 021267 001				NPP	Jan 29, 2022	
<u>VORICONAZOLE - VFEND</u>						
N 021630 001				NPP	Jan 29, 2022	

Footnote:

1. Patents are published upon receipt by the Orange book Staff and may not reflect the official receipt date as described in 21 CFR 314.53(d)(5).
2. Patents listed prior to August 18, 2003 are flagged with method of use claims only as applicable and submitted by the sponsor. They may not be flagged with respect to other claims which may apply.

PATENT AND EXCLUSIVITY TERMS

Due to space limitations in the patent and exclusivity columns, abbreviations and references have been developed. Refer to the APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS, 39th Edition for a full listing of patent and exclusivity terms (Abbreviations, Dosing Schedule, Indications, and Patent Use Codes).

The current complete list of patent terms is available at
http://www.accessdata.fda.gov/scripts/cder/ob/results_patent.cfm

The current complete list of exclusivity terms is available at
http://www.accessdata.fda.gov/scripts/cder/ob/results_exclusivity.cfm